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INTRODUCTION 
Non-communicable diseases (NCDs) are the leading cause of mortality and morbidity worldwide. 
Cardiovascular disease (CVD) is the main cause of death and its burden is growing1. By 2020 it is 
estimated that CVD will account for 73% of total global mortality and 56% of total morbidity1,2. 
Additionally, type 2 diabetes (T2D), which is associated with a marked increase (by two to four) in 
the risk of CVD3, is fast becoming a global epidemic. The International Diabetes Federation (IDF) 
has projected that the number of people with T2D in the world will increase from 382 million in 
2013 to 592 million by 20354. 
Economic Impact of Non-Communicable Diseases
NCDs, including CVD and T2D, have a large economic impact, leading to decreases in working-
age population participation in the labor force due to disability, and therefore undercut productivity, 
which, in turn, affects economic growth. NCDs have been estimated to reduce economic growth by 
about 5–10%5. Moreover, because NCDs are chronic conditions that require expensive treatment 
regimens and prolonged individual care by specialized healthcare services, they boost healthcare 
outlays6. Despite the understanding of the financial burden of NCDs, the impact of NCDs on 
macro-economic outcomes in various geographical regions is unclear. Exploring the studies that 
investigate the impact of NCDs on healthcare expenditures and national income can help shape 
nations’ future healthcare plans and strategies by better informing policy makers and healthcare 
planners about the emerging costs of NCDs. 
Obesity as a Major Determinant of NCDs
In 400 BC, the Greek physician Hippocrates observed that “Sudden death is more common in those 
who are naturally fat than in the lean.” Today, obesity is established as an underlying risk factor for 
several NCDs, including CVD and T2D. Obesity increases the risk for cardiometabolic diseases 
through other risk factors7. The latter include major risk factors, including hypercholestrerolemia, 
hypertension and hyperglycemia, as well as emerging risk factors, such as inflammation7. Increased 
adipose tissue mass contributes to an increase in circulating levels of proinflammatory cytokines, 
due to hypertrophied adipocytes and adipose tissue-resident immune cells (primarily lymphocytes 
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and macrophages). These proinflammatory cytokines may lead to vascular dysfunction and insulin 
resistance (Figure 1) 8-10. Moreover, obesity is associated with nonalcoholic fatty liver disease 
(NAFLD), which is characterized by an increase in intrahepatic triglyceride and is associated with 
increased risk for T2D and CVD (Figure 1) 11. Obesity can impair both physical and psychological 
health and wellbeing12,13. The net effect of the increase in fat mass and the enlarged fat cells is an 
increased mortality risk, which results in a decrease in life expectancy, estimated to be up to 13 
years14. Over the last decade, the prevalence of obesity in many countries has more than doubled15. 
Recently, an accumulating body of evidence suggests that regional fat distribution is more important 
in understanding the association of obesity with NCDs than is overall body fat mass16-18. Android 
obesity, which is characterized by the accumulation of body fat in the upper truncal region, is more 
common in men, and has been associated with an increased risk of atherosclerosis, T2D, CVD and 
total mortality19-23. Contrary to this, gynoid obesity, defined as an accumulation of body fat in hips 
and thighs, is more common in women, and has been independently associated with a reduced 
risk of metabolic complications16,17. Accumulation of abdominal fat increases with advancing 
age, and during the menopause transition, women are more prone to increase the accumulation of 
central fat24. Although epidemiological studies have identified potentially modifiable factors that 
affect body fat distribution, such as physical activity and cigarette smoking25-27, the role of dietary 
intake, particularly dietary fat, and its effect on the distribution of body fat remains unclear28-32. 
Furthermore, identifying biomarkers that are associated with body fat distribution may have 
clinical utility in identifying individuals at high risk of metabolic disturbances later in life who 
could benefit from effective preventive interventions.
The Role of Nutrition in Cardiometabolic Health 
According to the World Health Organization (WHO), CVD and its risk factors are closely 
related to unbalanced diet and other lifestyle factors33. Nevertheless, the optimal diet for 
prevention of cardiometabolic risk factors and the incidence of CVD and T2D remains uncertain. 
Epidemiological studies have identified nutritional factors that affect cardiometabolic health, such 
as salt, carbohydrates, fiber, fish, fruits and vegetables34-38. However, the role of other nutritional 
factors, including dietary fat and vitamin D in cardiometabolic health, in particular in inflammation 
and obesity remains controversial28-32. Several observational and experimental studies showed the 
beneficial effects of polyunsaturated fatty acids (PUFAs) in CVD, in particular of n-3 PUFAs39,40. 
PUFAs may exert their cardioprotective effect by reducing thrombosis, decreasing arrhythmias 
and by stabilizing atherosclerotic plaques41. The current dietary guidelines for prevention and 
management of CVD and other chronic diseases encourage high consumption of both classes of 
PUFAs, n-3 and n-6, as a replacement for other types of fatty acids, such as saturated fatty acids42,43. 
Despite the consistency of favorable recommendations regarding dietary PUFAs, there are concerns 
that high amount of n-6 PUFAs in the diet may contribute to increased inflammation44,45. 
Furthermore, in Western countries, the consumption of plant derived n-3 PUFAs has almost 
doubled during the last decades, moving from 1 to 1.9 g/day46. Thus far, there is little controversy 
on the topic of the beneficial effects of marine-derived n-3 PUFAs supplementation on chronic 
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systemic inflammation47, but very little is known about the effects of plant derived n-3 PUFAs 
on inflammation48. Furthermore, different types of fatty acid have different rates of oxidation 
depending on their chemical structure49,50. Impaired fat oxidation has been associated with the 
development of obesity51. However, no conclusion may yet be made on whether different dietary 
fatty acids also affect the distribution of body fat. 
Vitamin D is another nutritional factor that is emerging as more important to skeletal, cardiovascular, 
and other health outcomes52. Vitamin D is obtained from diet and dietary supplements; however, 
its main source in the body is its production in the skin under the influence of solar ultraviolet 
radiation53. Vitamin D deficiency is especially common among elderly people (its prevalence is 
usually reported to be above 40%), who often have less sun exposure because of reduced outdoor 
activity, and the limited capacity of their skin to produce vitamin D metabolites53. In addition 
to its role in skeletal health, vitamin D has also physiological functions in non-skeletal tissues, 
where local synthesis influences pathways that are integral to cardiovascular function and disease, 
including inflammation, thrombosis and the renin-angiotensin system54. Indeed, observational 
studies have linked vitamin D deficiency with an increased risk of CVD and randomized controlled 
trials have reported a beneficial effect of vitamin D supplementation in reducing the risk of CVD55-
57. Moreover, it is known that circulating levels of serum 25(OH)D are lower in obese individuals, 
however, it is not clear whether vitamin D status is associated with body fat distribution and the 
directionality of previously observed associations58. 
Biomarkers and Cardiometabolic health 
Primary prevention of CVD and T2D are public health priorities59. Scientific evidence shows that 
both CVD and T2D are life course diseases that begin with the evolution of risk factors that, in 
turn, contribute to the development of subclinical disease60,61. Subclinical disease culminates in 
overt CVD and T2D, which affect the prognosis and the risk of morbidity and mortality among 
diagnosed patients62,63.  Therefore, clinical assessment and early identification and treatment of risk 
factors are needed to accelerate disease prevention and morbidity improvement64. Measurement 
of various biomarkers is one tool that can be used to better document health risks. Clinicians may 
use relevant biomarkers to assess early changes in subclinical disease status preceding diagnosis of 
disease and biomarkers may also be used to identify people with a higher susceptibility to cardio 
metabolic diseases. Thus, measurement of biomarkers may help to identify novel pathways and 
subgroups in the population with greater susceptibility to cardometabolic diseases65. 
Extensive data have been accumulated to support the use of specific biomarkers for early 
identification of cardiometabolic risk, including blood pressure, serum cholesterol levels and 
glucose66,67. However, the current scientific knowledge does not completely explain the complex 
pathophysiology underlying cardiometabolic diseases so researchers still search for other 
pathways. Novel biomarkers of cardiometabolic health have been suggested, such as gamma-
glutammyltransaferase (GGT) and endogenous sex hormones. GGT is a marker of alcohol 
consumption and liver disease and has been associated with obesity-related outcomes, including 
hypertension, dyslipidemia, insulin resistance, CVD and cancer 68-73.GGT plays a pivotal role 
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in oxidative stress 74,75,  which may play a causal role in the development of obesity76. To date, 
however, very little attention has been given to GGT within normal range and its role in obesity and/
or body fat distribution among healthy individuals.  Furthermore, observationally, higher levels of 
gamma-glutamyltransferase (GGT) are consistently associated with increased risk of pre-diabetes 
and T2D 77-83. However, to date, controversy exists whether these effects are causal, confounded or 
a consequence of reverse causation. If the associations from observational studies are found to be 
causal, GGT-lowering therapies could be used in T2D prevention.  
Cardiovascular Health in Women
Despite improvements in prevention and treatment, CVD remains the leading cause of death for 
women worldwide84. Compared with age-matched men, premenopausal women have a lower risk 
of coronary heart disease (CHD) which gradually increases after menopause so that by their sixth 
decade of life, women have the same incidence of CHD as men85. Therefore, early recognition of 
women at high risk for CVD and timely implementation of appropriate lifestyle or therapeutic 
interventions are of tremendous public health importance. The disparity between the incidence 
of CVD among women in pre- and post-menopause has been largely ascribed to the changes in 
hormonal patterns during the menopause transition, including a marked decline in endogenous 
estradiol levels, leading to a period of relative excess of androgen86. The menopausal shift in 
 
 
Figure 1. Underlying mechanisms linking adiposity, menopause and its related changes with 
type 2 diabetes and cardiovascular disease.
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hormonal balance contributes to an increase in visceral adiposity and other cardiometabolic risk 
factors87. Therefore, women who have a premature or early menopause may live more years of their 
lives at an increased risk of adverse cardiovascular outcomes88-903–5. The relation between early 
menopause and adverse cardiovascular outcomes highlights the need to evaluate the role of both 
menopausal age and time since onset of menopause as risk factors for CVD. Furthermore, during 
their menopausal transition, up to 80% of women experience vasomotor symptoms (VMS), which 
typically include hot flushes and night sweats 91, and are known to impair the quality of life92,93. 
A growing body of evidence suggests a link between VMS and cardiovascular risk profile94-99, 
however, whether a link really exists remains unclear. Figure 1 describes the mechanisms linking 
menopause and its related hormonal changes with cardiometabolic outcomes. Furthermore, during 
the menopause, women get treatment for menopausal symptoms, including hormone replacement 
therapy (HT). Recent evidence show that use of HT may have a potentially negative impact on 
cardiovascular health100. Therefore, it is of importance identifying other medical therapies that may 
be used to treat menopausal symptoms avoiding the adverse cardiovascular effects induced by the 
use of HT.  There is a broad range of natural and plant-based therapies that purport to have a positive 
effect on menopausal symptoms and that are used by 40-50% of women in Western countries as 
complimentary therapies to manage menopausal symptoms101,102. These therapies include the oral 
use of phytoestrogens such as dietary isoflavones and soy extracts; herbal remedies such as red 
clover and black cohosh; and non-biological treatments, such as acupuncture and yoga. However, 
whether these therapies can help to manage menopausal symptoms remains unclear given that 
there in not yet a comprehensive assessment of the impact of natural and plant-based therapies on 
the presence and severity of menopausal symptoms.
General Aim of This Thesis
The first objective of this thesis was to identify nutritional factors and biomarkers that can play a role 
in cardiometabolic health. A second aim was to identify determinants of adverse cardiometabolic 
health in women. 
STUDY DESIGN 
Systematic reviews and meta-analysis 
Part of the research described in chapter 2 and 4 of this thesis are systematic reviews and meta-
analyses of the literature. Systematic searches of electronic medical databases were performed to 
retrieve scientific articles on the topic of interest. Two independent reviewers screened the retrieved 
titles and abstracts and selected eligible studies. Reference lists of the included studies were 
screened to identify additional relevant studies. Heterogeneity permitting, we sought to pool the 
results using a random effects meta-analysis model. Heterogeneity was assessed using the Cochrane 
χ2 statistic and the I2 statistic. Publication bias was evaluated through a funnel plot and Egger’s test. 
Study quality (for cohort and case-control studies) was assessed based on the Newcastle–Ottawa 
Scale(NOS)103 using three pre-defined domains, namely: selection of participants (population 
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representativeness), comparability (adjustment for confounders), and ascertainment of outcomes 
of interest. Further details on the methods can be found in the specific chapters. 
Rotterdam Study
The studies presented in chapter 3, 4 and 5 of this thesis were carried out within the framework 
of the Rotterdam Study, a population-based prospective cohort study, which started in 1990 in 
the Ommoord district, in the city of Rotterdam, The Netherlands.  Details regarding the design, 
objectives, and methods of the Rotterdam Study have been described in detail elsewhere104. In 
brief, in 1990, all inhabitants of a well-defined district of Rotterdam were invited to participate in 
the study, of whom 7,983 agreed (78.1%). In 2000, an additional 3011 participants were enrolled 
(RS-II), consisting of all persons living in the study district who had turned 55 years of age between 
1991 and 2000. ). The third cohort was formed in 2006 and included 3932 participants 45 years and 
older (RS-III). Follow up examinations were performed approximately every 3-5 years (Figure 
2)104. There were no eligibility criteria to enter the Rotterdam Study cohorts except the minimum 
age and residential area based on zip codes. Dietary intake used in this thesis was assessed by 
using a validated semi-quantitative food frequency questionnaire (FFQ) at baseline (1990-1993). 
Participants completed a checklist at home about foods and drinks they had consumed at least 
twice a month during the preceding year, as well as dietary habits and prescribed diets. 
Figure 2. Diagram of examination cycles of the Rotterdam Study (RS)*
    *Diagram of examination cycles of the Rotterdam Study (RS). RS-I-1 refers to the baseline examination of the original 
cohort (pilot phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). RS-I-2, RS-I-3, RS-I-4, RS-I-5, and RS-I-6 
refer to re-examinations of the original cohort members. RS-II-1 refers to the extension of the cohort with persons in the 
study district that became 55 years since the start of the study or those of 55 years or over that migrated into the study 
district. RS-II-2, RS-II-3, and RS-II-4 refer to re-examinations of the extension cohort. RS-III-1 refers to the baseline 
examination of all persons aged 45 years and over living in the study district that had not been examined already (i.e., 
mainly comprising those aged 45–60 years). RS-III-2 refers to the first re-examination of this third cohort. Examination 
RS-I-4 and RS-II-2 were conducted as one project and feature an identical research program. Similarly, examinations 
RS-I-5, RS-II-3, and RS-III-2 share the same program items. Also, examinations RS-I-6 and RS-II-4 are conducted as one 
project. RS-IV-1 refers to the baseline visit of a new cohort, to be established in February 2016. 
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Table 1 General outline of this thesis and the waves of the Rotterdam Study included in the analysis 
presented in each chapter
Chapter Exposure Exposure 
assessment
Outcome Outcome 
assess-
ment
Systematic Review/
Original Data 
Analysis
2.1 Non-communicable 
diseases
NA Health care 
spending and 
national income
NA Systematic Review
2.2 Non-communicable 
diseases
NA Macro-economic 
productivity
NA Systematic Review
3.1 Dietary 
polyunsaturated fatty 
acids 
RSI-I* Inflammation 
(C-reactive protein)
RSI-I and 
RSI-3
Original data analysis 
(Rotterdam Study)
3.2 Dietary fat 
composition 
RSI-1 Body fat (total fat, 
android fat, gynoid 
fat and android/
gynoid fat ratio)
RSI-4 Original data analysis 
(Rotterdam Study 
and Calcium Intake 
Fracture Outcome 
Study)
3.3 Plasma vitamin D 
levels
RSI-3 Body fat (total fat, 
android fat, gynoid 
fat and android/
gynoid fat ratio)
RSI-4 Original data analysis 
(Rotterdam Study)
3.4 Plasma gamma-
glutamyltransferase 
levels
RSI-3 Body fat (total fat, 
android fat, gynoid 
fat and android/
gynoid fat ratio)
RSI-4 Original data analysis 
(Rotterdam Study)
3.5 Plasma gamma-
glutamyltransferase 
levels
RSI-3, 
RSII-1 and 
RSIII-1
Glycemic traits and 
type 2 diabetes
Until 
January 1st 
2012
Original data analysis 
(Rotterdam Study)
4.1 Endogenous sex 
hormones (estradiol, 
sex hormone-binding 
globulin, testosterone)
RSI-3 and 
RSII-1
Incident type 2 
diabetes
Until 
January 1st 
2012
Original data analysis 
(Rotterdam Study) 
and Systematic 
Review 
4.2 Estrogen receptor beta NA Intermediate 
cardiovascular 
risk factors and 
cardiovascular 
outcomes
NA Systematic Review
4.3 Vasomotor symptoms NA Intermediate 
cardiovascular risk 
factors
NA Systematic Review
4.4 Menopausal symptoms NA Cardiovascular 
outcomes 
NA Systematic Review
4.5 Age of menopause NA Intermediate 
cardiovascular 
risk factors and 
cardiovascular 
outcomes
NA Systematic Review
4.6 Natural and plant-
based therapies
NA Menopausal 
Symptoms 
NA Systematic Review
*Roman numeral for the cohort and Arabic numeral for the visit. NA, non-applicable; RS, Rotterdam Study. RS-I-1 refers 
to the baseline examination of the original cohort (pilot phase 07/1989–12/1989; cohort recruitment 01/1990–09/1993). 
RS-I-2, RS-I-3, RS-I-4, RS-I-5, and RS-I-6 refer to re-examinations of the original cohort members. RS-II-1 and RS-III-1 
refers to the extensions of the cohort. 
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Next, during their visit to the research center, they underwent a standardized interview with a 
trained dietician based on the food and drink checklist, using a computerized validated 170-item 
semi-quantitative FFQ, taking into account seasonal variations in fruit, vegetable and fish intake. 
Nutrient intakes were calculated as the frequency of intake multiplied by the nutrient composition 
of the specified portion size. Nutrient estimates in the first visit of the first cohort (RSI-1) were based 
on the Dutch Food Composition Table of 1993 105. A validation study including 80 participants of 
the Rotterdam Study, showed that the FFQ is a suitable instrument for ranking individuals by 
fat and fiber intakes 106. Except the first visit of the first cohort, all blood samples were drawn 
in the morning (≤ 11:00 am) and were taken after the participants had fasted for 8 hours. Total 
body composition was assessed by DXA using total body-fat beam densitometer (GE Lunar 
Corp, Madison, WI, USA for RS and Hologic Corp, Waltham, MA, USA for CAIFOS). Table 1 
summarizes the rounds of the Rotterdam Study that were used in the studies included in this thesis.
Outline of This Thesis 
The objectives are addressed in several studies presented in this thesis (Table 1). Chapter 2 of this 
thesis describes the systematic reviews of the literature on economic impact of NCDs. In chapter 
3.1 and 3.2 we studied the association of dietary fat intake with inflammation and body composition 
whereas in chapter 3.3, we examined whether vitamin D plays a role in body fat. We studied 
the association between gamma-glutammyltransaferase (GGT) within normal range and regional 
body fat distribution and whether levels of GGT could be causally associated with glycemic traits, 
prediabetes and T2D in Chapter 3.4 and 3.5, respectively. Chapter 4 focuses on cardiometabolic 
health in women. In chapter 4.1 we present an original data analysis and comprehensive review 
on the association of endogenous sex hormones levels with the risk of T2D in women. Chapters 
4.2 to 4.5 provide comprehensive reviews and meta-analysis on the role of estrogen receptor 
beta in the female cardiovascular system, and the association of menopausal symptoms and age 
of menopause with intermediate CVD risk factors and cardiometabolic outcomes.  Chapter 4.6 
presents a systematic review and meta-analysis on the impact of plant-based and natural therapies 
on menopausal symptoms. Lastly, chapter 5 provides an overview of the main findings and 
conclusions from these studies and discusses implications and suggestions for future research. 
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Economic Impact of Non-Communicable Diseases
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ABSTRACT
IMPORTANCE: The impact of non-communicable diseases (NCDs) in populations extends 
beyond ill-health and mortality with large financial consequences.
OBJECTIVE: To systematically review and meta-analyze studies evaluating the impact of NCDs 
(including coronary heart disease, stroke, type 2 diabetes mellitus, cancer (lung, colon, cervical and 
breast), chronic obstructive pulmonary disease (COPD) and chronic kidney disease) at the macro-
economic level: healthcare spending and national income.
DATA SOURCES: Medical databases (Medline, Embase and Google Scholar) up to January 20th 
2014. For further identification of suitable studies, we searched reference lists of included studies 
and contacted experts in the field.
STUDY SELECTION: We included randomized controlled trials, systematic reviews, cohorts, 
case-control, cross-sectional, modeling and ecological studies carried out in adults assessing the 
economic consequences of NCDs on healthcare spending and national income without language 
restrictions. All abstracts and full text selection was done by two independent reviewers. Any 
disagreements were resolved through consensus or consultation of a third reviewer. 
DATA EXTRACTION: Data were extracted by two independent reviewers using a pre-designed 
data collection form.  
MAIN OUTCOME AND MEASURES: Studies evaluating the impact of at least one of the 
selected NCDs on at least one of the following outcome measures: healthcare expenditure, national 
2.1 The Global Impact of Non-Communicable Diseases on Healthcare Spending and National Income: a Systematic Review
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income, hospital spending, gross domestic product (GDP), gross national product (GNP), net 
national income (NNI), adjusted national income (NNI), total costs, direct costs, indirect costs, 
inpatient costs, outpatient costs, per capita healthcare spending, aggregate economic outcome, 
capital loss in production levels in a country, economic growth, GDP per capita (per capita income), 
percentage change in GDP, intensive growth, extensive growth, employment, direct governmental 
expenditure and non-governmental expenditure.
RESULTS: From 4364 references, 153 studies met our inclusion criteria. Most of the studies 
were focused on healthcare related costs of NCDs. 30 studies reported the economic impact of 
NCDs on healthcare budgets and 13 on national income. Healthcare expenditure for cardiovascular 
disease (12-16.5%) was the highest; other NCDs ranged between 0.7%-7.4%. NCD-related health 
costs vary across the countries, regions, and according to type of NCD. Additionally, there is an 
increase in costs with increased severity and years lived with the disease. Low- and middle-income 
countries were the focus of just 16 papers, which suggests an information shortage concerning the 
true economic burden of NCDs in these countries. 
CONCLUSIONS AND RELEVANCE: NCDs pose a significant financial burden on healthcare 
budgets and nations’ welfare, which is likely to increase over time. However further work is 
required to standardize more consistently the methods available to assess the economic impact of 
NCDs and to involve (hitherto under-addressed) LMI populations across the globe.
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INTRODUCTION
Due to lifestyle and environmental change, healthcare improvements and improved potential 
to survive until old age, non-communicable diseases (NCDs) (including coronary heart disease 
(CHD), stroke, chronic obstructive pulmonary disease (COPD), cancer, type 2 diabetes mellitus 
(DM) and chronic kidney disease (CKD) are currently the leading cause of adult death and disability 
worldwide1. The global burden of NCDs is expected to rise further as a result of an increasing 
global population and demographic shifts, especially increases in the older population. Indeed, the 
global population above the age of 60, the age group most affected by NCDs, is expected to double 
between 2000 and 20502. 
Most NCDs are chronic conditions that require expensive treatment regimens and prolonged 
individual care by increasingly specialized healthcare services. NCDs also detrimentally impact on 
national income, socio-economic development and economic growth3 through productivity losses, 
prolonged disability and increases in health and social care expenditure. Historically, high-income 
countries (HIC) experience the greatest economic consequences of NCDs. Yet, as a result of economic 
growth, epidemiological transition, ageing populations and healthcare system development, many 
low- and middle-income countries (LMIC) are now also experiencing a greater impact of NCDs. 
LMICs also suffer a substantial burden of NCD-related risk factors such as tobacco use, heavy 
alcohol consumption or unhealthy diet among their impoverished population groups.4 However, 
policy programs that respond to the increasing burden of NCDs in many LMIC remain limited. 5 
To date, however, little work has been done to systematically appraise the current evidence on the 
economic burden of NCDs globally. Exploring the studies that investigate the impact of NCDs on 
healthcare expenditure and national income can help shape future healthcare plans and strategies by 
better informing policy makers and healthcare planners about the emerging costs of NCDs.
We aimed to systematically review the literature evaluating the financial burden of six major NCDs 
(CHD, stroke, cancer (lung, colon, cervical and breast), COPD, DM and CKD) at the macro-
economic level in order to quantify: (i,) the costs related to NCDs (direct, indirect, aggregate, over 
time and by disease severity); (ii) the per capita healthcare expenditure on NCDs; and (iii) national 
economic loss due to NCDs; and (iv) the overall aggregate economic impact of the NCDs on 
national income and healthcare spending. 
METHODS
Search strategy and inclusion criteria
We conducted a systematic search of electronic medical databases (Medline, Embase and Google 
Scholar) until November 6th 2014 (date last searched) to retrieve scientific articles assessing the 
consequences of NCDs at the macro-economic level specifically the impact on national income 
and healthcare expenditure (including: health expenditure, national income, hospital spending, 
gross domestic product (GDP), gross national product (GNP), net national income (NNI), adjusted 
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national income (NNI), healthcare costs, direct costs, indirect costs, per capita healthcare spending, 
medical costs, non-medical costs, aggregate economic outcome, capital loss in production levels 
in a country, economic growth, percent rate of increase in GDP, GDP per capita (per capita 
income), intensive growth, extensive growth, employment, direct governmental expenditure and 
non-governmental expenditure) (see Appendix 1 in the Supplement). The step-wise inclusion 
and exclusion procedure outlined in Figure 1 was followed. Eligible study designs included 
randomized controlled trials (RCTs), cohort, case-control, cross-sectional, systematic reviews, 
ecological studies and modeling studies. We included studies evaluating the impact of at least 
one NCDs selected (CHD, stroke, COPD, type 2 diabetes mellitus, cancer (lung, colon, breast, 
and cervical), and CKD) on at least one measure of the impact on national income and healthcare 
expenditure (as specified above). Only studies carried out in adults (>18 years old) were included 
and we specified no language or date restrictions. 
Study selection
Two independent reviewers screened the abstracts retrieved by the search strategy and selected 
eligible studies. Any disagreements between the two reviewers were resolved through consensus or 
consultation of a third independent reviewer. The references of the retrieved studies were scanned 
to identify additional relevant publications that were missed by the initial search strategy. Authors 
of the included studies were contacted in order to identify additional publications.
Data extraction
A predesigned data collection form was prepared to extract the relevant information from the 
included full texts, including study design, WHO region, characteristics of the study participants, 
NCDs details and economic measures reported. 
Quality evaluation
We used the Newcastle- Ottawa Scale (NOS) to evaluate the quality of cross-sectional, case-control 
and cohort studies included in this review. 6 NOS scale assesses the quality of the articles in three 
domains of selection, comparability and exposure. Within the selection category, four items are 
assessed and a maximum of one star can be awarded to each item. Two stars can be awarded to the 
one item within the comparability category. Finally, one star can be awarded to each of the four 
items in the exposure category. A score will be made by adding up the number of stars and thus, 
NOS scale can have a maximum of nine stars in total. We used this scale for quality assessment 
of case-control and cohort studies. For cross-sectional and descriptive studies we used an adapted 
version of NOS scale (See Appendix 2 in the Supplement). No quality score was applied to the 
modeling studies.
Statistical methods
Heterogeneity permitting, we sought to pool the results using a random effects meta-analysis model. 
If pooled, results were expressed as the pooled estimate and the corresponding 95% confidence 
intervals. All costs presented are converted in USD 2013.
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Figure 1. Flowchart of Studies for the Global Impact of Non-communicable Diseases on Healthcare Spending and National 
Income
  
Records identified through 
database searching 
(n = 3535 ) 
Additional records identified 
through other sources 
(n = 484 ) 
Records after duplicates removed 
(n =4364) 
Records screened 
(n =4364) 
Records excluded based 
on title and abstract 
(n =4165) 
Records given full text 
detailed assessment 
(n = 199) 
Full-text articles excluded 
(n =  46) 
 Review (n=3) 
 No or unclear NCD (n=9) 
 Without detail of healthcare 
expenditures or national 
income (n=11) 
 No full text available (n=17) 
 Data extraction unfeasible 
(n=6) 
 
Studies included  
(n =153) 
RESULTS
In total, we identified 4364 potentially relevant citations (Figure 1). Based on the title and 
abstracts, full texts of 199 articles were selected for detailed evaluation. Of those, 153 articles met 
our eligibility criteria and were therefore included in the analysis (Table 1). 
Figure 1. Flowchart of Studies for the Global Impact of Non-communicable Diseases on Healthcare 
Spending and National Income
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General characteristics of the included studies
A wide geographical distribution was observed in the reviewed studies. The majority of the studies 
(n=68) were from the American WHO region (mainly USA and Canada), 57 studies were from the 
European, 19 from the Western Pacific, two from the South-East Asian, three and from the African 
WHO region  and the Eastern Mediterranean respectively, whereas two studies were conducted 
in multiple regions. The majority (n=137) of the reviewed studies were conducted in HIC, ten in 
upper middle-income countries, and five were conducted in low-income countries whereas one 
study included countries from the three income categories. Therefore, the GDP variation across 
the studies reviewed was narrow. The studies identified were mainly observational studies, having 
a retrospective or longitudinal design; 22 studies were modeling studies and only one study was 
an RCT. Medical records were the most frequently used method to select participants. In many 
cases, these medical records were linked to socio-economic databases to extract employment data. 
Adjustment for age, gender, ethnicity, co-morbidities/existing conditions, and geographic regions 
was usually applied. 
Of the 153 studies included in this review, 40 studies focused on the economic impact of CHD and 
stroke (cardiovascular disease), 32 on COPD, five on CKD, 24 on DM, 45 on cancer and 7 studies 
provide evidence on economic impact of a combination of NCDs (Table 1). Most of the studies 
investigated the economic impact of NCDs among people aged 45 years and over.
Table 1. General Characteristics of the Studies Included in this Review 
Lead Author Period of 
Surveillance
Location WHO 
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Abudagga, 
A; et al.117             
2013
2011-2012 USA AMR Cohort 17382 Both COPD 7
Ademi, Z; et 
al.11 2013
2004-2006 Australia WPR Cohort 2873 Both CVD 8
Aljunid, S; et 
al.77       2010
2007-2008 Malaysia WPR Modeling 444 Female Cervical 
cancer
NA
Anis, AH; et 
al.7           2000
1994-1995 Canada AMR Modeling 352 Both COPD, 
CVD
NA
Baker, MS; et 
al.15    1991
1974-1981 USA AMR Longitudinal 125831 Both Lung & 
breast cancer
6
Bakerly, N; et 
al.118  2009
2003-2004 UK EUR Cohort 225 Both COPD 4
Ballesta, M; et 
al.119   2006
1999 Spain EUR Descriptive 
observa-
tional
517 Both DM 5
Baumeister, 
SE; et al.21 
2009
1994-2005 Germany EUR Combined 4856 Both CKD 6
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Beaulieu, N; et 
al.87 2009
2009 Worldwide NA Modeling NA Both Lung, 
colorectal, 
cervical & 
breast cancer
NA
Biorac, N; et 
al.41    2009
2007 Serbia EUR Cohort 99 Both DM 2
Blanchette, 
CM; et al.50  
2008
2004 USA AMR Cohort 6243 Both COPD 7
Blanchette, 
CM; et al.120                   
2012
1987-
2007
USA AMR Cross-sectional 644 Both COPD 7
Bonastre, 
J; et al.121           
2012
1998-
2008
France EUR Cohort 290 Female Breast cancer 8
Boncz, I; et 
al.74    2010
Hungary EUR Survey NA Both Colorectal, 
cervical & 
breast cancer
5
Bottacchi, E; et 
al.28       2012
2004-
2007
Italy EUR Cost of illness 
(cohort)
800 Both Stroke 6
Bouvier, V; et 
al.122    2003
1997-
1998
France EUR Survey 142 Both Colorectal 
cancer
6
Broekx, S; et 
al.36    2011
1997-
2004
Belgium EUR Cost of illness 
(cross sectional)
20439 Female Breast cancer 3
Brown, ML; et 
al.123   1999
1990-
1994
USA AMR Modeling NA Both Colorectal 
cancer
NA
Caro, JJ; et al.124 
2006
1990-
1995
France EUR Cohort 18704 Both Stroke 6
Chang, S; et 
al.125     2004
1998-
2000
USA AMR Retrospective 
cohort
2858 Both Lung & 
colorectal 
cancer
9
Chirikos, 
TN; et al.126                
2008
1991-
1999
USA AMR Cohort 80421 Both Lung cancer 7
Chittleboroug, 
CR; et al.79                        
2009
1997-
2002
Australia WPR Cross-sectional 2352 Both COPD 7
Chodick, G; et 
al.46    2005
1999-
2001
Israel EUR Cohort 24632 Both DM 7
Chouaid, 
C; et al.127           
2004
1998-
1999
France EUR Modeling 428 Both Lung cancer NA
Christensen, 
MC; 
Munro, V;128              
2008
2004-
2005
UK EUR Cohort 1016 Both Stroke 5
34
Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Claesson, L; et 
al.47 
2000
1993-
1994
Sweden EUR RCT 249 Both Stroke 8
Clerc, L; et al.29   
2008
2004-
2005
France EUR Cohort 384 Both Colorectal 
cancer
4
Cocquyt, V; et 
al.14    2003
1997-
1998
Belgium EUR Modeling 118 Female Breast cancer NA
Costantino, 
ME; et al.129 
2014
2008-
2009
USA AMR Retrospective 
Cohort
389550 Both DM 6
Corrao, G; et 
al.130 2014
2011 Italy EUR Cohort 26949 Both Heart Failure 7
Dahlberg, L; et 
al.131  2009
2005-
2006
Sweden EUR Cohort 53 Female Breast cancer 6
Dalal, AA; et 
al.45  2011
2006-
2009
USA AMR Cohort 42166 Both COPD 4
Dalal, AA; et 
al.132           2011
2003-
2008
USA AMR Cohort 4594 Both COPD 4
Darkow, T; et 
al.34  2007
2001-
2004
USA AMR Cohort 1349 Both COPD 6
Davari, M; et 
al.75    2012
2005-
2010
Iran EMR Cross-sectional 435 Both Colorectal 
cancer
2
Degli Esposti, 
L; et al.133 
2013
2009 Italy EUR Retrospective 21586 Both DM 5
Dewey, HM; et 
al.85      2001
1997 Australia WPR Cost of illness 275 Both Stroke 4
Dewey, HM; et 
al.72  2003
1997 Australia WPR Cost of illness NA NA Stroke 4
Di Salvo, 
TG; et al.134        
1996
1991-
1992
USA AMR Cohort 292 Both AMI 4
Domingo, 
C; et al.135                
2006
NA Spain EUR Cohort 124 Both COPD 4
D’Souza, AO; 
et al.136 2014
2003-
2007
USA AMR Retrospective 40884 Both COPD 7
Elrayah-
Eliadarous, 
H; et al.137                    
2010
2005 Sudan EMR Retrospective 822 NA DM 3
Fernandez De 
Bobadilla, J; et 
al.138     2008
2006 Spain EUR Cohort 2858 Both Stroke 4
Ferrandinda, 
G; et al.139                    
2010
2000-
2007
Italy EUR Cohort 351 Female Cervical 
cancer
6
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Fireman, BH; et 
al.61  1997
1987-
1991
USA AMR Survey 21977 Both Lung, 
colorectal & 
breast cancer
8
Fletcher, MJ; et 
al.14  2009
2009 Cross-
country
NA Cross-sectional 2426 Both COPD 1
Gil, A; et al.76            
2007
1999-
2002
Spain EUR Retrospective 16604 Female Cervical 
cancer
6
Gruber, 
EV; et al.141           
2012
2009 Germany EUR Modeling 14000000 Female Breast cancer NA
Havlovicova, 
M; et al.142 
2001
1997               Czech 
Republic
EUR Cohort 224 Both Stroke 6
Hilleman, 
DE; et al.51                 
2000
1993-
1998
USA AMR Cohort 
(phamarco-
economic 
analysis)
413 Both COPD 4
Hodgson, TA; 
Cohen, AJ70            
1999
1995 USA AMR Survey NA NA CVD, CHD NA
Hogan, P; et 
al.81     2003
2002 USA AMR Survey/
modeling
NA Both DM NA
Hu, S; et al.143      
2013
2010-
2011
China WPR Cross-sectional 63 Both Stroke 1
Hutchinson, 
A; et al.52                 
2010
2001-
2002
Australia WPR Cohort 80 Both COPD 6
Jansson, 
SA; et al.49                
2002
1998-
1999
Sweden EUR Cohort 212 Both COPD 6
Jaworski, R; et 
al.9       2012
2005 Poland EUR Cohort 2593 Both CAD 3
Jensen, MB; et 
al.53  2013
2004-
2006
Denmark EUR Cohort 546 Both COPD 7
Jonsson, B; et 
al.68      2002
1999 Europe EUR Retrospective 6996 Both DM 3
Kabadi, GS; et 
al.144 2014
2005-
2006
Tanzanie AFR Prospective 16 Both Stroke 6
Kang, HY; et 
al.145   2011 
2002-
2004
Korea SEAR Modeling NA Both Stroke NA
Kang, S; et al.16   
2012
2005-
2008
Australia WPR Cohort 210 Both Lung cancer 6
Kangas, T; et 
al.146    1996
1987-
1989
Finland EUR Cross-sectional NA NA DM 4
Kerrigan, M; et 
al.147   2005
1996-
1998
USA AMR Case-control 346 Both Colorectal 
cancer
9
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Kim, TH; et 
al.148    2012
2005 Korea WPR Cohort 3125 Both DM 3
Kirigia, JM; et 
al.80   2009
2000 Africa AFR Cost of illness NA Both DM NA
Klever-
Deichert, 
G; et al.84                           
1999
1996 Germany EUR Modeling NA Both CVD NA
Kolominsky-
Rabas, PL; 
et al.149                    
2006
1994-
2003
Germany EUR Cost of illness 2458 Both Stroke 5
Kumar, A; et 
al.23            2008
2005-
2005
India SEAR Cross-sectional 819 Both DM 2
Kuwabara, 
H; et al.150                
2009
2003 Japan WPR Modeling 3490 Both Breast cancer NA
Laliberte, 
F; et al.151           
2009
2000-
2006
USA AMR Retrospective 91069 Both CKD 7
Lamerato, L; 
et al.152 2006
1996-
2002
USA AMR Cohort 1616 Female Breast cancer 7
Lamping, 
DL; et al.22                 
2000
1995-
1996
UK EUR Cohort 221 Both CKD 6
Lang, K; et 
al.63 2009
1996-
2002
USA AMR Cohort 56838 Both Colorectal 
cancer
8
Le, C; et al.27           
2013
2010-
2011
China WPR Cross-sectional 
survey
9396 Both DM 5
Leal, J; et al.64         
2006
2003 Europe EUR Cost of illness NA Both CVD, CHD 4
Lee, H; et al.153     
2002
1999-
2000
Canada AMR Prospective 166 Both CKD 4
Lee, HC; et al.12  
2013
1996-
2003
Taiwan WPR Cohort 2368 Both Stroke 6
Legorreta, AP; 
et al.57  1996
1989 USA AMR Longitudinal 205 Female Breast cancer 5
Leigh, JP; et 
al.154   2003
1999 USA AMR Modeling NA Both Colorectal 
cancer, CVD, 
CKD
NA
Likosky, 
DS; et al.42                
2013
1998-
1999/
/2008
USA AMR Cross-sectional 317043 Both AMI 5
Lokke, A; et 
al.39 2014
1998-
2010
Denmark EUR Case-Control 263622 Both COPD 7
Lopez-Batista, 
J; et al.31  2012
2004 Spain EUR Cross-sectional 448 Both Stroke 5
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Lou,P; et al.155     
2012
2008-
2009
China WPR Cross-sectional 8217 Both COPD 2
Low, JJ; et al.18     
2012
2008-
2033
Singapore WPR Modeling NA Female Cervical 
cancer
NA
Luo, Z; et al.58 
2009
1996-
2000
USA AMR Case-control 17945 Both Colon cancer 6
Macafee, DA; 
et al.17 2009
1981-
2002
UK EUR Retrospective 227 Both Colorectal 
cancer
4
Mandelblatt, JS; 
et al.156 2006
2000 USA AMR Cohort 418 Female COPD 7
Mapel, DW; et 
al.157    2000
1997 USA AMR Case-control 1522 Both COPD 8
Martin, S; et 
al.59   2007
1995-
2003
Germany EUR Cohort 3142 Both DM 2
Marton, P; et 
al.158           2006
2001 USA AMR Retrospec-
tive-Cohort
49510 Both COPD 8
Meen, P; et 
al.159   2012
2006-
2009
Germany EUR Cohort 2255 Both COPD 5
Menzin, J; et 
al.   2008
2001-
2002
USA AMR Cohort 16321 Both IHD 5
Menzin, J; et 
al.160           2008
2004 USA AMR Cohort 8370 Both COPD 5
Miravitlles, 
M; et al.161                 
2001
1996-
1997
Spain EUR Cohort 2414 Both COPD 6
Miravitlles, 
M; et al.54                 
2003
1997-
1998
Spain EUR Cohort 1510 Both COPD 7
Mittman, N; et 
al.90   2012
2005-
2009
Canada AMR Cohort 232 Both Stroke 4
Mohd Nordin, 
NA; et al.48                        
2012
2005-
2009
Malaysia WPR Cross-sectional 813 Both Stroke 6
Morsanutto, A; 
et al.162  2006
2001-
2002
Italy EUR Retrospective 
longitudinal
299 Both DM 3
Nakamura, 
K; et al.163                
2008
1990-
2001
Japan WPR Cohort 4535 Both DM 4
Nichols, 
GA; et al.69                
2010
2000-
2008
USA AMR Survey 12278 Both CVD NA
Nielsen, R; et 
al.19    2009
2003-
2004
Iceland/
Norway
EUR Survey 1415 Both COPD 6
Nielsen, R; et 
al.164           2011
2005-
2006
Norway EUR Cohort 286 Both COPD 6
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Nishimura, 
S; Zaher, C;33            
2004
1990-
2002
Japan WPR Modeling 501 Both COPD NA
Norlund, A; et 
al.40   2001
1992-
1993
Sweden EUR Cross-sectional 1677 Both DM 4
O’Brien, 
BD; et al.165                
2001
1989-
1994
Canada AMR Survey 593 Both Colorectal 
cancer
6
Odden, MC; et 
al.71  2011
NA USA AMR Modeling NA Both CHD NA
Oglesby, 
AK; et al.166                 
2006
1989-
2003
USA AMR Cohort 10780 Both DM 6
Ohinmaa, A; et 
al.65  2006
2000-
2001
Canada AMR Survey 2133413 Both CVD, COPD, 
DM
4
Oliva, J; et al.67  
2004
2002 Spain EUR Cost of illness 2010365 Both DM NA
Perera, PN; et 
al.167           2012
2006 USA AMR Retrospective 1254703 Both COPD 6
Petersen, 
M; Amer 
Diabet, A89                
2008
2007 USA AMR Survey/
Modeling
301736 Both DM NA
Ramsey, SD; et 
al.168 2003
1984-
1994
USA AMR Survey 68145 Both Colorectal 
cancer
6
Rao, S; et al.169      
2004
1997-
1999
USA AMR Cohort 397 Female Breast cancer 6
Ray, GT; et 
al.25     2000
1995-
1996
USA AMR Retrospective 2076303 NA Lung, colon 
& breast 
cancer, CVD, 
IHD, COPD, 
DM
7
Ray, NF; et 
al.92   1998
1989-
1995
USA AMR Survey/
Modeling
NA Both DM NA
Riley, GF; et 
al.62    1995
1984-
1990
USA AMR Retrospective 287013 Both Lung, breast 
& colorectal 
cancer
7
Ringborg, 
A; et al.170               
2008
2000-
2004
Sweden EUR Cohort 37756 Both DM 4
Rutten-van 
Molken, 
MPMH; et al.66     
1999
1993 Netherlands EUR Modeling NA Both COPD NA
Sasser, AC; et 
al.37     2005
1998-
2000
USA AMR Cohort 2265 Female Breast 
cancer, CVD
8
Schneider, M; 
et al.24     2009
2001-
2005
USA AMR Survey 1649574 Both COPD, CKD, 
cancer, Heart 
failure, DM
NA
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Seal, BS; et al.44 
2013
2005-
2009
USA AMR Longitudinal 5160 Both Colon Cancer 7
Selke, B; et al.73 
2003
1999 France EUR Cost of illness 69046 Both Colorectal 
cancer
6
Sharafk-haneh, 
A; et al.171             
2010
1997-
2004
USA AMR Cohort 59906 Both COPD 8
Simoni-Wastile, 
L; et al.172                        
2009
2003-
2005
USA AMR Cohort 3037 Both COPD 5
Simpson, 
AN; et al.173                
2013
2004-
2005
USA AMR Case-control 8928 Both Stroke 7
Sloss, EM;
 et al.174        
2004
1995-
1998
USA AMR Cohort 3149 Both Stroke 4
Smith, DH; et 
al.175           2004
1996-
2001
USA AMR Cohort 13796 Both CKD 8
Soekhlal, 
RR; et al.176                
2013
2008-
2012
Netherlands EUR Retrospective 25657 Both AMI 6
Song, X; et 
al.13       2011
2004-
2009
USA AMR Cohort 6675 Both Colorectal 
cancer
6
Sorensen, SV; 
et al.30     2012
2000-
2007
USA AMR Modeling 49674 Both Breast cancer NA
Spieler, JF; et 
al.177           2004
1997 France EUR Cohort 435 Both Stroke 6
Taplin, SH; et 
al.178       1995
1990-
1991
USA AMR Survey 6107 Both Colorectal & 
breast cancer
5
Taylor, TN; et 
al.91  1996
1990-
1993
USA AMR Modeling NA NA Stroke NA
Tiemann, O; et 
al.179  2008
2005 Europe EUR Cross-sectional 3942 Male AMI 8
Torres, US; et 
al.82 
2010
1996-
2008
Brazil AMR Survey 297108 Both Colorectal 
Cancer
6
Toure, K; et 
al.180      2005
1997 Senegal AFR Cross-sectional 383 Both Stroke NA
Trogdon, JG; et 
al.181 2007
2000-
2003
USA AMR Cohort 125052 Both Stroke 3
Tuck, J; et al.182   
1989
1985-
1986
UK EUR Cohort 85 NA Colorectal 
cancer
NA
Tunceli, 
O; et al.183           
2007
1999-
2002
USA AMR Cohort 512468 Both DM 8
Unroe, KT; et 
al.8     2011
2000-
2007
USA AMR Cohort 229543 Both Heart failure 7
40
Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period 
of 
Surveil-
lance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported 
NCDs
Quality 
score*
Van Boven, 
JFM; et al.88            
2013
2009 Netherlands EUR Cross-sectional 94158 Both COPD 6
Wan, Y; et al.32     
2013
2005-
2009
USA AMR Cohort 278 Female Breast cancer 7
Ward, A; et al.10   
2005
1994-
1998
Germany EUR Prospective 491 Both Stroke 5
Warren, JL; et 
al.38   2008
1991-
2002
USA AMR Survey 306709 Both Lung, 
colorectal & 
breast cancer
4
Winter, Y; et 
al.184     2008
2003 Germany EUR Cohort 76 Both Stroke 2
Wright, GE; et 
al.185      2007
1992-
1996
USA AMR Cohort 6108 Both Colorectal 
cancer
8
Yabroff, KR; et 
al.78  2008
1999-
2003
USA AMR Survey 2342558 Both Lung, 
colorectal, 
cervical & 
breast  cancer 
6
Yabroff, KR; et 
al.186  2009
1998-
2002
USA AMR Cohort 6377 Both Colorectal 
cancer
5
Yang, SC; et 
al.187           2013
1998–
2010
Taiwan WPR Cohort 66535 Both Lung cancer 6
Yoon, J; et al.83     
2011
2000-
2008
USA AMR Cohort 4892300 Both CVD, CKD, 
COPD, 
Stroke
4
Zheng, H; et 
al.86      2010
2004 Australia WPR Modeling NA Both CHD NA
Zhuo, X; et 
al.188     2013
2009-
2010
United 
Kingdom
EUR Modeling NA Both DM NA
Zorowitz, R; et 
al.189   2009
2003-
2006
USA AMR Cohort 3438 Both Stroke 6
NCD: Non-communicable diseases; NA: Not applicable; RCT: Randomized Control Trials; CVD Cardiovascular 
disease; CHD: Coronary Heart Disease; CAD: Coronary Artery Disease; IHD: Ischemic Heart Diseases; 
AMI: Acute myocardial infarction; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic  Kidney 
Disease; DM: Diabetes mellitus; AFR: African Region; AMR: Region of the Americas; EMR: Eastern 
Mediterranean Region; EUR: European Region; SEAR: South-East Asia Region; WPR: Western Pacific Region. 
*No quality score was applied to the modeling studies
Per patient global healthcare costs and non-healthcare costs of NCDs
Reported healthcare costs associated with NCDs varied across countries and regions, and across the 
type of NCDs. Reported annual direct costs of NCDs were the highest in the Americas, followed by 
European and Western Pacific regions; in the region of the Americas, the minimum and maximum 
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mean reported annual total direct costs for CVD were 6668 USD7 and 81096 USD8, respectively, 
whereas the average annual direct costs for CVD varied from 16439 USD to 69440 USD10, and 
from 3862 USD11 to 5693 USD12 for the European  and Western Pacific regions, respectively 
(Supplementary Table S1). A detailed description on the variation of any type of costs of NCDs 
per world regions is shown in Supplementary Table S1. 
(i) Direct costs 
In 107 studies, mean annual total direct costs and mean directly attributable costs per NCDs patient 
(Table 2a) were estimated. Worldwide, of all the selected NCDs, cancer and CVD (with estimated 
costs up to 197772 USD13 and 81096 USD8, respectively) had the highest reported mean annual 
total direct costs, whereas DM had the lowest. Average CVD-related direct costs ranged from 1643 
USD9 in Poland to 81096 USD8 in USA, with CHD having the lowest reported estimates and heart 
failure imposing the highest costs. Among cancers, the estimated mean annual total direct costs 
varied: from 4595 USD14 to 82794 USD15 for breast cancer; 4964 USD16 to 161048 USD15 for lung 
cancer and 220817 USD to 197722 USD17 for colorectal cancer. Only one study from Singapore 
reported annual total direct costs for cervical cancer with an average estimate of 8049 USD18. 
COPD annual direct costs varied substantially, with Norway reporting the lowest direct costs (431 
USD19) and USA reporting the highest (34101 USD20). The lowest direct costs for CKD were 
observed in Germany with an average estimate of 5439 USD21, whereas mean direct costs for CKD 
in USA were estimated to be up to 71824 USD22. DM average annual direct costs varied from 162 
USD 23 in India to 15611 USD in USA24. 
Direct attributable costs for the NCDs were available from only 18 studies. The highest direct 
attributable costs were observed for cancer (up to 190032 USD13), followed by CKD (up to 
33585 USD25), COPD (up to 22183 USD24), CVD (up to 21152 USD24) and finally, DM (up to 
12246 USD24) with the lowest average estimates. Some articles reported inpatient and outpatient 
costs for NCDs (Supplemental Table S2). These demonstrate that inpatient costs are the main 
source of direct costs for NCDs. Inpatient costs accounted for 47%-58% of total direct costs of 
COPD26 and 63% of total direct costs for DM27. Hospital costs represent the main driver of stroke 
expenditure, accounting for 90%28 of total direct costs. Hospitalization charges represented the 
greatest economic burden (55%)29 for the management of colorectal cancer, followed by medical 
purchases (24%) and outpatient care (18%). 
(ii) Indirect costs
18 studies estimated mean annual indirect costs (Table 2b). Mean annual estimated indirect costs 
for NCDs patients were highest for cancer and DM, with estimates up to 24740 USD30 and 23418 
USD31, respectively. Mean annual indirect costs for breast cancer varied extensively, from 2109 
USD32 to 24740 USD30. The lowest indirect cost for COPD was reported in Japan, with an average 
estimate of 326 USD33, and highest in USA (3393 USD34). Mean DM indirect annual costs were 
estimated at 104 USD in Serbia35 compared to 7797 USD in China27. No study, however, reported 
annual indirect costs of colorectal cancer, lung cancer, cervical cancer or CKD.
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs
Study Type of 
Outcome
Outcome 
Specified 
as
Assessment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Ademi, Z; 
et al. 
2013
Direct costs Patient/
year
Mean 3862 5508 CVD 2006 Australia
Anis, AH; 
et al 
2000
Direct costs Patient/
year
Mean 6668 391 CVD 1995 Canada
Di salvo, TG; 
et al. 
1996
Direct costs Patient/
year
Mean 13907 NA CVD 1992 USA
Nichols, GA; 
et al. 
2010
Direct costs Patient/
year
Mean 20512 42247 CVD 2008 USA
Sasser, AC; 
et al. 
2005
Direct costs Patient/
year
Mean 16313 NA CVD 2000 USA
Corrao, G; et 
al. 2014
Direct costs Patient/
year
Mean 15328 NA HF 2011 Italy
Ray, GT; 
et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 10647 NA HF 1996 USA
Ray, GT; 
et al. 
2000
Direct costs Patient/
year
Mean 27015 NA HF 1996 USA
Schneider, 
KM; et al. 
2009
Direct 
attributable costs
Patient/
year
Mean 21152 NA HF 2005 USA
Schneider, 
KM; et al. 
2009
Direct costs Patient/
year
Mean 24517 NA HF 2005 USA
Unroe, KT; et 
al. 2011
Direct costs Patient/
year
Mean 81096 89336 HF 2007 USA
Bottachi, E; 
et al. 
2012
Direct costs Patient/
year’
Mean 9030 NA Stroke 2007 Italy
Fernandez De 
Bodadilla, J; et 
al. 2008
Direct costs Patient/
year
Mean 4429 NA Stroke 2006 Spain
Cleason, L; 
et al. 
2000
Direct costs Patient/
year
Mean 39527 100233 Stroke 1994 Sweden
Hu, S; et al. 
2013
Direct costs Patient/
year
Mean 4779 NA Stroke 2011 China
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Lee, HC; et al.       
2013
Direct costs Patient/
year
Mean 5693 NA Stroke 2003 Taiwan
Lopez-Batista, 
J; et al. 
2012
Direct costs Patient/
year
Mean 21520 18535 Stroke 2004 Spain
Simpson, AN; 
et al. 
2013
Direct costs Patient/
year
Mean 33698 29486 Stroke 2005 USA
Simpson, AN; 
et al.  2013
Direct 
attributable costs
Patient/
year
Mean 11164 29486 Stroke 2005 USA
Sloss, EM; 
et al. 
2004
Direct costs Patient/
year
Mean 39641 NA Stroke 1998 USA
Spieler, JF; 
et al. 
2004
Direct costs Patient/
year
Mean 32291 26290 Stroke 1997 France
Taylor, TN; 
et al. 
1996
Direct costs Patient/
year
Mean 32467 NA Stroke 1993 USA
Trogdon, JG; 
et al. 
2007
Direct costs Patient/
year
Mean 7294 NA Stroke 2003 USA
Winter, Y; et al. 
2008
Direct costs Patient/
year
Mean 7386 9814 Stroke 2003 Germany
Yoon, J; et al.  
2011
Direct costs 
(2000)
Patient/
year
Mean 11251 NA Stroke 2008 USA
Yoon, J; et al. 
2011
Direct costs 
(2008)
Patient/
year
Mean 8436 NA Stroke 2008 USA
Ward, A; et a 
2005
Direct costs Patient/
year
Mean 69440 NA Stroke 1994-
1998
Germany
Zorowitz, R; et 
al. 2009
Direct costs Patient/
year
Mean 31969 NA Stroke 2006 USA
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 7669 NA IHD 1996 USA
Ray, GT; et al. 
2000
Direct costs Patient/
year
Mean 17776 NA IHD 1996 USA
Menzin, J; et al. 
2008
Direct costs Patient/
year
Mean 35005 NA IHD 2002 USA
Jaworski, R; et 
al.  2012
Direct costs Patient/
year
Mean 1643 NA CHD 2005 Poland
Likosky, DS; 
et al. 
2013
Direct costs Patient/
year
Mean 40071 NA AMI 1998-
1999
USA
44
Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Likosky, DS; et 
al.   2013
Direct costs Patient/
year
Mean 46667 NA AMI 2008 USA
Schneider, KM; 
et al. 
2009
Direct 
attributable costs
Patient/
year
Mean 15796 NA Cancer 2005 USA
Schneider, KM; 
et al. 
2009
Direct costs Patient/
year
Mean 19161 NA Cancer 2005 USA
Baker, MS; et 
al.1991
Direct costs Patient/
year
Mean 49032 NA Breast 
cancer
1974-
1981
USA
Baker, MS; et 
al. 1991
Lifetime 
attributable costs
Per patient Mean 82794 NA Breast 
cancer
1974-
1981
USA
Broekx, S; et al. 
2011
Direct 
attributable costs
Patient/
year
Mean 2989 NA Breast 
cancer
2004 Belgium
Cocquyt, V; 
et al. 
2003
Direct costs Patient/
year
Mean 4595 NA Breast 
cancer
1998 Belgium
Dahlberg, L; 
et al. 
2009
Direct costs Patient/
year
Mean 60519 NA Breast 
cancer
2006 Sweden
Fireman, BH; et 
al.  1997
Direct costs Patient/
year
Mean 11953 72 Breast 
cancer
1987-
1991
USA
Fireman, BH; et 
al.  1997
Direct 
attributable costs
Per patient Mean 58608 625 Breast 
cancer
1987-
1991
USA
Gruber, EV; 
et al. 
2012
Direct 
attributable costs
Patient/
year
Mean 10208 NA Breast 
cancer
2009 Germany
Lamerato, L; 
et al. 
2006
Direct costs Patient/
year
Mean 58973 NA Breast can-
cer (recur-
rence)
2002 USA
Legorreta, AP; 
et al.  1996
Direct costs Patient/
year
Mean 42514 NA Breast 
cancer
1989 USA
Rao,S; et al. 
2004
Direct 
attributable costs
Patient/
year
Mean 31140 NA Breast 
cancer
2004 USA
Rao,S; et al. 
2004
Direct costs Patient/
year
Mean 32118 NA Breast 
cancer
2004 USA
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 5065 NA Breast 
cancer
1996 USA
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Ray, GT; et al. 
2000
Direct costs Patient/
year
Mean 9899 NA Breast 
cancer
1996 USA
Riley, GF; et al.  
1995
Direct costs Patient/
year
Mean 22628 NA Breast 
cancer
1984-
1990
USA
Sasser, AC; 
et al. 
2005
Direct costs Patient/
year
Mean 18843 NA Breast 
cancer
2000 USA
Sorensen, SV; 
et al. 
2012
Direct costs Patient/
year
Mean 80572 NA Breast 
cancer
2007 USA
Yabroff, KR; et 
al.   2008
Direct 
attributable costs
Patient/
year
Mean 17315 NA Breast 
cancer
1999-
2003
USA
Baker, MS; et 
al.    1991
Direct costs Patient/
year
Mean 161048 NA Lung cancer 1974-
1981
USA
Baker, MS; et 
al.   1991
Lifetime 
attributable costs
Per patient Mean 28049 NA Lung cancer 1974-
1981
USA
Chang, S; et al.   
2004
Direct costs Patient/
year
Mean 105876 54132 Lung cancer 1998-
2000 
USA
Chouaid, C; et 
al. 2004
Direct costs Patient/
year
Mean 22003 NA Lung cancer 1999 France
Fireman, BH; et 
al.  1997
Direct costs Patient/
year
Mean 25128 253 Lung cancer 1987-
1991
USA
Fireman, BH; et 
al.  1997
Direct 
attributable costs
Per patient Mean 54972 653 Lung cancer 1987-
1991
USA
Kang, S; et al. 
2012
Direct costs Patient/
year
Mean 4964 NA Lung cancer 2008 Australia
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 12777 NA Lung cancer 1996 USA
Ray, GT; et al. 
2000
Direct costs Patient/
year
Mean 24099 NA Lung cancer 1996 USA
Riley, GF; et al.  
1995
Direct costs Patient/
year
Mean 32724 NA Lung cancer 1984-
1990
USA
Yabroff, KR; et 
al.  2008
Direct 
attributable costs
Patient/
year
Mean 68658 NA Lung cancer 1999-
2003
USA
Bouvier, V; et 
al.   2003
Direct costs Patient/
year
Mean 26577 NA Colorectal 
cancer
1997-
1998 
France
Brown, ML; 
et al. 
1999
Direct 
attributable costs
Patient/
year
Mean 13726 NA Colorectal 
cancer
1994 USA
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Brown, ML; 
et al. 
1999
Direct costs Patient/
year
Mean 27722 NA Colorectal 
cancer
1994 USA
Chang, S; et al.   
2004
Direct costs Patient/
year
Mean 66036 26304 Colorectal 
cancer
1998-
2000 
USA
Clerc,L; et al. 
2008
Direct costs Patient/
year
Mean 42688 NA Colorectal 
cancer
2005 France
Fireman, BH; et 
al.  1997
Direct costs Patient/
year
Mean 18189 236 Colorectal 
cancer
1987-
1991
USA
Fireman, BH; et 
al.  1997
Direct 
attributable costs
Per patient Mean 74860 1364 Colorectal 
cancer
1987-
1991
USA
Kerrigan, M; et 
al.   2005
Direct 
attributable costs
Patient/
year
Mean 60535 NA Colorectal 
cancer
1996-
1998
USA
Macafee, DA; 
et al. 2009
Direct costs (for 
female)
Patient/
year
Median 2208 NA Colorectal 
cancer
1981-
2002
UK
Macafee, DA; 
et al. 2009
Direct costs(for 
male)
Patient/
year
Median 2856 NA Colorectal 
cancer
1981-
2002
UK
Luo,Z; et al. 
2009
Direct 
attributable costs
Patient/
year
Mean 39507 NA Colorectal 
cancer
2000 USA
Seal, BD; et al.    
2013
Direct costs Patient/
year
Mean 105754 92290 Colorectal 
cancer
2009 USA
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 15588 NA Colorectal 
cancer
1996 USA
Ray, GT; et al. 
2000
Direct costs Patient/
year
Mean 22631 NA Colorectal 
cancer
1996 USA
Ramsey, SD; et 
al. 2003
Direct costs Patient/
year
Mean 6697 NA Colorectal 
cancer
1984-
1994
USA
Ramsey, SD; et 
al. 2003
Direct 
attributable costs
Patient/
year
Mean 2806 NA Colorectal 
cancer
1984-
1994
USA
Riley, GF; et al.  
1995
Direct costs Patient/
year
Mean 35631 NA Colorectal 
cancer
1984-
1990
USA
Wright,GE; et 
al.   2007
Direct costs Patient/
year
Mean 39399 NA Colorectal 
cancer
1996 USA
Yabroff, KR; et 
al.   2008
Direct 
attributable costs
Patient/
year
Mean 28090 NA Colorectal 
cancer
1999-
2003
USA
Yabroff, KR; et 
al. 2009
Direct 
attributable costs
Patient/
year
Mean 43611 NA Colorectal 
cancer
2002 USA
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Low, JJ; et al.         
2012
Direct costs Patient/
year
Mean 8049 NA Cervical 
cancer
2008-
2033
Singapore
Yabroff, KR; et 
al.   2008
Direct 
attributable costs
Patient/
year
Mean 22769 NA Cervical 
cancer
1999-
2003
USA
Song, X; et al. 
2011
Direct 
attributable  
costs
Patient/
year
Mean 197772 639672 Metastatic 
Colorectal 
cancer
2009 USA
Song, X; et al. 
2011
Direct costs Patient/
year
Mean 190032 NA Metastatic 
Colorectal 
cancer
2009 USA
Anis, AH; et al.    
2000
Direct costs Patient/
year
Mean 1777 221 COPD 1994-
1995
Canada
Miravitlles, 
M; et al.                 
2001
Direct costs Patient/
year
Mean 1869 NA COPD 1996-
1997
Spain
Blanchette, 
CM; et al.       
2012
Direct costs Patient/
year
Mean 18305 NA COPD 2007 USA
Blanchette, 
CM; et al.       
2012
Direct costs Patient/
year
Mean 13266 NA COPD 1987 USA
Blanchette, 
CM; et al. 2008
Direct costs Patient/
year
Mean 28966 45625 COPD 2004 USA
Chittleborough, 
CR; et al.                         
2009
Direct costs Patient/
year
Mean 551 551 COPD 1997-
2002
Australia
Dalal, AA; 
et al.  2011
Direct costs Patient/
year
Mean 4856 NA COPD 2006-
2009
USA
Dalal, AA; 
et al.      2011
Direct costs Patient/
year
Mean 2574 NA COPD 2003-
2008
USA
Domingo, C; et 
al.     2006
Direct costs Patient/
year
Mean 1881 3828 COPD 2006 Spain
D’Souza, AO; 
et al. 2014
Direct costs Patient/
Year
Mean 19587 682 COPD 2003-
2007
USA
D’Souza, AO; 
et al. 2014
Direct 
attributable costs
Patient/
Year
Mean 2323 NA COPD 2003-
2007
USA
Hilleman, DE; 
et al. 2000
Direct costs Patient/
year
Median 6429 NA COPD 1993-
1998
USA
Hutchinson, A; 
et al. 2010
Direct costs Patient/
year
Median 6656 NA COPD 2001-
2002
Australia
Jansson, SA; et 
al.   2002
Direct costs Patient/
year
Mean 692 NA COPD 1998-
1999
UK
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Nielsen, R; 
et al. 
2011
Direct costs Patient/
year
Mean 13583.25 NA COPD 2005-
006
Norway
Jensen, MB; et 
a2013
Direct costs Patient/
year
Mean 4751 NA COPD 2004-
2006
Denmark
Lokke, A; et al. 
2014
Direct costs Patient/
year
Mean 12321 NA COPD 1998-
2010
Denmark
Lokke, A; et al. 
2014
Direct 
attributable costs
Patient/
year
Mean 7855 NA COPD 1998-
2010
Denmark
Lou, P; et al.           
2012
Direct costs Patient/
year
Mean 14326 NA COPD 2008-
2009
China
Mandelblatt, 
JS; et al. 2006
Direct costs Patient/
year
Mean 2491 4215 COPD 2000 USA
Mapel, DW; et 
al.     2000
Direct 
attributable costs
Patient/
year
Mean 8512 NA COPD 1997 USA
Mapel, DW; et 
al.     2000
Direct costs Patient/
year
Mean 16949 NA COPD 1997 USA
Marton, JP; et 
al.     2006
Direct costs Patient/
year
Mean 17042 NA COPD 2001 USA
Meen, P; et al.    
2012
Direct costs Patient/
year
Mean 3826 NA COPD 2006-
2009
Germany
Meen, P; et al. 
2012
Direct costs Patient/
year
Mean 3826 NA COPD 2006-
2009
Germany
Menzin, J; et al. 
2008
Direct costs Patient/
year
Mean 34101 60664 COPD 2004 USA
Miravitlles, M; 
et al. 2003
Direct costs Patient/
year
Mean 2374 4908 COPD 2003 Spain
Nielsen, R; et 
al.  2009
Direct costs Patient/
year
Mean 431 NA COPD 2003-
2004
Norway
Nielsen, R; et 
al.2009
Direct costs Patient/
year
Mean 725 NA COPD 2003-
2004
Iceland
Nielsen, R; et 
al. 2011
Direct costs Patient/
year
Mean 13583 NA COPD 2005-
2006
Norway
Nishimura, 
S; Zaher, C;                    
2004
Direct costs Patient/
year
Mean 1311 NA COPD 1990-
2002
Japan
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 10176 NA COPD 1995-
1996
USA
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Ray, GT; et al.   
2000
Direct costs Patient/
year
Mean 25644 NA COPD 1995-
1996
USA
Rutten-Van 
Molken, 
MPMH; et al.           
1999
Direct costs Patient/
year
Mean 1413 NA COPD 1993 Netherlands
Schneider, KM; 
et al. 2009
Direct 
attributable costs 
Patient/
year
Mean 22183 NA COPD 2001-
2005
USA
Schneider, KM; 
et al. 2009
Direct costs Patient/
year
Mean 25547 NA COPD 2001-
2005
USA
Sharafk-haneh, 
A; et al.                       
2010
Direct costs Patient/
year
Mean 6083 NA COPD 1997-
2004
USA
Simoni-Wastila, 
L; et al.                  
2009
Direct costs Patient/
year
Mean 8819 16099 COPD 2003-
2005
USA
Van Boven, 
JFM; et al.                      
2013
Direct costs Patient/
year
Mean 1419 NA COPD 2009 Netherlands
Yoon, J; et al.          
2011
Direct costs Patient/
year
Mean 6616 NA COPD 2000 USA
Yoon, J; et al.          
2011
Direct costs Patient/
year
Mean 6112 NA COPD 2008 USA
Schneider, KM; 
et al. 
2009
Direct attrbitut-
able costs
Patient/
year
Mean 22183 NA COPD 2005 USA
Schneider, KM; 
et al. 
2009
Direct costs Patient/
year
Mean 25548 NA COPD 2005 USA
Baumeister, SE; 
et al. 2009
Direct costs Patient/
year
Mean 5439 13350 CKD 2004-
2005
Germany
Laliberte, F; et 
al.   2009
Direct costs Patient/
year
Mean 18314 52839 CKD 2000-
2006
USA
Lamping, DL; 
et al. 2000
Direct costs Patient/
year
Mean 71824 NA CKD 1995-
1996
UK
Lee, H; et al.          
2002
Direct costs Patient/
year
Mean 58871 27814 CKD 1999-
2000
Canada
Schneider, KM; 
et al. 2009
Direct 
attributable costs
Patient/
year
Mean 28462 NA CKD 2001-
2005
USA
Schneider, KM; 
et al. 2009
Direct costs Patient/
year
Mean 31826 NA CKD 2001-
2005
USA
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Yoon, J; et al. 
2011
Direct costs Patient/
year
Mean 23785 NA CKD 2000 USA
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 33585 NA CKD 1996 USA
Ray, GT; et al. 
2000
Direct costs Patient/
year
Mean 49286 NA CKD 1996 USA
Yoon, J; et al.         
2011
Direct costs Patient/
year
Mean 17681 NA CKD 2008 USA
Schneider, KM; 
et al. 
2009
Direct costs Patient/
year
Mean 31827 NA CKD 2005 USA
Schneider, KM; 
et al. 
2009
Direct 
attributable costs
Patient/
year
Mean 28462 NA CKD 2005 USA
Ballesta, M; et 
al.    2006
Direct costs Patient/
year
Mean 3714 NA DM 1999 Spain
Biorac, N; et al. 
2009
Direct costs Patient/
year
Mean 901 NA DM 2007 Serbia
Chodick, G; et 
al. 2005
Direct costs Patient/
year
Mean 2653 NA DM 1999 Israel
Chodick, G; et 
al.2005
Direct costs Patient/
year
Mean 3010 NA DM 2000 Israel
Chodick, G; et 
al. 2005
Direct costs Patient/
year
Mean 3422 NA DM 2001 Israel
Costantino ME; 
et al. 2014
Direct costs Patient/
year
Mean 9731 NA DM 2009 USA
Costantino ME; 
et al. 2014
Direct 
attributable costs
Patient/
year
Mean 3390 NA DM 2009 USA
Degli Esposti, 
L; et al. 2013
Direct costs Patient/
year
Mean 2291 5164 DM 2009 Italy
Elrayah-
Eliadarous, 
H; et al.                     
2010
Direct costs Patient/
year
Mean 215 166 DM 2005  Sudan
Jonsson, B             
2002
Direct costs Patient/
year
Mean 4092 NA DM 1999 Europe
Kangas, T; et al. 
1996
Direct costs Patient/
year
Mean 7408 NA DM 1987-
1989
Finland
Kirigia, JM; et 
al. 2009
Direct costs Patient/
year
Mean 1377 NA DM 2000 Africa
Kumar, A; et al.  
2008
 Direct Cost Patient/
year
Mean 162 NA DM 2005-
2005
India
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Table 2a. Results of the Included Studies Investigating Annual Direct Costs of NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified 
as
Assess-
ment
Type
Point
Estimate
SD for 
Mean
Reported
NCDs
Year Country
Le, C; et al.            
2013
Direct costs Patient/
year
Mean 952 NA DM 2010-
2011
China
Martin, S; et al.   
2007
Direct costs Patient/
year
Mean 2818 3276 DM 1995-
2003
Germany
Morsanutto, A; 
et al.  2006
Direct costs Patient/
year
Mean 2452 NA DM 2001-
2002
Italy
Norlund, A; et 
al. 2001
Direct costs Patient/
year
Mean 7570 NA DM 1992-
1993
Sweden
Nakamura, K;          
2008
Direct costs Patient/
year
Mean 4416 NA DM 1990-
2001
Japan
Oglesby, AK; et 
al.  2006
Direct 
attributable costs
Patient/
year
Mean 2077 NA DM 1989-
2003
USA
Oliva, J; et al.        
2004
Direct costs Patient/
year
Mean 1775 NA DM 2002 Spain
Petersen, M; 
Amer Diabet, A   
2008
Direct costs Capita/year Mean 13196 NA DM 2007 USA
Petersen, M; 
Amer Diabet, A   
2008
Direct 
attributable costs
Capita/year Mean 7471 NA DM 2007 USA
Ray, NF; et al.       
1998
Direct costs Capita/year Mean 14617 NA DM 1997 USA
Ray, NF; et al.       
1998
Direct 
attributable costs
Capita/year Mean 10743 NA DM 1997 USA
Ringborg, A; et 
al.   2008
Direct costs Patient/
year
Mean 4047 9525 DM 2000-
2004
Sweden
Tunceli, O; et 
al.      2010
Direct 
attributable costs
Patient/
year
Mean 3373 13198 DM 2006-
2009
USA
Tunceli, O; et 
al.      2010
Direct costs Patient/
year
Mean 4329 13198 DM 2006-
2009
USA
Ray, GT; et al. 
2000
Direct 
attributable costs
Patient/
year
Mean 2444 NA DM 1996 USA
Ray, GT; et al. 
2000
Direct Costs Patient/
year
Mean 9462 NA DM 1996 USA
Schneider, KM; 
et al.    2009
Direct 
attributable costs
Patient/
year
Mean 12246 NA DM 2005 USA
Schneider, KM; 
et al.    2009
Direct costs Patient/
year
Mean 15611 NA DM 2005 USA
SD:Standard deviation; NCD: Non-communicable diseases; CVD: Cardiovascular disease; CAD: Coronary Artery 
Disease ; IHD: Ischemic Heart Disease ; COPD: Chronic Obstructive PulmonaryDisease; CKD: Chronic Kidney Disease ; 
DM: Diabetes Mellitus
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Table 2b. Results of the Included Studies Investigating Annual Indirect Costs of NCDs 
Study Type of 
Outcome
Outcome 
Specified as 
Assessment
Type
Point
Estimate
SD for 
Mean 
Reported
NCDs
Year Country
Sasser, AC; et 
al.    2005
Indirect 
costs
Patient/year Mean 6752 NA CVD 2000 USA
Hu, S; et al. 
2013
Indirect 
costs
Patient/year Mean 2644 NA Stroke 2011 China
Lopez-Batista, 
J; et al.    2012
Indirect 
costs
Patient/year Mean 23418 19558 Stroke 2004 Spain
Winter, Y; et 
al.    2008
Indirect 
costs
Patient/year Mean 4018 4634 Stroke 2003 Germany
Jaworski, R; et 
al.   2012
Indirect 
costs
Patient/year Mean 1780 NA CAD 2005 Poland
Broekx, S; et 
al.    2011
Indirect 
costs
Patient/year Mean 23692 NA Breast 
cancer
2004 Belgium
Sasser, AC; et 
al.     2005
Indirect 
costs
Patient/year Mean 11145 NA Breast 
cancer
2000 USA
Sorensen, SV; 
et al.   2012
Indirect 
costs
Patient/year Mean 24740 NA Breast 
cancer
2007 USA
Wan, Y; et al. 
2013
Indirect 
costs
Patient/year Mean 2109 NA Breast 
cancer
2009 USA
Darkow, T; et 
al.  2007
Indirect costs Patient/year Mean 3393 NA COPD 2001-
2004
USA
Fletcher, MJ; 
et al.  2011
Indirect costs Patient/year Mean 910 NA COPD 2009 Cross-
country
Jansson, SA; 
et al. 2002
Indirect costs Patient/year Mean 970 NA COPD 1998-
1999
UK
Lokke, A; et 
al. 2014
Indirect costs Patient/year Mean 3264 NA COPD 1998-
2010
Denmark
Nishimura, 
S; Zaher, C;            
2004
Indirect costs Patient/year Mean 326 NA COPD 1990-
2002
Japan
Ballesta, M; 
et al.    2006
Indirect 
costs
Patient/
year
Mean 2675 NA DM 1999 Spain
Biorac, N; 
et al.    2009
Indirect 
costs
Patient/
year
Mean 104 NA DM 2007 Serbia
Le, C; et al.   
2013
Indirect 
costs
Patient/
year
Mean 7797 NA DM 2010-
2011
China
Kirigia, 
JM; et al.     
2009
Indirect 
costs
Patient/
year
Mean 2958 NA DM 2000 Africa
Norlund, A; 
et al.    2001
Indirect 
costs
Patient/
year
Mean 5350 NA DM 1992-
1993
Sweden
SD: Standard deviation; NCD: Non-communicable diseases; CVD: Cardiovascular disease; CAD: Coronary Artery 
Disease; COPD: Chronic Obstructive Pulmonary Disease; DM: Diabetes Mellitus
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(iii) Aggregate costs 
Mean annual total costs of NCDs per patient were reported in 17 articles (Table 2c). Cancer and 
stroke led the total costs with average estimates up to 105310 USD30 and 44937 USD31 respectively. 
The mean total cost per patient for breast cancer was estimated at 30000 USD in Belgium36 and the 
USA37, although the mean costs for metastatic breast cancer were three times higher (105310 USD30). 
For lung cancer, mean estimates varied from 4964 USD16 in Australia to 50495 USD in USA38 
whereas colorectal cancer total costs were 52068 USD38. Mean COPD total costs were estimated 
around 1700 USD in the UK and Japan33 but exceeded the value of 15500 USD in Denmark39. DM 
total costs were estimated at an average of 12920 USD in Sweden40 whereas estimated mean total 
costs in Serbia were 1005 USD41. No study reported total costs for cervical cancer or CKD. 
Table 2c. Results of the Included Studies Investigating Annual Total Costs of NCDs (continued)
Study Type of Out-
come
Outcome 
Specified 
as 
Assessment
 Type
Point
Estimate
SD for 
Mean 
Report-
ed
NCDs
Year Country
Sasser, AC; et 
al.  2005
Total costs Patient/
year
Mean 23065 NA CVD 2000 USA
Hu, S; et al.  
2013
Total costs Patient/year Mean 7422 NA Stroke 2011 China
Lopez-Batista, 
J; et al.2012
Total costs Patient/year Mean 44937 18535 Stroke 2004 Spain
Winter, Y; et al. 
2008
Total costs Patient/year Mean 11396 NA Stroke 2003 Germany
Jaworski, R; 
et al. 
2012
Total costs Patient/year Mean 3423 NA CHD 2005 Poland
Sorensen, SV; 
et al. 
2012
Total costs Patient/year Mean 105310 NA Metastat-
ic Breast 
cancer
2007 USA
Broekx, S; et al. 
2011
Total 
attributable 
costs
Patient/year Mean 26680 NA Breast 
cancer
2004 Belgium
Sasser, AC; 
et al. 
2005
Total costs Patient/year Mean 29988 NA Breast 
cancer
2000 USA
Warren, JL; et 
al.    2008
Total costs Patient/year Mean 26492 NA Breast 
cancer
1991-
2002
USA
Kang, S; et al.  
2012
Total costs Patient/year Mean 4964 NA Lung 
cancer
2008 Australia
Warren, JL; et 
al.    2008
Total costs Patient/year Mean 50495 NA Lung 
cancer
1991-
2002
USA
Warren, JL; et 
al.    2008
Total costs Patient/year Mean 52068 NA Colorec-
tal cancer
1991-
2002
USA
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Table 2c. Results of the Included Studies Investigating Annual Total Costs of NCDs (continued)
Study Type of Out-
come
Outcome 
Specified 
as 
Assessment
 Type
Point
Estimate
SD for 
Mean 
Report-
ed
NCDs
Year Country
Jansson, 
SA; et al.               
2002
Total costs Patient/year Mean 1662 NA COPD 1998-
1999
UK
Lokke, A; et al. 
2014
Total Costs Patient/year Mean 15585 NA COPD 1998-
2010
Denmark
Nishimura, 
S; Zaher, C;           
2004
Total costs Patient/year Mean 1637 NA COPD 1990-
2002
Japan
Ballesta, M; et 
al.  2006
Total costs Patient/year Mean 6206 NA DM 1999 Spain
Biorac, N; et al. 
2009
Total costs Patient/year Mean 1005 NA DM 2007 Serbia
Le, C; et al.          
2013
Total costs Patient/year Mean 8749 NA DM 2010-
2011
China
Kirigia, JM; et 
al.     2009
Total costs Patient/year Mean 4336 NA DM 2000 Africa
Norlund, A; et 
al.    2001
Total costs Patient/year Mean 12920 NA DM 1992-
1993
Sweden
SD: Standard deviation; NCD: Non-communicable diseases; CVD: Cardiovascular disease; IHD: Ischemic Heart Disease, 
AMI: Acute Myocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease; DM : Diabetes Mellitus
(iv) Costs of NCDs over time
There was an increase in healthcare costs associated with NCDs over time. One study showed that, 
despite a 19% decline in the hospitalization rate for CHD (acute myocardial infarction) in USA, 
overall healthcare expenditure per patient increased by 17% from 1998 to 2008 (absolute difference 
of 6595 USD) and use of outpatient services increased by 65% (absolute difference, 1000 USD)42 
and similarly for heart failure43. The average treatment cost of colorectal cancer patients in USA 
increased by 73% from 2005 to 200944, mainly driven by the use of new regimens, higher chances 
of surgery, and radiation. In USA, COPD-related healthcare costs increased by 5-6% annually45. 
Further, a 29% increase in medical treatment costs for diabetic patients was observed from 1999 to 
2001 in Israel (absolute difference, 771 USD)46. 
(v) Costs According to Disease Severity and Comorbidity
Overall healthcare costs secondary to NCDs increased with the severity of the disease, years lived 
with the condition and co-morbidity9,36,47-57. Patients with severe stroke had almost a 40% greater 
increase in costs compared to mild stroke patients47. Among cancer patients, given the same stage 
of diagnosis, those with one, two or three co-morbidities experienced increased costs of 3737 
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USD, 4188 USD and 10442 USD respectively58. Costs for a diabetic patient tripled between the 
first and seventh year59 after diagnosis. An increase in treatment costs of breast cancer by stage 
was reported, with approximately 52% higher treatment costs for stage II as compared to stage 
057. Similarly, a 29859 USD increase was seen with cancer progression from stage I to stage IV60. 
Patients with co-existence of COPD and CVD had 135% higher annual care costs compared 
with patients without CVD, whereas COPD related total costs were 38% higher56.  Some studies 
reported lifetime healthcare costs of NCDs (initial, continuing and terminal care), demonstrating 
that initial and terminal care are the most costly.13,15,61-63.  
Global healthcare expenditure on the NCDs
Among the reviewed studies, 30 reported healthcare expenditure attributable to specific NCDs 
(Table 3a). CVD accounted for 12% of all healthcare expenditure in the European Union (EU)64. 
CHD healthcare-related costs accounted for 14.2-16.5% of the annual healthcare budget in the 
American region. In contrast, in the EU, mean healthcare expenditure on CHD was 2.6%; within 
the EU, Malta has the lowest share (0.6%) and Slovakia the highest (5.9%)64. CKD and cancer 
accounted for 3.2% and 3.4%, of healthcare expenditure respectively25,65. In the USA, 1.2% of 
the healthcare budget was spent exclusively on the treatment of breast cancer25. The proportion 
of national healthcare-related expenditure for COPD ranged from 0.7% in Norway19, 1-3% in the 
Netherlands66 and up to 3.8% in Canada65. Again in Canada, 3.8% of healthcare expenditure is 
attributable to DM65 whereas in the European Union, DM-related healthcare expenditure was an 
estimated 7.4%67 (the Netherlands having the lowest share (1.6%), and Spain the highest)68.
Table 3a. Healthcare Expenditure and Total Direct Costs Associated with NCDs 
Study Type of Out-
come
Outcome 
Specified 
as 
Assess-
ment
 Type
Point
Estimate
Reported
NCDs
Year Country
Hodgson, TA; 
Cohen, AJ                        
1999
Direct costs Per year Mean 195.4 million CVD 1995 USA
Nichols, GA; 
et al. 
2010
Direct costs Per year Mean 400  billion CVD 2000-
2008
USA
Leal, J; et al.         
2006
Direct costs Per year EUR 151.3 billion CVD 2003 Europe (cross-
country)
*Leigh, JP; et al. 
2003
Direct costs Per year Mean 15.53 billion CVD, 
Cancer, 
COPD
1999 USA
Odden, MC; 
et al. 
2011
Direct costs Per year Mean 130.6 billion CVD, CHD 2010 USA
Hodgson, TA; 
Cohen, AJ                        
1999
Direct costs Per year Mean 59.1 million CHD 1995 USA
Leal, J; et al.         
2006
Direct costs Per year EUR 32.9 billion CHD 2003 Europe (cross-
country)
56
In absolute terms, annual CVD hospital costs in the USA reached an estimated 400 billion USD 
in 2008, doubling the 195 billion USD in 199569,70. In USA, CHD-related hospital costs were 
estimated at 59.1 million USD in 1995 whereas the CVD-related hospital costs were 130 USD 
billion in 201071.  In the EU, CVD-related hospital costs were estimated at 151 billion USD in 
2003, with CHD accounting for 32.9 billion USD64. In Australia, annual hospital costs due to 
CVD were estimated at 164 million USD in 199772. In France and Hungary the annual estimated 
colorectal cancer health related costs were 565 million USD and 43 million USD respectively73,74. 
In Iran, the minimum annual healthcare-related cost for colorectal cancer was estimated at 39 
million USD for the period between 2005 and 201075. For cervical cancer, the estimated costs 
were 1.83 million USD in Singapore18, 18.2 million USD in Spain76, and 12.98 million USD in 
Malaysia77. The estimated total healthcare costs in the USA for lung, colorectal, cervical and breast 
cancer combined were 5.2 billion78. In USA, health-related costs for COPD and CKD in 2005 were 
an estimated 9.2 billion USD24. COPD costs accounted for 232 million USD in Iceland19 whereas 
both COPD and DM accounted for 162 million USD in Australia79. DM hospital-related costs 
varied from 9.7 billion USA in the African Region80, to 41.1 billion USD68 in Europe and to 160 
billion USD in USA81 .  
A data series of hospital expenditure on CVD was only available in the USA. This showed a two 
fold increase in healthcare share from 1995 to 2008, with estimated health costs of 195 billion 
USD in 1995 to 400 billion USD in 200869,70. An increase in healthcare expenditure was also seen 
for colorectal cancer in Brazil, from 18.54 million USD in 1996 to 37.64 million USD in 200882. 
Yoon, J.J et al showed a sharp increase in healthcare spending on most chronic diseases from 2000 
to 2008, with CKD having the highest increase by more than 1.62 billion USD83. 
Table 3a. Healthcare Expenditure and Total Direct Costs Associated with NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
Type 
Point
Estimate
Reported
NCDs
Year Country            
Caro, JJ; et al.       
2006
Hospitalization 
costs
Per year Mean 20.5 million Stroke 1990-
1995
France 
Dewey, HM; et 
al.              2003
Hospitalization 
costs
Per year Mean 164 million Stroke 1997 Australia
Kolominsky-Ra-
bas, PL; et al.           
2006
Direct costs Per year Mean 10.6 billion Stroke 2004 Germany
*Simpson, A.N; 
et al. 
2013
Direct costs Per year Mean 133.41 
million
CVD, Stroke 2004 USA
Beaulieu, N; et 
al. 2009
Medication costs Per year Mean 31.8 billion Lung cancer 2009 Worldwide
Beaulieu, N; et 
al. 2009
Nonmedical 
costs
Per year Mean 12.0 billion Lung cancer 2009 Worldwide
Beaulieu, N; et 
al. 2009
Medication costs Per year Mean 20.2 billion Colorectal 
cancer
2009 Worldwide
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Table 3a. Healthcare Expenditure and Total Direct Costs Associated with NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
Type 
Point
Estimate
Reported
NCDs
Year Country            
Beaulieu, N; et 
al. 2009
Nonmedical 
costs
Per year Mean 7.9    billion Colorectal 
cancer
2009 Worldwide
Selke, B; et al. 
2003
Direct costs Per year Mean 564.59 
million
Colorectal 
Cancer
1999 France
Boncz, I; et al.       
2010
Direct costs Per year Mean 43.4 
million
Colorectal 
cancer
2001 Hungary 
Davari, M; et al.  
2012
Direct costs Per period 
of surveil-
lance
Minimum 39.3 
million
Colorectal 
cancer
2005 
-2010 
Iran
Torres, US; 
et al. 
2010
Direct costs Per year Mean 18.54 
million
Colorectal 
cancer
1996 Brazil
Torres, US; 
et al. 
2010
Direct costs Per year Mean 37.64 
million
Colorectal 
cancer
2008 Brazil
Beaulieu, N; et 
al. 2009
Medication 
costs
Per year Mean 14.2 
billion
Breast cancer 2009 Worldwide
Beaulieu, N; et 
al. 2009
Nonmedical 
costs
Per year Mean 8.3 
billion
Breast cancer 2009 Worldwide
Boncz, I; et al.  
2010
Direct costs Per year Mean 37.4 
million
Breast cancer 2001 Hungary 
Beaulieu, N; et 
al. 2009
Medication 
costs
Per year Mean 865.4 
million
Cervical cancer 2009 Worldwide
Beaulieu, N; et 
al. 2009
Nonmedical 
costs
Per year Mean 703.6 
million
Cervical cancer 2009 Worldwide
Boncz, I; et al.    
2010
Direct costs Per year Mean 4.5 
million
Cervical cancer 2001 Hungary 
Aljunid, S; et al. 
2010
Direct costs Per year Mean 12.98 
million
Cervical cancer 2007-
2008
Malysia
Gil, A; et al. 
2007
Hospitalization 
costs
Per year Mean 18.19 
million
Cervical cancer 1999-
2002
Spain
Low, JJ; et al.  
2012
Direct cost Per year Mean 45.7 
million
Cervical cancer 2008-
2033
Singapore
Yabroff, KR; et 
al.              2008
Aggregated 
costs
Per 5 years Mean 26 billion Lung, 
colorectal, 
cervical & 
breast  cancer
1999-
2003
USA
Yabroff, KR; et 
al.              2008
Aggregated 
costs
Per year Mean 5,2 
billion
Lung, 
colorectal, 
cervical & 
breast  cancer
1999-
2003
USA
Nielsen, R; et al. 
2009
Direct costs Per year Mean 232.3 
million
COPD 2003-
2004
Iceland
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Table 3a. Healthcare Expenditure and Total Direct Costs Associated with NCDs (continued)
Study Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
Type 
Point
Estimate
Reported
NCDs
Year Country            
Schneider, KM; 
et al.  2009
Direct costs Per year Mean 9.2 
billion
COPD, CKD 2001-
2005
USA
Chittleborough, 
CR; et al.                 
2009
Direct costs Per year Mean 162 
million
COPD, DM 2001-
2002
Australia
Chodick, G; et 
al.     2005
Direct costs Per year Mean 1159.2 
million
DM 2001 Israel
Dewey, HM; 
et al. 
2001
Direct costs Per year Mean 82.12 
million
CVD, Stroke 1997 Australia
Hogan, P; et al.      
2003
Direct 
attributable 
costs
Per year Mean 119 
billion
DM 2002 USA
Hogan, P; et al.      
2003
Direct costs Per year Mean 160 
billion
DM 2002 USA
Jonsson, B             
2002
Direct costs Per year Mean 41.1 
billion
DM 1999 Europe
Kirigia, JM; et 
al.            2009
Direct costs Per year Mean 9.7 
billion
DM 2000 Africa
Oliva, J; et al. 
2004
Direct costs Per year Mean 3.25 
billion
DM 2002 Spain
Oliva, J; et al.    
2004
Hospitalization 
costs
Per year Mean 1096 
million
DM 1999 Spain
Oliva, J; et al.   
2004
Hospitalization 
costs
Per year Mean 1198 
million
DM 2002 Spain
Petersen, M; 
Amer Diabet, A    
2008
Direct costs Per year Mean 230.5 
million
DM 2007 USA
Petersen, M; 
Amer Diabet, A    
2008
Direct 
attributable 
costs
Per year Mean 130.3 
billion
DM 2007 USA
Ray, NF; et 
al1998
Direct costs Per year Mean 112.8 
billion
DM 1989-
1995
USA
Ray, NF; et al.       
1998
Direct 
attributable 
costs
Per year Mean 64 billion DM 1997 USA
* Studies limited in a certain number of population, not for the entire country. 
SD: standard deviation; NCD: Non-communicable diseases; CVD: Cardiovascular disease; CHD: Coronary Heart Disease; 
COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic Kidney Disease; DM: Diabetes Mellitu
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Table 3b. Annual Income Losses (indirect costs) Associated with NCDs 
Study Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
 Type
Point
Estimate
Reported
NCDs
Year Country
Hogan, P; et al.   
2003
Indirect attribut-
able costs
Per year Mean 52 billion DM 2002 USA
Kirigia, JM; et 
al.             2009
Indirect costs Per year Mean 20.8 billion DM 2000 Africa
Leal, J; et al.         
2006
Indirect costs Per year Mean 92921 
million
CVD 2003 Europe 
(cross-
country)
Dewey, HM; 
et al. 
2001
Indirect costs Per year Mean 51.71 
million
CVD, Stroke 1997 Australia
Leal, J; et al.         
2006
Indirect costs Per year Mean 31835 
million
CHD 2003 Europe 
(cross-
country)
Selke, B; et al. 
2003
Indirect costs Per year Mean 679.12 
million
Color
tal Cancer
1999 France
Petersen, M; 
Amer Diabet, A   
2008
Indirect 
attributable 
costs
Per year Mean 65.2 billion DM 2007 USA
Ray, NF; et al.       
1998
Indirect 
attributable 
costs
Per year Mean 78.3 billion DM 1997 USA
Klever-
Deichert, G; 
et al. 
1999
Indirect costs Per year Mean 71 billion CVD 1996 Germany
Nichols, GA; 
et al. 
2010
Indirect costs Per year Mean 600 billion CVD 2000-
2008
USA
Zheng, H; et al. 
2010
Indirect costs Per year Mean 2.21 billion CHD 2004 Australia
Beaulieu, N; et 
al. 2009
Productivity 
loss
Per year Mean 13.7 billion Lung cancer 2009 Worldwide
Beaulieu, N; et 
al. 2009
Productivity 
loss
Per year Mean 8.2 billion Colorectal 
cancer 
2009 Worldwide
Beaulieu, N; et 
al. 2009
Productivity 
loss
Per year Mean 1.7 billion Cervical 
cancer 
2009 Worldwide
Beaulieu, N; et 
al. 2009
Productivity 
loss
Per year Mean 8.4 billion Breast 
cancer 
2009 Worldwide
Aljunid, S; et al. 
2010
Indirect costs Per year Mean 4.11 million Cervical 
cancer
2007-
2008
Malaysia
Van Boven, 
JFM; et al.           
2013
Indirect costs Per year Mean 388.6 million COPD 2009 Netherlands
NCD: Non-communicable diseases; CVD: Cardiovascular disease; CHD: Coronary Heart Disease; COPD: Chronic 
Obstructive Pulmonary Disease
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Impact of the NCDs on national income
In general, NCDs have a large impact on national income mainly due to loss of productivity as 
a result of absenteeism and inability to work in 13 studies (Table 3b). There was a 463 billion 
USD increase in economic loss in USA due to CVD for the period 1993-200869. In the EU, 
estimated economic loss in 2003 was 92.9 billion USD for CVD, of which CHD accounted for 
31.84 billion USD. Estimated loss in national income from CHD-related productivity loss in 1996 
was 71 billion USD in Germany84. Economic loss from stroke in 1997 was 51.7 million USD in 
Australia85 whereas CHD-related productivity loss was 2.2 billion USD in 200486. Worldwide, 
economic loss from colorectal, lung, breast and cervical cancer at 2009 year were 13.7, 8.2, 1.7 and 
8.4 billion USD respectively 87. In Malaysia, estimated income losses from cervical cancer-related 
productivity loss were 4.1 million USD. In the Netherlands, estimated losses in national income 
from COPD were 388 million USD77,88. National income losses from DM were estimated at 20.8 
billion in the African region in 2000 and at 65.2 billion in 2007 in USA80,89. 
Table 3c. Healthcare Expenditure and National Income Losses (direct and indirect costs) Associated with NCDs 
Study               Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
 Type
Point
Estimate
Reported
NCDs      
Year Country
Klever-Deichert, 
G; et al.      
1999
Direct + indirect 
costs
Lifetime Mean 108.9 
billion
CVD 1999 Germany
Nichols, GA; 
et al. 
2010
Direct + indirect 
costs
Per year Mean 1 trillion CVD 2000-
2008
USA
Dewey, HM; et 
al.              2003
Direct + indirect 
costs
Lifetime Mean 1.3 billion Stroke 1997 Australia
Dewey, HM; 
et al. 
2001
Direct + indirect 
costs
Per year Mean 868.8 
million
CVD, 
Stroke
1997 Australia
Mittman, N; et al. 
2012
Direct + indirect 
costs
Per year Mean 3.47 billion CVD, 
Stroke
2005-
2009
Canada
Taylor, TN; et al. 
1996
Direct + indirect 
costs
Lifetime Mean 72.37 
billion
CVD, 
Stroke
1990-
1993
USA
Leal, J; et al.         
2006
Direct + indirect 
costs
Per year Mean 244249 
million
CVD 2003 Europe 
(cross-
country)
Leal, J; et al.         
2006
Direct + indirect 
costs
Per year Mean 64.7   
billion
CHD 2003 Europe (cross-
country)
Beaulieu, N; et 
al. 2009
Direct + indirect 
costs
Per year Mean 57.4
billion
Lung 
cancer 
2009 Worldwide
Warren, JL; et al.   
2008
Direct + indirect 
costs
Per year Mean 2.5     
billion
Lung 
cancer
1991-
2002
USA
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Table 3c. Healthcare Expenditure and National Income Losses (direct and indirect costs) Associated with NCDs 
Study               Type of 
Outcome
Outcome 
Specified as 
Assess-
ment
 Type
Point
Estimate
Reported
NCDs      
Year Country
Beaulieu, N; et 
al. 2009
Direct + indirect 
costs
Per year Mean 36.3   
billion
Colorectal 
cancer 
2009 Worldwide
Selke, B; et al. 
2003
Direct + indirect 
costs
Per year Mean 1.24    
billion
Colorectal 
Cancer
1999 France
Warren, JL; et al.   
2008
Direct + indirect 
costs
Per year Mean 2.5     
billion
Colorectal 
cancer
1991-
2002
USA
Beaulieu, N; et 
al. 2009
Direct + indirect 
costs
Per year Mean 3.2     
billion
Cervical 
cancer 
2009 Worldwide
Aljunid, S; et al. 
2010
Direct + indirect 
costs
Per year Mean 17.08 
million
Cervical 
cancer
2007-
2008
Malaysia
Beaulieu, N; et 
al. 2009
Direct + indirect 
costs
Per year Mean 30.9    
billion
Breast 
cancer 
2009 Worldwide
Jansson, SA; et 
al.              2002
Direct + indirect 
costs
Per year Mean 1.1 billion COPD 1998-
1999
Sweden
Nishimura, 
S; Zaher, C;       
2004
Direct + indirect 
costs
Per year Mean 9.1 billion COPD 1990-
2002
Japan
Van Boven, JFM; 
et al.            2013
Direct + indirect 
costs
Per year Mean 133.7 
million
COPD 2009 Netherlands
Hogan, P; et al.     
2003
Total attributable 
costs (Direct + 
indirect)
Per year Mean 171 billion DM 2002 USA
Kirigia, JM; et al. 
2009
Direct + indirect 
costs
Per year Mean 30.4 billion DM 2000 Africa
Le, C; et al.          
2013
Direct + indirect 
costs
Per year Mean 46.7 million DM 2010-
2011
China
Petersen, M; 
Amer Diabet, A        
2008
Direct + indirect 
costs
Per year Mean 195.5 
billion
DM 2007 USA
Ray, NF; et al.       
1998
Direct + indirect 
costs
Per year Mean 142.5 
billion
DM 1997 USA
SD: standard deviation; NCD: Non-communicable diseases; CVD: Cardiovascular disease; COPD: Chronic Obstructive 
Pulmonary Disease, DM: Diabetes Mellitus
Combined impact of NCDs on national income and healthcare expenditure 
19 studies reported the impact of NCDs on both healthcare expenditure and national income (Table 
3c). The total estimated cost of CVD in Germany in 1999 was 108.9 billion USD whereas for the 
entire EU, the estimate was 244.3 billion USD for the year 2003, with CHD accounting for 26% 
of this cost64,84. Stroke costs were up to 1.3 billion USD in Australia, 3.47 billion USD in Canada 
and 72.4 billion USD in USA72,90,91. Worldwide, colorectal, lung, breast and cervical cancer made 
62
up 41% (127.8 billion USD) of the 310.15 billion USD aggregate cost of new cancer cases in 
2009, with lung cancer posing the highest economic burden (57.4 billion USD) 87. In the USA, 
colorectal cancer and lung cancer total costs were 2.5 billion USD38 each whereas in France, the 
total colorectal cancer costs were estimated at 1.24 billion USD73. In Malaysia, the total estimated 
cervical cancer costs were 17.1 million77. Total COPD costs varied from 133.7 million in the 
Netherlands to 1.1 billion USD in Sweden and 9.1 billion USD in Japan33,49,88. Total estimated costs 
of DM increased from 142.5 billion USD in 1997, to 171 billion USD in 2002 and to 195.5 billion 
USD in 200781,89,92. DM imposed 30.4 billion USD in costs on the African region and 46.7 billion 
USD in costs in China27,80. 
DISCUSSION
This systematic review summarizes 153 studies published worldwide that investigate the impact 
of six major NCDs (CHD, stroke, COPD, major cancers, type 2 diabetes and CKD) at the macro-
economic level (i.e. health-related costs, healthcare budgets and national income). The studies 
suggest a steady global increase in healthcare expenditure on NCDs over the years. Additionally, 
NCDs undermine national economic development, with estimated losses in national income in 
excess of 600 billion USD69. 
In most countries, the highest expenditure was attributable to CVD. Between 12% and 16.5% of 
the overall healthcare budget is spent on this one condition alone; the proportion spent on the other 
NCDs ranges from 0.7% to 7.4%. In the USA and Brazil hospital expenditure on major NCDs 
doubled in a decade to an estimated 200 billion USD. An increasing share of healthcare expenditure 
on major NCDs has been reported previously and especially so in Germany where an increase from 
27-51% of total health expenditure was reported93. Similarly, in the USA, CHD-related healthcare 
costs were five times higher in 2008 than in 1996. Yet, little is known about what drives current and 
future NCDs-related healthcare costs. Interesting insights come from Australia; these show that the 
introduction of new technologies and changes in treatment practices (volume of treatment services) 
are more likely to drive healthcare costs as compared to ageing or other factors94. In the overall 
projected increase in health expenditure in Australia up to 2032, volume of treatment services had 
the largest contribution (AUD 81.3 billion), followed by population ageing (AUD 37.8 billion) and 
population growth (AUD 34.4 billion). Also, Aaron, H et al. in a summary of the current evidence 
reported that most of the anticipated increase in total health care spending in USA is attributed 
to growth of age-specific health care spending and some will be caused by population ageing 95. 
However, although health care spending at a time point in time may be influenced by ageing and 
in particular by the remaining life expectancy (and increases in longevity), there is limited data 
available projecting how the health care spending curve will evolve as life expectancy increases 95. 
More research is warranted in this respect.
Further, NCDs have a large impact on national income, with estimated losses ranging from 4.1 
million USD due to cervical cancer in Malaysia, to 71 billion USD in Germany and 600 billion 
USD in the USA due to CHD. Large-scale productivity losses mainly due to absenteeism and an 
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inability to work, caused by the debilitating physical and mental impact of NCDs, have a direct 
detrimental impact on national income. A 2005 WHO report indicated that estimated losses in 
national income due to CVD, stroke and diabetes were 3 billion USD in Brazil, 9 billion USD 
in India, 11 billion USD in Russia and 18 billion USD in China96. Bradley et al. demonstrated 
that, with the same level of colorectal cancer risk factors in USA, estimated economic losses due 
to colorectal cancer would raise from 24.2 billion USD in 2011 to 339 billion USD in 202097. A 
macro-economic simulation presented at the World Economic Forum in 2011 showed that over 
the next two decades, NCDs would lead to a staggering 47 USD trillion cumulative output losses 
globally, representing 75% of global GDP in 201098.
While the current study is the most detailed systematic review on the topic, it is limited by the fact 
that the evidence on economic burden of NCDs in LMIC is generally scarce. Most of the evidence in 
this review originates from high-income countries. Limited research capacity, inadequate financial 
investment, healthcare system development, a lack of electronic health records, and language 
restrictions may contribute to this shortage99. Using a systematic search in Pubmed and Embase, 
14 review articles100 101-113 (including four systematic reviews100-102,107)  evaluating the economic 
impact of different NCDs on healthcare expenditure were found. The majority of these reviews 
were not performed systematically and previous systematic reviews 100-102,107 have been published 
on the costs of specific NCDs. Valtorta and colleagues 101 investigated the financial consequences 
of cancers, stroke, and heart failure but did not include diabetes, CVD, COPD, or CKD. Yabroff 
and colleagues 100 used only MEDLINE, were focused on recent articles in English language, and 
tackled only colorectal cancer. 
Findings of this systematic review generally concur with and further extend the previous reviews. 
This systematic review evaluates economic consequences of six major NCDs using a global 
perspective in a single comprehensive investigation. Two reviewers, working in tandem, screened 
and selected the studies, while references of the included studies were additionally screened for 
any missing evidence. This approach ensured that we included most of the relevant articles in our 
review. Similar to previous reviews, however, we found substantial methodological limitations. 
Age range or stage of disease at diagnosis or other patients characteristics that may influence care 
and costs, were frequently not reported. Furthermore, many studies did not clearly state the method 
used to estimate costs and among the others, different approaches were used to calculate the same 
type of costs; e.g. direct attributable costs to diabetes were calculated by 1) including the direct 
costs of the events undergoing investigation; 2) comparing the cost of diabetes patients to those with 
no diabetes history; or 3) comparing previous resource use to resources use after the event.  It may 
be argued that the studies using the first approach may not include all the costs associated with the 
disease. For example diabetes patients are more likely to have fractures than those without diabetes 
114. Moreover, several methodological concerns of the studies reviewed were observed, related 
to sample selection and representativeness, case definition, the nature of costs included (e.g. all-
cause or event-related) and the analysis costs of data over time. Also, there are differences among 
countries with regard to health care/welfare system which may partly explain the large variation 
of health care spending across countries and world regions. In many countries, private spending 
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accounts for three quarters of national health expenditure whereas in some others, there is a large 
burden of health care into the public purse 115,116. Although, it would be of interest to compare health 
care spending and the impact of NCDs on national income based on the organization of health care/ 
welfare system, this becomes challenging because of continuing pattern changes and shifts in health 
care/ welfare system in past several decades 116. Hence, comparisons across studies were difficult 
and a meaningful quantitative pooling of the existing data remains unfeasible. Therefore, future 
studies, especially those involving economic burden assessment using a standardized approach and 
based in LMI settings, are warranted. 
In spite of data limitations, the estimates reported here show that NCDs pose a significant financial 
burden on healthcare budgets and nations’ welfare that is likely to increase over time. Further 
work is necessary to standardize the methods to consistently assess the economic impact of NCDs 
worldwide and to involve hitherto under-addressed LMI populations across the globe. 
Supplementary Material can be found online: 
http://link.springer.com/article/10.1007%2Fs10654-014-9984-2 
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2.2 The Global Impact of Non-communicable Diseases on Macro-Economic Productivity:a Systematic Review
ABSTRACT
Non-communicable diseases (NCDs) have large economic impact at multiple levels. To 
systematically review the literature investigating the economic impact of NCDs (including 
coronary heart disease (CHD), stroke, type 2 diabetes mellitus (DM), cancer (lung, colon, cervical 
and breast), chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD)) on 
macro-economic productivity.  Systematic search, up to November 6th 2014, of medical databases 
(Medline, Embase and Google Scholar) without language restrictions. To identify additional 
publications, we searched the reference lists of retrieved studies and contacted authors in the field. 
Randomized controlled trials (RCTs), cohort, case-control, cross-sectional, ecological studies and 
modelling studies carried out in adults (>18 years old) were included. Two independent reviewers 
performed all abstract and full text selection. Disagreements were resolved through consensus or 
consulting a third reviewer. Two independent reviewers extracted data using a predesigned data 
collection form. Main outcome measure was the impact of the selected NCDs on productivity, 
measured in DALYs, productivity costs, and labor market participation, including unemployment, 
return to work and sick leave.  From 4542 references, 126 studies met the inclusion criteria, many 
of which focused on the impact of more than one NCD on productivity. Breast cancer was the most 
common (n=45), followed by stroke (n=31), COPD (n= 24), colon cancer (n=24), DM (n=22), 
lung cancer (n=16), CVD (n=15), cervical cancer (n=7) and CKD (n=2). Four studies were from 
the WHO African Region, 52 from the European Region, 53 from the Region of the Americas 
and 16 from the Western Pacific Region, one from the Eastern Mediterranean Region and none 
from South East Asia. We found large regional differences in DALYs attributable to NCDs but 
especially for cervical and lung cancer. Productivity losses in the USA ranged from 88 million 
US dollars (USD) for COPD to 20.9 billion USD for colon cancer. CHD costs the Australian 
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economy 13.2 billion USD per year. People with DM, COPD and survivors of breast and especially 
lung cancer are at a higher risk of reduced labor market participation. Overall NCDs generate a 
large impact on macro-economic productivity in most WHO regions irrespective of continent and 
income. The absolute global impact in terms of dollars and DALYs remains an elusive challenge 
due to the wide heterogeneity in the included studies as well as limited information from low- and 
middle-income countries.
INTRODUCTION
Non-communicable diseases (NCDs), such as coronary heart disease (CHD), stroke, chronic 
obstructive pulmonary disease (COPD), cancer, type 2 diabetes and chronic kidney disease (CKD) 
currently constitute the number one cause of morbidity and mortality worldwide, claiming 36 
million lives each year (accounting for 63% of all adult deaths) 1. Infectious disease prevention 
and control, economic growth, improvements in medical and scientific knowledge, and health and 
social systems development have all contributed to increased life expectancy, improved quality 
of life and increased likelihood of living to age 60 years and beyond. While these are notable 
achievements, together with lifestyle-related shifts, these epidemiological and socio-demographic 
changes also mean that the burden of NCDs will grow 2.
Productivity is a measure of the efficiency of a person, business or country in converting inputs into 
useful outputs. The productive age span of a person is from adulthood to retirement and ranges from 
18 years to around 65 years of age depending on, amongst other things, profession and country. The 
measurement of productivity greatly relies on the output and the economic or social system context. 
The focus in this report is macro-economic productivity loss in the productive age range due to 
NCDs. Key macro-economic measures related to the labor market include: (un-) employment, (loss 
in) hours worked (including full or part-time work status change), presenteeism (defined as impaired 
performance while at work), absenteeism, disability adjusted life years (DALYs) and productivity 
costs/losses. Key macro-economic outcomes are reduction in the able workforce, NCD-related 
health and welfare expenditure and loss of income earned by the productive workforce. While both 
the burden of NCDs and the socio-economic contexts vary greatly, the impact of the former on 
macro-economic outcomes across the global regions remains unclear. 
We aimed to systematically identify and summarize the literature investigating the impact of six 
NCDs (CHD, stroke, COPD cancer, type 2 diabetes and CKD) on macro-economic productivity 
and to determine directions for future research. 
METHODS
Search Strategy and Inclusion Criteria
We systematically searched the electronic medical databases (Medline, Embase and Google 
Scholar) up to November 6th, 2014 (date of last search) to identify relevant articles evaluating the 
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macro-economic consequences of the six selected NCDs, specifically the impact on economic 
productivity of working age citizens. The complete search strategy is available in Appendix 1. We 
defined the major NCDs of interest as coronary heart disease (CHD), stroke, chronic obstructive 
lung disease (COPD), type 2 diabetes mellitus (DM), cancer (lung, colon, breast and cervical) and 
chronic kidney disease (CKD). The step-wise inclusion and exclusion procedure is outlined in 
Figure 1. Eligible study design included randomized controlled trials (RCTs), cohort, case-control, 
cross-sectional, systematic reviews, meta-analysis, ecological studies and modeling studies. We 
included studies that estimated the impact of at least one of the NCDs defined above on at least 
one of the following measures of macro-economic productivity: DALYs, economic costs related 
to reduced work productivity, absenteeism, presenteeism, (un) employment, (non-) return to work 
(RTW) after sickness absence and medical/sick leave. DALY is also considered as essentially it 
is an economic measure of human productive capacity for the affected individual and when taken 
together (e.g. all those in a company, society etc.) forms an economic measure also on the group 
level. Only studies involving adults (>18 years old) were included, without any restriction on 
language or date. 
Study Selection
Two independent reviewers screened the titles and abstracts of the initially identified studies 
to determine if they satisfied the selection criteria. Any disagreements were resolved through 
discussion and consensus, or by consultation with a third reviewer. In order to ensure that all 
retrieved full texts (of the selected abstracts) satisfied the inclusion criteria appropriately, they 
were further assessed by two independent reviewers. We further screened the reference lists of 
all retrieved studies to retrieve relevant articles. Systematic reviews were not included in the 
data extraction but a supplementary scan of their reference lists was performed to identify any 
additional studies.  
Data Extraction
A data collection form (DCF) was prepared to extract the relevant information from the included 
full texts, including study design, World Health Organization (WHO) region, participants, NCD-
related exposure and macro-economic outcome characteristics. When evaluating economic costs, 
US dollars (USD) was used as outcome measure. If a study reported costs in another currency, 
the corresponding exchange rate to USD as reported by the study itself was used. However, if an 
exchange rate was not provided, we calculated USD applying the conversion rate for the indicated 
study time-period. 
Quality Evaluation
To evaluate the quality of the included non-randomized studies, we applied the Newcastle- 
Ottawa Scale (NOS) 3. The NOS scale assesses the quality of articles in three domains: selection, 
comparability and exposure. ‘Selection’ assesses four items and a maximum of one star can be 
awarded for each item. ‘Comparability’ awards a maximum of two stars to the one item within the 
category. Finally, ‘exposure’ includes four items for which one star can be awarded. A quality score 
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is made for each study by summing the number of stars awarded, and thus the NOS scale can have 
maximum of nine stars. We used this scale to assess the quality of case-control and cohort studies. 
For cross-sectional and descriptive studies, we used an adapted version of NOS scale (Appendix 2).
Statistical Methods
We aimed to pool the results using a random effects model. If pooled, results would be expressed 
as pooled relative risks with 95% confidence intervals. Pooling possibility was conditional on the 
level of heterogeneity between studies.
Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Adepoju OE; et 
al. 201371
2007-2012 USA RA Retrospective 376 Both DM
Ahn E; et 
al.200931
1993 - 2002 South Korea WPR Cross-sectional 1,594 Female Breast Cancer
Alavinia SM, 
Burdorf A. 
200869
2004 10 EU 
countries
ER Cross-sectional 11,462 Both CVD, Stroke, DM
Alexopoulos 
EC, Burdorf A. 
200154
1993 - 1995 The 
Netherlands
ER Prospective 
cohort
326 Male COPD
Anesetti-
Rothermel A, 
Sambamoorthi 
A.  201110
2007 USA RA Cross-sectional 12,860 Both COPD, CVD, 
Stroke, DM
Angeleri F; et al. 
199380
NR Italy ER Prospective 
study
180 Both Stroke
Arrossi S; et al. 
200723
2002 - 2004 Argentina RA Cross-sectional 120 Female Cervical Cancer
Bains M; et al. 
201244
2008 - 2009 UK ER Prospective 
cohort
50 Female Colon Cancer
Balak F; et al. 
200834
2001 - 2007 The 
Netherlands
ER Retrospective 
cohort
72 Female Breast Cancer
Bastida E; Pagan 
JA 200281
1994-1999 USA RA Population based 1,021 Both DM
Black-Schaffer 
RM, Osberg JS. 
199082
1984 – 1986 USA RA Prospective 
study
79 Both Stroke
Bogousslavsky J, 
Regli F. 198783
NR Switzerland ER Prospective 
study
41 Both Stroke
Boles M; et al. 
200484
2001 USA RA Cross-sectional 2,264 Both DM
Bouknight RR; 
et al. 200637
2001-2002 USA RA Prospective 
study
416 Female Breast Cancer
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Bradley C, 
Bednarek  H 
200285
1999 USA RA Cross-sectional 184 Both Breast Cancer, 
Colon Cancer, 
Lung Cancer
Bradley C; et al. 
2002a86
1992 USA RA Retrospective 
study
5,974 Female Breast cancer
Bradley C; et al. 
2002b87
1992 USA RA Cross-sectional 5,728 Female Breast cancer
Bradley C; et al. 
200588
2001-2002 USA RA Prospective 
study
817 Female Breast Cancer
Bradley C; et al. 
200689
2001-2002 USA RA Prospective 
study
239 Female Breast Cancer
Bradley C; 
Dahman B. 
201333
2007 - 2011 USA RA Cross-sectional 828 Both Breast Cancer
Bradley CJ; et al. 
201140
2005 USA RA Modelling study NR Both Colon Cancer
Bradshaw D; et 
al. 200766
2000 - 2000 South Africa AR Modelling NR Both DM
Broekx S; et al. 
201190
1997 - 2004 Belgium ER Cost-of-Illness 
analysis
20,439 Female Breast Cancer
Burton WN; et 
al. 200491
2002 USA RA Survey 16,651 Both DM
Carlsen K; et al. 
201445
2001 - 2009 Denmark ER Epidemiological 4,343 Both Colon Cancer
Carlsen K; et al. 
201429
2001-2011 Denmark ER Cross-sectional 
and propective
14750 Female Breast Cancer
Catalá-López F; 
et al. 201413
2008 Spain ER Cross-sectional 37,563,454 Both Stroke
Choi SK; et al. 
200742
2001 - 2003 South Korea WPR Prospective 
cohort
305 Male Colon Cancer
Collins JJ; et al. 
200592
2002 USA RA Survey 7,797 Both DM
Costilla R; et al. 
201322
2006 New 
Zealand
WPR Modelling NR Both Breast Cancer, 
Colon Cancer, 
Lung Cancer, 
Cervical Cancer
Da Costa 
DiBonaventura 
M; et al. 201253
2009 USA RA Cross-sectional 20,024 Both COPD
Dall TM; et al. 
200968
2007 - 2007 USA RA Modelling NR NR DM
Darkow T; et al. 
200763
2001 - 2004 USA RA Case-control 4,045 Both COPD
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
De Backer G; et 
al. 200693
1994 – 1998 Belgium ER Prospective 
cohort
15,740 Both DM
Eaker S; et al. 
201194
1993 - 2003 Sweden ER Cross-sectional 28,566 Female Breast Cancer
Earle CC; et al. 
201046
2003 - 2005 USA RA Prospective 
cohort
2,422 Both Lung Cancer, 
Colon Cancer
Ekwueme D; et 
al. 201426
1970 - 2008 USA RA Retrospective 
Cohort
53,368 Female Breast Cancer
Etyang AO; et al. 
20146
2007-2012 Kenya AR Prospective 
surveillance
18,712 Both CVD, Stroke, DM
Fantoni SQ; et 
al. 201038
2004-2005 France ER Cross-sectional 379 Female Breast cancer
Fernandez de 
Larrea-Baz N; et 
al. 200995
2000 Spain ER Ecological 40,376,294 Both Breast Cancer, 
Colon Cancer, 
Lung Cancer
Ferro J; Crespo 
M. 199496
1985 - 1992 Portugal ER Prospective 
cohort
215 Both Stroke
Fu AZ; et al. 
200997
2004-2006 USA RA Survey 46,617 Both DM
Gabriele W, 
Renate S. 
200918
2001 - 2004 Germany ER Prospective 
cohort
70 Both Stroke
Genova-Maleras 
R; et al. 20124
2008 Spain ER Modelling NR Both CVD, Stroke, 
COPD, Lung 
Cancer, Colon 
Cancer, Breast 
Cancer, DM
Gordon L; et al. 
200847
2003 - 2004 Australia WPR Prospective 
cohort
975 Both Colon Cancer
Hackett M; et al. 
201219
2008 - 2010 Australia WPR Prospective 
cohort
441 Both Stroke
Halpern MT; et 
al. 200398
2000 USA RA Economical 
evaluation
447 Both COPD
Hansen JA; 2008 
et al.99 
NR USA RA Cross-sectional 203 Female Breast Cancer
Hauglann B; et 
al. 201230
1992 - 1996 Norway ER National 
Registry cohort
3,096 Female Breast Cancer
Hauglann BK; et 
al. 201449
1992-1996 Norway ER Case-control 1480 Both Colon Cancer
Helanterä I; et al. 
201265
2007 Finland ER Cross-sectional 2,637 Both CKD
Herquelot E; et 
al. 2011100
1989-2007 France ER Prospective 
cohort
20,625 Both DM
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Holden L; et al. 
201152
2004 - 2006 Australia WPR Cross-sectional 78,430 Both CVD, COPD, DM
Hoyer M; et al. 
2013101
2007 - 2008 Sweden ER Prospective 
cohort
651 Female Breast Cancer
Jansson SA; et 
al. 200259
1999 Sweden ER Economic 
Evaluation
212 Both COPD
Kabadi GS; et al. 
201317
2005-2006 Tanzania AR Prospective 
surveillance 
Study
16 Both Stroke
Kang H-Y; et al. 
201116
2008 South Korea WPR Economic 
Evaluation
Both Stroke
Kappelle JL; et 
al.1994102
1977 - 1992 USA RA Prospective 
study
296 Both Stroke
Katzene 
llenbogen 
JM; et al. 
201114
1997-2002 Western 
Australia
WPR Modelling, 
ecologocial 
68,661 Both Stroke
Kessler, RC; et 
al. 200170
1995-1996 USA RA Survey 2,074 Both DM
Klarenbach S; et 
al. 200264
1988 - 1994 USA RA Cross-sectional 5,558 Both CVD, COPD, DM, 
CKD
Kotila M; et al. 
1984103
1978-1980 Finland ER Prospective 255 Both Stroke
Kremer AM; et 
al. 200655
2000 - 2001 Australia ER Cross-sectional 826 Both COPD
Kruse, M; et. Al. 
2009104
1980 - 2003 Denmark ER Cohort 2,212 Both CHD
Lauzier S; et al. 
200835
2003 Canada RA Prospective 
cohort
962 Female Breast Cancer
Lavigne JEl; et 
al. 200367
1999 - 1999 USA RA Cross-sectional 472 Both DM
Leigh JP; et al. 
2002105
1996 USA RA Ecological study 2,395,650 Both COPD 
Leng CM. 
2008106
2004 - 2005 Singapore WPR Retrospective 
Cohort
29 NR Stroke
Lenneman, J; et 
al.  2011107
2005-2009 USA RA Survey 577,186 Both DM
Lindgren P; et al. 
2008108
1994 Sweden ER Cross-sectional 393 Both Stroke
Lokke, A; et al. 
(1) 201462
1998-2010 Denmark ER Case-control 262,622 Both COPD
Lokke, A; et al. 
(2) 201461
1998-2010 Denmark ER Case-control 1,269,162 Both COPD
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Lopez-Bastida J; 
et al. 201215
2004 Canary 
Islands, 
Spain
ER Cross-sectional 448 Both Stroke
Mahmoudlou A; 
201439
2008 Iran EMR Cross-sectional 72,992,154 Both Colon Cancer
Maunsell E; et 
al. 200432
1999 - 2000 Canada RA Cross-sectional 57,307 Female Breast Cancer
Mayfield, JA; et 
al.1999109
1987 USA RA Survey 35,000 Both DM
McBurney CR; 
et al. 2004110
1999-2000 USA RA Cross-sectional 
survey
89 Both CVD
Molina R; et al. 
2008111
2004 – 2005 Spain ER Cross-sectional 347 Both Breast Cancer, 
Colorectal Cancer, 
Lung Cancer
Molina 
Villaverde R et 
al. 2008112
NR Spain ER Cohort 96 Female Breast Cancer
Moran Al; et al. 
20085
2000 - 2029 China WPR Ecological and 
Modelling
1,270,000,000 Both CVD
Nair K; et al. 
2012113
2000 - 2007 USA RA Economic 
Evaluation
853,496 Both COPD
Neau JP; et al. 
1998114
1990 – 1994 France ER Retrospective 67 Both Stroke
Niemi ML; et al. 
1988115
1978 – 1980 Finland ER Retrospective 
case-series
46 Both Stroke
Nishimura S, 
Zaher C. 200458
1990 - 2002 Japan WPR Modelling study 1,848,000 Both COPD
Noeres D; et al.  
201328
2002 - 2010 Germany ER Prospective 
cohort
874 Female Breast Cancer
Nowak D; et al. 
200460
2001 Germany ER Cross-sectional 814 Both COPD
O’Brien A; et al. 
2010116
NR USA RA Cross-sectional 98 Both Stroke
Ohguri T et al; 
2009117
2000-2005 Japan WPR Cross-sectional 43 Both Lung Cancer, 
Colon Cancer
Orbon K; et al. 
200556
1998 - 2000 The 
Netherlands
ER Cross-sectional 2,010 Both COPD
Osler M; et al. 
201412
2001-2009 Denmark ER Cohort 21,926 Both CVD
Park JH; et al. 
200848
2001 - 2006 South Korea WPR Cross-sectional 2,538 Both Lung Cancer, 
Colon Cancer, 
Breast Cancer, 
Cervical Cancer
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Park JH; et al. 
2009118
2001 - 2006 South Korea WPR Prospective 
study
1,602 Both Lung Cancer, 
Colon Cancer, 
Breast Cancer, 
Cervical Cancer
Peters G; et al. 
2013119
NR Nigeria AR Cross-sectional 110 Both Stroke
Peuckmann V; et 
al. 2009120
1989 – 1999 Denmark ER Cross-sectional 1,316 Female Breast Cancer
Quinn AC; et al. 
201420
1998-2008 UK ER Prospective 
Cohort
214 Both Stroke
Robinson N; et 
al. 1989121
1985 – 1989 UK ER Cross-sectional 2,104 Both DM
Roelen CAM; et 
al. 2009122
2001 - 2005 The 
Netherlands
ER Ecological 259 Female Breast Cancer
Roelen CAM; et 
al. 201150
2004 - 2006 The 
Netherlands
ER Retrospective 
Cohort
300,024 Both Lung Cancer, 
Breast Cancer
Saeki S, 
Toyonaga T. 
2010123
2006 - 2007 Japan WPR Prospective 
cohort
325 Both Stroke
Sasser AC; et al. 
20058
1998 - 2000 USA RA Economic 
Evaluation
38,012 Female Breast cancer, 
CVD
Satariano WA; et 
al. 199627
1984-1985 
1987-1988
USA RA Cross-sectional 1,011 Female Breast Cancer
Short PF; et al. 
2005124
1997-1999 USA RA Cross-sectional 1,433 Both Breast Cancer
Short PF; et al. 
200811
2002 USA RA Cross-sectional 6,635 Both CVD, Stroke, 
COPD, DM
Sin DD; et al. 
2002125
1988 - 1994 USA RA Cross-sectional 12,436 Both COPD
Sjovall K; et al. 
201236
2004-2005 Sweden ER Ecological study 14,984 Both Breast Cancer, 
Colon Cancer, 
Lung Cancer
Spelten ER; et al. 
2003126
NR The 
Netherlands
ER Prospective 
cohort
235 Female Breast Cancer
Stewart DE; et 
al. 2001127
NR Canada RA Cross-sectional 378 Female Breast Cancer
Strassels SA; et 
al. 2001128
1987 – 1988 USA RA Cross-sectional 238 Both COPD
Syse A; et al. 
200851
1953-2001 Norway ER Cross-sectional 
population based
1,116,300 Both Breast Cancer, 
Lung Cancer, 
Colorectal Cancer
Taskila-Brandt T; 
et al. 200424
1987-1988 
1992-1993
Finland ER Cross-sectional 
population based
5,098 Both Cervical Cancer, 
Breast Cancer, 
Colon Cancer 
Lung Cancer
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Table 1. General Characteristics of the Studies Included in this Review (continued)
Lead Author Period of 
Surveillance
Location WHO
region
Study 
Design
Number in 
Analysis
Gender Reported NCDs
Taskila T; et al. 
2007129
1997-2001 Finland ER Cross-sectional 394 Female Breast Cancer
Teasell RW; et 
al. 2000130
1986-1996 Canada RA Retrospective 
cohort
563 Both Stroke
Tevaarwerk AJ; 
et al. 201343
2006 - 2008 USA and 
Peru
RA Cross-sectional 530 Both Breast Cancer, 
Lung Cancer, 
Colon Cancer
Timperi AW; et 
al. 2012131
2006 - 2011 USA RA Prospective 
cohort
2,013 Female Breast Cancer
Torp S; et al. 
201225
1999 - 2004 Norway ER Prospective 
Registry
9,646 Both Cervical Cancer, 
Breast Cancer, 
Colon Cancer, 
Lung Cancer
Traebert J; et al. 
201321
2008 Brazil RA Modelling, 
Ecological
NR Both Cervical Cancer, 
Breast Cancer, 
Colon Cancer, 
Lung Cancer
van Boven JFM; 
et al. 201357
2009 The 
Netherlands
ER Economic 
Evaluation
45,137 Both COPD
Van der Wouden 
JC et al. 1992132
1978-1980 The 
Netherlands
ER Cross-sectional 313 Female Breast Cancer
Vestling M; et al. 
2003133
NR Sweden ER Retrospective 
study
120 Both Stroke
Wang PS; et al. 
2003134
NR USA RA Cross-sectional 199 Both CVD, COPD, 
Diabetes
Ward ME; et al. 
2002135
1993 – 1994 USA RA Cross-sectional 2,529 Both COPD
Wozniak; et al. 
1999136
NR USA RA Retrospective 
study
203 Both Stroke
Yaldo A; et al. 
201441
2006-2009 USA RA Case-Control 330 Both Colon Cancer
Yabroff KR; et 
al. 2004137
2000 USA RA Cross-sectional 496 Both Breast Cancer, 
Colon cancer
Zhao Z; Winget 
M. 20117
2003 - 2006 USA RA Retrospective 
Cohort
10,487 Both CVD (CHD)
Zheng H; et al. 
20109
2004 Australia WPR Economic 
Evaluation
NR Both CVD (CHD)
Abbreviations: AR: African Region, COPD: Chronic Obstructive Pulmonary Disease, CKD: Chronic Kidney Disease, 
CVD: Cardiovascular Disease, DM: Diabetes Mellitus, EMR; Eastern Mediterranean Region, ER: European Region, NCD: 
No-communicable Diseases, NR: Not Reported, RA: Region of the Americas,  USA: United States of America, WHO: 
World Health Organization, WPR: Western Pacific Region.
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RESULTS
General Characteristics of the Included Studies
From 4542 references initially identified, a total of 126 unique studies met the inclusion criteria 
(Figure 1 and Table 1). All eligible studies were published between 1984 and 2014.
Of the 126 studies identified, 52 were from the WHO European Region, 53 from the Region of the 
Americas (of which all but two were from Canada or the United States of America [USA]), 16 from 
the Western Pacific Region, four were from the WHO African Region and one from the Eastern 
Mediterranean Region. We found no studies from South East Asia. The majority of the identified 
studies were observational in design, analyzed prospectively as well as cross-sectional. Two studies 
reported cross-sectional data from an RCT and six were modeling studies. National or hospital-
based disease registries were often used to select patients, which were in some cases linked to 
national socio-economic databases to extract corresponding employment data. The control group, 
if used, was often a sample from the general population and sometimes sought within the same 
environment of the patients (e.g. same company). Many studies focused on the impact of more 
than one NCD on productivity. Most studies used one measure of productivity. Of all the published 
studies including cancers, cervical cancer was included in seven studies, breast cancer in 45, colon 
cancer in 24 and lung cancer in 16. Stroke was included in a total of 31 studies, COPD in 24, DM 
in 22 and CHD was included in 15 studies. Relevant data on CKD was included in only two of the 
studies and two of the studies mention NCDs in general.
Measures of Productivity 
Measures of productivity impact in the available studies included DALYs, absenteeism, 
presenteeism, labor market (non-) participation, RTW, change in hours worked and medical/sickness 
leave. Most studies focused on the direct impact on the patient but a minority also examined the 
impact on caregivers/spouses. Outcomes were quantified using risks, proportions, odds, dollars, 
years and days. In some studies, time-to-event data was analyzed using Cox proportional-hazards 
regression. Adjusting for education, age and employment status was most frequently applied, 
although the measurement of education and employment was not consistently defined, measured 
or validated. A small minority of studies reported differences in impact according to ethnicity. 
Pooling of outcomes was not possible due to substantial heterogeneity across and within NCD 
groups (I2> 70%). 
Impact of Cardiovascular Disease on Productivity
Of all DALYs on a population level in Spain (Table 2a), 4.2% were attributable to CHD 4 with an 
estimated age-standardized rate of 4.7 per 1000 persons per year. In China, DALYs attributable 
to CHD were estimated to be 8,042,000 for the year 2000 and predicted to more than double in 
2030, rising up to 16,356,000 5. In the same study, the estimated  DALY in 2000 was 16.1 per 1000 
persons and predicted to be 20.4 in 2030 (estimate not accounted for age). A study from Kenya 
estimated the DALY to be 68 per 100,000 person-years of observation 6. CHD-related productivity 
86
loss in the USA was estimated to be 8539 USD per person per year (PP/PY), at 10175 USD PP/PY 
7 for absenteeism and 2698 USD PP/PY for indirect work-related loss 8. Total absenteeism-related 
costs in Australia were estimated at 5.69 billion USD, mortality-related costs at 23 million USD 
and costs related to lower employment at 7.5 billion USD 9. An estimated 4.7 working days PP/PY 
were lost in the USA owing to CHD 10. Also in the USA, the odds of experiencing limited amount 
of paid work due to illness were significantly higher for those with CHD compared to the control 
group, with an odds ratio (OR) of 2.91 for women (95% CI 2.34 – 3.61) and 2.34 for men (95% 
CI 1.84 – 2.98) 11. In Denmark workforce participation increased with increasing time from 37% 
after 30 days to 65% after 5 years of diagnosis12. In a study conducted in 10 European Union (EU) 
countries, no difference was found for the risk of non-participation in the labor force between those 
with and without self-reported CHD with an OR of 0.96 (95% CI 0.66 – 1.40).     
Impact of Stroke on Productivity
Stroke accounted for 3.5% of all DALYs reported in Spain (Table2b) with a rate of 3.8 per 1000 
people 4.  Another study from Spain reports a total count of DALYs of 418,052 with a higher 
number of male than for female (220,005 vs. 198,046) 13 . A study from Kenya reports a rate 
of 166 DALYs per 100,000 person-years observed 6. In Western Australia, the average annual 
stroke-attributable DALY count is an estimated 26315 for men and 30918 for women 14. In Spain, 
costs after diagnosis increased over time for caregivers but declined for patients (14732 USD in 
caregivers compared to 2696 USD among patients after one year and 15621 USD to 1362 USD 
after two years) 15. Modeled productivity losses in South Korea were higher for a severe stroke 
among men (537724 USD) than women (171157 USD) 16. A prospective surveillance study from 
Tanzania report a mean costs of productivity loss to be 213 USD 17. Inconclusive evidence of the 
impact of stroke on RTW was reported. Estimates ranged from 26.7% to 75% in studies reporting 
RTW in stroke patients after one year of the event 18,19. In Nigeria, 55% returned to work at a 
mean of 19.5 months after stroke. A report from the United Kingdom (UK) found that 47% were 
unemployed one year after stroke 20.  Increased odds to report limited ability for paid work were 
found among men (3.86) and women (2.26) after stroke 11.
Impact of Cervical Cancer on Productivity
There are strong regional differences in the percentage of DALYs attributable to cervical cancer 
(Table 2c) among women, from 1.6% (absolute DALYs, 1061 per year) in New Zealand to 13.4% 
(2516 per year) in Brazil 21,22. Cervical cancer patients in Argentina reported negative outcomes 
after one year; 45% of patients reported reduced labor market participation, 28% experienced 
work interruption and 5% changed work 23.  Compared to the general population, the relative risk 
(RR) for cervical cancer survivors in labor force participation was 0.77 (95% CI 0.67 – 0.90), 2 to 
3 years after diagnosis in Finland 24. In Norway however, no differences were found 5 years from 
diagnosis with an OR of 0.92 (0.63 – 1.34) 25.
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Impact of Breast Cancer on Productivity
Of all the DALYs attributable to cancers among women, 27.3% (17840 per year) in New Zealand 
(Table 2d) and 13.4% (6280 per year) in Brazil are attributable to breast cancer 21,22. Total 
mortality-related lifetime productivity loss costs in the USA were estimated to be 5.5 billion USD 
26. This was differentially distributed between the two ethnic groups reported, with 71% (or 3.9 
billion USD) of the costs attributable to white women and 24% (or 1.3 billion) attributable to black 
women. Differential RTW and sick absence rates are also observed comparing black and white 
women in the USA; the percentage of white women returning to work three months after diagnosis 
was 74.2% compared to 59.6% of black women; the proportion reporting sick leave was 25.8% of 
white women compared to 40.4% of black women 27. One year after primary surgery in Germany, 
nearly three times as many cancer survivors had left their job as compared to women in the control 
group. 28 Various studies suggest higher unemployment among breast cancer survivors, reported 
by around half after one year, 72% after two years 29, 43% after six years and 18% after nine 
years 27,28,30-32.  In contrast, in a study assessing unemployment among the spouses of breast cancer 
patients, no differences were found 33.  Differences between countries in average time to RTW 
were also found, from 11.4 months in the Netherlands 34 and 7.4 months in Canada 35 to only three 
months in Sweden 36. Percentage of RTW after one year ranged from 54.3% in a cross-sectional 
study from France to 82% in a prospective study from the USA 37,38.
Impact of  Cancer on Productivity
In New Zealand, of all the DALYs attributable to cancers, 12.9% (8431 per year) among women 
and 13.5% (8316 per year) among men are attributable to colon cancer (Table 2e) 22. In Brazil, 
these proportions are 9.3% among women and 7.5% among men 21. In Spain, 2.1% of DALY’s 
overall are attributable to colon cancer 4. In Iran the total burden of colorectal cancer in 2008 was 
52,534 DALYs and higher for men than for women 39. In the USA, annual productivity losses 
were calculated to be 20.9 billion USD 40, while costs due to absenteeism after 1 year of diagnosis 
was 4,245 USD per patient compared to the general population 41. Although the DALY and dollar 
costs of colon cancer are undoubtedly large, the evidence for micro-level labor market indicators 
including risk and proportions of RTW, sickness absence and employment following diagnosis and 
treatment is however inconclusive 25,42-49. In New Zealand, of all cancer-attributable DALYs, 14.4% 
(9334 per year) among women and 15.9% (9806 per year) among men are attributable to lung 
cancer (Table 2f) 22. In Brazil, lung cancer results in an estimated 10832 DALYs per year, 9.8% of 
all cancer-related DALYs among women and 24.5% among men 21. In Spain, 3.4% of all DALYs 
are attributable to lung cancer 4. Most of the first year of disease (275 days) is spent in sickness 
absence in Sweden 36 and between 33-79% of lung cancer patients in the USA were unemployed 15 
months after diagnosis  43,46. Average time to re-enter the labor market was 484 days for full-time 
work and 377 for part-time work in the Netherlands 50. The odds of re-entry into the labor market 
were significantly lower for lung cancer than the general population 24,25,51.
88
Impact of COPD on Productivity
COPD patients have a higher chance of working fewer hours, of absenteeism and of poorer work 
performance (presenteeism) (Table 2g). 11,52,53. A COPD patient loses around 8.5 workdays per 
year due to disease  10,54. Between 39-50% of people stopped working due to the onset of COPD 
in the Netherlands 55,56. COPD-related productivity losses cost the US economy around 88 million 
USD or around 482966 working days per year 57. Modeled annual costs of COPD, estimated at 
1.47 billion USD 58, are higher in Japan than the USA. The productivity loss costs PP/PY were 
somewhat comparable between Germany, Sweden and the Netherlands (566, 749 and938 USD 
respectively) 57,59,60,  but differed four-fold to estimated costs in Denmark (2816 to 3819 USD)61,62 
and more than 10-fold to what was estimated (9815 USD) in the USA 63. In the USA, 8.5 work days 
are lost PP/PY on average10, while COPD patients take an estimated 8.6 days of sickness absence 
in the Netherlands during a two year follow-up period 54. Also in the Netherlands, 39% of COPD 
patients left the labor force due to disease onset 55.
Impact of Chronic Kidney Disease on Productivity
Only two studies (Table 2h) examined the impact of CKD on productivity. One found that renal 
dysfunction was independently associated with labor force non-participation, with an odds ratio 
of 7.94 (95% confidence interval, 1.60 to 39.43)  64. The second study, evaluating labor market 
participation in CKD patients specifically after dialysis or transplantation, found that 35% of these 
CKD patients were unemployed 65.
Impact of Diabetes Mellitus on Productivity
In Spain, nearly 2% of all mortality-related DALYs are attributable to DM 4. In South Africa, 
162877 DALYs annually are attributable to DM (Table 2i) 4,66. A study from Kenya reports a rate of 
364 DALYs per 100,000 observed person-years 6. An estimated 7.2 days are lost PP/PY due to DM 
in the USA10 and DM patients have an increased risk of absenteeism, presenteeism and inability to 
work 4,10,11,52,64,67-69.  Productivity days lost per year due to diabetes ranged from 3.6 to 7.3 10,70. In the 
USA, proportion of productivity loss was large due to premature mortality (49%) and presenteeism 
(44%) compared to absenteeisim (4%) and total productivity related costs were estimated to be 
1,962,314 USD 71.The odds of non-participation of the labor force for diabetes patients compared 
to the general population were slightly higher with borderline significance in the EU, an OR of 1.38 
(95% CI 0.99 – 1.93) 69. 
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DISCUSSION
This systematic review identified 126 studies investigating the impact of NCDs on productivity. 
Most studies (96%)were from the Western world (North America, Europe or Asia Pacific), with 
limited evidence available from Brazil, South Africa, Kenya, Tanzania, Iran,  Japan, South 
Korea and Argentina. Macro-economic productivity losses were measured in percentage and 
absolute numbers of DALYs and annual productivity loss costs (in USD). Studies also estimated 
productivity losses using labor market indicators including unemployment, RTW, absenteeism, 
presenteeism, sickness absence and loss in working hours. There is a clear scarcity in literature 
concerning the effect of CKD on productivity, with only two studies both reporting a substantial 
impact on productivity 64,65.
Diversity in the Macroeconomic Measures and Outcomes  
There were considerable global differences in the NCD-attributable DALY burden, especially the 
differential impact of each NCD comparing high-income countries (HIC) and low- and middle-
income countries (LMIC). Lung and colon cancer account for nearly 30% of all cancer-attributable 
DALYs in men in New Zealand whereas in Brazil, lung cancer alone accounts for nearly 25%. 
Among women in HIC, breast cancer seems to impose a large productivity burden whereas cervical 
cancer impacts more dramatically in LMIC  4,21,22. Although DALYs are a reliable measure and 
capture both years of life lost and years spent in ill-health, we found inconsistent application in 
the identified studies; some estimated proportions within specific disease groups or of the overall 
DALY burden in a country; others estimated absolute DALY numbers.
Diversity in the Macro-economic Impact of the Cardiopulmonary Diseases 
Absolute costs (measured in USD) were estimated for COPD, CHD, and stroke events 15,57,7,9,58,71. 
These studies mainly came from HIC, although two studies, one from Kenya and one from 
Tanzania, were also retrieved. In Australia, absenteeism and lower employment  due to CHD cost 
13.2 billion USD annually, as well as an additional 23 million USD in mortality-related costs9. 
Evidence suggests that COPD costs around 88 million USD or nearly 500,000 working days 
per year in the US compared to 1.47 billion (modeled) in Japan. While annual COPD-related 
productivity costs were comparable in Germany, Sweden and the Netherlands (between 566-938 
USD), costs differed four-fold (2816-3819 USD) in Denmark, 10-fold (9815 USD) in the USA57,59-
63. In the USA, nearly half of the annual 1.96m USD productivity losses due to DM are attributable 
to mortality, with 44% attributable to presenteeism and just 4% to absenteeism  In South Korea, 
modeled productivity losses for a stroke were 68% higher among men compared to women 16. 
Around half of all stroke survivors in unemployed after one year 20. In Tanzania, productivity 
losses after six months following stroke were 213 USD on average although these losses were 
most acutely experienced by those in higher skill roles 17. Interestingly, indirect productivity losses 
were higher among caregivers than stroke patients themselves and costs increased for caregivers 
but declined for patients after one and two years following a stroke in Spain. COPD patients 
116
experience reduced working hours, unemployment, absenteeism and presenteeism 10,11,52-56. DM 
patients also have an increased risk of reduced labor market participantion 10,11,52,64. By contrast, 
other than for absenteeism10 the evidence for the risk of reduced labor market participation due 
to CVD is inconclusive. In Kenya, 68/100,000 person year observed are attributable to CVD 
compared to 166/100,000 for stroke and 364 /100,000 for DM 6. Although evidence is limited, 
the higher productivity impact associated with diseases with a large morbidity was perhaps to be 
expected; chronic diseases such as COPD and DM affect people during their productive years and 
cannot really be ‘cured’, only managed. The extent to which employers or societies support and 
enable NCD populations to remain members of the productive workforce will also differentially 
distribute the impact. The extent to which secondary or tertiary prevention is possible will also 
affect productivity estimates, specifically so for labor market indicators such as RTW, change in 
work status or unemployment
Diversity in the Macroeconomic Impact of Cancer 
Lung cancer survival is associated with reduced labor market participation through sickness 
absence, extended RTW 36,50 and unemployment  25,43,46. Total mortality-related lifetime productivity 
loss due to breast cancer were an estimated 5.5 billion USD in the USA 26 and annual productivity 
losses due to colon cancer costs the US economy 20.9 billion USD 40.We found inconclusive 
evidence of risk of reduced labor market participation (RTW, sickness absence and unemployment) 
following colon cancer diagnosis and treatment 25,42-46,48. The evidence for breast cancer-related 
labor market drop-out shows higher unemployment among survivors one, two, six and nine years 
after diagnosis 29-32. Evidence from the USA also suggests ethnicity-patterned differences in sick 
leave and unemployment  27. Along with possible socio-economic differences associated with these 
outcomes 72, pathophysiological differences may also play a role. African-American women have 
lower incidence of breast cancer but higher mortality and are also diagnosed in later stages and 
with more aggressive types of tumors 73. However, we are cautious in over interpretation of this 
finding as few studies included ethnicity. Geographic differences in average months to RTW were 
observed from 11.4 in the Netherlands 34 to 7.4 in Canada 35 to just three months in Sweden 36.
Although evidence is limited, the higher productivity impact associated with diseases with a large 
morbidity was perhaps to be expected; chronic diseases such as COPD and DM affect people 
during their productive years and cannot really be ‘cured’, only managed. It is surprising that half 
of all productivity losses in the USA attributable to DM are due to mortality rather than absenteeism 
and presenteeism. The extent to which employers or societies support and enable NCD populations 
to remain members of the productive workforce will also differentially distribute the impact both 
within societies but also comparing more affluent to less affluent countries. The extent to which 
secondary or tertiary prevention is possible will also affect productivity estimates, specifically so 
for labor market indicators such as RTW, change in work status or unemployment. 
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Comparison with the Previous Work
Findings of this systematic review generally concur with and further extend the previous reviews. 
This study is a comprehensive systematic review tackling work-related burden of six major NCDs 
using a global perspective and without language limitation. Two reviewers included and assessed 
the studies and references of the included studies were tracked for any missing evidence. These 
approaches ensured that we included most of the relevant articles in our review. Similar to previous 
reviews, we found that, due to a great amount of variation in the studies included, comparability 
and pooling the studies were not possible. Most of the previous reviews were performed non-
systematically and previous systematic reviews have included studies only in English. Previous 
studies were mainly focused on the impact of cancers 74-78 on work-related outcomes (mainly 
RTW) and often included a mix of cancers without specifying the type of cancer. Van Muijen and 
colleagues 78 reviewed only cohort studies of cancer-related work outcomes and were focused 
on English language. Steiner and colleagues 76  reviewed English publications published up until 
2003, Breton and colleagues were focused only on diabetes and Krisch and colleagues focused on 
COPD in Germany79.
Strengths and Limitations of the Current Work
In this systematic review we evaluated the literature concerning the impact on productivity of 
six top NCDs. These six were selected based on their dominance in the global burden of disease 
and together make a huge contribution to mortality and morbidity worldwide. Several important 
issues are out of scope for this work but do merit future research.  First, we did not look into the 
underlying mechanisms of what forces people with NCDs in and out of the labor force, specifically 
in terms of co-morbidities (certain NCDs cluster in the same populations) and financial/social 
means available at an individual and collective level. How these mechanisms interact will also 
be different according to the level of economic and social development. For example, children 
in LMIC are more likely to be forced into the labor market due to the onset of NCDs in parents 
compared to children in HIC and the productive output of this child cannot replace the loss 
due to drop out by the parents. These related topics should be addressed separately to better 
understand how to modify and target these outcomes more specifically. Second, we observed 
wide heterogeneity in all domains within the studies selected, including study design, methods 
and sources used to measure productivity, adjustment for confounders and analyses. Third, no 
identified studies quantified the differential productivity impact by national economic development 
and labor market structure across countries. How these inter-country macro-economic differences 
might mitigate or magnify productivity losses associated with NCDs is worth further exploration. 
Fourth, we identified a crucial gap of relevant information from LMICs – limiting the relevance of 
our review most acutely in these settings. This lack of evidence could reflect differences in disease 
burden, in research capacity, in welfare systems and in epidemiological surveillance. The burden of 
NCDs is growing rapidly in LMIC; countries that often lack capacity in these key areas of support, 
prevention and knowledge generation. Further evaluation, therefore, of the macro-economic impact 
in the LMIC countries is urgently needed. Also, many NCDs affect people cumulatively over time; 
people may suffer DM, may experience absenteeism/presenteeism as a result, may reduce work as 
DM worsens and may finally drop out of the workforce due a stroke or CHD, which is related to 
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the DM. Given NCDs are shifting more and more into chronic conditions, as our understanding of 
treatment and natural history improve, it would be of great interest to investigate the effects over 
the life course rather than using short time horizons such as a year. This is no mean feat, but could 
be crucial for developing a better understanding of the economic impact of NCDs on a regional, 
national and international level. Also out of scope for this review but of interest for future work 
are the productivity-related impact of behavioural risk factors that contribute to the development 
of NCDs.
Conclusions
In summary, available studies indicate that the six main NCDs generate a large impact on macro-
economic productivity in the WHO regions. However, this evidence is heterogeneous, of varying 
quality and not evenly geographically distributed. Data from LMI countries in economic and 
epidemiological transition are virtually absent. Further work to reliably quantify the absolute 
global impact of NCDs on macro-economic productivity and DALYs is urgently required. 
Supplementary Material can be found online: http://www.ncbi.nlm.nih.gov/pmc/articles/
PMC4457808/ 
119
2
Ec
on
om
ic
 Im
pa
ct
 o
f N
on
-C
om
m
un
ic
ab
le
 D
is
ea
se
s
REFERENCES
1. Alwan AA, T.; Bettcher, D.; Branca, F.; Chisholm, 
D.; Ezzati, M.; Garfield, R.; MacLean, D.; Mathers, 
C.; Mendis, S.; Poznyak, V.; Riley, L.; Cho Tang, K.; 
Wild, C. Global status report on noncommunicable 
diseases World Health Organization. 2010.
2. World Population Prospects: The 1998 Revision,vol. 
II, Sex and Age Distribution of the World Population 
United Nations Population Division  1999.
3. Wells G, Shea B, O’Connell D, et al. The Newcastle-
Ottawa score for non-randomized studies. 
2010. http://www.ohri.ca/programs/clinical_
epidemiology/oxford.asp. Accessed 11 Feb 2014.
4. Genova-Maleras R, Alvarez-Martin E, Morant-
Ginestar C, Fernandez de Larrea-Baz N, Catala-
Lopez F. Measuring the burden of disease and 
injury in Spain using disability-adjusted life years: 
an updated and policy-oriented overview. Public 
Health. 2012;126(12):1024-1031.
5. Moran A, Zhao D, Gu D, et al. The future impact 
of population growth and aging on coronary heart 
disease in China: projections from the coronary 
heart disease policy model-China. BMC Public 
Health. 2008;8:394.
6. Etyang AO, Munge K, Bunyasi EW, et al. Burden of 
disease in adults admitted to hospital in a rural region 
of coastal Kenya: An analysis of data from linked 
clinical and demographic surveillance systems. 
Lancet Global Health. 2014;2(4):E216-E224.
7. Zhao Z, Winget M. Economic burden of illness of 
acute coronary syndromes: medical and productivity 
costs. BMC Health Serv Res. 2011;11:35.
8. Sasser AC, Rousculp MD, Birnbaum HG, Oster 
EF, Lufkin E, Mallet D. Economic burden of 
osteoporosis, breast cancer, and cardiovascular 
disease among postmenopausal women in an 
employed population. Women’s Health Issues. 
2005;15(3):97-108.
9. Zheng H, Ehrlich F, Amin J. Productivity loss 
resulting from coronary heart disease in Australia. 
Appl Health Econ Health Policy. 2010;8(3):179-
189.
10. Anesetti-Rothermel A, Sambamoorthi U. Physical 
and mental illness burden: Disability days 
among working adults. Popul Heath Manage. 
2011;14(5):223-230.
11. Short PF, Vasey JJ, BeLue R. Work disability 
associated with cancer survivorship and other chronic 
conditions. Psycho-Oncology. 2008;17(1):91-97.
12. Osler M, Martensson S, Prescott E, Carlsen K. 
Impact of gender, co-morbidity and social factors 
on labour market affiliation after first admission for 
acute coronary syndrome. A cohort study of Danish 
patients 2001-2009. PLoS ONE. 2014;9(1).
13. Catala-Lopez F, Fernandez de Larrea-Baz N, 
Morant-Ginestar C, Alvarez-Martin E, Diaz-
Guzman J, Genova-Maleras R. The national burden 
of cerebrovascular diseases in Spain: A population-
based study using disability-adjusted life years. Med 
Clin. 2014.
14. Katzenellenbogen JM, Vos T, Somerford P, Begg 
S, Semmens JB, Codde JP. Burden of stroke in 
indigenous western australians: A study using data 
linkage. Stroke. 2011;42(6):1515-1521.
15. Lopez-Bastida J, Oliva Moreno J, Worbes Cerezo 
M, Perestelo Perez L, Serrano-Aguilar P, Monton-
Alvarez F. Social and economic costs and health-
related quality of life in stroke survivors in the 
Canary Islands, Spain. BMC Health Serv Res. 
2012;12:315.
16. Kang HY, Lim SJ, Suh HS, Liew D. Estimating the 
lifetime economic burden of stroke according to the 
age of onset in South Korea: a cost of illness study. 
BMC Public Health. 2011;11:646.
17. Kabadi GS, Walker R, Donaldson C, Shackley P. The 
cost of treating stroke in urban and rural Tanzania: A 
6-month pilot study. Afr J Neurol Sci. 2013;32(2).
18. Gabriele W, Renate S. Work loss following stroke. 
Disabil Rehabil. 2009;31(18):1487-1493.
19. Hackett ML, Glozier N, Jan S, Lindley R. Returning 
to paid employment after stroke: The psychosocial 
outcomes in stroke (POISE) cohort study. PLoS 
ONE. 2012;7(7).
20. Quinn AC, Bhargava D, Al-Tamimi YZ, Clark MJ, 
Ross SA, Tennant A. Self-perceived health status 
following aneurysmal subarachnoid haemorrhage: A 
cohort study. BMJ Open. 2014;4(4).
21. Traebert J, Schneider IJC, Colussi CF, de Lacerda 
JT. Burden of disease due to cancer in a Southern 
Brazilian state. Cancer Epidemiol. 2013;37(6):788-
792.
120
22. Costilla R, Tobias M, Blakely T. The burden 
of cancer in New Zealand: a comparison of 
incidence and DALY metrics and its relevance 
for ethnic disparities. Aust N Z J Public Health. 
2013;37(3):218-225.
23. Arrossi S, Matos E, Zengarini N, Roth B, 
Sankaranayananan R, Parkin M. The socio-
economic impact of cervical cancer on patients 
and their families in Argentina, and its influence 
on radiotherapy compliance. Results from a cross-
sectional study. Gynecol Oncol. 2007;105(2):335-
340.
24. Taskila-Brandt T, Martikainen R, Virtanen SV, 
Pukkala E, Hietanen P, Lindbohm ML. The impact 
of education and occupation on the employment 
status of cancer survivors. European Journal of 
Cancer. 2004;40(16):2488-2493.
25. Torp S, Nielsen RA, Fossa SD, Gudbergsson 
SB, Dahl AA. Change in employment status of 
5-year cancer survivors. Eur J Public Health. 
2013;23(1):116-122.
26. Ekwueme DU, Guy Jr GP, Rim SH, et al. Health and 
economic impact of breast cancer mortality in young 
women, 1970-2008. Am J Prev Med. 2014;46(1):71-
79.
27. Satariano WA, DeLorenze GN, Bush GW. The 
likelihood of returning to work after breast cancer. 
PUBLIC HEALTH REP. 1996;111(3):236-243.
28. Noeres D, Park-Simon TW, Grabow J, et al. Return to 
work after treatment for primary breast cancer over 
a 6-year period: Results from a prospective study 
comparing patients with the general population. 
Supportive Care Cancer. 2013;21(7):1901-1909.
29. Carlsen K, Ewertz M, Dalton SO, Badsberg JH, 
Osler M. Unemployment among breast cancer 
survivors. Scand J Public Health. 2014;42(3):319-
328.
30. Hauglann B, Benth JS, Fossa SD, Dahl AA. A 
cohort study of permanently reduced work ability 
in breast cancer patients. J Cancer Survivorship. 
2012;6(3):345-356.
31. Ahn E, Cho J, Shin DW, et al. Impact of breast 
cancer diagnosis and treatment on work-related life 
and factors affecting them. Breast Cancer Res Treat. 
2009;116(3):609-616.
32. Maunsell E, Drolet M, Brisson J, Brisson C, Masse 
B, Deschenes L. Work situation after breast cancer: 
Results from a population-based study. J Natl 
Cancer Inst. 2004;96(24):1813-1822.
33. Bradley CJ, Dahman B. Time away from work: 
Employed husbands of women treated for breast 
cancer. J Cancer Survivorship. 2013;7(2):227-236.
34. Balak F, Roelen CAM, Koopmans PC, Ten Berge 
EE, Groothoff JW. Return to work after early-stage 
breast cancer: A cohort study into the effects of 
treatment and cancer-related symptoms. J Occup 
Rehabil. 2008;18(3):267-272.
35. Lauzier S, Maunsell E, Drolet M, et al. Wage 
losses in the year after breast cancer: Extent and 
determinants among Canadian women. J Natl 
Cancer Inst. 2008;100(5):321-332.
36. Sjovall K, Attner B, Englund M, et al. Sickness absence 
among cancer patients in the pre-diagnostic and the 
post-diagnostic phases of five common forms of cancer. 
Supportive Care Cancer. 2012;20(4):741-747.
37. Bouknight RR, Bradley CJ, Luo Z. Correlates of 
return to work for breast cancer survivors. Journal 
of Clinical Oncology. 2006;24(3):345-353.
38. Fantoni SQ, Peugniez C, Duhamel A, Skrzypczak 
J, Frimat P, Leroyer A. Factors related to return 
to work by women with breast cancer in northern 
France. J Occup Rehabil. 2010;20(1):49-58.
39. Mahmoudlou A, Yavari P, Abolhasani F, Khosravi A, 
Ramazani R. Estimation of the attributable burden of 
colorectal cancer in Iran in 2008. Iran J Epidemiol. 
2014;9(4):1-9.
40. Bradley CJ, Lansdorp-Vogelaar I, Yabroff KR, et 
al. Productivity savings from colorectal cancer 
prevention and control strategies. Am J Prev Med. 
2011;41(2):e5-e14.
41. Yaldo A, Seal BS, Lage MJ. The cost of absenteeism 
and short-term disability associated with colorectal 
cancer: A case-control study. J Occup Environ Med. 
2014;56(8):848-851.
42. Choi KS, Kim EJ, Lim JH, et al. Job loss and 
reemployment after a cancer dignosis in Koreans 
- A prospective cohort study. Psycho-Oncology. 
2007;16(3):205-213.
43. Tevaarwerk AJ, Lee JW, Sesto ME, et al. Employment 
outcomes among survivors of common cancers: The 
Symptom Outcomes and Practice Patterns (SOAPP) 
study. J Cancer Survivorship. 2013;7(2):191-202.
44. Bains M, Munir F, Yarker J, et al. The impact of 
colorectal cancer and self-efficacy beliefs on work 
ability and employment status: A longitudinal study. 
Eur J Cancer Care. 2012;21(5):634-641.
45. Carlsen K, Harling H, Pedersen J, Christensen KB, 
Osler M. The transition between work, sickness 
absence and pension in a cohort of Danish colorectal 
cancer survivors. BMJ Open. 2013;3(2).
46. Earle CC, Chretien Y, Morris C, et al. Employment 
among survivors of lung cancer and colorectal cancer. 
Journal of Clinical Oncology. 2010;28(10):1700-
1705.
47. Gordon L, Lynch BM, Newman B. Transitions in 
work participation after a diagnosis of colorectal 
cancer. Aust New Zealand J Public Health. 
2008;32(6):569-574.
121
2
Ec
on
om
ic
 Im
pa
ct
 o
f N
on
-C
om
m
un
ic
ab
le
 D
is
ea
se
s
48. Park JH, Park EC, Park JH, Kim SG, Lee SY. Job 
loss and re-employment of cancer patients in Korean 
employees: A nationwide retrospective cohort study. 
Journal of Clinical Oncology. 2008;26(8):1302-
1309.
49. Hauglann BK, SaltyteBenth J, Fossa SD, Tveit KM, 
Dahl AA. A controlled cohort study of sickness 
absence and disability pension in colorectal cancer 
survivors. Acta Oncol. 2014;53(6):735-743.
50. Roelen CA, Koopmans PC, Schellart AJ, van der 
Beek AJ. Resuming work after cancer: a prospective 
study of occupational register data. J Occup Rehabil. 
2011;21(3):431-440.
51. Syse A, Tretli S, Kravdal O. Cancer’s impact on 
employment and earnings--a population-based study 
from Norway. Journal of Cancer Survivorship. 
2008;2(3):149-158.
52. Holden L, Scuffham PA, Hilton MF, Ware RS, 
Vecchio N, Whiteford HA. Which health conditions 
impact on productivity in working Australians? J 
Occup Environ Med. 2011;53(3):253-257.
53. Dacosta Dibonaventura M, Paulose-Ram R, Su 
J, et al. The impact of COPD on quality of life, 
productivity loss, and resource use among the 
elderly united states workforce. COPD J Chronic 
Obstructive Pulm Dis. 2012;9(1):46-57.
54. Alexopoulos EC, Burdorf A. Prognostic factors for 
respiratory sickness absence and return to work 
among blue collar workers and office personnel. 
Occup Environ Med. 2001;58(4):246-252.
55. Kremer AM, Pal TM, Keimpema ARJ. Employment 
and disability for work in patients with COPD: A 
cross-sectional study among Dutch patients. Int Arch 
Occup Environ Health. 2006;80(1):78-86.
56. Orbon KH, Schermer TR, van der Gulden JW, et al. 
Employment status and quality of life in patients 
with chronic obstructive pulmonary disease. Int 
Arch Occup Environ Health. 2005;78(6):467-474.
57. Van Boven JFM, Vegter S, Van Der Molen T, 
Postma MJ. COPD in the working age population: 
The economic impact on both patients and 
government. COPD J Chronic Obstructive Pulm 
Dis. 2013;10(6):629-639.
58. Nishimura S, Zaher C. Cost impact of COPD in 
Japan: Opportunities and challenges? Respirology. 
2004;9(4):466-473.
59. Jansson SA, Andersson F, Borg S, Ericsson 
A, Jonsson E, Lundback B. Costs of COPD in 
Sweden according to disease severity. Chest. 
2002;122(6):1994-2002.
60. Nowak D, Dietrich ES, Oberender P, et al. [Cost-
of-illness Study for the Treatment of COPD 
in Germany] Krankheitskosten von COPD in 
Deutschland. Pneumologie. 2004;58(12):837-844.
61. Lokke A, Hilberg O, Kjellberg J, Ibsen R, Jennum P. 
Economic and health consequences of COPD patients 
and their spouses in Denmark-1998-2010. COPD J 
Chronic Obstructive Pulm Dis. 2014;11(3):237-246.
62. Lokke A, Hilberg O, Tonnesen P, Ibsen R, Kjellberg 
J, Jennum P. Direct and indirect economic and health 
consequences of COPD in Denmark: A national 
register-based study: 1998-2010. BMJ Open. 
2014;4(1).
63. Darkow T, Kadlubek PJ, Shah H, Phillips AL, 
Marton JP. A retrospective analysis of disability 
and its related costs among employees with chronic 
obstructive pulmonary disease. J Occup Environ 
Med. 2007;49(1):22-30.
64. Klarenbach S, Stafinski T, Longobardi T, Jacobs 
P. The effect of renal insufficiency on workforce 
participation in the United States: An analysis using 
National Health and Nutrition Examination Survey 
III data. Am J Kidney Dis. 2002;40(6):1132-1137.
65. Helantera I, Haapio M, Koskinen P, Gronhagen-
Riska C, Finne P. Employment of patients receiving 
maintenance dialysis and after kidney transplant: A 
cross-sectional study from Finland. Am J Kidney 
Dis. 2012;59(5):700-706.
66. Bradshaw D, Norman R, Pieterse D, Levitt NS, 
South African Comparative Risk Assessment 
Collaborating G. Estimating the burden of disease 
attributable to diabetes in South Africa in 2000. S Afr 
Med J. 2007;97(8 Pt 2):700-706.
67. Lavigne JE, Phelps CE, Mushlin A, Lednar 
WM. Reductions in individual work productivity 
associated with type 2 diabetes mellitus. 
Pharmacoeconomics. 2003;21(15):1123-1134.
68. Dall TM, Mann SE, Zhang Y, et al. Distinguishing 
the economic costs associated with type 1 and type 2 
diabetes. Popul Health Manag. 2009;12(2):103-110.
69. Alavinia SM, Burdorf A. Unemployment and 
retirement and ill-health: A cross-sectional analysis 
across European countries. Int Arch Occup Environ 
Health. 2008;82(1):39-45.
70. Kessler RC, Greenberg PE, Mickelson KD, 
Meneades LM, Wang PS. The effects of chronic 
medical conditions on work loss and work cutback. 
Journal of Occupational and Environmental 
Medicine. 2001;43(3):218-225.
71. Adepoju OE, Bolin JN, Ohsfeldt RL, et al. Can 
chronic disease management programs for patients 
with type 2 diabetes reduce productivity-related 
indirect costs of the disease? Evidence from a 
randomized controlled trial. Popul Heath Manage. 
2014;17(2):112-120.
72. Siegel R, Ward E, Brawley O, Jemal A. Cancer 
statistics, 2011: the impact of eliminating 
socioeconomic and racial disparities on premature 
122
cancer deaths. CA: a Cancer Journal for Clinicians. 
2011;61(4):212-236.
73. DeSantis C, Siegel R, Bandi P, Jemal A. Breast 
cancer statistics, 2011. CA: a Cancer Journal for 
Clinicians. 2011;61(6):409-418.
74. Mehnert A. Employment and work-related issues 
in cancer survivors. Critical Reviews in Oncology-
Hematology. 2011;77(2):109-130.
75. Molina R, Feliu J. The return to work of cancer 
survivors: The experience in Spain. Work. 
2013;46(4):417-422.
76. Steiner JF, Cavender TA, Main DS, Bradley 
CJ. Assessing the impact of cancer on work 
outcomes: what are the research needs? Cancer. 
2004;101(8):1703-1711.
77. Steiner JF, Nowels CT, Main DS. Returning to work 
after cancer: quantitative studies and prototypical 
narratives. Psychooncology. 2010;19(2):115-124.
78. van Muijen P, Weevers NL, Snels IA, et al. 
Predictors of return to work and employment in 
cancer survivors: a systematic review. European 
Journal of Cancer Care. 2013;22(2):144-160.
79. Kirsch F, Teuner CM, Menn P, Leidl R. 
Krankheitskosten fur Asthma und COPD bei 
Erwachsenen in der Bundesrepublik Deutschland. 
Gesundheitswesen. 2013;75(7):413-423.
80. Angeleri F, Angeleri VA, Foschi N, Giaquinto S, 
Nolfe G. The influence of depression, social activity, 
and family stress on functional outcome after stroke. 
Stroke. 1993;24(10):1478-1483.
81. Bastida E, Pagan JA. The impact of diabetes on adult 
employment and earnings of Mexican Americans: 
Findings from a community based study. Health 
Economics. 2002;11(5):403-413.
82. Black-Schaffer RM, Osberg JS. Return to work 
after stroke: development of a predictive model. 
Archives of Physical Medicine & Rehabilitation. 
1990;71(5):285-290.
83. Bogousslavsky J, Regli F. Ischemic Stroke in 
Adults Younger Than 30 Years of Age - Cause and 
Prognosis. Arch Neurol-Chicago. 1987;44(5):479-
482.
84. Boles M, Pelletier B, Lynch W. The relationship 
between health risks and work productivity. Journal 
of Occupational and Environmental Medicine. 
2004;46(7):737-745.
85. Bradley CJ, Bednarek HL. Employment patterns 
of long-term cancer survivors. Psychooncology. 
2002;11(3):188-198.
86. Bradley CJ, Bednarek HL, Neumark D. Breast 
cancer survival, work, and earnings. Journal of 
Health Economics. 2002;21(5):757-779.
87. Bradley CJ, Bednarek HL, Neumark D. Breast 
cancer and women’s labor supply. Health Services 
Research. 2002;37(5):1309-1328.
88. Bradley CJ, Neumark D, Bednarek HL, Schenk M. 
Short-term effects of breast cancer on labor market 
attachment: results from a longitudinal study. 
Journal of Health Economics. 2005;24(1):137-160.
89. Bradley CJ, Oberst K, Schenk M. Absenteeism 
from work: the experience of employed breast and 
prostate cancer patients in the months following 
diagnosis. Psychooncology. 2006;15(8):739-747.
90. Broekx S, Den Hond E, Torfs R, et al. The costs of 
breast cancer prior to and following diagnosis. Eur J 
Health Econ. 2011;12(4):311-317.
91. Burton WN, Pransky G, Conti DJ, Chen CY, 
Edington DW. The association of medical conditions 
and presenteeism. Journal of Occupational and 
Environmental Medicine. 2004;46(6):S38-S45.
92. Collins JJ, Baase CM, Sharda CE, et al. The 
assessment of chronic health conditions on work 
performance, absence, and total economic impact 
for employers. Journal of Occupational and 
Environmental Medicine. 2005;47(6):547-557.
93. De Backer G, Leynen F, De Bacquer D, Clays E, 
Moreau M, Kornitzer M. Diabetes mellitus in 
middle-aged people is associated with increased 
sick leave: the BELSTRESS study. International 
Journal of Occupational & Environmental Health. 
2006;12(1):28-34.
94. Eaker S, Wigertz A, Lambert PC, Bergkvist L, 
Ahlgren J, Lambe M. Breast cancer, sickness 
absence, income and marital status. A study on life 
situation 1 year prior diagnosis compared to 3 and 5 
years after diagnosis. PLoS ONE. 2011;6(3).
95. Fernandez De Larrea-Baz N, Alvarez-Martin E, 
Morant-Ginestar C, et al. Burden of disease due to 
cancer in Spain. BMC Public Health. 2009;9.
96. Ferro JM, Crespo M. Prognosis after transient 
ischemic attack and ischemic stroke in young adults. 
STROKE. 1994;25(8):1611-1616.
97. Fu AZ, Qiu Y, Radican L, Wells BJ. Health care and 
productivity costs associated with diabetic patients 
with macrovascular comorbid conditions. Diabetes 
Care. 2009;32(12):2187-2192.
98. Halpern MT, Stanford RH, Borker R. The burden of 
COPD in the U.S.A.: results from the Confronting 
COPD survey. Respiratory Medicine. 2003;97 Suppl 
C:S81-89.
99. Hansen JA, Feuerstein M, Calvio LC, Olsen CH. 
Breast cancer survivors at work. J Occup Environ 
Med. 2008;50(7):777-784.
100. Herquelot E, Gueguen A, Bonenfant S, Dray-Spira 
R. Impact of Diabetes on Work Cessation Data 
123
2
Ec
on
om
ic
 Im
pa
ct
 o
f N
on
-C
om
m
un
ic
ab
le
 D
is
ea
se
s
from the GAZEL cohort study. Diabetes Care. 
2011;34(6):1344-1349.
101. Hoyer M, Nordin K, Ahlgren J, et al. Change in 
working time in a population-based cohort of 
patients with breast cancer. Journal of Clinical 
Oncology. 2012;30(23):2853-2860.
102. Kappelle LJ, Adams HP, Jr., Heffner ML, Torner 
JC, Gomez F, Biller J. Prognosis of young adults 
with ischemic stroke. A long-term follow-up study 
assessing recurrent vascular events and functional 
outcome in the Iowa Registry of Stroke in Young 
Adults. Stroke. 1994;25(7):1360-1365.
103. Kotila M, Waltimo O, Niemi ML, Laaksonen 
R, Lempinen M. The Profile of Recovery from 
Stroke and Factors Influencing Outcome. Stroke. 
1984;15(6):1039-1044.
104. Kruse M, Sorensen J, Davidsen M, Gyrd-Hansen 
D. Short and long-term labour market consequences 
of coronary heart disease: A register-based 
follow-up study. Eur J Cardiovasc Prev Rehabil. 
2009;16(3):387-391.
105. Leigh JP, Romano PS, Schenker MB, Kreiss K. 
Costs of occupational COPD and asthma. Chest. 
2002;121(1):264-272.
106. Leng CM. Description of a return-to-work 
occupational therapy programme for stroke 
rehabilitation in Singapore. Occup Ther Int. 
2008;15(2):87-99.
107. Lenneman J, Schwartz S, Giuseffi DL, Wang C. 
Productivity and Health An Application of Three 
Perspectives to Measuring Productivity. Journal 
of Occupational and Environmental Medicine. 
2011;53(1):55-61.
108. Lindgren P, Glader EL, Jonsson B. Utility loss 
and indirect costs after stroke in Sweden. Eur J 
Cardiovasc Prev Rehabil. 2008;15(2):230-233.
109. Mayfield JA, Deb P, Whitecotton L. Work disability 
and diabetes. Diabetes Care. 1999;22(7):1105-1109.
110. McBurney CR, Eagle KA, Kline-Rogers EM, Cooper 
JV, Smith DE, Erickson SR. Work-related outcomes 
after a myocardial infarction. Pharmacotherapy. 
2004;24(11):1515-1523.
111. Molina R, Feliu J, Villalba A, et al. Employment in a 
cohort of cancer patients in Spain. A predictive model 
of working outcomes. Clinical & Translational 
Oncology: Official Publication of the Federation 
of Spanish Oncology Societes & of the National 
Cancer Institute of Mexico. 2008;10(12):826-830.
112. Molina Villaverde R, Feliu Batlle J, Villalba Yllan 
A, et al. Employment in a cohort of breast cancer 
patients. Occup Med (Lond). 2008;58(7):509-511.
113. Nair K, Ghushchyan V, Van Den Bos J, et al. 
Burden of illness for an employed population with 
chronic obstructive pulmonary disease. Popul Heath 
Manage. 2012;15(5):267-275.
114. Neau JP, Ingrand P, Mouille-Brachet C, et al. 
Functional recovery and social outcome after 
cerebral infarction in young adults. Cerebrovascular 
Diseases. 1998;8(5):296-302.
115. Niemi ML, Laaksonen R, Kotila M, Waltimo 
O. Quality of Life 4 Years after Stroke. Stroke. 
1988;19(9):1101-1107.
116. O’Brien AN, Wolf TJ. Determining work outcomes 
in mild to moderate stroke survivors. Work. 
2010;36(4):441-447.
117. Ohguri T, Narai R, Funahashi A, et al. Limitations 
on work and attendance rates after employees with 
cancer returned to work at a single manufacturing 
company in Japan. Journal of Occupational Health. 
2009;51(3):267-272.
118. Park JH, Park JH, Kim SG. Effect of cancer diagnosis 
on patient employment status: a nationwide 
longitudinal study in Korea. Psychooncology. 
2009;18(7):691-699.
119. Peters GO, Buni SG, Oyeyemi AY, Hamzat TK. 
Determinants of return to work among Nigerian 
stroke survivors. Disabil Rehabil. 2013;35(6):455-
459.
120. Peuckmann V, Ekholm O, Sjogren P, et al. Health care 
utilisation and characteristics of long-term breast 
cancer survivors: nationwide survey in Denmark. 
European Journal of Cancer. 2009;45(4):625-633.
121. Robinson N, Yateman NA, Protopapa LE, Bush L. 
Unemployment and diabetes. Diabetic Medicine. 
1989;6(9):797-803.
122. Roelen CAM, Koopmans PC, de Graaf JH, Balak F, 
Groothoff JW. Sickness absence and return to work 
rates in women with breast cancer. Int Arch Occup 
Environ Health. 2009;82(4):543-546.
123. Saeki S, Toyonaga T. Determinants of early return 
to work after first stroke in Japan. J Rehabil Med. 
2010;42(3):254-258.
124. Short PF, Vasey JJ, Tunceli K. Employment 
pathways in a large cohort of adult cancer survivors. 
Cancer. 2005;103(6):1292-1301.
125. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. 
The impact of chronic obstructive pulmonary 
disease on work loss in the United States. American 
Journal of Respiratory & Critical Care Medicine. 
2002;165(5):704-707.
126. Spelten ER, Verbeek JH, Uitterhoeve AL, et al. 
Cancer, fatigue and the return of patients to work-a 
prospective cohort study. European Journal of 
Cancer. 2003;39(11):1562-1567.
127. Stewart DE, Cheung AM, Duff S, et al. Long-term 
breast cancer survivors: confidentiality, disclosure, 
effects on work and insurance. Psychooncology. 
2001;10(3):259-263.
124
128. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. 
The costs of treating COPD in the United States. 
Chest. 2001;119(2):344-352.
129. Taskila T, Martikainen R, Hietanen P, Lindbohm 
ML. Comparative study of work ability between 
cancer survivors and their referents. European 
Journal of Cancer. 2007;43(5):914-920.
130. Teasell RW, McRae MP, Finestone HM. Social 
issues in the rehabilitation of younger stroke patients. 
Archives of Physical Medicine & Rehabilitation. 
2000;81(2):205-209.
131. Timperi AW, Ergas IJ, Rehkopf DH, Roh JM, Kwan 
ML, Kushi LH. Employment status and quality of 
life in recently diagnosed breast cancer survivors. 
Psycho-Oncology. 2013;22(6):1411-1420.
132. Vanderwouden JC, Greavesotte JGW, Greaves 
J, Kruyt PM, Vanleeuwen O, Vanderdoes E. 
Occupational Reintegration of Long-Term 
Cancer Survivors. Journal of Occupational and 
Environmental Medicine. 1992;34(11):1084-1089.
133. Vestling M, Tufvesson B, Iwarsson S. Indicators for 
return to work after stroke and the importance of 
work for subjective well-being and life satisfaction. 
J Rehabil Med. 2003;35(3):127-131.
134. Wang PS, Beck A, Berglund P, et al. Chronic 
medical conditions and work performance in 
the health and work performance questionnaire 
calibration surveys. Journal of Occupational and 
Environmental Medicine. 2003;45(12):1303-1311.
135. Ward MM, Javitz HS, Smith WM, Whan MA. 
Lost income and work limitations in persons with 
chronic respiratory disorders. Journal of Clinical 
Epidemiology. 2002;55(3):260-268.
136. Wozniak MA, Kittner SJ, Price TR, Hebel JR, Sloan 
MA, Gardner JF. Stroke location is not associated 
with return to work after first ischemic stroke. 
Stroke. 1999;30(12):2568-2573.
137. Yabroff KR, Lawrence WF, Clauser S, Davis WW, 
Brown ML. Burden of illness in cancer survivors: 
findings from a population-based national sample. J 
Natl Cancer Inst. 2004;96(17):1322-1330.


Chapter 3
Nutrition and Cardiometabolic Risk Factors

129
3
N
ut
rit
io
n 
an
d 
C
ar
di
om
et
ab
ol
ic
 R
is
k 
Fa
ct
or
s
Taulant Muka, Jessica C. Kiefte-de Jong, Albert Hofman, Abbas Dehghan, 
Fernando Rivadeneira, Oscar H. Franco
3.1 Polyunsaturated Fatty Acids and Serum C-reactive Protein: the Rotterdam Study
ABSTRACT
We aimed to investigate whether total and individual (n-3, n-6 and n-3/n-6 ratio) polyunsaturated 
fatty acids (PUFAs) intake are prospectively associated with serum C-reactive protein (CRP), a 
marker of inflammation. We included 4,707 participants (1,943 men and 2,764 women) of the 
Rotterdam Study, a prospective follow-up study among subjects aged 55 years and older in the 
Netherlands. At baseline (1989-1993), dietary intake of PUFAs was assessed by a validated food 
frequency questionnaire. CRP was measured at baseline and at the third center visit (1997-1999). 
Regression coefficients (βs) and 95% CI were obtained by using linear generalized estimating 
equations. Dietary intake of butter and margarines explained most of the variance of PUFAs intake. 
After adjusting for possible confounding factors, higher intake of total PUFAs was associated with 
lower levels of CRP (β=-0.08, 95%CI=-0.15, -0.01; 4th quartile vs. 1st quartile). Similarly, intake of 
n-6 PUFAs was inversely related to CRP (β=-0.09, 95%CI=-0.16, -0.01 4th quartile vs. 1st quartile). 
No consistent trends were observed regarding n-3 PUFAs or n-3/n-6 PUFAs ratio and CRP. This 
study suggests that high intakes of total PUFAs are associated with lower levels of CRP reflecting 
diminished chronic systemic inflammation, which was mainly driven by n-6 PUFAs.
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INTRODUCTION
Several dietary guidelines on cardiovascular disease and other chronic diseases encourage high 
consumption of both classes of polyunsaturated fatty acids (PUFAs), n-3 and n-6, as a replacement 
for other types of fatty acids such as saturated fatty acids1,2. Despite the consistency of favorable 
recommendations regarding dietary PUFAs, there are concerns that high amount of n-6 PUFAs in 
the diet may contribute to increase inflammation3,4. N-6 PUFAs trigger the formation of arachidonic 
acid, and therefore the synthesis of pro-inflammatory eicosanoids5. Elevated production of pro-
inflammatory eicosanoids could increase levels of biomarkers of chronic systemic inflammation 
such as C-Reactive Protein (CRP) which has been associated with cardiometabolic outcomes 
and other age related disorders6-8. In addition, n-6 PUFAs compete with n-3 PUFAs for the same 
enzymes in fatty acids elongation and desaturation, and therefore could reduce the formation of 
anti-inflammatory eicosanoids that are derived from long chain n-3 PUFAs such as resolvins and 
neuroprotectins9. Thus far, only a few human studies have investigated the role that dietary intake of 
n-6 PUFAs may play on inflammation with contradictory results10-13. Also, there is little evidence to 
support a detrimental role of n-6 PUFAs on cardiovascular diseases14,15. In contrast, several studies 
found n-3 and n-6 PUFAs intake combined to be associated with lower inflammatory profile and 
cardiovascular outcomes16,17. Moreover, in the western diet, the consumption of plant derived n-3 
PUFAs has almost doubled during the last decades, moving from 1 to 1.9 g/day18. Thus far, there is 
little controversy on the beneficial role of marine-derived n-3 PUFAs supplementation on chronic 
systemic inflammation19, but, very little is known about the role of plant derived n-3 PUFAs on 
inflammation and particularly on CRP20. 
In this study we investigated the association between total PUFAs and individual PUFAs intake 
(n-3, n-6 and n-3/n-6 PUFAs ratio) and serum CRP in the Rotterdam Study, a prospective cohort of 
individuals 55 years old and above.
METHODS
Study population
The study was performed within the framework of the Rotterdam Study (RS), a population-based 
cohort among persons ≥55 years and older in the Ommoord district of Rotterdam, the Netherlands. 
The rationale and design of the RS is described elsewhere21 . The baseline examination took place 
in 1989-1993 (RS-I). Trained research assistants collected data on current health status, use of 
medication, medical history, lifestyle and risk indicators for chronic diseases during an extensive 
home interview. Subsequently, the participants visited the study center for detailed clinical 
examinations and assessment of diet. Follow up visits were held every 2-3 years21. The study 
was approved by the Medical Ethical Committee of Erasmus University, and all participants gave 
informed consent. The present study used data from the baseline examination of the original cohort 
(RS-I). Among the participants there were 4,707 persons with available measurements for the 
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Participants Eligible for Dietary 
Interview in the First Wave of the 
Rotterdam Study (August 1989-
September 1993) 
(n = 6,521) 
1,552 Participants Excluded 
        No information on nutrition intake 
(n = 874) 
Unreliable data (n = 678) 
Participants with Baseline Information 
about Nutritional Intake 
(n = 4,969) 
262 Participants Excluded 
        Did not have C-reactive protein 
measured at baseline 
Participants Included in the Analysis 
with Baseline Information on 
Nutritional Intake and Baseline C-
Reactive Protein. 
(n = 4,707) 
 
Among 4,707 participants, 428 
participants died during the follow-up 
and 1,368 did not have C-Reactive 
Protein measured at the Third Visit 
(March 1997-December 1999) 
 
analyses (Figure 1). Among them, 1,796 participants died or did not have serum CRP measured 
(because of logistic reasons or no consent) at the third round visit (March 1997- December 1999). 
Our subset included 537 participants who reported use of anti-inflammatory drugs at baseline and/
or during the follow up. A sensitivity analysis was performed after removing these subjects. 
Figure 1 Flow Chart of Participants in the Study, The Rotterdam Study, 1989-1993
Assessment of diet
At baseline (1989-1993), participants indicated on a checklist at home all foods and beverages that 
they consumed at least twice a month during the preceding year. The completed checklist formed 
the basis for an interview at the study center by a trained dietician. A computerized validated 170-
item semi-quantitative food frequency questionnaire (FFQ) was used22. These dietary data were 
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converted into total energy intake and fatty acid intakes per day using the Dutch Food Composition 
Table of 199323. In a validation study including 80 participants of the RS, the FFQ was compared 
with fifteen 24-h food records collected over a 1-y period and with 24-h urinary urea excretion 
during 4 nonconsecutive days22. After adjustment for age, sex, energy, and within-person variation, 
the partial Pearson correlation coefficient was 0.62 for polyunsaturated fat22.
Serum CRP 
High-sensitivity CRP was measured in non-fasting frozen serum of study participants at baseline 
(1989-1993) and at the third center visit (1997-1999). A rate near-infrared particle immunoassay 
(Immage Imunnochemistry System, Beckman Coulter, Fullerton, CA, USA) was used. This system 
measures concentrations from 0.2 to 1.440 mg/l, with a within-run precision of 0.5%, a total 
precision <7.5% and a reliability coefficient of 0.995.
Assessment of covariates
The information on current health status, medical history, medication use, smoking, and 
socioeconomic status were assessed at the home interview at baseline. Education was defined 
as low (primary education), intermediate (secondary general or vocational education), or 
high (higher vocational education or university). Household income was categorized in low 
(<1700 euro/month), middle (1700-3000 euro/month) or high (≥3000 euro/month). Participants 
were asked whether they were currently smoke cigarettes, cigars, or pipe. Blood pressure was 
measured in the sitting position at the right upper arm with a random-zero-sphygmomanometer. 
Cardiovascular disease was defined as a history of myocardial infarction, coronary artery bypass, 
or percutaneous transluminal coronary angioplasty. Type 2 diabetes mellitus was diagnosed 
if a random serum glucose level was ≥11 mmol/L or if a person used glucose lowering drugs. 
Development of chronic diseases until the third round of the study was defined as the presence of 
cardiovascular disease, diabetes mellitus and cancer at the baseline and until the end of the third 
round visits (December 1999). Serum cholesterol was determined by an automated enzymatic 
procedure in a non-fasting blood sample. Anti-inflammatory drug use was defined as use of 
anti-inflammatory and anti-rheumatic drug, immunosuppressive and immune-modulating agent 
and bile and liver therapy at baseline and third round and dichotomized: Yes or No. The Dutch 
Healthy Diet (DHD)-index was used to take into account overall dietary quality. The DHD-
index represents compliance to the Dutch Guidelines for a Healthy Diet as assessed from the 
FFQ at baseline24 . To avoid over adjustment, the PUFAs component was removed from the 
DHD-index. Therefore, the following components were included within the DHD-index in this 
study: intake of vegetable, fruit, dietary fiber, fish, trans fat, saturated fat, alcohol and sodium. 
At the third visit to research center, the total weekly duration of physical activity was assessed by 
an adapted version of the Zutphen Physical Activity Questionnaire and the Longitudinal Aging 
Study Amsterdam Physical Activity Questionnaire25,26. Body mass index was calculated as weight 
divided by height squared (kg/m2).
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Statistical analyses
Continuous variables are reported as mean ± SD unless stated otherwise and categorical variables 
were presented as percentages. Pearson correlations were used to assess the association between 
PUFAs intake and their main dietary food sources. We used natural log-transformed values of 
serum CRP concentrations to better approximate normal distribution. To account for systematic 
measurement error and gender differences in dietary fatty acids intake, dietary fat intake was 
adjusted for total energy intake and gender by using the residual method in the analysis27. Dietary 
PUFAs intake was analyzed continuously and after categorization into quartiles. We fitted linear 
regression models using generalized estimating equations (GEE) with exchangeable correlation 
structure adjusting for the within-subject correlations due to the repeated measurements of CRP 
in the same individual (partial Pearson correlation=0.55 and intra-class correlation=0.67 for 
natural log transformed CRP)28. Regression coefficients (βs) and 95% Confidence Intervals on 
the basis of robust standard errors (95% CIs) were obtained. First, we calculated age and gender 
adjusted coefficients for the following exposures: total PUFAs, n-6, n-3 and n-3/n-6 PUFAs ratio. 
Subsequently, we adjusted for potential confounders based on previous findings29,30, or when the 
covariate changed the estimate by more than 10%. Hence, final multivariable models were adjusted 
for: education level, household income, energy adjusted dietary cholesterol intake, physical 
activity, body mass index, smoking, anti-inflammatory drug use, DHD-index, prevalent chronic 
diseases at 3rd round, total serum cholesterol, HDL-cholesterol, systolic blood pressure, and n-3 
or n-6 PUFAs for the analysis concerning n-6 and n-3 PUFAs respectively. Variables that were 
studied but did not alter the estimates by 10% or more included: dietary protein intake, hormone 
replacement therapy, statin use, and diastolic blood pressure. All analyses were also performed 
in men and women separately and the results presented are only for the multivariable models. In 
case of stratification, the intake of each fatty acids was divided into sex-specific quartiles. Before 
stratification, an interaction term between quartiles of exposure of interest and gender was added 
in the fully adjusted model and tested. We stratified by dietary fish intake (fish eaters vs. non fish 
eaters) and margarine and butter intake (stratified by median intake) to examine if dietary sources 
of n-3 PUFAs may play a role on the association between n-3 PUFAs and CRP. Moreover, to look 
if inclusion of subjects with no information on the second measure of CRP (1,719 subjects) could 
affect our results, we rerun all the analyses excluding them. To adjust for potential bias associated 
with missing data we used multiple imputation procedure (N= 5 imputations) (Web Table S1). 
Rubin’s method was used for the pooled regression coefficients (β) and 95% CIs. All analyses were 
done using SPSS statistical software (SPSS, version 21.0; SPSS Inc, Chicago, Illinois). 
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Table 1 Characteristics of Study Participants, The Rotterdam Study, 1989-1997
Male  
(n=1,943)
Female  
(n=2,764)
Characteristic Mean (SD) No. % Mean (SD) No. %
Age, years 67.15  
(7.29)
67.86 
(8.00)
Total PUFAs (g/day) 18.07 
(8.41)
13.60  
(6.83)
N-6 PUFAs (g/day) 14.68 
(7.85)
11.10  
(6.32)
N-3 PUFAs (g/day) 1.20 
(0.54)
0.98 
(0.48
Dietary protein intake (g/day) 88.77 
(20.69)
76.72  
(17.04)
Dietary cholesterol intake (g/day) 257.86 
(88.95)
217.14  
(72.15)
Total energy intake (kcal/day) 2247.54  
(506.34)
1791.46 
(406.18)
Education status 
  Low 721 37.2 1704 61.7
  Intermediate 916 47.1 941 34.0
  High 306 15.7 119 4.3
Household income (%, N)
  Low (<1700 euro/month) 185 9.5 654 23.7
  Middle (1700-3000 euro/month) 951 49 1385 50.1
  High (≥3000 euro/month) 807 41.5 725 26.2
Physical activity-overall (min/
week)
2436.37 (1137.78) 2652.64 
(1094.57)
Body mass indexa 25.76  
(2.91)
26.68  
(4.00)
Never/former smokers 71.1 1381 71.1 2238 81.0
Current smokers 28.9 562 28.9 526 19.0
Anti-inflammatory drugs 7.9 154 7.9 383 13.9
Lipid reducing drugs 2.7 53 2.7        72 2.6
Total DHD-index 45.50 
(9.86)
50.28  
(9.88)
Diseases at 3rd visit
Prevalent chronic disease 909 46.8 836 30.2
CHD 596 30.7 401 14.5
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Diabetes 329 16.9 415 15.0
Cancer  197 10.1 157 5.7
Total cholesterol (mmol/l) 6.36  
(1.13)
6.89  
(1.19)
HDL-cholesterol (mmol/l) 1.22 
(0.33)
1.46  
(0.36)
Systolic blood pressure (mmHg) 138.36  
(21.82)
138.36  
(74.61)
Diastolic blood pressure (mmHg) 74.61 
(11.29)
73.35  
(11.16)
HRT 0.02 6 0.02 75 2.7
CRP, 1st round (mg/dl)b 0.187  
(6.71)
0.176  
(5.30)
CRP, 2nd round (mg/dl)b 0.235  
(11.48)
0.241  
(9.02)
Vegetable oils (g/day) 2.21  
(4.31)
1.81  
(3.27)
Butter, margarines and hard frying 
fats (g/day)**
35.18 
(18.85)
26.46  
(15.11)
Fish (g/day) 15.04 
(19.20)
13.98  
(17.61)
Poultry(g/day) 12.61  
(14.57)
12.49  
(13.74)
Red and processed meat (g/day) 111.96  
(50.05)
85.56  
(41.52)
Sweet desserts and confectionary 
(g/day)
118.85  
(81.00)
95.69  
(70.55)
Chips (g/day) 0.44  
(3.75)
0.28  
(2.28)
Wholegrain (g/day) 148.95  
(89.58)
114.80  
(62.85)
Total dairyc (g/day) 382.80 
( 273.35)
395.10 
(242.65)
CHD: Coronary Heart Disease; CRP, C-reactive protein; DHD-index, The Dutch Healthy Diet-index; HRT, hormone 
replacement therapy; No., number; %, percentage; PUFAs, polyunsaturated fatty acids; SD, standard deviation.
a kg/m2 
b median (range) 
c including cheese
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Table 2 Correlations Coefficients between n-6 and n-3 Polyunsaturated Fatty Acids and their Dietary Food 
Sources, The Rotterdam Study, 1989-1993a.
Food Source n-6 PUFAs (g/day) 
 Pearson Correlation ( r)
n-3 PUFAs (g/day)
elation ( r)
Vegetable oils (g/day) 0.26 0.06 
Butter, margarines and hard frying fats (g/day) 0.31 0.44 
Fish (g/day) 0.03 0.33 
Poultry(g/day) 0.08 0.12 
Red and processed meat (g/day) 0.15 0.24 
Sweet desserts and confectionary (g/day) 0.14 0.13 
Chips (g/day) NSc 0.03
Wholegrain (g/day) 0.20 0.15
Total dairy (g/day)b NS 0.05 
  
NS, not significant (P<0.05); PUFAs: polyunsaturated fatty acids 
a Overall variance explained by these food items: 22% for n-6 PUFAs; 37% for n-3 PUFAs. 
b including cheese 
c does not significantly contribute to n-3 or n-6 PUFAs (p-value >0.05), otherwise, the p-value<0.05
RESULTS
Characteristics of the study population and dietary intake of nutrients are shown in Table 1. Intake 
of total PUFAs, n-6 and n-3 PUFAs were lower in women than in men (13.60 g/day ± 6.83 g/day 
vs. 18.07 g/day ± 8.41 g/day  for total PUFA , 11.10 g/day ± 6.32 g/day vs.14.68 g/day ± 7.85 g/day 
for n-6 PUFAs and 0.98 g/day ± 0.48 g/day vs. 1.20 g/day ± 0.54 g/day for n-6 PUFA) (Table 1). 
Specific dietary food intakes that significantly contributed to n-6 PUFAs and n-3 PUFAs intake are 
shown in table 2. Pearson (r) correlations of 0.31, 0.26 and 0.20 were found between n-6 PUFAs 
intake and butter (including margarines and hard frying fats), vegetable oils and wholegrain 
respectively (Table 2). The correlations of n-3 PUFAs with the specific dietary foods intake (Table 
2), showed the highest correlations for butter (including margarines and hard frying fats), fish and 
red and processed meat (r=0.44, 0.33 and 0.24 respectively). The overall variance explained by 
these food items for n-6 PUFAs and n-3 PUFAs was 22% and 37% respectively, with butter and 
margarines explaining most of the variance for both n-6 and n-3 PUFAs (Table 2).
Dietary intake of PUFAs and serum CRP
We observed an inverse association between total PUFAs intake and serum CRP after adjustment 
for age and gender (comparing extreme quartiles, β=-0.12, 95%CI=-0.19, -0.04; P for trend=0.003) 
(Table 3). The overall results changed only slightly after multivariable adjustment (Table 3).  Also, 
higher n-6 PUFAs intake was associated with lower levels of CRP (comparing extreme quartiles: 
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multivariable β= -0.09, 95%CI=-0.16, -0.01; P for trend=0.033) (Table 3). Intake of n-3 PUFAs 
was associated with an increase in serum CRP in the age and gender adjusted model (comparing 
extreme quartiles: β= 0.08, 95%CI= 0.006, 0.16; P for trend=0.01) (Table 3). Nevertheless, after 
adjustment for other covariates, no consistent relationship was found (Table 3; P for trend=0.16). 
Similarly, no linear trend was observed between n-3/n-6 PUFAs ratio and serum CRP in the 
multivariable model (P for trend=0.23) (Table 3). 
Table 3 Dietary Intake of Polyunsaturated Fatty Acids and Serum C-Reactive Protein, The Rotterdam 
Study, 1989-1997
Quartile, by 
PUFAs Type
CRP First 
Round, mg/DL 
(Median)
CRP Third 
Round, mg/
DL (Median)
Model 1b Model 2c
β 95% CI β 95% CI
Total PUFAs
  Continuousc -0.06 -0.1, -0.02 -0.03 -0.07, 0.01
  Quartile 1 0.195 0.261 0 Referent 0 Referent
  Quartile 2 0.176 0.230 -0.11 -0.19, -0.04 -0.009 -0.16, -0.02
  Quartile 3 0.174 0.234 -0.12 -0.20, -0.05 -0.10 -0.17, -0.02
  Quartile 4 0.173 0.233 -0.12 -0.19, -0.04 -0.08 -0.15, -0.01
 P valued 0.003 0.039
n-6 PUFAs
  Continuous -0.06 -0.1, -0.02 -0.03 -0.08, 0.01
  Quartile 1 0.198 0.253 0 Referent 0 Referent
  Quartile 2 0.178 0.240 -0.07 -0.15, 0.004 -0.07 -0.14, -0.004
  Quartile 3 0.174 0.240 -0.09 -0.16, -0.01 -0.07 -0.14, 0.005
  Quartile 4 0.172 0.227 -0.12 -0.20, -0.04 -0.09 -0.16, -0.01
 P value 0.002 0.033
n-3 PUFAs
  Continuous 0.39 -0.20, 0.99 0.17 -0.43, 0.76
  Quartile 1 0.169 0.207 0 Referent 0 Referent
  Quartile 2 0.179 0.238 0.09 0.01, 0.16 0.05 -0.03, 0.12
  Quartile 3 0.193 0.262 0.15 0.08, 0.23 0.08 0.01, 0.16
  Quartile 4 0.178 0.246 0.08 0.006, 0.16 0.05 -0.03, 0.12
 P value 0.01 0.16
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n-3/n-6 PUFAs 
ratio
  Continuouse 0.06 -0.05, 0.17 0.00 -0.10, 0.11
  Quartile 1 0.165 0.221 0 Referent 0 Referent
  Quartile 2 0.183 0.230 0.06 -0.01, 0.14 0.02 -0.06, 0.09
  Quartile 3 0.193 0.256 0.14 0.07, 0.21 0.09 0.02, 0.16
  Quartile 4 0.178 0.246 0.06 -0.02, 0.13 0.02 -0.05, 0.09
 P value 0.05 0.23
β, regression coefficients; CI, confidence intervals; CRP, C-reactive protein; PUFAs: polyunsaturated fatty acids 
aIn all the analyses, serum CRP is natural log-transformed.  
bModel 1:adjusted for age (continuous) and gender 
cModel 2: Model 1 + education level (low, intermediate, high), household income (low, middle, high), smoking status 
(current vs. former/never) physical activity (continuous), body mass index (continuous), dietary cholesterol intake 
(continuous), total serum cholesterol (continuous), HDL-cholesterol  (continuous), anti-inflammatory drugs (yes vs. no), 
Dutch Healthy Diet-index excluding PUFAs component (continuous), systolic blood pressure (continuous) and presence 
of chronic disease (yes vs. no). The analysis on n-3 and n-6 PUFAs were additionally adjusted for each other (continuo 
cReported per 10 units increase in energy adjusted dietary fatty acids intake 
dTests for trend were carried out by entering the categorical variables as continuous variables in multivariable linear 
models fitted in Generalized Estimated Equations. 
e2 subjects were removed because of extreme negative values
Dietary intake of PUFAs and serum CRP by gender
A linear negative trend between total PUFAs and CRP was observed only in women (P for 
trend=0.014 in women vs. 0.39 in men) (Figure 2 A). Also, high intake of n-6 PUFAs was 
associated with lower levels of CRP in females (comparing extreme quartiles: multivariable β=-
0.11, 95%CI=-0.21, -0.02, P for trend=0.03) but not in males (Figure 2 B). Among females, 
3rd quartile of n-3 PUFAs was positively associated with CRP (compared to the 1st quartile, 3rd 
quartile: β=0.11, 95%CI=0.02, 0.20) but not in males (Figure 2 C). Nevertheless, no linear trend 
was observed neither in men, nor in women (Figure 2 C). In contrast, high dietary n-3/n-6 PUFAs 
ratio was related to higher serum CRP in females but not in males (comparing extreme quartiles: 
multivariable β=0.09, 95%CI=0.01, 0.18; P for trend=0.007;PInteraction=0.029 for gender x n-3/n-6 
PUFA interaction; Figure 2 D).
Additional analysis
When stratified by dietary fish intake, the positive association between n-3 PUFAs or n-3/n-6 
PUFAs ratio and CRP was observed only among participants who did not consume fish or among 
participants with high butter consumption (higher than median) (Web Figure S1). No association 
was observed between n-3 PUFAs or n-3/n-6 PUFAs ratio and CRP among fish-eater participants 
or among participants with butter consumption lower than median (Web Figure S2). 
Exclusion of subjects who reported use of anti-inflammatory drugs at baseline and during the 
follow-up from our analyses or restriction of all analyses on participants with available information 
of both measures of CRP (2,911 participants) did not substantially affect our results (results 
presented stratified by gender) (Web Figure S3-S4). 
140
DISCUSSION
Overall we observed an inverse association for total PUFAs intake and serum CRP irrespective of 
gender, other dietary factors, lifestyle and cardiovascular risk factors. These associations seemed 
to occur more prominently in women. 
Our findings are in accordance with previous studies reporting decreased CRP with total PUFAs 
intake10,16. Pischon and his colleagues showed that a combination of both n-3 and n-6 PUFAs is 
related to a lower inflammatory profile16. Also, a recent prospective study showed that total PUFAs 
intake are inversely associated with plasma CRP10. 
Both n-3 and n-6 PUFAs inhibit the activities of delta 6 and delta 5 desaturase and the activity 
of cyclooxygenase, which are all involved in fatty acid regulation that influences pro- and anti-
inflammatory mediators31-33. Therefore, high intake of both n-3 and n-6 PUFAs could lead to a 
reduction in inflammation. Also, PUFAs can modify the activity of transcription factors, such as 
peroxisome proliferator activated receptors and nuclear factor kappa B. Peroxisome proliferator 
activated receptors can interfere with the activation on nuclear factor kappa B, by inhibiting 
signaling molecules, and therefore impeding the production of pro-inflammatory cytokines34. 
Concerns have been raised that high consumption of n-6 PUFAs in diet may increase the risk 
of chronic diseases by enhancing inflammation3,4. These concerns comes from the fact that n-6 
PUFAs intake has been generally assumed to be associated with production of eicosanoids which 
have pro-inflammatory properties35. However, recent studies suggest that arachidonic acid, a 
metabolite of n-6 PUFAs, serves as a precursor for a group of anti-inflammatory mediators as 
well36. Also, it has been reported that some arachidonic acid -derived eicosanoids have both pro 
and anti-inflammatory roles. For instance, it decreases the production of 4-series leukotrienes11, and 
promotes the formation of lipoxins11 that have been found to have anti-inflammatory properties12. 
Thus far, few studies have been published that directly explore whether dietary n-6 PUFAs affect 
serum CRP. A recent systematic review of randomized clinical on dietary n-6 PUFAs intake and 
inflammation concluded that there is no evidence that dietary intake of n-6 PUFAs increases 
inflammatory markers37. However the studies included in the systematic review had not enough 
statistical power which was limited by their small number of participants and their internal and extern 
validity was questioned ( the largest study had 60 subjects that completed the experiment and some 
of the studies were conducted in metabolic wards with 6 to 9 participants).  Moreover, Ferruci and 
colleagues observed that higher levels of plasma arachidonic acid concentrations  were associated 
with lower interleukin-6 and higher transforming growth factor beta levels38. Interleukin-6 is a 
marker of inflammation and regulates the production of CRP whereas transforming growth factor 
beta has potent anti-inflammatory activities.
A few studies focused on total n-3 PUFAs and CRP, have shown inverse or no associations so 
far13,39-41. Different from our study, most of these studies were of cross-sectional design and could 
not address the causality. Moreover, the studies showing inverse associations between dietary 
n-3 PUFAs intake and CRP, come mainly from Japan, where the consumption of fish intake, and 
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therefore long-chain n-3 PUFAs is high39-41. One of these studies showed that the associations 
were stronger when eicosapentaenoic acid (EPA) and  docosahexaenoic acid (DHA) intakes were 
high41. Also, the only prospective study conducted in middle-age populations, but based on only 
one measure of serum CRP available at follow up, concluded that the inverse association found 
between total n-3 PUFAs and CRP was mainly driven by long chain n-3 PUFAs10
Previously, it has been suggested that the inconsistent findings of n-3 PUFAs from epidemiological 
studies might be due to different sources of PUFAs42. Also, it has been shown that plant-derived n-3 
PUFAs can have different roles on health (including immunity and inflammation) as compared to 
marine-derived n-3 PUFAs20,43,44. The n-3 fatty acids are present in the diet as alpha linolenic acid 
(ALA), EPA and DHA. ALA is found in some vegetable oils, meat and margarine products whereas 
the richest dietary source of EPA and DHA is fatty fish. ALA is de-saturated into EPA, which is 
converted later into DHA, but this conversion is limited in humans45. EPA and DHA increases an 
alternative family eicosanoids which frequently have lower potency than those produced from 
arachidonic acid 5. 
In our study, the main source of n-3 PUFAs was butter and margarine. Also, a strong correlation 
between n-3 PUFAs and red and processed meat was seen. In a large European study by Saadatian-
Elahi  et al, a positive correlation between processed meat and ALA, EPA and DHA was reported, 
but not between red meat and ALA46. In the Netherlands, red and processed meat generally may 
contain limited levels of EPA and DHA. The difference between our results and those from 
Saadatian-Elahi may be explained by different food practices related to meat consumption (e.g. 
addition of sauces and oils). Therefore we postulate that the correlation between meat intake and 
n-3 fatty acids we found is probably explained by ALA.  Moreover, 39% of the study participants 
did not consume fish, which may imply a higher ALA intake as compared to EPA and DHA, and 
thus may further add to explaining the results of our study. In addition, the association between n-3 
PUFAs or n-3/n-6 PUFAs ratio and CRP was observed mainly among participants with lower fish 
intake and higher butter consumption. This may suggest that dietary sources of n-3 PUFAs might 
be important to take into account when evaluating their role on inflammation and other health 
outcomes.
We found potential gender differences in the association between dietary PUFAs intake and CRP, 
which is in line with previous studies16,40. It has been suggested that the observed differences 
between men and women may be mainly due to differences in dietary intake. In our study, we 
corrected for gender differences in dietary intake, therefore, the differences observed in men and 
women are not likely to be due to differences in dietary intake. Previous studies have reported 
gender differences in the conversion of ALA to EPA and DHA47. It has been shown that women have 
more ALA availability than men because of lower partitioning of women toward beta oxidation48,49. 
In addition, there might be gender differences in the activity of desaturation-elongation pathway 
for the conversion of EPA to DHA50. Also, this may be explained by the action of estrogen in the 
conversion of ALA to EPA and DHA because DHA synthesis is almost threefold greater in women 
using oral contraceptives than those without it49. 
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Our study is unique among previous investigations because of its prospective design, large 
population-based study group and adjustment for a broad range of confounders. Also, to our 
knowledge, this is the first prospective study to use measures of CRP in two time points. 
First, dietary fat intake was assessed at baseline, and there may have been changes in fat 
consumption over time. Second, the FFQ can be limited by errors in reporting and recall and 
by incomplete assessment of all sources of fat intake, which may introduce misclassification in 
dietary intakes and would bias results toward the null.  However, the data are suitable for ranking 
people and the FFQ we used was validated and showed a relatively high correlation with the 
intake of fatty acids. Third, we were not able to investigate associations with specific n-3 PUFAs 
or serum levels of fatty acids. Furthermore, although CRP has been associated with cardiovascular 
disease in many observational studies6, the nature of the association remains under discussion 
since Mendelian randomization studies did not establish a relation with cardiovascular disease and 
causality might not be present51. Hence, if PUFAs intake contribute to lower inflammation and to 
reducing subsequent cardiometabolic risk needs to be further established. Also, we did not have 
repeated measurements of other inflammatory markers. Investigation of for example interleukin-6 
or TNF-alpha could have strengthen our results and further clarify the association between fatty 
acids intake and inflammation. Finally, physical activity was measured in the third round of the 
Rotterdam Study. Therefore, we cannot fully exclude residual confounding by physical activity 
levels. 
In conclusion, we found that high intake of PUFAs (mainly n-6 PUFAs) are associated with lower 
levels of CRP which might reflect diminished chronic systemic inflammation. The current study 
may provide additional support for the maintenance of the present level of n-6 PUFAs intake. At 
the same time, these results suggest that substitution of plant-derived n-3 PUFAs with marine 
derived n-3 PUFAs may be considered and further evaluated.
Supplementary Material can be found online: http://aje.oxfordjournals.org/content/
early/2015/04/21/aje.kwv021
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3.2 Dietary Fat Composition, Total Body Fat and Regional Body Fat Distribution in Two Caucasian Populations.
ABSTRACT
Objective: We aimed to study whether dietary fat composition is associated with total body fat 
(TF) and body fat distribution in middle-aged and elderly women participants in two population-
based cohorts in the Netherlands and Australia.
Methods: The study was performed in the Rotterdam Study (RS), a prospective cohort study 
among subjects aged 55 years and older (N=1,182 women) and the Calcium Intake Fracture 
Outcome Study (CAIFOS), a 5-year randomized controlled trial among women age 70+ (N=846). 
At baseline, diet (i.e. polyunsaturated and saturated fatty acids (PUFAs and SFA) was measured by 
validated food frequency questionnaires. TF was assessed using Dual-energy X-ray absorptiometry 
in both studies and android abdominal fat (AF), gynoid fat (GF) and the android/gynoid ratio (A/G 
ratio) in the RS but not the CAIFOS. 
Results: No association was found between dietary n-3/n-6 PUFAs ratio or SFA/PUFAs ratio with 
TF in both cohorts. In the RS, a high n-3/n-6 PUFAs ratio was associated with a higher AF (3rd 
vs 2ndtertile (reference): β: 0.15; 95%CI: 0.05, 0.24) but not with the A/G ratio. A low SFA/PUFA 
ratio was associated with a lower AF (1st vs 2ndtertile (reference): β: -0.12; 95%CI: -0.22, -0.06) 
but not with the A/G ratio. 
Conclusion: These findings do not support the hypothesis that dietary fat composition is 
consistently associated with TF and body fat distribution in a population-based setting. 
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INTRODUCTION
There is a large variability in body fat distribution in both lean and obese adults. Android obesity 
is characterized by the accumulation of body fat in the upper truncal region and is most common 
in men, whereas gynoid obesity is defined as an accumulation of body fat in hips and thighs and 
is most common in women1. Regional fat distribution has been considered to be more important 
in understanding the association of obesity with chronic disease than overall body fat mass2-4. 
Android obesity has been associated with an increased risk of atherosclerosis, type 2 diabetes 
mellitus, cardiovascular disease and total mortality5-9. Contrary to this, gynoid obesity has been 
independently associated with a reduced risk of metabolic complications2,3.
Although epidemiological studies have identified potentially modifiable factors that affect body 
fat distribution, such as physical activity and cigarette smoking10-12, the role of dietary intake, 
particularly dietary fat composition, and its effect on the distribution of body fat remains 
controversial13-17. There is some evidence that different types of fatty acid have different rates 
of oxidation, depending on their chemical structure18,19. Impaired fat oxidation has been found to 
be associated with the development of obesity20. However, whether different dietary fatty acids 
also affect the distribution of body fat remains unclear. Some but not all studies suggest that high 
dietary polyunsaturated fatty acids (PUFAs) intake is associated with a greater fat mass loss in 
the abdominal region21,22 whereas dietary saturated fatty acids (SFAs) intake is associated with 
abdominal obesity23. Nevertheless, results from long-term studies linking dietary fat intake to 
regional fat distribution remain scarce. Additionally, previous studies generally used anthropometric 
measures such as waist circumference or BMI21,23-27 instead of more accurate measures of body 
composition by dual-energy X-ray absorptiometry (DXA) 28,29. Moreover, previous research on the 
relation of dietary fat with body fat has focused primarily on men 23,27,30,31 whereas there may be 
gender-specific differences32. Furthermore, previous studies have not taken into account the role 
that chronic disease may play in the association between dietary fat intake and body fat. Chronic 
disease may alter weight and waist measures and therefore body fat33,34, as well as dietary intake35.
We therefore examined the hypothesis that dietary fat composition (i.e. dietary ratios of n-3/n-6 
PUFAs and SFAs/PUFAs) is associated with total body fat and regional body fat distribution, as 
measured by DXA, and the presence of chronic disease modifies this association, in two Caucasian 
study populations from the Netherlands and Australia. 
SUBJECTS AND METHOD
The present study included two geographically distinct study populations, the Rotterdam Study 
(RS) and the Calcium Intake Fracture Outcome Study (CAIFOS). The RS is a community based 
prospective cohort study that started in 1990 to examine the determinants of disease and health 
in the elderly. Inhabitants of a suburb of Rotterdam, the Netherlands (n=7,983), aged 55 years or 
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older were included. The rationale and design of the RS is described elsewhere36. Trained research 
assistants collected data on current health status, use of medication, medical history, lifestyle and 
risk indicators for chronic disease during an extensive home interview at baseline examination 
which took place in 1989-1993. Subsequently, the participants visited the study center for detailed 
clinical examinations and assessment of diet. Follow up visits were held every 2-3 years36. The 
present study used data from the baseline examination of the original cohort. Out of 6,521 non-
institutionalized subjects (85% of the cohort) who visited the study center at baseline were eligible 
for a dietary interview. Dietary data was not obtained in 271 subjects who participated in the pilot 
phase of the Rotterdam Study. Also, diet was not assessed in 122 subjects suspected with dementia 
because of expected difficulties in dietary recall, and in a random group of 481 subjects due to 
logistic reasons. Additionally, 678 dietary reports were excluded because they were considered to 
be unreliable by the dietician or because of extreme total energy intake (2 interquartile ranges of 
the 25th and 75th percentile of the distribution of total energy). Dietary data was thus available for 
4,969 subjects. During 14 years of follow up, there were 1,454 participants who died (710 women 
and 744 men) and 1,488 subjects (454 women and 1,033 men) with no DXA scan examination, 
leaving 2,028 subjects for analysis. 848 male subjects were further excluded from the main 
analyses. Therefore, 1,182 women were included in the analysis
The Calcium Intake Fracture Outcome Study (CAIFOS) started in 1998 as a randomized, controlled 
trial of oral calcium supplements to prevent osteoporotic fractures as described previously37. 
Briefly, 1,460 ambulant women with no medical conditions (e.g. cancer) that may influence 5-year 
survival were recruited from the Western Australian general population of women older than 70 
years. Participants were similar in terms of disease burden but were more often from a higher 
socioeconomic background relative to the general population38. During 5 years of follow-up, 
participants received 1.2 g of elemental calcium supplementation (calcium carbonate) daily or a 
placebo. For the present study, 906 participants who completed a food frequency questionnaire 
(FFQ) at baseline in 1998 and had DXA measured 5 years later in 2003 were included. Forty-six 
women were further excluded because of missing data on covariates, leaving 860 women for the 
final analysis.
Assessment of dietary fat composition
In both cohorts, information on dietary intake at baseline was collected by using self-administered 
FFQ but that were adapted for and validated in the Dutch and Australian setting for each cohort as 
described in detail previously30,39. The FFQ asked respondents to recall how often, on average, they 
consumed a standard serving size of food in the previous 12 months. Energy and nutrient intakes 
were estimated based on frequency of consumption, standardized portion sizes and using the Dutch 
food composition table for RS40 and the NUTTAB95 food composition database for CAIFOS41. 
Previous studies have demonstrated that the FFQs were a valid instrument for ranking individuals 
by fat intake in the RS and CAIFOS30,39. For example, in the RS, in a comparison of the FFQ 
with fifteen day-food records collected over a year, partial Pearson correlation coefficients of 
150
this comparison, after adjustment for age, sex, energy, and within-person variation were 0.52 for 
saturated fat and 0.62 for polyunsaturated fat30. 
Measures of body composition
Total body composition was assessed by DXA during the fourth visit of RS (January 2002-July 
2004) and at the 5 year visit (2003) after baseline (1998) in CAIFOS using total body-fat beam 
densitometer (GE Lunar Corp, Madison, WI, USA for RS and Hologic Corp, Waltham, MA, USA 
for CAIFOS). Body weight (grams) was divided into bone mineral content, lean (non-fat) and fat 
mass. In both cohorts, fat distribution was determined by measuring fat mass at the total-body, 
whereas in the RS was additionally determined by measuring fat mass in android and gynoid 
regions. Body fat was assessed as percentage of body fat taking into consideration the weight of 
the individual and total fat as well (when using android and gynoid fat as outcomes). Body fat mass 
index (BFMI) was calculated as total body fat mass (kg) divided by body surface (the square of the 
height in m i.e. m2)42. This fat mass index eliminates the differences of the body fat associated with 
an individual’s height. Total body fat mass, android and gynoid fat mass were available in the RS, 
whereas in CAIFOS, total body fat mass was the only measure of body fat available.
Potential confounding variables
Information on current health status, medical history, medication use, smoking behavior, and 
socioeconomic status was obtained at baseline for both studies. Participants were asked whether 
they were currently smoking cigarettes, cigars, or pipes. Education was defined as low (primary 
education), intermediate (secondary general or vocational education), or high (higher vocational 
education or university). Alcohol intake was assessed in grams of ethanol per day. Cardiovascular 
disease was defined as a history of myocardial infarction, coronary artery bypass, or percutaneous 
transluminal coronary angioplasty. Development of chronic disease was defined as the presence of 
cardiovascular disease, diabetes mellitus and cancer at the baseline and until the DXA measurements 
took place. Baseline hypertension was defined as a blood pressure ≥140/90 mmHg or use of blood 
pressure lowering medication, prescribed for the indication of hypertension. Baseline diabetes 
mellitus was defined as a serum glucose level ≥11 mmol/L or use of glucose lowering drugs. To 
take into account overall dietary quality we used The Dutch Healthy Diet (DHD)-index43 for the 
Rotterdam Study and the Nutrient-Rich Foods (NRF)-index for CAIFOS, adapted for use with 
Australian dietary recommendations. In the RS, at the third visit to the research center, the total 
weekly duration of physical activity was assessed by an adapted version of the Zutphen Physical 
Activity Questionnaire and the LASA Physical Activity Questionnaire44,45. In CAIFOS, women 
were asked if they participate in any sport, recreational, or regular physical activity. Those who 
answered ‘no’ scored zero and those who answered ‘yes’ were asked to list up to four types of 
physical activity undertaken in the last 3 months. Activity levels were calculated in kcal/day using 
a previous method utilizing body weight, number of hours and type of physical activity and energy 
costs of such activities46,47. Physical height (m) and body weight (kg) were measured at baseline 
with the participants standing without shoes and heavy outer garments. Body mass index (BMI) 
was calculated as weight divided by height squared (kg/m2).
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Statistical analysis
Data are presented as the mean ± SD unless indicated otherwise. Pearson correlations coefficients 
were computed to identify the major food source of dietary PUFAs and SFAs in both populations. 
Dietary PUFAs and SFAs intake were adjusted for total energy intake using the residual method 
to account for systematic measurement error48. Dietary fat was analyzed in tertiles and the second 
tertile was considered the reference group since this included the mean intake of the population.
Multivariable linear regression models were used to examine whether dietary n-3/n-6 PUFAs ratio 
and the SFAs/PUFAs ratio were independently associated with, total body fat mass (%) in both 
cohorts. In the RS, additional analyses were performed to investigate the relationship between the 
these two exposures and android fat mass (%), gynoid fat mass (%) and android/gynoidfat mass 
ratio. We calculated age-adjusted (model 1) regression coefficients and 95% confidence intervals 
(CIs) for each type of dietary fatty acid intake and each of the outcomes of interest. To control 
for potential confounding factors, a second multivariable model was built (model 2), which was 
adjusted for relevant covariates. The following covariates were tested: baseline total energy intake 
(continuous), BMI (continuous variable), total alcohol intake (quartiles), total physical activity 
(quartiles), smoking status (current smokers vs. never/former smokers), education (intermediate, 
high education vs. primary education),  income (intermediate, high income vs. low income), 
hypertension (yes vs. no), more than 3 kg weight loss in the last 12 months (yes vs. no), the presence 
of a chronic disease during follow-up (coronary heart disease, diabetes mellitus and cancer: yes 
vs. no), and overall dietary quality by using the DHD-index (continuous) for the RS and the NRF-
index (continuous) for CAIFOS respectively. The components of SFAs and PUFAs were removed 
from the DHD-index and NRF-index to avoid over- adjustment. Potential confounding factors 
were considered relevant if their inclusion in the model resulted in a change of at least 10% in 
the regression coefficient of the exposure32. In all analysis for the CAIFOS, we adjusted for the 
intervention effect by adding treatment (yes vs. no) to the models. We tested for possible nonlinear 
effects of the exposure of interest using quadratic and cubic effects. The F test was used to test 
whether there were overall significant differences in fat mass (total, android or gynoid fat mass) 
between levels of dietary fat intake. To test for effect modification by the presence of chronic 
disease, the product term of tertiles of fatty acids and prevalent chronic disease were added to the 
model. Effects with a P-value lower than 0.05 were considered statistically significant. In case of 
significant effect modification, stratified analyses were performed.
The following sensitivity analyses were performed: First, since calcium may affect body weight49, 
an interaction term between fatty acids and calcium-treatment was tested in the age-adjusted 
models for the CAIFOS cohort to evaluate if the intervention had an impact on the relationship 
between the exposure and outcome. Second, since most of the previous studies were performed in 
men only23,27,30,31, to establish whether findings were similar for men and women, we performed the 
analysis in the male participants of the RS as well.
To reduce the potential bias due to missing covariate data multiple imputation (m=5 imputations) 
was applied to the RS data. Pooled regression coefficients (β) and 95% CIs were calculated using 
Rubin’s rules50. All analyses were performed in IBM SPSS Statistics 21.
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Table 1 Selected characteristics of study population in the Rotterdam Study and Calcium Intake Fracture 
Outcome Study.
Baseline characteristics RS  (N=1182) CAIFOS (N=860)
Age 64.12 ± 6.03 74.86 ± 2.57
N-3 PUFAs (g/day) 0.98 ± 0.47 1.29 ± 0.63
N-6 PUFAs (g/day) 11.27 ± 6.43 8.76 ± 4.02
Total PUFAs (g/day) 13.70 ± 6.98 10.79 ± 4.69
Total Saturated Fat (g/day) 28.56 ± 10.12 25.16 ± 10.90
Total energy intake (kcal/day) 1790.54 ± 391.11 1650.10 ± 490.46
BMI (kg/m2) 26.34 ± 3.8 26.85 ± 4.52
Total alcohol (g/day)* 6.89 (66.82) 2.04 (66.15)
Lower Education, n (%) 398 (33.6) 272 (30.8)
Medium Education (%) 685 (58.0) 368 (41.7)
High Education (%) 99 (8.4) 243 (27.5)
Income (%)
low 394 (33.3) 301 (34.0)
Medium 442 (37.4) 315 (35.5)
High 346 (29.3) 270 (30.5)
Never/former smokers 959 (81.1) 885 (99.8)
Current smokers 223 (18.9) 2 (0.2)
Physical activity (min/week) 2912.6 ± 1056.4 125.93 (1478.40)*@
Hypertension (%) (540) 45.7 375 (42.1)
More than 3 kg loss in last 12 months (%) 86 (7.3) 91 (10.3)
Total DHDI/ NRFI  52.75 ± 10.45 37.85 ± 9.55
Characteristics at the end and during the follow-up
Total whole body fat mass (kg) 23.31  ± 7.56 24.84 ± 7.38
Total body fat mass index (kg/m2) 10.66 ± 3.35 9.59 ± 2.87
Android Fat (kg) 2.41  ± 0.94 NA
Gynoid Fat (kg) 4.51 ± 1.39 NA
Prevalent chronic disease (%)$ 346 (30) 160 (18.0)
Chronic disease development (%)# 225 (19.0) 64 (7.2)
 
DHDI, Dutch Healthy Diet-index; NRFI, Nutrient-Rich Foods Index, PUFAs: polyunsaturated fatty acids 
Plus-minus values are means ±SD 
* median (range) 
@kcal expended/day
$Percentage of participants who have at least one of the chronic disease (cardiovascular disease, diabetes or cancer) when 
the body composition was assessed. 
#Percentage of participants who developed a chronic disease (cardiovascular disease, diabetes or cancer) from baseline 
until the measurements of body composition. 
153
3
N
ut
rit
io
n 
an
d 
C
ar
di
om
et
ab
ol
ic
 R
is
k 
Fa
ct
or
s
Table 2. Correlation coefficients between n-6 and n-3 PUFAs and their dietary food sources*.
n-6 PUFAs (g/day) Rotterdam Study 
 Pearson Correlation ( r) 
CAIFOS  
Pearson Correlation ( r) 
Vegetable oils (g/day) 0.23 NA 
Butter, margarines and hard frying fats (g/day) 0.34 0.60
Fish (g/day) - 0.16 
Poultry(g/day) 0.09 0.16 
Processed red meat (g/day) 0.12 0.18 
Sweet desserts and confectionary
(g/day)
0.13 0.31 
Chips (g/day) - 0.13
Wholegrain (g/day) 0.11 0.31
Total dairy** (g/day) - 0.12 
n-3 PUFAs (g/day) Rotterdam Study 
 Pearson Correlation ( r) 
CAIFOS  
Pearson Correlation ( r) 
Vegetable oils (g/day) - NA 
Butter, margarines and hard frying fats (g/day) 0.38 0.47 
Fish (g/day) 0.29 0.67 
Poultry(g/day) 0.13 0.30 
Processed red meat (g/day) 0.27 0.21 
Sweet desserts and confectionary
(g/day)
0.09 0.31
Chips (g/day) - 0.10
Wholegrain (g/day) - 0.31
Total dairy** (g/day) - 0.18 
SFAs (g/day) Rotterdam Study 
 Pearson Correlation ( r) 
CAIFOS  
Pearson Correlation ( r) 
Vegetable oils (g/day) - NA 
Butter, margarines and hard frying fats (g/day) 0.58 0.38
Fish (g/day) -0.09 0.17
Poultry(g/day) - 0.25
Processed red meat (g/day) 0.37 0.42
Sweet desserts and confectionary 
(g/day)
0.31 0.59
Chips (g/day) - 0.33
Wholegrain (g/day) 0.09 0.08
Total dairy** (g/day) 0.12 0.20
PUFA: polyunsaturated fatty acids 
*Overall variance explained by these food items: 22% for n-6 PUFAs; 37% for n-3 PUFAs. 
**including cheese 
-does not significantly contribute to n-3 or n-6 PUFAs (p-value >0.05), otherwise, the p-value<0.05
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RESULTS
Characteristics
Table 1 displays the selected characteristics of the 2 populations. In the RS, the mean age of study 
participants were younger (64.12 ± 6.03 vs. 74.86 ± 2.57 years), used to smoke more (18.9% vs. 
0.2%) and consume more alcohol (6.89 vs. 2.04 g/day) than in CAIFOS. Also, the mean intake of 
total PUFAs was higher in the RS than in CAIFOS (13.70 ± 6.98 g/day vs. 10.79 ± 4.69). Main 
sources of n-6 PUFAs intake were butter, margarines and frying fats in both the RS and CAIFOS 
(r=0.34 and 0.60 respectively) (Table 2). However, the main sources of n-3 PUFAs in the RS 
were also butter, margarines and hard frying fats (r=0.38) whereas fish was the main source of n-3 
PUFAs in CAIFOS (r=0.67) (Table 2). The main source of SFAs were butter, margarines and hard 
frying fats in the RS (r=0.58) and sweet desserts and confectionary in CAIFOS (r=0.59). 
Dietary fat composition, total body fat and regional body fat distribution
We found no association between dietary intake of n-3/n-6 PUFAs and SFAs/PUFAs ratio and total 
body fat mass (%) in either study (Table 3 and Table 4). However, in the RS high a dietary n-3/n6 
PUFAs ratio was associated with higher android fat (3rd vs. 2ndtertile: β=0.15; 95%CI: 0.05 – 0.24; 
P for F-test, 0.08, Table 3) but not with higher android/gynoid ratio (Table 3). Low SFAs/PUFAs 
ratio was associated with lower android fat (1st vs. 2ndtertile: β=-0.12; 95%CI: -0.22 – 0.06; P for 
F-test, 0.30, Table 3) but not with andoid/gynoid ratio (Table 3).
Effect modification by chronic disease
The presence of chronic disease was found to be a significant effect modifier in the analysis of 
n-3/n-6 PUFAs and total body fat mass in both studies (Pinteraction<0.05, Table 3 and Table 4). In the 
RS, among women without chronic disease, high n-3/n-6 PUFAs ratio was positively associated 
with total body fat mass (%) (3rd tertile vs. 2ndtertile: β=0.94; 95%CI: 0.12, 1.76; P for F-test, 
0.07) whereas no association was found between n-3/n-6 PUFAs ratio and total body fat mass (%) 
in participants with the presence of chronic disease (Figure 1). Effects in the opposite direction 
were found in CAIFOS but after stratification by chronic disease, none of the associations were 
significant (Figure 1). No effect modification by presence of chronic disease was observed in 
the association between n-3/n-6 PUFAs ratio and android and gynoid fat or android/gynoid ratio 
(Table 3). Also, no effect modification in the association of SFAs/PUFAs ratio and regional body 
fat distribution was observed (Table 3) in the RS.
In the CAIFOS cohort, effect modification by the presence of chronic disease was found in the 
relationship between SFAs/PUFAs ratio and % body fat (Table 4; P-interaction=0.02) but this was 
not confirmed in the RS cohort. After stratification by chronic disease, participants with low 
SFAs/PUFAs ratio had a lower total body fat % (1st vs. 2ndtertile: β=-2.27; 95%CI: -3.99, -0.55; 
P for F-test, 0.03; Figure 2). Similar effects were found in the RS cohort but none of them was 
statistically significant (Figure 2).
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Additional analysis
To evaluate the consistency of our findings, we reanalyzed the data using BFMI as the outcome in 
both cohorts. The results were similar to the ones observed when using total body fat mass (%) as 
an outcome (Supplemental Table S1, Supplemental Figure S1). There was no evidence against 
a linear relationship between dietary fat composition and body fat composition measures in either 
cohort (data not shown). Furthermore, no effect modification by treatment was observed in any 
of the analysis in CAIFOS (all P>0.05). Moreover, analyses were not different between strata of 
gender in the RS (data not shown). 
DISCUSSION
By using two large population-based cohort studies, we showed that dietary n-3/n-6 PUFAs and 
SFAs/PUFAs ratios were not consistently associated with total body fat and its distribution. 
Little is known about the effects of dietary fatty acids intake on body fat distribution with few 
prospective studies evaluating the associations between n-3 PUFAs on body fat composition. Cout 
at al. reported, in six volunteers, a beneficial effect of a diet rich in n-3 fatty acids on body fat51 
whereas Kratz at al. did not find an association between n-3 fatty acids and body fat among twenty-
six overweight or moderately obese individuals52. It has been proposed that a diet rich in n-6 
PUFAs may promote adiposity53, a view that is not supported by our study or others. It has been 
previously reported that a diet rich in n-6 PUFAs may also reduce subcutaneous tissue21 and trunk 
adipose tissue54. Within contrast to the current study, high consumption of dietary SFAs have been 
reported to promote weight gain and increases in adiposity, particularly in abdominal adiposity23, 
whereas a higher dietary PUFAs has been associated with a greater fat mass loss in the abdominal 
region 21,22. A diet higher in PUFAs has been shown to have a greater fat-oxidizing effect 55,56 which 
may imply a lower fat retention in the body20. However, unlike this study, most of the previous 
studies focused on dietary PUFA intake as an individual component, whereas our study took the 
dietary fat composition into account by using the n-3/n-6 PUFAs ratio and the SFAs/PUFAs ratio 
which is suggested to affect regional body fat distribution 22,57. 
To our knowledge, this is the first study to account for potential modification by chronic disease on 
the association between dietary fat intake and body fat distribution. Although we found evidence 
for effect modification, the results showed differential directions in both populations. Hence, 
it is unclear whether the effect modification by chronic disease found in our study presents a 
physiological effect modification, or it’s due to confounding factors, which may be differently 
distributed among subjects with and without chronic disease. It can be suggested that chronic 
disease may dilute any association between dietary fat intake and regional fat distribution since 
the presence of chronic disease may be associated with weight change and therefore body fat 
alterations and/or may also alter dietary intake58. Furthermore, factors that affect the metabolism 
of fatty acids, such as estrogen and blood lipid levels differ between people with and without 
chronic disease. For example, it has been reported that DHA synthesis is almost threefold grater in 
women using oral contraceptives than those with it59. Additionally, the presence of chronic disease 
is associated with an inflammatory profile,60,61 which has been shown to be associated with obesity 
and in particular abdominal obesity62 but dietary fat intake may also play a role in the inflammatory 
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Table 4 Dietary fat composition and total body fat (%), the CAIFOS. 
n-3/n-6 PUFAs Total body fat (%) 
 β (95% CI)
MODEL 1 MODEL 2a MODEL 1 MODEL 2b$
1stTertile -0.43 
(-1.35, 0.50)
0.08 
(-0.18, 0.35)
-0.48 
(-1.41, 0.44)
-0.55 
(-1.20, 0.11)
2nd Tertile reference reference reference reference
3rd  Tertile -0.64 
(-1.56, 0.29)
0.11 
(-0.16, 0.37)
-0.25 
(-1.17, 0.68)
-0.36 
(-1.02, 0.29)
P for F-test (3 df) 0.39 0.76 0.59 0.28       
PInteraction 0.026* 0.022#
 
Model 1: Adjusted by age 
Model 2: Multivariable adjusted as follows
a Model 1 + additional adjusted for baseline BMI, energy intake, alcohol intake, education, income status and treatment 
code. Additional adjustment for other covariates did not change the effect estimate with more than 10%.
b Model 1 + additional adjusted baseline BMI, hypertension, more than 3kg loss over 12 months, energy intake, alcohol 
intake, income status and NRFI. Additional a    djustment for other covariates did not change the effect estimate with 
more than 10%.
*PInteraction=0.026 for n-3/n-6 PUFAs ratio continuous x prevalent chronic disease (yes vs. no)
*PInteraction=0.02 for SFA/PUFAs ratio Quartile 1 x prevalent chronic disease (yes vs. no);
PInteraction=0.76 for SFA/PUFAs ratio Quartile 1 x prevalent chronic disease (yes vs. no)
process 63. Furthermore, dietary fat composition is linked to other cardiovascular risk factors and 
health outcomes by the same proposed mechanisms that are linked to obesity64. Hence, further 
large-scale studies should confirm our findings, focusing on the effect of dietary fat intake on body 
fat distribution and the interaction with the presence of chronic disease. 
Although not statistical significant, effects in opposite directions were observed in the two 
studies for the association between dietary fat composition and total body fat. This may be true to 
differences in the food sources of n-3 PUFAs in the RS and CAIFOS. In the CAIFOS, the main 
contribution of n-3 PUFAs was dietary fish intake; whereas the n-3 PUFAs in the RS cohort are 
mainly plant derived n-3 PUFAs (i.e. 29.3% of women participating in the RS did not consume 
fish at all). It has been reported previously that the health effects of PUFAs may differ with the 
food they are consumed in; for example, marine derived n-3 PUFAs have been shown to have 
differential health effects than n-3 plant derived n-3 PUFAs65,66. Therefore, it may be useful to 
evaluate different sources of fatty acids on body composition in future studies. 
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Strengths of this study include the large prospective population-based nature of both cohorts, the 
use of accurate measures of body composition such as DXA, and the extensive adjustment for a 
broad range of possible confounders Nevertheless, to appreciate the results some limitations need 
to be discussed. Because dietary intake was self-reported by using a FFQ, measurement error in 
the exposure can occur due to incomplete nutrient databases, accuracy of memory or willingness 
to divulge details. Although the FFQ that we used was validated in both studies and showed a 
relatively high correlation with the intake of fatty acids, errors in the measurement of fat intake 
have been suggested to lead to an underestimation of the true magnitude of the association67. Also, 
dietary fat intake was assessed at baseline, and there may have been changes in fat consumption 
over time. Another limiting factor to the current investigation is that body fat in both cohorts was 
measured only once and that that measurement was taken several years after the exposure was 
measured. However, in all analyses we adjusted for baseline BMI, which correlates well with 
total body fat; for example in the RS, partial correlation coefficient between BMI and total body 
fat percentage at the fourth visit is 0.81. However, we cannot rule out the possibility of selection 
bias. People who are in poor health are more likely to drop out from the study which may affect 
the generalizability of our results. Also, it has been shown that using a selected source population 
for a cohort study  may lead to bias towards the null68. In addition, in the RS there was no baseline 
data on physical activity, which is known to be a determinant of body fat composition. Although 
we used data on physical activity measured that was measured in the third follow-up visit of the 
RS, we cannot fully exclude residual confounding. Moreover, we did not have data on android fat 
and gyonid fat from the CAIFOS, and therefore we were not able to investigate the associations of 
dietary fat composition with this measure of body fat distribution, which may have strengthened 
our results.  
In conclusion, our findings suggest that dietary fat composition is not consistently associated with 
body fat and its distribution in older individuals. The role of chronic disease warrants further 
investigation.
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Supplemental material
Supplemental Table S1 Dietary fat composition intake and body fat mass index. 
n-3/n-6 PUFA Body fat mass index (kg/m2) 
 β (95% CI) 
SFA/PUFA Body fat mass index (kg/m2) 
 β (95% CI) 
 MODEL 1 MODEL 2a MODEL 1 MODEL 2b  MODEL 1 MODEL 2c MODEL 1 MODEL 2d
 
1st Tertile -0.12 
(-0.59, 0.34) 
0.08 
(-0.18, 0.35) 
-0.20 
(-0.66, 0.26) 
-0.23 
(-0.69, 0.22) 
1st   Tertile 0.04 
(-0.42, 0.51) 
-0.06 
(-0.33, 0.20) 
-0.15 
(-0.61, 0.32) 
-0.24 
(-0.69, 0.22) 
2nd  Tertile reference reference reference reference 2nd   Tertile reference reference reference reference 
3rd  Tertile 0.20 
(-0.26, 0.67) 
0.11 
(-0.16, 0.37)* 
-0.18 
(-0.64, 0.29) 
-0.16 
(-0.62, 0.30) 
3rd  Tertile -0.09 
(-0.55, 0.38) 
0.08 
(-0.19, 0.35) 
0.02 
(-0.44, 0.48) 
-0.40 
(-0.49, 0.41) 
P  for F-test: 0.38 0.68 0.65 0.59 P  for F-test: 0.84 0.31 0.74 0.86 
Rotterdam Study Rotterdam Study CAIFOS  CAIFOS  
Model 1: Adjusted by age 
Model 2: Multivariable adjusted as follows 
a Model 1 + additional adjusted for baseline energy intake, income status, education status, smoking status, hypertension, DHDI-index 
excluding PUFA component, BMI and prevalent chronic disease at 4th round. Additional adjustment for other covariates did not change the 
effect estimate with more than 10%. 
b Model 1 + additional adjusted for baseline 3kg loss over 12 months, alcohol intake, education status, income status and treatment code. 
Additional adjustment for other covariates did not change the effect estimate with more than 10%. 
c Model 1 + additional adjusted for baseline energy intake, hypertension, income status, alcohol intake, physical activity, DHDI-index 
excluding PUFA component and BMI. Additional adjustment for other covariates did not change the effect estimate with more than 10%. 
d Model 1 + additional adjusted for baseline hypertension, more than 3kg loss over 12 months, smoking status, alcohol intake, physical 
activity, education, income status, NRFI and prevalent chronic disease in 2003. Additional adjustment for other covariates did not change 
the effect estimate with more than 10%. 
# Significant interaction term, dietary fat composition x prevalent chronic disease
Supplemental Figure S1 The association (β, 95% CI) between n-3/n-6 PUFAs ratio intake and body fat 
mass index in participants with and without prevalent chronic disease (fully adjusted model, Model 2).
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Supplemental Table S2 Selected characteristics of male participants in the Rotterdam Study.
RS  (N=846)
Baseline characteristics
Age 64.0 ± 5.5
N-3 PUFAs (g/day) 1.23 ± 0.54
N-6 PUFAs (g/day) 15.24 ± 7.62
Total PUFAs (g/day) 18.70 ± 8.26
Total Saturated Fat (g/day) 36.34 ± 12.33
Total energy intake (kcal/day) 2298.4 ± 515.2
BMI (kg/m2) 27.1 ± 6.4
Total alcohol (g/day)* 15.87 (95.58)
Lower Education, n (%) 152 (17.9)
Medium Education (%) 504 (59.6)
High Education (%) 190 (22.5)
Income (%)
low 127 (15.0)
medium 330 (39.0)
high 389 (46.0)
Never/former smokers 959 (81.1)
Current smokers 210 (24.8)
Physical activity (min) 2626.47 ± 1130.45
Hypertension (%) (385) 45.5
More than 3 kg loss in last 12 
months (%) 62 (7.3)
Total DHDI-index 48.68 ± 10.58
Characteristics at the end and 
during the follow-up
Total whole body fat mass (kg) 23.31  ± 7.56
Total body fat mass index (kg/m2) 23.31  ± 7.56
Android Fat (kg) 2.58  ± 0.95
Gynoid Fat (kg) 3.24 ± 1.03
Prevalent chronic disease (%)$ 366 (43.3)
Chronic disease development (%)# 266 (31.4)
Dutch Healthy Diet-index; PUFAs: polyunsaturated fatty acids 
Plus-minus values are means ±SD 
* median (range) 
$Percentage of participants who have at least one of the chronic disease (cardiovascular disease, diabetes or cancer) when 
the body composition was assessed. 
#Percentage of participants who developed a chronic disease (cardiovascular disease, diabetes or cancer) from baseline 
until the measurements of body composition. 
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Supplemental Table S3 Correlations coefficients between n-6 and n-3 PUFAs and their dietary food 
sources in male participants of the Rotterdam Study*.
Rotterdam 
Study
n-6 PUFAs (g/day) 
 Pearson Correlation ( r)
n-3 PUFAs (g/day) 
Pearson Correlation ( r)
SFAs (g/day) 
Pearson Correlation ( r)
Vegetable oils 
(g/day)
0.25 - -
Butter, 
margarines 
and hard 
frying fats (g/
day)
0.32 0.47 0.59
Fish (g/day) - 0.29 -0.04
Poultry(g/day) - 0.10 -0.07
Processed red 
meat (g/day)
0.09 0.23 0.36
Sweet 
desserts and 
confectionary 
(g/day)
0.07 0.14 0.36
Chips (g/day) - - 0.07
Wholegrain (g/
day)
0.16 0.13 0.17
Total dairy** 
(g/day)
- 0.07 0.22
PUFA: polyunsaturated fatty acids 
*Overall variance explained by these food items: 22% for n-6 PUFAs; 37% for n-3 PUFAs. 
**including cheese 
-does not significantly contribute to n-3 or n-6 PUFAs (p-value >0.05), otherwise, the p-value<0.05
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3.3Vitamin D and Body Composition in the Elderly: the Rotterdam Study
ABSTRACT
Objective: To investigate the association between vitamin D status and body composition in the 
elderly. 
Methods: This study was embedded in the Rotterdam Study, a population-based prospective study in 
Rotterdam, the Netherlands, including subjects aged 55 years and older. Serum 25-hydroxyvitamin 
D (25(OH)D) was measured between 1997 and 1999. Total body fat, android fat, gynoid fat and 
lean mass were assessed using dual-energy X-ray absorptiometry (DXA) during a follow-up 
visit after a median time of 5 years (2002-2004).We calculated body fat percentage, lean mass 
percentage, and android/gynoid fat ratio. We had 2,158 participants included in our analysis. We 
used multivariable linear regression models. Serum 25(OH)D was analyzed continuously and after 
categorization according to cut-offs.
Results: Mean (±SD) serum 25(OH)D concentration of the study population was 52.6 ± 25.4nmol/L. 
Compared to subjects with an adequate vitamin D status (25(OH)D ≥75nmol/L),vitamin D deficient 
participants (25(OH)D <50nmol/L) had a higher body fat percentage (β=1.29, 95%CI: 0.55, 2.04)
whereas no association was found with lean mass (β=0.01, 95%CI: -0.33, 0.35). Lower 25(OH)
D was associated with higher total body fat percentage specifically in participants without cardio-
metabolic disease. Each 10 unit increase in serum 25(OH)D was associated with 0.03 unit decrease 
in android fat (β=-0.03, 95%CI: -0.06, -0.01); after adjustment for BMI the association was no 
longer significant. Serum 25(OH)D was also associated with the android/gynoid fat ratio but this 
was also mainly explained by BMI.
Conclusion: Lower serum 25(OH)D concentrations were associated with a higher fat mass 
percentage. The association between serum 25(OH)D and differential fat distribution in the elderly 
was mainly explained by BMI and deserves further study.
172
INTRODUCTION
Low concentrations of Vitamin D (25(OH)D) have been associated with bone health and also with 
obesity and many obesity-related disorders such as metabolic syndrome, cardiovascular disease, 
diabetes mellitus, and mortality1 2.The prevalence of obesity is common worldwide3 and obesity 
is a well-known risk factor for diseases like type 2 diabetes mellitus and cardiovascular disease4 5. 
Fat tissue located in the abdominal region, especially around the internal organs, is considered to 
be hormonally active, causing low grade inflammation, which contributes to the development of 
insulin resistance and subsequently type 2 diabetes mellitus6-8. 
It is known that circulating concentrations of serum 25(OH)D are lower in obese individuals, 
most likely due to sequestration of serum 25(OH)D in the fat tissue and due to other lifestyle 
factors related with sun exposure (e.g. physical activity)9. On the other hand, there are numerous 
mechanisms reported in the literature describing the involvement of vitamin D in adipose tissue 
metabolism 9and also mechanisms describing the role of muscle cells in metabolism of vitamin 
D 10. For example, it has been suggested there might be increase in catabolism of vitamin D in 
the adipose tissue11, while, on the other hand, active 1,25(OH)2D might activate muscle tissue 
growth and improve muscle function12-14. Observational studies found serum 25(OH)D associated 
with different anthropometric measures and body composition measures such as body mass index, 
body fat mass, but also visceral fat and lean mass9 15 16. Conversely, a study using a bidirectional 
Mendelian randomization approach found higher body mass index causing lower serum 25(OH)D 
concentrations but not the other way around17. 
However, it is unclear whether vitamin D status is associated with fat mass stored in specific regions 
of the body and what is the direction of this association. Furthermore, since most of the research 
on this topic was performed in younger populations the association between vitamin D status and 
body composition in the elderly remains unexplored. In addition, the relation between vitamin D 
status and body composition may be complicated by the presence of cardio-metabolic diseases 
since these may be associated with both vitamin D and body composition18 19. Also, patients who 
are diagnosed with cardio-metabolic disease might have been advised to lose weight and change 
their lifestyle in general which might have led to changes in vitamin D status 20. 
Knowledge on potential preferential storage of vitamin D in specific fat depots is important to 
clarify because it might help further elucidate the mechanisms how vitamin D and obesity are 
associated and may have implications for supplementation of specific populations. Therefore, 
we investigated whether there is an association between vitamin D status and body composition 
including measures of fat and lean mass and fat distribution by DXA in the elderly. Additionally, 
we evaluated whether this association differed by age, gender, presence of cardio-metabolic disease 
and metabolic syndrome since these are all factors that might relate to vitamin D status and also 
body composition. 
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METHODS
The Rotterdam Study
The Rotterdam Study is an ongoing prospective population-based follow-up study comprising of 
people aged 45 years or older from a suburb of Rotterdam, the Netherlands21. Baseline measurements 
were performed from 1990 to 1993. At this time point we collected the information on current health 
status, different medication use, medical history, lifestyle factors, and risk indicators for chronic 
diseases. Subsequently, the participants visited the study center for detailed clinical examinations 
and assessment of diet. Every 2 to 3 years the participants were invited for the follow-up visits to 
the research centre21. The vital status of the participants was obtained regularly from the municipal 
population registry. Morbidity and mortality data were collected from the general practitioners 
records or, in case of hospitalization, from discharge reports by the medical specialists. Data were 
also collected from pathology registries. The Rotterdam Study has been approved by the Medical 
Ethics Committee of the Erasmus Medical Center and by the Ministry of Health, Welfare and Sport 
of the Netherlands , implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: 
Rotterdam Study). All participants provided written informed consent to participate in the study 
and to obtain information from their treating physicians.
Serum 25-hydroxyvitamin D
Between years 1997 and 1999 (the third examination round of the cohort) serum 25(OH)D 
concentrations were measured using electrochemiluminescence immunoassay (COBAS< Roche 
Diagnostics GmbH, Germany). The range of the test for serum 25(OH)D concentrations was 
7.5nmol/L to 175nmol/L. The sensitivity of the test was 10nmol/L, within-run precision was 
<7.8%, and intermediate precision was <13.1%. We categorized serum 25(OH)D concentrations 
as follows: <50nmol/L as vitamin D deficiency, 50-75nmol/L as vitamin D insufficiency, and 
≥75nmol/L as adequate vitamin D status1. 
Anthropometrics
Participants’ height, weight, waist circumference, and hip circumference were measured at the third 
examination round of the cohort (1997-1999) and at the fourth examination round of the cohort 
(2002-2004). For these measurements the participants were standing without their shoes and heavy 
clothes, they were asked to empty their pockets and to breathe gently. Waist circumference was 
measured at the level midway between the lower rib margin and the iliac crest. Hip circumference 
was measured as the maximum circumference over the buttocks. Based on these measurements we 
subsequently calculated body mass index (BMI, kg/m2) and waist-to-hip ratio (WHR).
Measures of body composition
Body composition was assessed using Dual-energy X-ray absorptiometry (DXA) during the fourth 
examination round of the Rotterdam Study (2002-2004). For the whole body DXA scans we used 
174
ProdigyTM total body-fan beam densitometer (GE Lunar Corp, Madison, WI, USA) 22. Total body 
weight (grams) was divided into bone mineral content, lean mass, and fat mass. In addition, we 
analyzed fat mass of the android body region and gynoid body region. We calculated body fat 
percentage, android fat percentage, gynoid fat percentage and lean mass percentage as percentages 
of total body weight. We calculated the ratio of android fat and gynoid fat, and a ratio of fat mass 
and lean mass as additional measures of body fat distribution.
Potential confounding variables
During the first examination round of the Rotterdam Study cohort (baseline visit) we collected 
the information on current health status, medical history, smoking behavior, education level 
attained and socioeconomic status. This was done during the home interviews. Education was 
defined as low (primary education), intermediate (secondary general education or secondary 
vocational education), or high (higher vocational education or university). Household income 
was categorized as low (<1700 euro/month), middle (1700-3000 euro/month) or high (≥3000 
euro/month). Cardio-metabolic disease was defined as presence of cardiovascular disease and/
or presence of type 2 diabetes mellitus. History of cardiovascular disease was defined as having a 
history of coronary heart diseases (myocardial infarction, revascularization, coronary artery bypass 
graft surgery or percutaneous coronary intervention). This information and was verified from the 
general practitioners’ medical records. Baseline diabetes mellitus was defined as having a serum 
glucose level higher or equal to 11mmol/L or if the use of glucose lowering drugs was reported. We 
defined chronic kidney disease as an estimated glomerular filtration rate (eGFR) lower than 60mL/
min/1.73m2. The metabolic syndrome was defined according to the interim definition proposed 
by Alberti and colleagues23. Physical activity of the participants was assessed with an adapted 
version of the Zutphen Physical Activity Questionnaire24. We assigned a MET-value according to 
the 2011 Compendium of Physical Activities25 to every activity mentioned in the questionnaire. 
The questionnaire contained questions on walking, cycling, gardening, diverse sports, hobbies 
and on housekeeping. Total time spent on physical activity was calculated as the sum of minutes 
per week for each type of activity. At baseline examination round of the cohort the food intake 
was assessed. For this purpose a semi-quantitative food frequency questionnaire was used. To 
assess overall quality of the diet, the Dutch Healthy Diet (DHD) index was used26. This index 
is a continuous score representing compliance to the Dutch Guidelines for a Healthy Diet. The 
following components of the diet were available and included in the DHD index in this study: 
intake of vegetables, fruits, polyunsaturated fatty acids, saturated fatty acids, trans fatty acids, fish, 
dietary fiber, alcohol and sodium. Dates when the blood samples were drawn were categorized into 
summer, autumn, winter and spring according to the Dutch standard seasons. The weight change 
was calculated as the difference between weight at the third visit and weight at the fourth visit of 
the cohort.
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Study population
Participants from the third visit of the first cohort of the Rotterdam Study (1997-1999) were 
eligible for inclusion into this analysis (N=4,787). We had data on serum 25(OH)D concentrations 
available for 3,828 of these participants. During 7 years of follow-up 337 participants from the 
initial population died and 1,333 participants had no dual-energy X-ray absorptiometry (DXA) 
scan examinations performed. Thus, we had 2,158 participants eligible for our final analysis.
Statistical analysis
Descriptives are presented as mean ± standard deviation (SD) unless indicated otherwise. 
Multivariable linear regression was used to examine whether vitamin D status was independently 
associated with total body fat percentage, lean mass percentage, android fat percentage, gynoid 
fat percentage, android fat/gynoid fat ratio and total fat mass/lean mass ratio. In the first model, 
we calculated the age and gender adjusted regression coefficients and their 95% confidence 
intervals (CIs). Further, for all the outcomes of our analyses we built the second model, which was 
additionally adjusted for the season when the blood was drawn, total alcohol intake (continuous), 
total physical activity (continuous), smoking status, education, income, DHD-index (continuous), 
prevalent cardio-metabolic disease (cardiovascular diseases and diabetes mellitus) and presence of 
chronic kidney disease. Finally, the third model was built depending on the outcome of interest; 
for the analysis concerning total body fat percentage, lean mass percentage and total fat mass/
lean mass ratio as the outcomes, we additionally adjusted for height (continuous), weight change 
(continuous) during the follow up and lean mass or total fat mass in kilogram respectively; whereas 
for the analyses concerning android fat percentage and gynoid fat percentage, and android fat/
gynoid fat ratio as outcomes, we additionally adjusted for BMI measured at the third visit (the 
baseline visit for this analysis). The confounders used in our analyses we chosen based on a 10% 
change in regression coefficient 27 as well as based on previously published literature on this topic. 
We tested for possible nonlinear effects by adding a quadratic term of 25(OH)D into the model. 
To test for effect modification by age, gender, cardio-metabolic diseases or metabolic syndrome, 
the product term of 25(OH)D with each one of the potential effect modifiers separately was 
added as independent variable to the models. The analyses were stratified if an interaction term 
was significant at a P-value lower than 0.05. In order to compare how well the data fit the three 
models we also reported R2. To examine the association between serum 25(OH)D concentrations 
and anthropometric measurements measured repeatedly (waist circumference, waist to hip ratio 
and BMI) we fitted linear regression models using generalized estimating equations (GEE) with 
exchangeable correlation structure adjusting for the within-subject correlations due to the repeated 
measurements of anthropometric measurements in the same individual28. To account for the time 
difference in measurements at the three time points, we entered a time variable in the model and 
coded as 1,6 and 13.  Finally, to account for the potential effect of vitamin D  supplementation we 
performed sensitivity analysis excluding participants with osteoporosis or receiving any vitamin 
supplementation. To adjust for potential bias associated with missing data, a multiple imputation 
procedure was performed (N= 5 imputations). 
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Table 1. Selected characteristics of the study population. 
Deficient (N=1129) Insufficient 
(N=621)
 Adequate 
(N=408)
% 
Missing
Age 71.6 ± 6.2 69.6 ± 5.4 68.8 ± 5.2 0
Female %(n) 66.7 (753) 50.4 (313) 39.5 (161) 0
Smoking status (current smokers) %(n) 16.4 (185) 13.7 (85) 16.7 68 0.5
Physical activity (total MET hours) 85.9 ± 43.7 85.9 ± 44.4 95.9± 48.2 0.6
Alcohol intake (g/day)* 2.1 (10.2) 3.6 (13.6) 4.3 (16.4) 0.5
Education Level 0.9
Low % (n) 46.7 (527) 42.0 (261) 36.5 (149)
Medium % (n) 43.4 (990) 43.3 (269) 50.7 (207)
High % (n) 9.9 (112) 14.7 (91) 12.7 (52)
Income 10.0
Low % (n) 19.3 (218) 13.5 (84) 11.8 (48)
Medium % (n) 42.3 (478) 40.7 (253) 38.0 (155)
High % (n) 38.4 (433) 45.7 (284) 50.2 (205)
BMI 3rd visit (kg/m2) 27.30 ± 4.1 26.4 ± 3.4 26.2 ± 3.4 0.4
BMI 4th visit (kg/m2) 27.8 ± 4.4 27.0 ± 3.7 26.2 ± 3.4 1.8
BMI 5th visit 27.9 ± 4.6 27.02 ± 3.7 26.9 ± 3.4 42.8
WC 3rd visit 93.7 ± 12.0 92.7 ± 10.9 92.6 ± 10.29 0.37
WC4th visit (kg/m2) 93.6 ± 12.1 93.29 ± 11.4 93.8 ± 11.03 0.32
WC 5th visit 92.5 ± 12.9 92.2 ± 12.1 92.2 ± 11.8 43.0
WHR3rd visit (kg/m2) 0.91 ± 0.10 0.92 ± 0.09 0.93 ± 0.1 0.37
WHR4th visit (kg/m2) 0.90 ± 0.09 0.91 ± 0.09 0.92 ± 0.09 0.32
WHR 5th visit 0.89 ± 0.09 0.90 ± 0.09 0.91 ± 0.09 43.0
Weight change (%) -0.83 ± 4.6 -1.2 ± 3.9 -1.5 ± 3.8 2.0
DHDI 49.3 ± 10.2 49.1 ± 10.3 47.3 ± 10.1 11.8
Cardio-metabolic disease %(n) 73.1 (304) 22.2 (138) 22.88 (93 0
Metabolic Syndrome %(n) 46.0 (519) 35.7 (222) 30.1 (123) 1.8
Chronic Kidney Disease %(n) 13.0 (147) 9.8 (61) 11.3 (46) 0.2
Vitamin D (nmol/L) 33.2 ± 10.3 61.2 ± 6.9 93.3 ± 15.5 0
DHDI, Dutch Health Diet Index; BMI, Body mass index; WC, Waist circumference; WHR, Waist hip ratio 
Values presented are mean ± SD;
*Median (interquartile range). 
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For the pooled regression coefficients (β) and 95% CIs we used Rubin’s method 29. All analyses were 
performed using IBM SPSS Statistics 20. A P-value lower than 0.05 was considered statistically 
significant.
RESULTS
The mean (± SD) age of the participants was 70.5± 5.9 years; mean time difference between 
the 25(OH)D measurements and DXA measurements was 4.6 years; 19% of study participants 
had adequate vitamin D status (25(OH)D≥75 nmol/L), 29% had vitamin D insufficiency (50-75 
nmol/L) and 52% had vitamin D deficiency (<50 nmol/L) (Table 1). 
Vitamin D, total body fat mass and lean mass
In the age, gender and covariates adjusted model, subjects with vitamin D deficiency had a 1.29 unit 
higher body fat percentage than participants with adequate vitamin D status (95%CI=0.55, 2.04) 
(Table 2). When analyzed continuously an inverse association was observed between serum 25(OH)
D and body fat percentage: a 10 nmol/L increase in serum 25(OH)D was associated with a 0.24unit 
lower body fat percentage (95%CI=-0.35, -0.13)in model 3 (the fully adjusted model) (Table 2). 
A higher serum 25(OH)D was also associated with a lower fat mass/lean mass ratio(β=-0.01, 
95%CI= -0.01, -0.00, model 3)  (Table 2).In contrast, a 10 nmol/L increase in serum 25(OH)D was 
associated with a 0.23higherlean mass percentage(95%CI=0.11, 0.35) in model 2 (Table 2), and 
did not remain significant after further adjustment for height, weight change and total fat mass in 
kilogram (model 3).The corresponding analyses of 25(OH)D cutoffs yielded very similar results 
as the analyses of 25(OH)D continuous (see the P for trend, Table 2). Additionally we performed 
the same analysis using absolute total body fat and absolute lean mass (Supplementary Table 
S1). The results changed slightly: the association between 25(OH)D and total fat mass weakened 
but remained significant (β=-0.06, 95%CI= -0.01, -0.00, model 3) while the association between 
25(OH)D and lean mass became significant (β=0.06, 95%CI= 0.01, 0.12, model 3). Furthermore, 
we observed an interaction between 25(OH)D and presence of cardio-metabolic diseases on total 
body fat percentage (Pinteraction=0.03).The inverse association between 25(OH)D and body fat 
percentage was present among subjects without cardio-metabolic diseases (β=1.70, 95%CI=0.87, 
2.53 for deficiency vs. adequate vitamin D status, P for trend<0.001), but not among participants 
with cardio-metabolic disease (Figure 1). No effect modification by age, gender and metabolic 
syndrome was present (Pinteraction>0.05).
Vitamin D and regional body fat distribution
There was no consistent association between vitamin D status and android fat percentage, gynoid 
fat percentage or android/gynoid fat ratio after adjustment for confounders (Table 3). Continuous 
analyses showed a weak inverse association between 25(OH)D and android fat percentage and 
android/gynoid ratio, but this was not independent of BMI (P for trend when analyzed by categories 
of 25(OH)D 0.04 and 0.08 respectively). Also, a significant quadratic term was observed in the 
association between serum 25(OH)D and android fat and in the association between 25(OH)D and 
android/gynoid fat ratio suggesting non-linear associations (Table 3).
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Additional analysis
We observed an inverse association between vitamin D status and BMI; in the fully adjusted 
model a10 nmol/L increase in serum 25(OH)D was associated with a 0.16 unit decrease in BMI 
(95%CI=-022, -0.09)  (Supplementary Table S2). When stratified by metabolic syndrome status 
(Pinteraction=0.001) a decrease in BMI with increasing concentrations of serum 25(OH)D was 
observed only among subjects with metabolic syndrome (P for trend=0.001), but not in those 
without (Supplementary Figure S3). The analysis of serum 25(OH)D and waist circumference 
showed a statistically significant inverse association while in the case of serum 25(OH)D and 
waist to hip ratio this inverse association was weaker and not independent of BMI (Supplementary 
Table S2). Sensitivity analysis excluding participants with osteoporosis or receiving any vitamin 
supplementation did not change the results (data not shown). Even though the gender differences 
in body composition are to be expected, the association between 25(OH)D and body composition 
was not significantly different between men and women (Pinteraction=0.051).
DISCUSSION
We found adequate vitamin D status to be inversely associated with total body fat mass percentage. 
Our results suggest a BMI dependent role for vitamin D status in the regional distribution of body 
fat in the elderly.
Comparison with other studies
In our study, it was observed that low concentrations of serum 25(OH)D are associated with a 
higher body fat percentage. Several previous studies also investigated this association and found 
similar results however, most of them were of cross-sectional design. For example, a cross-
sectional study by Kremer et al. (2008)30found that vitamin D insufficiency was associated with 
increased body fat in young women. Similarly, a study by Snijder et al. (2005)31found an inverse 
association between total body fat and serum 25(OH)D concentrations in older men and women. 
This latter study was performed in a population similar to ours (mean age ±75 years), but with 
only 453 participants included in the analysis. However, the conclusions coming from intervention 
studies are inconsistent. For example, Salehpour et al. (2012)32found that supplementation 
with vitamin D3 for 12 weeks in 77 overweight and obese healthy subjects led to a statistically 
significant decrease in body fat in the intervention group compared to placebo group. Conversely, 
Wamberg et al. (2013)33found that increasing serum 25(OH)D concentrations with cholecalciferol 
treatment during 26 weeks in 52 obese subjects had neither an effect on body fat, nor specifically 
on subcutaneous or visceral adipose tissue. However, not many studies investigated the association 
between vitamin D status and regional fat distribution specifically in the elderly. We found a cross-
sectional study by Moschonis et al. (2009)reporting on vitamin D status as an outcome and body 
composition, including regional fat mass(measured by calibrated Lange skinfold caliper) as an 
exposure. This study was performed in 112 non-osteoporotic, overweight, postmenopausal women 
(mean age 60 years)15 and showed inverse associations of vitamin D status with total body fat 
and with all measures of regional body fat mass(assessed as arms fat mass percentage, legs fat 
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mass percentage and trunk fat mass percentage) and a positive association with fat-free mass. 
Compared to this study by Moschonis and colleagues15 we had a bigger sample but we did not find 
a consistent association between vitamin D status and gynoid fat but we did find an association 
between vitamin D status and android fat even though it was not independent of BMI. However, 
our findings of an inverse association between vitamin D status and total body fat are in line with 
the results reported by Moschonis et al.15. 
Potential mechanisms
Even though many studies report associations between low vitamin D status and obesity, the 
underlying mechanisms and the direction of this association are not fully understood. There are 
several pathways by which vitamin D and body composition may be connected in both directions. 
Firstly, obese people have commonly lower serum 25(OH)D concentrations compared to lean 
people9. This might be a result of decreased bioavailability of vitamin D because of sequestration 
of vitamin D by the adipose tissue11; dilution of vitamin D in the large fat mass of obese people 34; 
increased catabolism of vitamin D in the adipose tissue35; decreased synthesis of 25(OH)D in the 
liver36; reduced sun-exposure 37; or decreased hepatic synthesis of 25(OH)D caused by a negative 
feedback loop of 1,25(OH)2D and parathyroid hormone (PTH)
38.Also, clearance of vitamin 
D might be increased by inflammation related to obesity39. In addition, vitamin D might have 
anti-inflammatory effects40 and low vitamin D has been associated with visceral adiposity that is 
associated with inflammation 41. Furthermore, a study using bidirectional Mendelian randomization 
approach found higher BMI leading to lower 25(OH)D but not the other way around17. Secondly, 
it has been suggested that low serum 25(OH)D concentrations lead to increase in PTH levels as 
a normal physiological response, which in turn may favor the lipid storage metabolism42 43. In 
vitro studies found that receptors for vitamin D (VDRs) and the enzyme 1-α-hydroxylase needed 
for production of 1,25-dihydroxyvitamin D (1,25(OH)2D), are both present in adipocytes
35 44 45 
suggesting a role of 1,25(OH)2D in metabolism of the adipose tissue.Also,1,25(OH)2D was found 
to regulate expression of some genes involved in genesis of adipose tissue46. Thirdly, it was found 
that skeletal muscles act as a functional store of 25(OH)D - a proportion of circulating 25(OH)
D binds to vitamin D binding protein in muscle cells and can be released back to the circulation. 
This retention by muscle cells protects the 25(OH)D from degradation by the liver10. Additionally, 
active 1,25(OH)2D bound to VDR receptor in muscle tissue activates muscle growth and improves 
muscle function and may thereby influence overall body composition12-14. With this in mind, 
we speculate that with the increase in body fat percentage the concentration of 25(OH)D in the 
circulation decreases, subsequently leading to a decrease in the functional store of 25(OH)D in 
the skeletal muscles. This decrease in the functional store of 25(OH)D might in turn lower serum 
25(OH)D concentration that might contribute to more unfavorable body composition.
Interactions
We found an interaction between 25(OH)D, body composition and cardio-metabolic diseases. 
Several studies have shown vitamin D status to be associated with metabolic syndrome, 
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cardiovascular disease and type 2 diabetes mellitus1 18. Also, body fat and BMI are associated with 
an increased risk of cardiovascular disease, metabolic syndrome and type 2 diabetes mellitus7.
We found an association between 25(OH)D and total fat percentage only in subjects free of 
cardio-metabolic disease. This finding can be explained in several ways. Firstly, it might be 
possible that people with cardio-metabolic disease at baseline changed their life-style after 
diagnosis47. This change might have resulted in for example weight loss or improvement of 
vitamin D status and diluting any association between 25(OH)D and body composition. Secondly, 
it might be that due to inflammatory processes that may come along with cardiovascular 
disease48 and type 2 diabetes mellitus49 the clearance of vitamin D is increased 39diluting the 
association with 25(OH)D in individuals with cardiovascular disease and type 2 diabetes 
mellitus. In contrast, we only found a significant association between 25(OH)D and BMI 
in those with a metabolic syndrome suggesting that a complex interaction between 25(OH)D, 
body composition and cardio-metabolic diseases may exist and it needs further elucidation. 
At last, literature has consistently shown that body composition and vitamin D status are different 
among men and women 50. Our study showed that the association between vitamin D and body 
composition was not significantly different between men and women. Nonetheless, since we found 
that women had more often vitamin D deficiency, future intervention studies may be targeted to 
men and women separately.
Strengths and limitations
Main strengths of our study are the prospective, population-based design, large sample size, use 
of accurate measures of body fat, as well as collection of numerous population characteristics. 
However, it is also important to mention the limitations of our study. There is a time difference 
between measurements of 25(OH)D and measurements of body composition, and changes in 
serum 25(OH)D could have occurred during this time . However, the study on reproducibility of 
25(OH)D measurements by Sonderman et al. found the reproducibility of 25(OH)D measurements 
over time to be relatively high 51. Another limiting factor to the current investigation is that body fat 
was measured only once. However, where appropriate we adjusted our analyses for baseline BMI, 
which correlates well with total fat (partial Pearson correlation coefficient 0.87) and our results 
were also confirmed by BMI that was repeatedly measured. Another limitation is the fact that we 
did not have PTH levels measured and therefore could not test if the observed association between 
25(OH)D and body fat might be explained by PTH. 
Main conclusion and future directions
Lower serum 25(OH)D concentrations were associated with higher total body fat percentage. 
However, the association between 25(OH)D and fat distribution in this population was mainly 
explained by BMI. The association between 25(OH)D and body composition might be modified 
by cardio-metabolic disease. Further studies are needed to confirm our findings and to clarify the 
underlying mechanisms. 
Supplementary Material can be found at Clinical Nutrition
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ABSTRACT
BACKGROUND Little data is available on gamma-glutamyltransferase (GGT) within normal 
range and body fat distribution in healthy individuals. 
OBJECTIVE We examined whether GGT within normal range is prospectively associated with 
total body fat (TF) and regional body fat distribution.
METHODS This study was embedded in the Rotterdam Study, a prospective follow-up study 
among subjects 55 years and older (n= 1715). GGT was measured between 1997-1997 by enzymatic 
photometry method. TF, android fat (AF), gynoid fat (GF) and android/gynoid ratio (A/G ratio) was 
assessed using Dual-energy X-ray absorptiometry during follow-up visit (2002-2004). Regression 
coefficients and 95% Confidence Intervals were calculated using multivariable linear regression 
models adjusting for confounders. 
RESULTS Mean value of GGT of the study population was 21.64 U/L (ranging from 6 to 48 
U/L). There was no association between GGT and TF. After adjustments for potential confounders, 
increased GGT was associated with higher AF (top tertile relative to the lowest: ß=0.35; 95%CI: 
0.19, 0.52), lower GF (top tertile relative to the lowest: ß=-0.48; 95%CI: -0.69,.-0.27) and higher 
AF/GF ratio (top tertile relative to the lowest: ß=0.04; 95%CI: 0.03, 0.06). These associations were 
independent of C-reactive protein, insulin resistance and non-alcoholic fatty liver disease. 
CONCLUSIONS This study suggests that an increase in GGT concentrations within its 
physiological normal range is a sensitive and early biomarker of unfavorable body fat distribution. 
As measurement of serum GGT is reliable, easy and inexpensive, its assessment may have clinical 
utility in identifying individuals at high risk of metabolic disturbances later in life that could benefit 
from effective preventive interventions.
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INTRODUCTION
Gamma-glutamyltransferase (GGT), a marker of alcohol consumption and liver disease, has been 
strongly associated with obesity related outcomes, including diabetes, hypertension, dyslipidemia, 
metabolic syndrome, cardiovascular diseases and cancer. 1-6 Also, GGT levels correlate positively 
with markers of chronic inflammation, such as C-reactive protein (CRP) and fibrinogen6,7 which 
are associated with obesity and its phenotypes. 8,9 Furthermore, an increase in serum GGT activity 
has been suggested to be used as a marker of increased oxidative stress in humans due to the pivotal 
role of GGT in oxidative stress. 10,11 Recently, it has been reported a causal role of oxidative stress 
in the development of obesity12 and a GGT-mediated oxidative stress is capable of inducing lipid 
oxidation. 11 On the other hand, GGT plays a critical role in cysteine metabolism and is linked to 
insulin resistance as well, which have been shown to be obesogenic in both animals and human 
studies. 13-15 Moreover, serum GGT levels seems closely related to liver fat and is included in the 
diagnostic criteria of fatty liver index. 16 
Despite this evidence, and the global epidemic of obesity, very little attention has been given 
to GGT within normal range and its role on obesity and/or body fat distribution and healthy 
individuals. Measurement of serum GGT is accurate, reliable, easy and inexpensive. 17 Therefore, 
if serum GGT is a marker of total fat and body fat distribution, it might have important implications 
both clinically and epidemiologically. Thus far, few studies looking at GGT and obesity, have 
shown a positive correlation between GGT and abdominal obesity in both children and elderly, 
but the studies mostly used anthropometric measures instead of more accurate measures of body 
composition, 18 or were often related to a restricted sample 19 or clinical setting. 20,21 Moreover, the 
studies were limited because of the cross-sectional design and therefore causality could not be 
addressed. 
Hence, in a large cohort study among middle-aged and elderly, we prospectively assessed whether 
GGT within normal range was associated with total body fat and body fat distribution and whether 
this association was dependent of CRP, insulin resistance or (non-alcoholic) fatty liver disease.
SUBJECTS AND METHODS
The Rotterdam Study is an ongoing prospective population-based cohort study that focuses on 
the causes and consequences of chronic and disabling diseases in the elderly. The cohort started 
enrollment in 1990 and included 7,983 participants aged ≥55 years living in Ommoord, a district 
of the city of Rotterdam in the Netherlands. Baseline measurements were obtained between 1990 
and 1993. Trained research assistants collected data on current health status, use of medication, 
medical history, lifestyle and risk indicators for chronic diseases during an extensive home 
interview. Subsequently, the participants visited the study center for detailed clinical examinations 
and assessment of diet. Follow up visits were held every 3-5 years. 22 This study was approved 
by the Medical Ethics Committee of the Erasmus Medical Center. All participants gave written 
informed consent to participate in the study. 
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Gamma-glutamyltransferase (GGT)
Fasting blood samples were collected by venipuncture during the third visit (RSI-3)(1997-1999), 
and immediately frozen (−20°C). Serum GGT, ALP, ALT and AST levels were determined within 
two weeks using a Merck Diagnostica kit (Merck, Whitehouse Station, NJ, USA) on an Elan 
Autoanalyzer (Merck). All liver biochemistry measurements were obtained in the laboratory of the 
Department of Epidemiology, Erasmus University Medical Center. 
Fatty liver index (FLI)
We used FLI as a surrogate marker for the presence of Non-Alcoholic Fatty Liver Disease 
(NALFD) in our study, using data from the third visit of the original cohort (RS-I-3; 1997-1999) 
when ultrasonography was not yet available. The FLI was recently validated in the Rotterdam 
Study, and was found to correlate closely to the presence of liver steatosis on ultrasonography, 
performed in a later cohort (AUROC 0.81, sensitivity 64%, specificity 83%). 22 The index uses an 
algorithm based on BMI, waist circumference, triglycerides (TGs) and GGT with an accuracy of 
0.81 (95%CI: 0.80, 0.83) in detecting FL. 16 In accordance with previous studies, presence of FL 
was defined as a FLI>=60 (probability to have FL is 81%).
Measures of body composition
Body composition was assessed by Dual-energy X-ray absorptiometry (DXA) in the fourth visit of 
Rotterdam Study (2002-2004). Whole body DXA scans were acquired by using a ProdigyTM total 
body-fan beam densitometer (GE Lunar Corp, Madison, WI, USA) 23. Body weight (grams) was 
divided into bone mineral content, lean (non-fat) and fat mass. Body fat distribution was determined 
by measuring fat mass at the total-body, and fat mass in android and gynoid regions. Body fat was 
assessed as percentage of body fat taking into consideration the weight of the individual and total 
fat as well (when using android and gynoid fat as outcomes).  
Potential confounding variables
Information on current health status, medication use, smoking behavior, physical activity and 
socioeconomic status was obtained between February 1997 - December 1999. Participants were 
asked whether they were currently smoking cigarettes, cigars, or pipe. Education was defined 
as low (primary education), intermediate (secondary general or vocational education), or high 
(higher vocational education or university). Household income was categorized in low (<1700 
euro/month), middle (1700-3000 euro/month) or high (≥3000 euro/month). Alcohol intake was 
assessed in grams of ethanol per day. Cardiovascular disease was defined as a history of myocardial 
infarction, coronary artery bypass, or percutaneous transluminal coronary angioplasty. Diabetes 
mellitus was defined as a serum glucose level ≥11 mmol/L or use of glucose lowering drugs. 
Cardio-metabolic disease was defined as the presence of cardiovascular disease and diabetes 
mellitus at the third visit and until the DXA measurements took place. Serum cholesterol, CRP, 
glucose and insulin levels were determined by automated enzymatic procedures in a fasting blood 
sample. Data on fasting glucose and fasting insulin levels were used to calculate the degree of 
insulin resistance according to homeostasis model assessment for insulin resistance (HOMA-IR) 
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which is calculated by dividing the product of fasting levels of glucose and insulin by a constant. 
24 Medication use was defined as use of any of the following drugs: antiparkinson, psycholeptic, 
psychoanaleptics, cytostatics, bile and liver therapy, serum lipid reducing agents, antimycotics for 
systemic use and use of anti-diabetic therapy at third round and dichotomized: yes or no. The total 
weekly duration of physical activity was assessed by an adapted version of the Zutphen Physical 
Activity Questionnaire and the LASA Physical Activity Questionnaire. 25,26 Physical height and 
body weight were measured at baseline with the participants standing without shoes and heavy 
outer garments. BMI was calculated as weight divided by height squared (kg/m2). To take into 
account overall dietary quality we used the Dutch Healthy Diet (DHD)-index assessed at the first 
visit. 27 Briefly, the DHD-index is a continuous score that represents compliance to the Dutch 
Guidelines for a Healthy Diet as assessed from the FFQ at baseline. 27 
Population of analysis
The present study used data from the third visit of the original cohort (RS-I-3; February 1997 –
December 1999). There were 3920 persons eligible for laboratory measurements. Among them, 11 
subjects were excluded because of no information available on GGT (because of logistic reasons 
or no consent). Additionally, 1711 participants died or did not have DXA measures (because of 
logistic reasons) performed at the fourth round visit (January 2002- July 2004). Moreover, 483 
subject were excluded because of GGT values not within the normal range (for men: <12 U/L 
or >48 U/L and for women: <6 U/L or >28 U/L) and thus leaving 1715 participants for our final 
analysis. 
Statistical analysis
All analyses were performed by IBM SPSS Statistics 21. Data are presented as the mean ± SD 
unless indicated otherwise. We investigated the association between serum GGT with body 
fat both as continuous (one-standard deviation increment in GGT) variable and by tertiles. We 
used natural log-transformed values of serum CRP concentrations and HOMA-index, to better 
approximate normal distribution. Multivariate linear regression was used to examine whether 
GGT or FLI were independently associated with, total body fat android fat mass (%), gynoid 
fat mass (%) and android/gynoid fat mass ratio. We built minimally adjusted models, with age, 
sex and body mass index (continuous) as covariates (Model 1); and multivariable models with 
the following additional covariates: education level (low, intermediate, high), income status (low, 
middle, high), smoking status (ever, never), total physical activity (continuously), alcohol intake 
(continuously), serum total cholesterol, DHD-index (continuously), presence of cardio-metabolic 
diseases and medication use (Model 2). In model three to evaluate the effect of intermediate factors 
we additionally adjusted for CRP (continuous) and HOMA-index (Model 3). For the association 
between GGT and total body fat and regional body fat distribution, a fourth model was built, 
which included the covariates within model 2 and the presence of FL (yes vs. no). The F test 
was used to test whether there were overall significant differences in fat mass (total, android or 
gynoid fat mass) between levels of GGT and FLI. We constructed multivariate linear regression 
models for pooled sexes because formal tests of interaction (sex×log-GGT) were not statistically 
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significant for any outcome. Furthermore, to examine if the association between GGT and body fat 
differs by smoking status, alcohol consumption and BMI, we tested for statistical interaction by 
adding a product term in model 2. In case of significant effect modification, stratified analysis was 
performed and the results were presented for model 3 and 4.  To check for non-linear relationship, 
a quadratic term was tested in multivariable model 2. A P-value lower than 0.05 was considered 
as statistically significant. Multiple imputation procedure was used (N= 5 imputations) to adjust 
for potential bias associated with missing data. Rubin’s method was used for the pooled regression 
coefficients (β) and 95% Confidence Intervals. 28
Sensitivity analyses
To explore the possibility of selection bias, we examined whether there were differences in age, 
sex, prevalent cardio-metabolic diseases, BMI and GGT levels between participants included in our 
analysis and those excluded due to no data on DXA measurements. Additionally, using generalized 
estimated equations with exchangeable correlation structure 29, we evaluated the relation of GGT 
within normal range to 11-year changes in BMI, waist circumference and waist to hip ratio in 
participants included in our analysis (n=1715) and further extended to participants of the third 
visit of the first cohort of the Rotterdam Study and first visit of the second cohort of the Rotterdam 
Study (n=4595).  Our subset included 412 participants who had cardio-metabolic disease at third 
visit and/or during the follow up and therefore, a sensitivity analysis was performed after removing 
these subjects. Moreover, additional models were built by adding ALT and AST or wait to hip ratio 
to covariates in model 2. To see if GGT values not within the normal range could play a role in total 
body fat and body fat distribution, we rerun all analysis including subjects with values of GGT not 
within the normal range (n=483). Because the distribution of GGT values was right-skewed when 
these subjects were included in the analysis, a natural log-transformation was applied and GGT 
teriles were calculated using the natural log-transformed GGT. 
RESULTS
Table 1 displays the selected characteristics of the study population. The mean age was 70.51 ± 
5.88 and the mean GGT was 21.64 ± 20.0 U/L (Table 1).
Association between GGT, total body fat and regional body fat distribution
There was no association between GGT analyzed continuously or in tertiles and total body fat 
(table 2).  In multivariable linear models adjusted for age, gender, education level, income status, 
smoking status, physical activity, body mass index, serum total cholesterol, DHD-index, cardio-
metabolic disease, medication use (Model 2), higher GGT was associated with higher android fat 
mass (per SD increase in GGT: ß=0.17; 95%CI: 0.09, 0.24 and top tertile relative to the lowest: 
ß=0.35; 95%CI: 0.19, 0.52; P for F-test, 3 df: 0.7 10-05, Table 3), lower gynoid fat mass (per SD 
increase in GGT: ß=-0.25; 95%CI: -0.35, -0.16 and top tertile relative to the lowest: ß=-0.48; 
95%CI: -0.69,.-0.27; P for F-test, 3 df: 5.9 10-07, Table 3) and higher android/gynoid fat mass 
ratio (per SD increase in GGT: ß=0.023; 95%CI: 0.015, 0.03 and top tertile relative to the lowest: 
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Table 1 Selected characteristics of study participants
 (N=1715)
Age 70.71 ± 5.96
Female % (n) 935 (54.5)
Smoking status n (%) 242 (14.1)
Physical activity (min/week) 2783.84  ± 1084.98
Alcohol intake g/day* 2.86 (158732,86)
Education Level n (%)
Low 753 (43.9)
Medium 762 (44.4)
High 200 (11.7)
Income n (%)
Low 438 (25.5)
Medium 622 (36.3)
High 655 (38.2)
BMI (kg/m2) 26.59 ± 3.66
Waist to hip ratio 0.91 ± 0.096
DHD-index 48.85 ± 10.18
Prevalent cardio-metabolic disease n (%) 412 (24%) 
Medication use n (%) 266 (15.5)
GGT 21.64 ±  20.0 
ALT 21.51 ± 9.12
AST 23.75 ± 5.80
Hepatic Steatosis n (%)** 425 (24.8)
Insulin (pmol/l)* 64 (1124)
Glucose  (mmol/l) 5.75 ± 1.19
HOMA-IR (units)* 2.93 (97.18)
C-reactive protein (mg/ml)* 2.05 (144.80)
Serum total cholesterol (mmol/l) 5.80 ± 0.94
Total fat mass (%) 33.60 ± 8.40
Abdominal fat mass (%) 9.43 ± 1.95
Gynoid fat mass (%) 15.28 ± 2.13
Andorid/Gynoid fat mass rato 0.64 ± 0.20
ALT: Alanine Aminotransferase; AST: Aspartate Aminotransferase; DHD-index: Dutch Healthy Diet Index; HOMA-IR: 
HOMA-insulin resistance; GGT: gamma glutamyltransferase; kg: kilogram; Plus minus values are mean ± SD
*Median(range)
**Defined by a fatty liver index ≥60
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Table 2 Gamma-glutamyltransferase (GGT) and total body fat mass
Total body fat mass (%) 
β (95% CI)
GGT MODEL 1a MODEL 2 MODEL 3 MODEL 4
1st tertile reference reference reference reference
2nd  tertile 0.03 
(-0.46, 0.53 )
-0.03  
(-0.53, 0.47 )
-0.10 
(-0.59, 0.40)
-0.03 
(-0.52, 0.47)
3rd  tertile 0.50 
(-0.06, 1.06 )
0.37 
(-0.19, 0.94 )
0.19 
(-0.38, 0.76)
0.51 
(-0.07, 1.09)
P for F-test 0.31 0.43 0.87 0.23
Continuous (per SD 
increase)*
0.16 
(-0.07, 0.39)
0.12 
(-0.14, 0.38)
0.003 
(-0.26, 0.27)
0.20 
(-0.07, 0.47)
Model 1: Adjusted by age, gender and body mass index 
Model 2: Model 1 + alcohol intake, Dutch Healthy Diet-index, smoking status, education level, income level, cardio-
metabolic diseases, serum total cholesterol, medication use 
Model 3: Model 2 + C-reactive protein and insulin resistance 
Model 4: Model 2  + presence of fatty liver 
*Quadratic term not significant (p>0.05)
ß=0.04; 95%CI: 0.03, 0.06; P for F-test, 3 df: 7.4 10-08, Table 4).  The overall results changed only 
slightly after further adjustments for CRP, HOMA-index or FL (Table 2-4). Significant quadratic 
terms were observed for the association between GGT and android fat and gynoid fat mass (Table 
3). In contrast, no significant quadratic terms were observed for the association of GGT with total 
body fat mass or android/gynoid fat mass ratio. (Table 2-4).
Effect-modification by alcohol intake, smoking status and body mass index 
No significant interaction terms with alcohol intake and smoking status were observed for the 
association between serum GGT, total body fat and regional body fat distribution (P-interactions 
>0.05). However, for the association of GGT with total body fat mass and gynoid fat mass, 
significant interaction terms were observed with BMI (P-interaction<0.05). After stratification by 
BMI (P-interaction=0.005), higher GGT was associated with higher total fat mass in participants 
with BMI<median (Model 3-top tertile relative to the lowest: ß=1.45; 95%CI: 0.54, 2.37; P for 
F-test, 3 df: 0.014, Figure 1). In contrast, high levels of GGT were associated with lower total 
body fat in subjects with BMI≥ median (Model 3-top tertile relative to the lowest: ß=-0.93; 
95%CI: -1.18, -0.06; P for F-test, 3 df: 0.28, Figure 1). Similarly, after stratification by BMI 
(P-interaction=0.026), raised GGT was associated with lower gynoid fat mass in participants with 
BMI<median (Model 3-top tertile relative to the lowest: ß=-0.52; 95%CI: -0.84, -0.19; P for F-test, 
3 df: 0.0004, Figure 2) but not in subjects with BMI≥ median (Model 3-top tertile relative to the 
lowest: ß=-0.16; 95%CI: -0.41, 0.10; P for F-test, 3 df: 0.12, Figure 2). There was no significant 
interaction term with BMI for the association of GGT with AF or A/G ratio (P-interactions>0.05).
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Table 4 Gamma-glutamyltransferase (GGT) and android/gynoid fat mass ratio
Android/Gynoid fat mass ratio 
β (95% CI)
GGT MODEL 1a MODEL 2 MODEL 3 MODEL 4
1st  tertile reference reference reference reference
2nd  tertile 0.02 
(0.001, 0.03 )
0.01  
(-0.001, 0.03 )
0.009 
(-0.006, 0.02)
0.014 
(-0.001, 0.029)
3rd  tertile 0.05 
(0.03, 0.06 )
0.04 
(0.03, 0.06 )
0.03 
(0.01, 0.05)
0.04 
(0.02, 0.06)
P for F-test 6.2 10-09 7.4 10-08 0.0001 3.0 10-06
Continuous (per SD 
increase)* 
0.024 
(0.02, 0.028)
0.023 
(0.015, 0.03)
0.016 
(0.01, 0.024)
0.019 
(0.01, 0.027)
Model 1: Adjusted by age, gender and body mass index 
Model 2: Model 1 + alcohol intake, Dutch Healthy Diet-index, smoking status, education level, income level, cardio-
metabolic diseases, serum total cholesterol, medication use 
Model 3: Model 2 + C-reactive protein and insulin resistance 
Model 4: Model 2  + presence of fatty liver 
* Quadratic term not significant (p>0.05) 
Sensitivity analyses
There were significant differences in gender (56.5% female vs. 61.2 %), age (mean age=70.5 vs. 
75.3 years old), prevalent cardio-metabolic diseases (26.1% vs. 38.9%) but not with regard to BMI 
or GGT levels among participants included in our analysis and participants that were excluded 
because of no data on DXA measurements. All associations that were statistically significant 
in the main analysis remained unchanged in terms of statistical significance when reanalyzed, 
excluding subjects with cardiometabolic disease and/or subjects who had (non-alcoholic) fatty 
liver disease.  The association of GGT with regional body fat distribution remained robust in 
models adjusted additionally for serum AST and ALT or waist to hip ratio measured at third round 
visit (February 1997- December 1999). Also, the results did not change in terms of statistically 
significance when we repeated all analysis including subject with abnormal values of GGT (all: 
data not shown). Similarly to the results with body fat, GGT did not affect long-term changes in 
BMI, but one unit increase in log GGT was associated with an annual rise of 0.28 cm and 0.004 in 
waist circumference and waist to hip ratio respectively independent of CRP, HOMA-IR or FL, in 
the population included in our analysis and as well in the population extended to both cohorts of 
the Rotterdam Study (Supplementary Table 1 and 2).
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DISCUSSION
In this prospective study, we found that GGT levels within the normal range are associated with 
unfavorable body fat distribution, independent of age, gender, socioeconomic status, lifestyle 
factors, and other confounders. These associations were independent of CRP, insulin resistance or 
non-alcoholic fatty liver disease.  
To our knowledge, this is the first prospective study to show an association between levels of GGT 
and body fat distribution. Previous studies reporting on obesity and GGT have mostly tested the 
hypothesis that obesity, and in particular central obesity may predict levels of GGT, 21,30-33 and 
not vice versa. Furthermore, all these studies have been on cross-sectional design and therefore 
causality could not be addressed. Nevertheless, most of them have reported a strong positive 
correlation between GGT and abdominal obesity; for example, in a study of 2704 women and men, 
35-80 years of age, a positive correlation was observed between GGT, waist circumference and 
waist to hip ratio. 18 Similar correlations were reported also by Mager and colleagues in a study 
of 44 children. 19 In addition, Iwasaki et al in a cross-sectional study of 257 Japanese patients, by 
using more accurate measures of body composition such as by dual-energy X-ray absorptiometry, 
showed that higher levels of GGT were significantly associated with higher visceral fat whereas 
no association was observed with subcutaneous fat, proposing that the serum GGT may be useful 
as a convenient indicator of visceral adiposity.20 However, in contrast to our study, Iwasaki and his 
colleagues did not examine the association of GGT with gynoid fat or android/gynoid fat ratio. 
Although the current study suggests that GGT may be used as a marker for abdominal fat, we did 
not measure visceral or subcutaneous fat separately and therefore we were not able to distinguish 
these fat compartments. It has been shown that visceral adipose tissue is associated with more 
adverse cardiometabolic risk factor profiles than abdominal subcutaneous adipose tissue. 34 
Measurement of serum GGT is reliable, easy and inexpensive and therefore, if serum GGT is a 
marker of unfavorable body fat distribution, it might have important implications both clinically 
and epidemiologically. Future research is thus needed to validate our findings and to assess if GGT 
within normal range can be a specific marker to visceral fat.  
It is at present unclear the mechanism underlying the association between GGT and body fat. An 
increase in concentrations of GGT is conventionally interpreted as a marker of alcohol abuse, 
insulin resistance and/or liver damage; 35 however, neither of these interpretations explains the 
observed association in the current study of GGT within what is considered its physiological 
normal range with body fat distribution. Nor chronic inflammation, as measured by CRP, could 
explain the association. GGT and body fat distribution has been shown to positively correlate 
with markers of chronic inflammation, such as CRP and fibrinogen, 6 which on the other hand, 
closely correlate with obesity. 8,9 However, other mechanisms may explain the association of 
GGT with body fat distribution. Although GGT has been regarded as marker of liver diseases, 
GGT is widely distributed in the human body. 36 There is evidence that cellular GGT plays a 
pivotal role in antioxidant defense system. 11 As a primary function, ectoenzyme GGT maintains 
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intracellular concentrations of glutathione, the most important non-protein antioxidant of the cell. 
11 Increased GGT activity can be a response to oxidative stress, facilitating increased transport of 
glutathione precursors into cell. 11 Also, ectoplasmatic GGT may be involved in the generation of 
reactive oxygen species (ROS), particularly in the presence of Fe3+ and CU2+34. Recently, oxidative 
stress was shown to induce obesity 37 and a GGT-mediated oxidative stress was reported to be 
capable of inducing oxidation of lipids. 11 GGT plays an important role in homeostasis of plasma 
cysteine as well 13 which similar to GGT induces oxidative stress mainly in the presence of cooper 
ions. 38 Cysteine has been related with body fat in both men and women, independent of GGT. 13 
Furthermore, GGT levels have been reported to correlate with adipokines such as adiponectin, 39 
which play an important role in obesity by different pathways i.e. increased energy expenditure, 
insulin sensitivity or fatty acid oxidation. 37 Therefore, it still remains to be established whether 
the observed association between GGT and body fat distribution reflects other truly detrimental 
pathways, whether it is intermediate in the pathology of obesity or is a true risk factor initiating a 
mechanistic pathway on the road to obesity. 
The main strength of this study are its prospective design, the relative large sample size, use of 
accurate measures of body fat and very detailed information elicited on several covariates related 
to GGT. A further strength is that we enrolled participants randomly selected from the general 
population. Moreover, there were no differences in GGT levels among participants included in 
our study and those excluded due to no data on DXA measurements, and therefore minimizing the 
possibility of selection bias which could have influenced the validity of our results. Furthermore, 
it has been shown that using a restricted source population for a cohort study does not compromise 
validity of exposure-outcome association40. Several limitations of our approach merit comment. 
Establishing that GGT is a risk factor for development of abdominal obesity would require additional 
prospective and experimental studies to understand the potential pathways behind the association. 
Also, there is a time difference between measurement of GGT and body fat distribution, which is 
a potential limitation because changes could occur over time. However, we measured serum GGT 
levels at the baseline visit of The Rotterdam Study (1990-1993) in a subgroup of study participants 
(n=2753 participants) and at the fifth visit (2009-2011) (n=1395 participants) and observed high 
correlations with GGT measure at the third visit (1997-1999) (interclass correlation coefficients 
between the first and the third visit and the third and the fifth visit of the Rotterdam Study were 
0.84 and 0.81 respectively), supporting internal consistency and validity. Another limiting factor 
to the current investigation is that body fat was measured only once and five years later after 
baseline. However, in all analysis we adjusted for baseline BMI, which correlates well with total 
fat; for example partial Pearson correlation coefficient between BMI and total fat at the fourth 
round visit (January 2002-July 2004) was 0.87. Moreover, additional adjustment for waist to hip 
ratio, a surrogate marker of android/gynoid fat mass ratio, did not affected our results (partial 
Pearson correlation coefficient between waist to hip ratio and android/gynoid fat mass ratio at the 
fourth round visit (year 2002-2004) was 0.77. Lastly, the participants enrolled in our study are all 
white, limiting the generalizability to other ethnicities.
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In conclusion, our findings suggest that serum levels of GGT within physiological normal 
range could be an early biomarker of unfavorable body fat distribution and that the well-known 
associations of obesity with cardiometabolic and other chronic disease may be modified by serum 
GGT. However, it is at present unclear whether medications or lifestyle factors that alter GGT 
metabolism can be usefully used in prevention of obesity and its complications. Also, further 
investigations are needed to clarify the underlying mechanisms. 
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Supplemental material
Supplementary Table 1 The longitudinal association between gamma-glutamyltransferase (GGT) within 
normal range and 11-year change in anthropometric measures (n=1715)* 
GGT 
Continuous (per unit log 
increase)
Body Mass Index (kg/m2) Waist circumference (cm) Waist to hip ratio
Model 1 β(95% CI) -0.01 (-0.04; 0.02) 0.28 (0.18; 0.38) 0.004 (0.002; 0.005)
Model 2 β(95% CI) -0.01 (-0.03:0.01) 0.28 (0.23; 0.34) 0.004 (0.003; 0.004)
Model 3 β(95% CI) -0.01 (-0.03:0.01) 0.28 (0.23; 0.33) 0.004 (0.003; 0.004)
Model 4 β(95% CI) -0.01 (-0.03; 0.01) 0.28 (0.23; 0.34) 0.004 (0.003; 0.004)
*Gamma-glutamyltransferase was measured at baseline (third visit of the first cohort of the Rotterdam Study) 
whereas body mass index, waist circumference and waist to hip ratio were assessed at baseline, 5 and 10 years 
later. Linear regression models fitted into generalized estimating equations were used to analyze relations of 
GGT to average annual individual anthropometric factors changes.
Model 1: Adjusted by age, gender and body mass index
Model 2: Model 1 + alcohol intake, smoking status, physical activity, cardio-metabolic diseases, serum total 
cholesterol, medication use
Model 3: Model 2 + C-reactive protein and insulin resistance
Model 4: Model 2  + presence of fatty liver
Supplementary Table 2 The longitudinal association between gamma-glutamyltransferase (GGT) within 
normal range and 11-year change in anthropometric measures (n=4595)*
GGT 
Continuous (per unit log 
increase)
Body Mass Index (kg/m2) Waist circumference (cm) Waist to hip ratio
Model 1 β(95% CI) -0.01 (-0.04; 0.01) 0.24 (0.17; 0.30) 0.003 (0.002; 0.004)
Model 2 β(95% CI) -0.01 (-0.02:0.00) 0.23 (0.17; 0.30) 0.003 (0.002; 0.004)
Model 3 β(95% CI) -0.02 (-0.04:0.01) 0.23 (0.17; 0.29) 0.003 (0.002; 0.004)
Model 4 β(95% CI) -0.02 (-0.04; 0.01) 0.23 (0.16; 0.30) 0.003 (0.003; 0.004)
*Gamma-glutamyltransferase was measured at baseline (third visit of the first cohort of the Rotterdam Study and first visit 
of the second cohort of the Rotterdam Study) whereas body mass index, waist circumference and waist to hip ratio were 
assessed at baseline, 5 and 10 years later. Linear regression models fitted into generalized estimating equations were used 
to analyze relations of GGT to average annual individual anthropometric factors changes.
Model 1: Adjusted by age, gender and body mass index 
Model 2: Model 1 + alcohol intake, smoking status, physical activity, cardio-metabolic diseases, serum total cholesterol, 
medication use
Model 3: Model 2 + C-reactive protein and insulin resistance
Model 4: Model 2  + presence of fatty liver
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Gamma-Glutamyltransferase Levels, 
Prediabetes and Type 2 Diabetes Risk: 
a Mendelian Randomization Study
Jana Nano, Taulant Muka, Symen Ligthart, Albert Hofman, Sarwa Darvish, 
Oscar H. Franco, A Dehghan
ABSTRACT
Background: High levels of gamma-glutamyltransferase (GGT) are consistently associated with 
increased risk of prediabetes and type 2 diabetes in observational studies. Whether levels of GGT 
are causally associated with prediabetes and type 2 diabetes remains still unknown. 
Methods: We used data of the prospective population-based Rotterdam Study, compromising 8,611 
individual. Cox models were used for both the observational and genetic analysis. A Mendelian 
Randomization Study was performed using a genetic risk score consisted of 26 GGT-related loci, 
based on a genome-wide association study (GWAS) on liver enzymes and using data from the 
Rotterdam Study and large GWAS on glycemic traits and type 2 diabetes. 
Results: During follow-up, 1125 cases of prediabetes (mean follow up 5.7 years) and 811 cases 
of type 2 diabetes (6.9 years) were ascertained. The corresponding observational predicted hazard 
ratios in the multivariable model were 1.10 for prediabetes (95% CI: 1.02 to 1.19) and 1.19 for 
type 2 diabetes risk (95% CI: 1.30 to 1.32). The genetic risk score increa sed GGT levels by 0.09 
U/L per SD and explained 3.2% of the GGT variation. However, GGT genetic risk score was not 
associated with prediabetes (HR= 0.97 [95% CI: 0.91 to 1.04], P-value= 0.4) or type 2 diabetes 
(HR= 0.96 [95% CI: 0.89 to 1.04], P-value= 0.3) in the Rotterdam Study. Using data from GWAS 
on glycemic traits and type 2 diabetes did not change the results.
Conclusion: Our study does not support a causal effect of GGT levels on the risk of prediabetes 
or diabetes. The association of GGT with diabetes in observational studies is likely to be driven by 
confounding bias or reverse causation.
3.5
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INTRODUCTION
Circulating levels of gamma-glutamyltransferase (GGT) are strongly associated with increased 
risk of  prediabetes and type 2 diabetes in observational studies 1. A meta-analysis of 24 cohorts 
reported 34% higher diabetes risk in a comparison of extreme thirds of baseline levels of GGT 1. 
It is, however, unclear whether the association between GGT and diabetes is free of unobserved 
confounding. In addition, GGT levels could be changed as a consequence of type2 diabetes 
pathology (i.e., reverse causality). Therefore, causal role of GGT on type2 diabetes  is uncertain. 
In recent years, genetic information has commonly been used to infer causality in the pathogenesis 
of complex diseases. The inference is based on the fact that alleles are allocated randomly during 
gamete formation; therefore, genetic variants are inherited independent of potential confounding. 
We are aware of one previous study (4,360 individuals) where a single nucleotide polymorphism 
(SNP) in the GGT1 gene was used to support a causal relation between GGT and fasting insulin 
employing a Mendelian Randomization (MR) approach 2. This SNP explains only 1.2%  of the 
variation in GGT levels. Its known that a weak instrumental variable makes the association 
susceptible to false positive findings. So far 26 loci have been identified for GGT. Thus, a genetic 
risk score (GRS) combining the effect of all these loci could provide a stronger instrument for the 
Mendelian Randomization analysis. 
In this study, we investigated the association between serum GGT levels and risk of incidence 
prediabetes and type 2 diabetes in the Rotterdam Study, a large prospective population-based 
cohort study of participants ≥ 55 years. Capitalizing on Mendelian Randomization, we created a 
genetic risk score using 26 variants that are identified for GGT in a recent GWAS and examined 
its association with prediabetes and type 2 diabetes in the Rotterdam Study. We then boosted the 
statistical power by using summary-level data from the largest GWAS on glycemic traits and type 
2 diabetes 3-5. 
METHODS
Study population
This study was performed among participants of the prospective population-based Rotterdam 
Study. In 1989, all residents aged 55 years or older in Ommoord, a suburb of Rotterdam, were 
invited to participate in the study (RS-I). Seventy-eight percent of the invitees agreed to participate 
(n= 7,983). In 1999, the Rotterdam Study was extended by including 3,011 participants from 
those who either moved to Ommoord or turned 55 (RS-II). The third cohort was formed in 2006 
and included 3,932 participants 45 years and older (RS-III). There were no eligibility criteria to 
enter the Rotterdam Study cohorts except the minimum age and residential area based on ZIP 
codes. Participants have been re-examined every 3-4 years and have been followed up for a variety 
of diseases. A more detailed description of the Rotterdam Study can be found elsewhere 6. The 
Rotterdam Study has been approved by the medical ethics committee according to the Population 
Screening Act: Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of 
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Figure 1. Flow Chart of Study Population
Figure 1. 
Excluded:
308 no informed consent 
1,372 no fasting blood 
glucose measurement 
241 no information on 
gamma glutamyltransferase  
2,436 no 
genotyping 
data
2,556 prevalent prediabetes 1,208 prevalent Type 2 Diabetes 
11,740 
RSI-3, RSII-1 and RSIII-1
9,819 eligible for analysis 
 8,611 included in 
the longitudinal 
analysis for Type 2 
Diabetes 
7,263 included in 
the longitudinal 
analysis for 
prediabetes
7,383 included for the 
genetic analysis of type 2 
diabetes
6,236 included for the 
genetic analysis of 
prediabetes
3,583 no 
genotyping 
data
210
the Netherlands. All participants in the present analysis provided written informed consent to 
participate and to obtain information from their treating physicians.
Population for analysis
We used the third visit of the first cohort (RSI-3, 1997-1999, n= 3,877) and the first center visit for 
both the second cohort (RSII-1, 2000-2001, n= 2,507) and the third cohort (RSIII-12006-2008, n= 
3,437) as baseline. We excluded 1,372 participants with no fasting glucose measurement and 241 
other participants with no information on GGT. Next, we excluded individuals with prevalent type 
2 diabetes or prediabetes depending on the studied outcome (Figure 1). To perform the genetic 
analysis for prediabetes, we further excluded 3,583 participants due to lack of genotyping data; for 
type 2 diabetes, we excluded 2,436 participants (Figure 1).
Measurement of gamma-glutamyltransferase.
Fasting blood samples were collected by venipuncture, and immediately frozen −20ºC. Serum 
GGT was determined within two weeks using a Merck Diagnostica kit on an Elan Autoanalyzer 
Merck. All liver biochemistry measurements were obtained in the laboratory of the Department of 
Epidemiology, Erasmus University Medical Center. 
Ascertainment of prediabetes and type 2 diabetes.
The participants were followed from the date of baseline center visit onwards. At baseline and 
during follow-up, cases of prediabetes and type 2 diabetes were ascertained through active follow-
up using general practitioners’ records, glucose hospital discharge letters and glucose measurements 
from the Rotterdam Study visits which takes place approximately every 4 years. According to the 
WHO guidelines, prediabetes was defined as a fasting blood glucose between 6.0 mmol/L and 
7.0 mmol/L and type 2 diabetes was defined as a fasting blood glucose > 7.0 mmol/L, or the use 
of blood glucose lowering medication7. Information regarding the use of blood glucose lowering 
medication was derived from both structured home interviews and linkage to pharmacy records. At 
baseline, more than 95% of the Rotterdam Study population were covered by the pharmacies in the 
study area. All potential events of prediabetes and type 2 diabetes were independently adjudicated 
by two study physicians. In case of disagreement, consensus was sought with a specialist. Follow-
up data was complete until January 1st 2012 8. 
Covariates
Body mass index (BMI) was calculated by dividing weight in kilograms by height in meters 
squared. Information on current smoking was acquired from questionnaires. Alcohol intake was 
assessed in grams of ethanol per day from the questionnaires. Participants were asked for the 
average daily consumption. Lipid-lowering and antihypertensive medication use was assessed 
during a structured home interview. Blood pressure was measured twice by an oscillometric device 
after five minutes of rest and the mean was taken as the subject’s reading. Data on fasting glucose 
and insulin levels were used to calculate the degree of insulin resistance according to homeostasis 
model assessment for insulin resistance (HOMA-IR) which is calculated by dividing the product 
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of fasting levels of glucose and insulin by a constant 9. Serum total cholesterol, triglycerides and 
high-density lipoprotein (HDL) cholesterol levels were determined using an automated enzymatic 
method. Blood glucose and insulin levels were quantified using standard laboratory technics. At 
RSI-1, C-reactive protein (CRP) was measured using a rate near-infrared particle immunoassay 
(IMMAGE Immunochemistry System, Beckham Coulter, Fullerton, CA).In RSII-1 and RSIII-1, 
CRP was measured using a particle enhanced immunoturbidimetric assay (Roche Diagnostics, 
Mannheim, Germany). Prevalent cardiovascular disease (CVD) was defined as having a history 
of coronary heart disease (CHD) including myocardial infarction or coronary revascularization 
procedures or heart failure, as previously described 8. 
Genotyping
Genotyping was conducted, in self-reported white participants in all three cohorts using the Illumina 
Infinium HumanHap550K Beadchip in RS-I-1and RS-II-3 and the Illumina Infinitum HumanHap 
610 Quad chip in RS-III-1at the Genetic Laboratory of the Erasmus MC, Department of Internal 
Medicine, Rotterdam, the Netherlands. Participants were excluded if they had excess autosomal 
heterozygosity, mismatch between called and phenotyping sex, or recognized as being outlier with 
identical-by-state clustering analysis. Before imputation, SNPs with minor allele frequency MAF 
< 0.01, call rate < 95% and departure from Hardy-Weinberg equilibrium cut off P-value 1×10-6 
were excluded. SNPs were imputed based on the 1000 Genomes cosmopolitan phase 1 version 3 
reference.
Construction of the genetic risk score
In this study, we selected 26 single-nucleotide polymorphisms (SNPs) that passed the genome-
wide significance threshold (P value < 5 × 10-8) in a genome-wide association study (GWAS) of 
GGT levels on more than 61,089 individuals of European descent 10. SNPs were not in linkage 
disequilibrium with each other (R2 > 0.8). Supplementary Table 1 provides an overview of the 
SNPs included in the genetic score and weights assigned to each SNP. The effect allele (coded 0-2) 
was the GGT raising allele. We then calculated the GRS by multiplying the number of risk alleles 
at each locus by corresponding reported beta coefficient and sum the products. The total score was 
then divided by twice the average effect size multiplied by 100 to rescale it.
Statistical Analysis
For the observational association of GGT with prediabetes and type 2 diabetes, we estimated 
hazard ratios (HR) in four adjustment Cox proportional hazards models. Model 1 was adjusted 
only for age, sex and cohort effect. Model 2 was further adjusted for BMI and ALT. In model 3, 
potential risk factors and confounders of type 2 diabetes were added to model 2 including total 
and HDL cholesterol, triglycerides, CRP,  waist circumference, current smoking status, systolic 
blood pressure, antihypertensive medication use, lipid lowering medication use and prevalent 
CVD. Model 4 was further adjusted for fasting insulin and fasting glucose levels. Participants with 
prevalent prediabetes and type 2 diabetes at baseline were excluded accordingly. CRP, ALT, GGT, 
fasting insulin were naturally log transformed. Hazard ratios were also calculated for sex-specific 
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quartiles of GGT levels for prediabetes and type 2 diabetes. Results were reported per SD of log 
transformed GGT levels. 
Associations of individual SNPs and GGT genetic score with GGT levels were assessed with linear 
regression analysis among participants in the Rotterdam Study. SNPs were modeled per GGT-
increasing allele (additive model). Participants with prevalent prediabetes and type 2 diabetes at 
baseline were excluded, and hazard ratios were computed using Cox proportional hazard models 
adjusted for sex, age and cohort effect. We further investigated the association of GGT genetic 
score with glycemic traits (fasting glucose, fasting insulin, HOMA-IR).In a sensitivity analysis, 
participants with prevalent CVD were excluded. To increase our sample size, we examined the 
association of genetic risk score with a combination of both prevalent and incident prediabetes 
and type 2 diabetes cases. Taking to consideration any pleiotropic effect of the score genes, we 
reanalyzed the genetic estimate excluding SNPs that have been reported to be associated with 
any other cardiometabolic trait ( rs1260326, rs10513686, rs4074793, rs17145750, rs7310409, 
rs516246) 10. 
Mendelian Randomization using data from MAGIC and DIAGRAM Consortia
To maximize the statistical power, we examined the association of the genetic risk score and 
glycemic traits and diabetes using data from the largest GWAS meta-analyses. For  diabetes, we 
used data from the DIAGRAM consortium, which meta-analyzed genetic variants in 34, 840 case 
subjects with diabetes and 114,981 control subjects from 37 studies 4. For fasting glucose (n= 
58, 074), fasting insulin (n= 133,000) and HOMA- insulin resistance (n=37,073), we used data 
form the Meta-Analyses of Glucose and Insulin-related Traits Consortium (MAGIC), which is a 
collaborative effort that combined data from 55 studies to identify genetic determinants that affect 
glycemic traits. Participants were of European ancestry and genotyped with the Metabochip 11. 
We selected the same 26 SNPs as described previously 3 and extracted the odds ratios (ORs) and 
accompanying SEs. Then we estimated the association between GGT- genetic score using data 
from MAGIC for glycemic traits and DIAGRAM for type 2 diabetes. 
We estimated the power for the Mendelian randomization analysis for a binary outcome at a two 
sided α of 0.05 based on the proportion of cases in the study, strength of the genetic instrument, and 
the true odds ratio of the outcome variable per standard deviation of the exposure variable using the 
online tool mRnd (http://cnsgenomics.com/shiny/mRnd/). 
Tests were considered statistically significant at P- values lower than 0.05. Proportional hazard 
assumptions were inspected visually using log-minus-log plots, with no deviations detected for 
both the observational and genetic analysis. Statistical analysis were done using SPSS version 20 
(IBM, Armonk, NY, USA) and R version 2.15.1 (R Foundation for Statistical Computing, Vienna, 
Austria). Missing values for all covariates were imputed using expectation maximization in SPSS. 
213
3
N
ut
rit
io
n 
an
d 
C
ar
di
om
et
ab
ol
ic
 R
is
k 
Fa
ct
or
s
Table 2. Association of log transformed GGT levels (per SD) with incident prediabetes and incidence type 
2 diabetes.
Incident prediabetes (n= 1125/7263) Incident type 2 diabetes
 (n= 811/8628)
HR (95% CI) P-value HR (95% CI) P-value
Model 1 1.26 (1.19 - 1.34) 1.0 × 10-14 1.39 (1.3 - 1.4) 2.0 × 10-16
Model 2 1.16 (1.09 - 1.25) 1.3 × 10-5 1.23 (1.14 - 1.33) 1.7 × 10-7
Model 3 1.10 (1.02  - 1.19) 0.008 1.19 (1.1 - 1.3) 2.6 × 10-5
Model 4 1.08 (1.01 - 1.17) 0.02 1.11 (1.02 - 1.21) 0.01
 
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CI confidence interval; CRP, C-reactive protein; 
CVD, cardiovascular disease; HDL, high density lipoprotein; HR, Hazard Ratio; SD, standard deviation.
Model 1: age, sex and cohort effect
Model 2: Model 1 and BMI, ALT 
Model 3: Model 2 and additionally adjusted for triglycerides, CRP, BMI, waist circumference, cholesterol, HDL, 
smoking, alcohol, systolic blood pressure, indication for hypertension, lipid lowering medication and prevalence CVD
Model 4: Model 3 and additionally adjusted for fasting insulin, fasting glucose
Table 1. Baseline characteristics of participants
Characteristics Total 
Women (n, %) 3753 (58)
Age (years) 65.6 (9.8)
Waist circumference (cm) 93 (11.8)
BMI (kg/m2) 26.9 (3.9)
Total Cholesterol (mmol/L) 5.7 (0.9)
Triglycerides (mmol/L) 1.4 (0.7)
HDL cholesterol (mmol/L) 1.4 (0.4)
Lipid lowering medication (n, %) 907 (13.9)
Systolic blood pressure (mmHg) 139.4 (20.8)
Antihypertensive medication use (n, %) 1885 (29)
Alcohol (g/day) 10 (13.3)
Prevalent CVD (n, %) 478 (7)
Current smoking (n, %) 1042 (16)
ALT (U/L) 21 (16 - 27)
GGT (U/L) 24 (17 - 36)
CRP (mg/L) 1.6 (0.6 - 3.5)
Fasting insulin (pmol/L) 73 (51 - 106)
Fasting glucose (mmol/L) 5.4 (0.7)
     
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular 
disease; HDL, high density lipoprotein; GGT, gamma-glutaryltransferase;
Values are mean ± standard deviation or median (interquartile range) for characteristics with skewed distributions.
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Results
Baseline characteristics of the population used for analysis from the Rotterdam Study are shown 
in Table 1. Mean (SD) age of participants was 65.6 (9.8), 58% of the population were women and 
mean (SD) serum GGT level was 24 (SD) U/L. During a mean follow up time of 5.7 years, 1,125 
individuals progressed to prediabetes (incidence rate: 27.1 per 1000 person-years). For type 2 
diabetes, the mean follow up was 6.9 years and 811 individuals developed diabetes (incidence rate: 
13.6 per 1000 person-years).
The age and sex adjusted hazard ratio (HR) for prediabetes per 1 standard (SD) change in natural 
logarithm of GGT was 1.26 (95% CI: 1.19 to 1.34; P-value < 1.0 × 10-14) , as shown in Table 2. 
Further adjustments for BMI and ALT yielded a HR of 1.16 (95% CI: 1.09 to 1.25; P-value < 1.3 × 
10-5) in model 2. Controlling for conventional risk factors in model 3 diminished the magnitude of 
the association (HR=1.10; 95% CI: 1.02 to 1.19; P-value < 0.008) , however, adjustment for fasting 
glucose and fasting insulin did not materially change the stimate in model 4 (HR =1.08, 95% CI: 
1.0 to 1.16; P-value < 0.02). For type 2 diabetes, the age- and sex- adjusted HR was 1.39 (95% 
CI: 1.3 to 1.4; P-value < 2 × 10-16). The results were largely attenuated after adjustment for BMI 
and ALT in model 2 (HR = 1.27; 95% CI: 1.07 to 1.2; P-value 3.2 × 10-7). The association further 
attenuated after adjustment for confounders in model 3 (HR=1.19; 95% CI: 1.1 to 1.3; P-value 
2.6 × 10-5) and for fasting glucose and fasting insulin in model 4 (HR=1.11; 95% CI: 1.02 to 1.21; 
P-value < 0.01). However, the association remained significant in all these models. Prediabetes and 
Type 2 diabetes risk were significantly increased across sex-specific quartiles when compared with 
the first quartile (Figure 2). 
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GGT genetic risk score and risk of prediabetes and type 2 diabetes.
Nearly all GGT SNPs were associated with GGT levels in the Rotterdam Study (Supplementary 
Table 2), however, none of them were associated with prediabetes and type 2 diabetes. The 
genetic risk score composed of 26 SNPs was normally distributed among the study participants. 
The genetic risk score was associated with GGT levels (Beta per SD= 0.09, 95% CI: 0.07 to 
0.1, P value= 2 × 10-16) and explained 3.2 % of the variation in serum GGT levels (F statistic = 
93). Supplementary Figure 1 shows increasing mean levels of GGT in quartiles of the genetic 
risk score. The genetic risk score did not associate with the risk of prediabetes (HR = 0.98; 95% 
CI: 0.91 to 1.04) and type 2 diabetes (HR = 0.96; 95% CI: 0.88 to 1.03) in the sex- and age-
adjusted model (Table 3). Furthermore, there was no evidence for an effect of GGT genetic score 
on glycemic traits in the Rotterdam Study (Table 3). Excluding prevalent CVD cases did not affect 
the estimates (Supplementary Table 3). Combining prevalent and incident cases of prediabetes 
and type 2 diabetes did not change the results (Supplemental Table 3). Excluding SNPs which had 
a pleiotropic effect did not affect association between GGT genetic risk score, prediabetes and type 
2 diabetes (Supplementary Table 4). Nevertheless, adjusting for these variables in the genetic 
analysis model did not change the estimates (HR for prediabetes 0.95 [95% CI: 0.89 to1.01]; HR 
for type 2 diabetes 0.93 [95% CI: 0.83 to1.01]). Rs2017869 of GGT1 gene, previously reported to 
be associated with fasting insulin, was negatively associated with GGT levels (Beta= - 0.1; 95% 
CI: -0.1 to -0.08; P-value < 2 × 10-16) and it was explaining 2.3% of the variance in the GGT levels. 
In a separate genetic analysis of rs2017869, we could not evidence any significant relation between 
our outcomes of interest (Table 3). 
The GGT genetic score was not associated with the risk of type 2 diabetes using data from the 
DIAGRAM Consortium (OR = 0.99; P-value= 0.2). As shown in Table 3, we observed no 
association with fasting glucose (Beta = -0.002, P- value = 0.1), fasting insulin (Beta = -0.001, 
P- value = 0.3), and HOMA-IR (Beta = -0.001, P- value = 0.2).  Excluding pleiotropic SNPs from 
this analysis did not alter the results (Supplementary Table 5). Relation between individual SNPs 
and type 2 diabetes, fasting glucose, fasting insulin, insulin resistance are shown graphically in 
Supplementary Figure 2 and annotation of SNPs with their effect estimates on Supplementary 
Table 6.
Discussion
In this cohort study, we found a 10% higher risk of prediabetes and19% higher risk of diabetes per 
SD increase in GGT levels. Instrumental variable analysis through GGT genetic risk score did not 
support this association to be causal. Altogether, our results suggest that the association could be 
mainly due to confounding or reverse causation.
Although a large and broadly consistent body of evidence has established GGT as strongly linked 
to the development of type 2 diabetes, its causal role is uncertain. It is suggested that GGT links to 
type 2 diabetes through hepatic lipid accumulation and  non-alcoholic fatty liver disease (NAFLD), 
both implicated in the impaired hepatic insulin resistance, major features of pathophysiology of 
type 2 diabetes 12. In addition, GGT is involved in the catabolism of glutathione and is associated 
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with increased oxidative stress, which is involved in the development of insulin resistance and 
diabetes 13,14. This evidence is confirmed from animal models that relate dysregulated glutathione 
metabolism with impaired insulin action in adipocytes 15. However, GGT could also be associated 
with type 2 diabetes and glycemic traits based on reverse causality. We observed in our study 
that further adjustment for potential confounder including fasting glucose and insulin as well, 
considerably diluted the association. In agreement with this observation, a recent study from Scott 
et al. found a significant association between a genetic risk score for insulin resistance and GGT 
levels 16 suggesting a causal role of insulin resistance in increasing GGT levels. 
The direction of estimates in the observational analysis is in line with a previous meta-analysis of 
24 cohort studies 1 that reported a pooled relative risk of top vs bottom tertiles of GGT levels with 
type 2 diabetes incidence of 1.34 (1.27 – 1.42). However, the substantial heterogeneity  (I2 >70%) 
that was observed between studies, together with the younger mean age of participants (50 years old 
vs 65.6 years old in our study)  might be the reasons to explain the difference in magnitude with our 
study. The effect estimates in our analysis were substantially and steeply attenuated by adjustment 
for conventional risk factors and confounders across models. This suggests that potential residual 
and unmeasured confounders remain a concern and might explain the association. On the other 
hand, we do not rule out the possibility of reverse causation, despite adjusting for fasting glucose 
and insulin at the fourth model.  
Our genetic analysis provides evidence that GGT is not causally affecting the glycemic traits, 
prediabetes or risk of type 2 diabetes. There is evidence to suggest that the GGT1 locus, which is 
the main protein-coding gene for GGT, may account for GGT levels variation 17,18 and therefore 
variants within this locus have been used as instrumental variables for Mendelian Randomization 
(MR) studies. Conen and colleagues 2 used a MR approach and found evidence for a causal effect 
of GGT1 variant on fasting insulin levels in a sample size of ~ 4000 participants. The instrumental 
variable (rs2017869) was explaining only ~1.6% of the variance of GGT levels. These results were 
not replicated in the Rotterdam Study. Similarly, we could not replicate the causal analysis when 
using the multi-locus genetic instrument (explaining 3.2% the variance of GGT levels). Although the 
Rotterdam study sample size couldn’t help yield high precision estimates from the genetic analysis, 
we were unable to confirm an association in the GWAS data where we had 83% power to detect 
an HR of 1.34 of GGT levels on type 2 diabetes risk 19 meaning that the estimates derived from 
the replication analysis were well powered. Mendelian randomization is a valid way to explore 
evidence for causality when certain assumptions are met. First, there should be a strong association 
between the genetic risk score and the risk factor of interest. All SNPs that we used in our study 
showed to be strongly associated with GGT levels in a large meta-analyses of GWAS 10. Second, the 
instrumental variable must be independent of confounders that are associated with both GGT and 
type 2 diabetes which is met since the alleles are inherited in random. Third, genetic risk score affects 
the outcome only though the risk factor of interest. This assumption cannot be tested and should 
be considered using information on the underlying biology. However, GCKR, SLC2A2,and HNF1A 
have been reported to be associated with glucose 20 and type 2 diabetes 21. Other reason that might 
have influenced our results is the pleiotropic effect of the genetic variants with serum CRP 22, low 
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density lipoprotein cholesterol, and coronary artery disease 23 . We excluded the pleiotropic variants 
from the genetic risk score in a sensitivity analysis and we controlled for potential confounders in 
these pathways. Thus, it is unlikely that our results are affected by pleiotropic effects of the genes. 
The major strength of this study is the large sample size for measurements of both GGT and 
glycemic indices, prediabetes and diabetes in the Rotterdam Study and the boosted power 
through utilization of the GWAS data. By also examining associations with incident prediabetes, 
we provided insight into the early development of subclinical disease. Additionally, we used 
data from a well-characterized prospective population-based cohort study, which allowed us to 
have a comprehensive assessment of this association using both observational and genetic data. 
Nevertheless, several issues may compromise our approach in assessing causality. We only used 
GGT measured in serum but there have been reported differences in plasma levels and different 
types of GGT fractions 24,25. Furthermore, the results may not be valid for all ethnic groups since 
our population consisted of Caucasian individuals.
In conclusion, our results provide no evidence that genetically elevated GGT levels affect the 
risk of prediabetes and type 2 diabetes, and thus do not support a causal role for GGT levels. 
The observed association between GGT levels and the risk of prediabetes and type 2 diabetes is 
possibly due to residual confounding or reverse causation. These findings may further highlight the 
importance of adequate sample size in Mendelian Randomization studies. 
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Supplemental material
Supplementary Table 1. Alleles used in the genetic risk score.
SNP Coded Allele Beta Weight used for deriving externally 
weighted genetic score
Gene
rs1497406 G 3.8 4.9 RSG1, EPHA2
rs12145922 A 2.8 4.8 CCBL2, PKN2
rs1335645 A 4.3 3.7 CEPT1, DENND2D
rs10908458 T 3.7 2.8 DPM3, EFNA1, PKLR
rs1260326 T 3.2 3.2 C2orf16, GCKR
rs13030978 T 3.7 4.8 MYO1B, STAT4
rs2140773 A 2.9 3.7 EFHD1, LOC100129166
rs10513686 A 4.9 4.3 SLC2A2
rs4547811 C 6.4 3.8 ZNF827
rs6888304 A 2.7 4.5 CDH6
rs4074793 G 5.5 12.3 ITGA1
rs9296736 T 3 2.9 MLIP
rs17145750 C 4.5 3.7 MLXIPL
rs754466 T 3.5 4.5 DLG5
rs7310409 G 6.8 5.5 HNF1A, C12orf27
rs944002 G 6.3 3.6 C14orf73
rs339969 A 4.5 6.4 RORA
rs8038465 T 2.4 3.2 CD276
rs4581712 A 3.2 2.3 DYNLRB2
rs9913711 C 2.4 2.7 FLJ37644, SOX9
rs12968116 C 4.8 6.8 ATP8B1
rs4503880 T 3.6 3.5 NEDD4L
rs516246 T 2.3 2.4 FUT2
rs1076540 C 4.8 3 MICAL3
rs2739330 T 3.7 6.3 DDT, DDTL, GSTT1, GSTT2B, 
MIF
rs2073398 G 12.3 2.4 GGT1, GGTLC2
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Supplementary Table 3. Sensitivity analysis of GGT-related genetic score association  with diabetes and 
prediabetes in the Rotterdam Study
Sensitivity Analysis N Risk Estimate (95% CI) P-value
All T2D (and prediabetes) 3,126/ 8,386 *0.97 (0.92- 1.01) 0.18
Excluding cases with  CHD[T2D as outcome] 611/ 6,815 **0.95 (0.85- 1.06) 0.37
Excluding cases with  CHD [Prediabetes as outcome] 903/ 5,784 **0.96 (0.89- 1.03) 0.26
*Odds Ratio ** Hazard Ratio
Supplementary Table 4. Sensitivity analysis of GGT-related genetic score association  with prediabetes 
and diabetes, after exclusion of pleiotropic SNPs
Sensitivity Analysis HR (95% CI)  of 
prediabetes 
HR (95% CI) of 
T2D 
Excluding pleiotropic SNPs (rs1260326, rs10513686, 
rs4074793, rs17145750,  rs7310409,  rs516246)
1.0 (0.93- 1.07) 0.95 (0.88- 1.03)
*HR, Hazard Ratio
Supplementary Table 5. Sensitivity analysis of GGT-related genetic score  with diabetes and glycemic 
traits in GWAS data excluding the pleiotropic genes from the score.
OR (SE) P-value
T2D 0.99 (0.23) 0.5
β (SE) P-value
Glucose (mmol/L) 4.5 × 10-3 (4.2 × 10-3) 0.2
Insulin (mmol/L) -1.7 × 10-3 (4.5 × 10-3) 0.7
HOMA-IR (log units) -3.8 × 10-3 (4.7 ×10-3) 0.4
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Supplementary Table 6. SNPs and their estimates from the GWAS data.
SNP OR type 2 diabetes β Fasting Insulin β HOMA-IR β Fasting glucose β  GGT
rs10513686* 1.05 0.0061 0.0 -0.025 4.9
rs1076540 1.02 0.003 0.002 -0.0016 4.8
rs10908458 1.01 0.001 6.00 × 10-4 -0.0047 3.7
rs12145922 1.04 -0.0065 -0.007 -0.0012 2.8
rs1260326* 1.04 -0.015 -0.02 -0.027 3.2
rs12968116 1.07 -0.0018 -0.0035 -0.0024 4.8
rs13030978 1.04 -0.0056 -0.0041 -0.0012 3.7
rs1335645 1.00 0.0066 0.0039 0.0074 4.3
rs1497406 1.01 0.001 7.00 × 10-4 -0.0012 3.8
rs17145750* 1.01 0.0066 0.0049 0.0019 4.5
rs2073398 1.03 0.002 0.004 -0.0057 12.3
rs2140773 1.03 -3.00 × 10-4 6.00 × 10-4 0.0036 2.9
rs2739330 1.03 -0.0036 -0.0031 0.0027 3.7
rs339969 1.02 0.0023 4.00 × 10-4 -0.0016 4.5
rs4074793* 1.03 -0.0029 -0.005 -0.0096 5.5
rs4503880 1.03 -0.0046 -0.0059 -0.0067 3.6
rs4547811 1.03 0.0014 0.0 0.0067 6.4
rs4581712 1.00 -1.00 × 10-4 0.0024 0.0046 3.2
rs516246* 1.01 -0.0035 -0.0055 -0.0037 2.3
rs6888304 1.00 0.0065 0.0063 -0.0049 2.7
rs7310409* 1.06 -0.0073 -0.0065 7.00 × 10-4 6.8
rs754466 1.04 0.0056 0.0048 0.0039 3.5
rs8038465 1.02 4.00 × 10-4 7.00 × 10-4 -7.00 × 10-4 2.4
rs9296736 1.01 5.00 × 10-4 4.00 × 10-4 -0.002 3.0
rs944002 1.01 0.0038 0.0017 -0.013 6.3
rs9913711 1.00 0.0033 0.0022 -0.0028 2.4
*pleiotropic genes 
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Supplementary Figure 2. Relationship between GGT SNPs effect estimates and type 2 diabetes Odds 
Ratio(OR),fasting insulin, fasting glucose, HOMA-IR: insulin resistance across all 26 GGT SNPs in the 
GWAS data. Regression line are fitted. Annotation of the SNPs are found in Supplementary Table 7. Red 
points annotate pleiotropic SNPs.
Supplementary Figure 1. GGT levels in relation to quartiles of genetic risk score. (P for trend = 4.9 x 10-4. 
Error bars represent 95% confidence intervals)
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Associations of Steroid Sex Hormones 
and Sex Hormone-Binding Globulin with 
the Risk of Type 2 Diabetes in Women: 
a Population-Based Cohort Study and 
Meta-Analysis
Taulant Muka, Jana Nano, Loes Jaspers, Cindy Meun, Wichor M. Bramer, 
Albert Hofman, Abbas Dehghan, Maryam Kavousi1, Joop S.E. Laven, Oscar 
H. Franco
ABSTRACT
Background: The relation between endogenous sex hormones and type 2 diabetes (T2D) in women 
is unclear. We examined whether sex hormones were associated with the risk of T2D in women. 
Methods and Findings: Data of 3117 postmenopausal women participants of the Rotterdam Study 
(RS), a prospective population based cohort, were available. At baseline of the RS, sex hormone-
binding globulin (SHBG), total testosterone (TT) and total estradiol (TE) were measured. Free 
androgen index, calculated as (T/SHBG)*100 was used as a surrogate measure of bioavailable 
testosterone (BT). T2D events were diagnosed on the basis of medical records. Relative risks 
(RRs) and 95% Confidence Intervals (CIs) were calculated using Cox regression models adjusted 
for confounders. For the systematic review and meta-analysis, six electronic databases (Medline, 
Embase.com, Web of Science, the Cochrane Library, PubMed and Google Scholar) were searched 
for studies assessing the association of endogenous sex hormones with T2D in women. During a 
median follow-up of 11.1 years, we identified 384 incident cases of T2D in the RS. No association 
was observed between TT or BT with T2D. SHBG was inversely associated with the risk of T2D 
(3rd tertile vs. 1st tertile: RR: 0.56; 95%CIs=0.40-0.79) whereas TE was associated with increased 
risk of T2D (3rd tertile vs. 1st tertile: RR: 1.42; 95%CIs=1.01 -2.00). In a meta-analysis of 12 
population-based prospective studies involving 1912 incident T2D cases, the pooled multivariable-
adjusted RRs comparing 3rd tertile vs. 1st tertile were 0.44 (0.30-0.66), 1.32 (0.79-2.21), 1.75 
(0.92-3.33), 1.99 (1.21-3.27) and 3.58 (0.86-14.84) for SHBG, TT, BT, TE and bioavailable 
estradiol respectively.
Conclusions: Our findings suggest that endogenous sex hormones are independent risk factors for 
the development of T2D in women; specifically lower levels of SHBG and higher levels of TE are 
associated with increased risk of T2D.
4.1
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INTRODUCTION
The menopause transition is marked by changes in hormonal patterns, including a marked decline 
in endogenous estradiol levels, leading to a period of relative androgen excess1. This shift in 
hormonal balance contributes to an increase in visceral adiposity that is associated with glycemic 
traits, and therefore may be associated with the risk of type 2 diabetes (T2D)2.  
Although an inverse association between sex hormone-binding globulin (SHBG) and T2D 
has been previously reported3,4, studies of the association between endogenous estradiol and 
testosterone and T2D are limited. Ding and his colleagues, in a nested case-control study of 719 
postmenopausal women, showed a positive association between plasma estradiol and testosterone 
and the risk of T2D 5.  In contrast, no association was reported between these sex hormones and 
the risk of T2D in two other case cohort studies of postmenopausal women, including up to 1728 
participants6,7. SHBG, T and E have been associated with glucose tolerance and development of 
insulin resistance8-11. Furthermore, pregnancy, a state of high endogenous estrogen and polycystic 
ovary syndrome, a condition of anovulation and hyperandrogenism, have been both associated 
with insulin resistance and increased risk of T2D 12,13. Besides the contradictory results, to date, no 
large studies have examined simultaneously the association of T2D with SHBG, T and E in healthy 
postmenopausal women. 
We aimed to investigate the association between sex hormones and T2D in postmenopausal 
women. Furthermore, to contextualize these findings and clarify the contradictory results, we 
systematically review and meta-analyse studies evaluating the association between sex hormones 
and T2D in women. 
SUBJECTS AND METHOD
The Rotterdam Study
The Rotterdam Study is a prospective cohort study which started since 1990 in the Ommoord district, 
in the city of Rotterdam, The Netherlands.  Details regarding the design, objectives, and methods 
of the Rotterdam Study have been described in detail elsewhere14. In brief, in 1990 all inhabitants 
of a well-defined district of Rotterdam were invited, of whom 7,983 agreed (78.1%). In 2000, an 
additional 3011 participants were enrolled (RS-II), consisting of all persons living in the study 
district who had become 55 years of age. Follow up examinations were performed periodically, 
approximately every 3-5 years14. There were no eligibility criteria to enter the Rotterdam Study 
cohorts except the minimum age and residential area based on ZIP codes. The Rotterdam Study 
has been approved by the medical ethics committee according to the Population Screening Act: 
Rotterdam Study, executed by the Ministry of Health, Welfare and Sports of the Netherlands. All 
participants in the present analysis provided written informed consent to participate and to obtain 
information from their treating physicians. 
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Ascertainment of type 2 diabetes
The participants were followed from the date of baseline center visit onwards. At baseline and during 
follow-up, cases of T2D were ascertained through active follow-up using general practitioners’ 
records, glucose hospital discharge letters and glucose measurements from Rotterdam Study visits 
which take place approximately every 4 years 15. T2D was defined according to recent WHO 
guidelines, as a fasting blood glucose ³ 7.0 mmol/L, a non-fasting blood glucose ³ 11.1 mmol/L 
(when fasting samples were absent), or the use of blood glucose lowering medication 16. Information 
regarding the use of blood glucose lowering medication was derived from both structured home 
interviews and linkage to pharmacy records 15. At baseline, more than 95% of the Rotterdam Study 
population was covered by the pharmacies in the study area. All potential events of T2D were 
independently adjudicated by two study physicians. In case of disagreement, consensus was sought 
with an endocrinologist. Follow-up data was complete until January 1st 2012.
Sex steroid measurements
All blood samples were drawn in the morning (≤ 11:00 am) and were fasting. Total estradiol 
(TE) levels were measured with a radioimmunoassay and SHBG with the Immulite platform 
(Diagnostics Products Corporation Breda, the Netherlands). Serum levels of total testosterone 
(TT) were measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS). Free 
androgen index (FAI), calculated as (T/SHBG)*100 is used as a surrogate measure of bioavailable 
testosterone (BT)17.
Population of analysis
The present study used data from the third visit of the first cohort (RSI-3) and the baseline 
examinations of the second (RSII-1) cohort. Overall, there were 3683 women eligible for blood 
measurements. Among them, 122 women did not have information on sex hormones and 32 did 
not have T2D follow-up, and were therefore excluded from the analysis.  Furthermore, 412 women 
with prevalent T2D were excluded, leaving 3117 for our final analysis.  
Potential confounding variables
Potential confounding variables are described in detail in S1 Appendix.
Statistical analysis
Person years of follow-up were calculated from study entrance (March 1997- December 1999 for 
RSI-3, February 2000-December 2001 for RSII-1) to the date of diagnosis of T2D, death or the censor 
date (date of last contact of the living), whichever occurred first. Follow-up was until January 1st 
2012. Cox proportional hazard modelling was used to evaluate whether SHBG, TT, TE and BT were 
associated with T2D. Relative Risks (RR) and 95% confidence intervals (95% CIs) were reported. 
All sex hormones variables were assessed in separate models, continuously and in tertiles. To 
study the relations across increasing tertiles, trend tests were computed by entering the categorical 
variables as continuous variables in multivariable Cox’s proportional hazard models. To achieve 
approximately normal distribution, skewed variables (SHBG, TT, BT, plasma triglyceride, low 
density lipoprotein cholesterol (LDL-C), C-reactive protein (CRP), thyroid-stimulating hormone 
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(TSH) and insulin) were natural log transformed. In the base model (Model 1), we adjusted for age, 
cohort (1 and 2), fasting status (fasting sample vs. non-fasting sample). Model 2 included terms for 
model 1, body mass index (BMI) (continuous), glucose (continuous) and insulin (continuous). BMI 
and waist circumference were highly correlated (Pearson’s correlation coefficient = 0.81, P<0.001), 
so only BMI was used as a measure of adiposity, consistent with previous studies 5,18. Model 3 
included all covariates in model 2 and further potential intermediate factors including: metabolic 
risk factors (total cholesterol, systolic blood pressure (continuous), indication for hypertension 
(yes vs. no) and use of lipid-lowering medications (yes vs. no)), lifestyle factors (alcohol intake 
(continuous) and smoking status (current vs. former/never)), prevalent coronary heart disease (yes 
vs. no), age of menopause, hormone replacement therapy (yes vs. no), CRP (continues) and sex 
hormones for each other. Effect modifications of sex hormones by BMI and years since menopause 
were tested in the final multivariable model in addition to performing stratified analysis. We also 
performed sensitivity analysis (i) substituting BMI for waist circumference, (ii) substituting total 
cholesterol with HDL-C, triglycerides and LDL-C, (iii) further adjusting for THS, physical activity 
or type of menopause (non-natural vs. natural ) and (iv) excluding the first three years of follow up. 
Multiple imputation procedure was used (N= 5 imputations) to adjust for potential bias associated 
with missing data. Rubin’s method was used for the pooled regression coefficients (β) and 95% 
Confidence Intervals 19. A p-value of less than 0.05 was considered as statistically significant. 
All analyses were done using SPSS statistical software (SPSS, version 21.0; SPSS Inc, Chicago, 
Illinois).
Systematic Review and Meta-Analysis
Data sources and search strategy 
The review was conducted using a predefined protocol and in accordance with the PRISMA20 
and MOOSE21 guidelines (S2 and S3 Appendix). Medline, Embase.com, Web of Science, the 
Cochrane Llibrary, PubMed and Google Scholar were searched from inception until November 
2nd 2015 (date last searched) with assistance of an experience biomedical information specialist. 
The computer-based searches combined terms related to the exposure (eg, sex hormone binding 
globulin, testosterone, estradiol) with outcomes (eg, type 2 diabetes), without any language 
restriction. Details on the search strategy are provided in S4 Appendix. Furthermore, in order to 
identify further studies, we checked reference lists and contacted authors and experts in the field.
Study selection and eligibility criteria
Studies were included if they (i) were observational cohort, case-cohort studies, or prospective 
nested case control studies; (ii) had reported on at least one of the sex hormones as exposures: 
SHBG, TT, BT, TE and bioavailable estradiol (BE); and (iii) had assessed associations with risk 
of T2D in women (pre and postmenopausal). Two independent reviewers screened the titles and 
abstracts of all initially identified studies according to the selection criteria. Full texts were retrieved 
from studies that satisfied all selection criteria. 
235
4
C
ar
di
om
et
ab
ol
ic
 H
ea
lth
 in
 W
om
en
Data extraction and quality assessment 
Data were extracted by two independent reviewers and a consensus was reached with involvement 
of a third. A predesigned data abstraction form was used to extract relevant information. This 
included questions on study size; study design; baseline population; location; age at baseline; 
duration of follow-up (for cohort studies) and menopausal status. Additionally, in the case of 
multiple publications, the most up-to-date or comprehensive information was included. Study 
quality was assessed based on the nine-star Newcastle–Ottawa Scale (NOS)22 using three pre-
defined domains namely: selection of participants (population representativeness), comparability 
(adjustment for confounders), and ascertainment of outcomes of interest. The NOS assigns a 
maximum of four points for selection, two points for comparability, and three points for outcome. 
Nine points on the NOS reflects the highest study quality. 
Data synthesis and analysis
For the meta-analysis, we used the risk estimates of the most adjust models reported by each study. 
To enable a consistent approach for the meta-analysis, we used previously described methods23 to 
transform RR estimates for associations between sex hormones with T2D risk which were often 
differentially reported by each study (for example, per unit change, per one standard deviation 
change, or comparing quarters or thirds, and other groupings), and therefore, to consistently 
correspond to comparison of the top third versus the bottom of the baseline distribution by 
sex hormone levels in each study. Briefly, we transformed the log RR by assuming a normal 
distribution, with the comparison between extreme thirds being equivalent to 2.18 times the log 
risk ratio for one standard deviation increases (or equivalently as 2.18/2.54 time the log RR for a 
comparison of extreme quarters). We calculated standard error of the log RR by using published 
CIs and standardised them in the same way. Hazard ratios, RRs, and odds ratios were assumed to 
approximate the same measure of RR. 
The inverse variance weighted method was used to combine relative risks to produce a pooled 
relative risk using random-effects models to allow for between study heterogeneity. Also, 
additionally we reported the estimates using fixed effect models. Heterogeneity was assessed using 
the Cochrane χ2statistic and the I2 statistic. Publication bias was evaluated through a funnel plot 
and Egger’s test. All tests were two-tailed and p-values of 0.05 or less were considered significant. 
STATA release 12 (Stata Corp, College Station, Texas) was used for all statistical analyses.
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RESULTS
Table 1 summarizes the baseline characteristics of the participants included in the analysis. Of the 
3117 women without diabetes at baseline, 384 women developed diabetes over a median follow-up 
of 11.1 years. 
Table 1 Selected Characteristic of Study Participants, the Rotterdam Study.  
Age (years) 69.7 ± 8.7
Years since menopause (years) 20.9 ± 10.0
Age of menopause (years) 48.9 ± 5.2
Natural menopause, n (%) 2433 (78.1)
Current smokers, n (%) 218 (9.2)
Alcohol intake g/day 1.3 (10)a
BMI (kg/m2) 27.0  ± 4.3
Waist circumference (cm) 89.4  ± 11.6
Prevalent coronary heart disease, n (%) 86 (2.8)
Estradiol  (pmol/l) 34.2 (41.62)a
Total testosteron (nmol/l) 0.8 (0.56) a
Sex-hormon binding globuline (nmol/l) 69.6 ± 33.0
Free androgen index 1.3 (1.1) b
Thyroid-stimulating hormone  (mU/l) 1.95 (1.7)a
Hormone replacement therapy, n (%) 159 (5.3)
Insulin (pmol/l) 67 (47)a
Glucose (mmol/l) 5.5 ± 0.6
C-reactive protein (mg/ml) 1.7 (2.93)a
Total cholesterol (mmol/l) 6.0 ± 1.0
Low density lipoprotein cholesterol (mmol/l) 4.2 (1.22) a
High density lipoprotein cholesterol (mmol/l) 1.5 ± 0.4
Statin use, n (%) 681 (14)
Triglycerides (moml/l) 1.27 (0.74) a
Systolic Blood pressure (mm/Hg) 142.0 ± 21.1
Indication for hypertension, n (%) 794 (25.5)
BMI, body mass index; HRT, hormone replacement therapy; NA, non-applicable. Plus minus values are mean ± SD 
a Median (interquartile range)
Sex-hormones and the risk of developing T2D
In models adjusted for age, cohort effect and fasting status, lower SHBG levels (3rd tertile vs.1st 
tertile: RR=0.33, 95% CI=0.25 -0.43, p-trend<0.001) and higher levels of BT (3rd tertile vs.1st 
tertile: RR=2.01, 95% CI=1.55-2.60, p-trend<0.001) and TE (3rd tertile vs.1st tertile: RR=2.02, 
95% CI=1.50 -2.70, p-trend<0.001)  were associated with an increased risk of T2D (Table 2). 
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Further adjustments for BMI, insulin and glucose attenuated but did not abolish the association 
between SHBG (3rd tertile vs.1st tertile: RR=0.56, 95% CI=0.41 -0.77, p-trend<0.001) or TE and 
incident T2D (3rd tertile vs.1st tertile: RR=1.39, 95% CI=1.004 -1.93, p-trend=0.07). On the other 
hand, adjustment for obesity and glycemic traits weakened the associations of BT with T2D such 
that they were not longer statistically significant (Table 2). Controlling for metabolic risk factors, 
lifestyle factors, inflammatory markers and prevalent coronary heart disease did not materially 
affect these associations (Table 2). No association was found between TT and incident T2D in any 
of the models (Table 2).
Because associations of continues hormone variables with T2D in the Model 1 appeared linear, 
RRs stratified and sensitivity analyses were expressed per unit log or unit increase in hormone 
biomarkers. In the sensitivity analysis, substituting BMI with waist circumference as a measure 
of adiposity, substituting total cholesterol for other blood lipids, adjusting further for serum TSH, 
physical activity or menopause type, and excluding the first three years of follow up did not affect 
any of the associations (S1 Table). Also, in the stratification analysis, no significant interactions 
were found for SHBG and TE with BMI or years since menopause (S1 Table). Significant 
interaction terms were found for TT (p-interaction = 0.019) and FAI (p-interaction = 0.03) with 
years since menopause. However, no association was found between these hormones and T2D 
after stratification for time since menopause (S1 Table). Also, no effect modification by BMI was 
found for TT and BT (S1 Table).
Figure 1 Relative risks of type 2 diabetes comparing top vs. bottom thirds of baseline plasma sex hormone-
binding globulin. 
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Systematic Review and Meta-Analysis
Literature Search, Characteristics and Quality of Eligible Studies 
Initial search identified 3209 potentially relevant citations. After screening and detailed assessment, 
14 articles based on 11 unique studies were included (S1 Figure and S5 Appendix). Therefore, 
we meta-analysed estimates from 12 studies (including the current study) involving a total of 
12,972 unique participants with 1912 incident T2D cases reporting on the association between sex 
hormones and T2D risk. Detailed characteristics of these studies and quality assessment have been 
summarized in S2 Table. 
Sex hormones and T2D in Pooled Analysis 
The meta-analysis for BT, TE and BE is based only on studies examining postmenopausal women; 
the meta-analysis for TT is based on 4 studies including postmenopausal women and 1 study 
including pre and postmenopausal women, whereas the findings for SHBG derive from studies 
including premenopausal women (n=2), postmenopausal women (n=4) and combined (3). The 
pooled RR for T2D adjusted for several metabolic risk factors comparing 3rd tertile vs. 1st tertile 
of SHBG, TT, BT, TE and BE were  0.44 (95%CI: 0.30-0.66, I2=77,9%, p<0.001), 1.32 (95%CI: 
0.79-2.21, I2=53.8%, p=0.07), 1.75 (95%CI: 0.92-3.33, I2=80.7%, p=0.001), 1.99 (95%CI: 1.21-
3.27, I2=55.1%, p=0.06) and 3.58 (95%CI: 0.86-14.84, I2=81.0%, p=0.02) (Figure 1-3). There 
was evidence of between-study heterogeneity for all these analyses with possible exception of 
the meta-analysis on the association between TE and the risk of T2D (Figure 1-3). Four studies 
were not possible to include in the meta-analyses. Soriguer found that, in pre- and postmenopausal 
women, per one unit log increase in SHBG, TT and BT, the corresponding RRs were 0.23 (0.1 to 
0.53), 1.04 (0.59 to 1.83) and 1.12 (0.59 to 2.13) respectively.  Boyd-Waschinko at al. reported a 
5-fold increase in T2D incidence in the lowest quintile of SHBG. Similarly, Lindstedt et al. found 
that among patients in the low SHBG terile, 18% converted to T2D as compared with 5% in mid 
SHBG tertile and 2.5% in high SHBG tertile. Okubo et al reported lower levels of SHBG in T2D 
converters (59.7 ± 8.4 nmol/l) than non-converters (69.5 ± 2.5 nmol/l) during 3 years of follow-
up but that was not significant different after adjusting for age, body mass index and waist to hip 
ratio24.
Publication bias
The appearance of funnel plots was asymmetrical for the analysis on SHBG and T2D, and Egger’s 
test results were significant (P = 0.014) (S2 Figure). This suggested that publication bias may be 
present. After exclusion of the four studies that included 50 or fewer T2D cases findings were not 
statistically significant (Egger’s test, P=0.93, data not shown). No evidence of publication bias was 
observed for the analysis of TT or TE and T2D (S2 Figure). 
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DISCUSSION 
Our findings in the Rotterdam Study generally concur and further extend previous studies, 
providing relevant findings that have not been previously addressed. In this large population based 
study of postmenopausal women free of T2D at baseline, we showed that lower levels of SHBG 
and higher levels of TE are associated with the risk of T2D. These associations were independent 
of established risk factors, including body mass index, glucose and insulin. In our study, however, 
we did not find any association between testosterone and the risk of T2D. 
Pooled results from the systematic meta-analysis of 12 studies reinforce the validity and 
generalizability of our findings, suggesting that SHBG and TE are robust risk markers of T2D in 
women. Unlike the previous meta-analysis by Ding EL et al, which was based mainly on studies 
with cross-sectional design and examined only mean differences between T2D cases and non T2D 
controls, our current pooled analysis is based on findings from 11 prospective studies (only two 
studies were included in the previous review were eligible), including 10873 participants with 
1623 T2D cases. Therefore, our meta-analysis provides a more detailed assessment of the nature 
and magnitude of the association between sex hormones and T2D in women. 
SHBG levels have been associated with metabolic syndrome, glucose and insulin levels, established 
risk factors for T2D9,10,25. Also, women with PCOS, a condition of anovulation and hyperandrogenism, 
are at increased risk of T2D, and levels of SHBG are decreased in these women 13. The complex 
biological mechanisms that explain the association between circulating SHBG levels and the risk 
for T2D are not fully understood. Classically, the primary function of SHBG was thought to be 
the binding of circulating hormones in order to regulate free sex hormone bioavailability to target 
tissues. Therefore, it has been hypothesized that the relation between SHBG and T2D may results 
from indirect influence of alterations in SHBG on sex hormone bioavailability. However, in our 
study, the association between SHBG and T2D risk remains significant after adjustment for TT, BE 
and TE, implicating SHBG levels as a risk factor for T2D independent of serum androgen levels. 
Additional evidence in support of an independent effect of SHBG on T2D comes from recent 
studies that have found several polymorphisms in the SHBG to associate with insulin resistance 
and T2D, suggesting that altered SHBG physiology may be a primarily defect in the pathogenesis 
of disease26-29.  Furthermore, a growing body of evidence show that SHBG may directly mediate 
cell-surface signalling, cellular delivery and biologic action of sex hormones via activation of a 
specific plasma receptor30-32. At the target tissue level, the fraction of SHBG that is not bound to 
sex steroid has the ability to bind plasma membrane high-affinity receptors (RSHBG)
30. Sex steroids 
of variable biologic potency can activate the anchored SHBG- RSHBG complex and the activated 
complex can have either an agonist or antagonist effect. For example, SHBG- RSHBG complex 
can have direct cellular antagonistic properties against estrogen; SHBG may interact with cellular 
estrogen receptors which can trigger a biologic antiestrogenic response30.  Specific downstream 
effects of the SHBG-receptor complex merit further investigation since may help to clarify the 
underlying mechanisms linking SHBG to T2D.  
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Our result for a positive relation between estradiol and T2D are in contrast with the results from 
previous trials of oral estrogen therapy, which showed a lower risk of T2D among postmenopausal 
women who used estrogen treatment33-35. In contrast, pregnancy, a state of high endogenous estrogen, 
is associated with insulin resistance12. Exogenous estrogen may have different physiological effects 
depending on type, route, duration and dose of estrogen therapy36-39.  For example, opposing effects 
of oral estrogen on fasting glucose vs glucose tolerance have been reported36,37. Also, transdermal 
estradiol elevated CRP levels up to 12 months of treatment but not oral estrogen in a randomized 
trial of postmenopausal women39. Moreover, a bimodal relationship of estrogen dose may exist. 
In a clinical trial of postmenopausal women, lower dose of estrogen therapy increased insulin 
sensitivity whereas higher dose had the opposite effect40. 
Endogenous estradiol may be associated with diabetes risk through its relation to glucose, insulin, 
adiposity and inflammation. Indeed, previous cross-sectional studies have linked both BE and 
TE with higher glucose and insulin resistance levels in postmenopausal women, independently 
of obesity11,41,42. Also, animal studies show that estradiol may have a direct effect on adipocyte 
enlargement and weight gain43, although other studies44 do not support this hypothesis. Furthermore, 
elevated inflammatory factors such as CRP have been reported in women on oral estrogen 
treatment39. However, in our study, the association between TE and T2D, although attenuated, 
remained significant after adjustment for plasma levels of glucose and insulin, BMI and CRP, 
suggesting that estradiol may play a direct role in the pathophysiology of T2D. Furthermore, 
additional adjustment for TT did not affect this association, suggesting that estradiol may be more 
than just a marker of increased aromatase conversion. Explicit mechanisms of estrogen in relation 
to T2D require further study. 
Our study showed no association between TT and the risk of T2D whereas a suggestive positive 
association was observed between BT and T2D. The lack of association between FT and the risk 
of T2D in our study might be due to lack of a direct measure of BT in the blood which could 
have biased our results toward the null. These findings are in line with previous studies reporting 
higher levels of insulin resistance with increasing levels of BT in postmenopausal women, while 
no association has been observed between TT and insulin resistance15,42.  Similarly, BT has been 
related to increased odds of having impaired fasting glucose15. 
Strengths of our study include its prospective design; the long follow-up and adequate adjustments 
for a broad range of possible confounders. We also performed several sensitivity analyses such 
as excluding the first three years of follow up to avoid potential bias of undiagnosed disease at 
baseline. Furthermore, our study included in addition to analysis of primary data also a systematic 
review of all available published prospective cohorts, which is the first-ever quantitative synthesis 
of these associations thus far in women. Also, most of the studied included in our meta-analysis 
adjusted for potential confounding. However, there are several limitations that need to be taken 
into account. First, we did not have measures of bioavailable estradiol in the Rotterdam Study, 
which could have strengthened our results. Second, free T levels were not measured directly in the 
blood and therefore have to be interpreted with caution. Nevertheless, free T levels in this study 
were derived from the ratio of T to SHBG, which is considered a precise proxy for bioavailable 
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T45. Third, we observed a moderate to high level of heterogeneity across the included studies. Since 
the number of available studies included in each meta-analysis was generally small, it precluded 
our ability to investigate the sources of the observed heterogeneity by subgroup analyses involving 
various study-level characteristics (such as age). Fourth, there was evidence of publication bias for 
the association between SHBG and the risk of T2D, so it is possible that our results constitute an 
overestimation of the performance of the test. However, when we excluded small studies differences 
were not statistically significant and therefore, the effect of publication bias may be only minor. 
Fifth, the meta-analyses on BE, BT and T2D included estimates from four or less studies. The 
use of random-effects models is limited in the presence of few studies for analysis and the use 
of fixed-effects models may be preferred46. Contrary to the results of random-effects models, the 
fixed-effects models showed a significant association of both BE and BT with the risk of T2D. 
Last, except for SHBG, the other findings come from studies conducted mainly in postmenopausal 
women, and therefore these results cannot be extended to pre or perimenopause women.
In conclusion, findings of this review indicate that endogenous sex hormones are associated with the 
risk of T2D in postmenopausal women. Further studies are needed to establish hormones thresholds 
at which diabetes risk is increased, because this may aid in identifying high-risk postmenopausal 
women in the clinical setting. Also, future studies are needed to investigate the effect of medication 
or lifestyle factors the affect sex hormone levels on glucose metabolism and T2D, which may help 
in development of novel glucose-lowering therapies and diabetes prevention.  
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Supplemental material
S1 Figure Flowchart of studies investigating the association between endogenous sex hormones and the risk 
of type 2 diabetes.
 
Records identified through 
database searching  
(n = 3209) 
Records screened  
(n =3209) 
Records excluded based on 
title and abstract  
(n =3187) 
Records given full text 
detailed assessment  
(n = 22)
Full-text articles excluded
(n = 8) 
 Not the appropriate exposure 
or outcome (n=6) 
 Case-control study (n=2) 
Article included (n=14) 
based on 11 unique studies 
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S2 Figure Assessment of small study effects by funnel plots and Egger’s test in prospective studies of age 
at menopause and cardiovascular disease outcomes
Sex hormone-binding globulin
Total testosterone Total estradiol
The dotted lines show 95% confidence intervals around the overall summary estimate calculated using a fixed effect model; 
p-values for bias calculated using Egger’s test was 0.014, 0.08 and 0.18 for sex hormone-binding globulin, total testosterone 
and total estradiol respectively.
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S1 Table Sensitivity analysis of sex and the risk of type 2 diabetes postmenopausal women, the Rotterdam 
Study.
Sex hormone-
binding globulinaa
Total 
Testosteronea
Estradiolb Free androgen 
indexa
Multivariable model 0.66 (0.51-0.86) 0.93  (0.76-1.14) 1.002 (1.001-1.004) 1.15 (0.85-1.54)
Multivariable model  + waist 
circumference
0.69 (0.53-0.90) 0.96  (0.78-1.19) 1.003 (1.001-1.005) 1.11 (0.92-1.33)
Multivariable model  + HDL + 
TG + LDL
0.72 (0.55-0.95) 0.94  (0.76-1.16) 1.003 (1.001-1.004) 1.07 (0.89-1.29)
Multivariable model  + serum 
thyroid stimulating hormone 
0.66 (0.51-0.87) 0.89 (0.73-1.09) 1.002 (1.001-1.004) 1.11 (0.93-1.33)
Multivariable model  + physical 
activity
0.66 (0.50-0.86) 0.89 (0.73-1.09) 1.003 (1.001-1.004) 1.12 (0.94-1.34)
Multivariable model  + 
menopause type (surgical vs. 
natural)
0.65 (0.50-0.85) 0.89 (0.72-1.08) 1.003 (1.001-1.004) 1.12 (0.94-1.34)
Multivariable model excluding the 
first 3years of follow-up
0.68 (0.51-0.91) 0.98 (0.79-1.23) 1.003 (1.001 -1.005) 1.13 (0.93-1.37)
BMI (kg/m2)c
<25 0.50 (0.28-0.91)d 0.90 (0.56-1.45)d 1.003 (1.001-1.006)d 1.18 (0.78-1.78)d
25-29.9 0.80 (0.54-1.18) 1.20 (0.88-1.62) 1.003 (1.00-1.006) 1.22 (0.94-1.58)
≥30 0.76 (0.48-1.22) 0.86 (0.59-1.24) 1.001 (1.00-1.005) 0.99 (0.72-1.36)
Time since menopausec
<15 0.84 (0.47-1.50)d 1.26 (0.84-1.89)e 1.004 (1.001-1.007)d 1.22 (0.86-1.73)k
15-25 0.78 (0.51-1.19) 1.01 (0.73-1.40) 1.002 (0.998 -1.006) 1.09 (0.83-1.44)
>25 0.46  (0.28-0.75) 0.78 (0.55-1.10) 1.003 (0.996 -1.01) 1.08 (0.79-1.48)
Multivariable model adjusted for variables in model 3 of Table 2.  
a Values are + 1 log increase  
b Values are per 1 unit increase 
c Results are adjusted for variables in model 3 of Table 2 
d P-interaction >0.05 
e P-interaction=0.019 
k P-interaction=0.03
251
4
C
ar
di
om
et
ab
ol
ic
 H
ea
lth
 in
 W
om
en
S2
 T
ab
le
 C
ha
ra
ct
er
is
tic
s o
f t
he
 in
cl
ud
ed
 st
ud
ie
s t
ha
t a
ss
es
se
d 
th
e 
as
so
ci
at
io
n 
of
 se
x 
ho
rm
on
es
 w
ith
 th
e 
ris
k 
of
 ty
pe
 2
 d
ia
be
te
s
L
ea
d 
A
ut
ho
r, 
Pu
bl
ic
at
io
n 
D
at
e 
Source of 
participants 
Location
Ye
ar
 o
f 
ba
se
lin
e 
su
rv
ey
B
as
el
in
e 
ag
e 
ra
ng
e/
 a
ve
ra
ge
 
ag
e 
(y
ea
rs
)
St
ud
y 
de
si
gn
Follow up 
years
Total 
participants
N
o.
 o
f 
st
ud
y 
ev
en
ts
M
en
op
au
sa
l 
St
at
us
C
ov
ar
ia
te
s a
dj
us
te
d 
fo
r
Study 
quality*
O
h 
20
02
RBS
USA
19
84
-1
98
7
72
.4
 ±
 6
.1
4
C
as
e-
co
ho
rt
8
233
17
Po
st
m
en
op
au
sa
l
A
ge
, B
M
I, 
sy
st
ol
ic
 b
lo
od
 p
re
ss
ur
e,
 
7
C
he
n 
B
H
 e
t 
al
.2
01
2 
D
in
g 
20
09
WHI-OS
USA
19
94
-1
99
8
61
.1
 ±
 5
.2
C
as
e-
co
ho
rt
5.9 (median)
1928
64
2
Po
st
m
en
op
au
sa
l
A
ge
, 
ra
ce
/e
th
ni
ci
ty
, 
cl
in
ic
al
 
ce
nt
er
, 
tim
e 
of
 
bl
oo
d 
fl
ow
, 
du
ra
ti
on
 
of
 
fo
ll
ow
-u
p,
 
po
st
m
en
op
au
sa
l 
ho
rm
on
e 
th
er
ap
y,
 p
hy
si
ca
l 
ac
tiv
ity
, 
sm
ok
in
g 
st
at
us
, 
al
co
ho
l 
in
ta
ke
, 
hi
st
or
y 
of
 
hy
pe
rte
ns
io
n,
 
fa
m
ily
 
hi
st
or
y 
of
 d
ia
be
te
s, 
bo
dy
 m
as
s 
in
de
x,
 C
-r
ea
ct
iv
e 
pr
ot
ei
n,
 
H
O
M
A
-I
R
, 
te
st
os
te
ro
ne
, 
LD
L,
 
H
D
L-
ch
ol
es
te
ro
l, 
gl
yc
at
ed
 h
ae
m
og
lo
bi
n.
8
K
al
ya
ni
 2
00
9
MESA
USA
20
00
-2
00
02
65
.2
 ±
 9
.0
Pr
os
pe
ct
iv
e
6
1612
11
6
Po
st
m
en
op
au
sa
l
A
ge
, 
ra
ce
/e
th
ni
ci
ty
, 
ed
uc
at
io
n,
 
in
co
m
e,
 
fa
m
ily
 h
is
to
ry
 o
f d
ia
be
te
s, 
ex
am
in
at
io
n 
si
te
, 
B
M
I, 
H
O
M
A
-I
R
, L
D
L,
 H
D
L,
 tr
ig
ly
ce
rid
es
, 
us
e 
of
 l
ip
id
-lo
w
er
in
g 
m
ed
ic
at
io
ns
, 
sy
st
ol
ic
 
bl
oo
d 
pr
es
su
re
, a
nt
ih
yp
er
te
ns
iv
e m
ed
ic
at
io
n,
 
to
ta
l 
da
ily
 c
al
or
ic
 i
nt
ak
e,
 p
hy
si
ca
l 
ac
tiv
ity
, 
sm
ok
in
g,
 I
L-
6,
 C
R
P,
 a
ge
 a
t 
m
en
op
au
se
, 
ye
ar
s 
si
nc
e 
m
en
op
au
se
, t
yp
e 
of
 m
en
op
au
se
, 
ag
e 
at
 
fi
rs
t 
li
ve
 
bi
rt
h,
 
fi
ve
 
or
 
m
or
e 
li
ve
 
bi
rth
s, 
an
d 
pa
st
 u
se
 o
f h
or
m
on
e 
re
pl
ac
em
en
t 
th
er
ap
y 
r o
ra
l c
on
tra
ce
pt
iv
e 
pi
lls
. 
9
O
na
t 2
01
0
TARFS
Turkey
48
.4
 ±
 1
1.
7
C
as
e-
co
ho
rt
9
1067
20
2
Pr
e-
 a
nd
 p
os
t-
m
en
op
au
sa
l
A
ge
, B
M
I, 
C
-r
ea
ct
iv
e 
pr
ot
ei
n,
 H
D
L-
ch
ol
es
te
ro
l, 
lip
id
 lo
w
er
in
g 
dr
ug
s a
nd
 
A
po
lip
op
ro
te
in
 A
-1
7
H
af
fn
er
 1
99
3
SAHS
USA
19
79
-1
98
2
25
-6
4
C
as
e-
co
ho
rt
8
109
38
Pr
e-
 a
nd
 p
os
t-
m
en
op
au
sa
l
Fa
st
in
g 
gl
uc
os
e 
an
d 
in
su
lin
7
So
rig
ue
r 2
01
1
PCS
Italy
19
95
-1
99
7
36
 ±
 2
3
C
as
e-
co
ho
rt
11
691
10
6*
Pr
e-
 a
nd
 p
os
t-
m
en
op
au
sa
l
A
ge
, b
od
y 
m
as
s i
nd
ex
 a
nd
 w
ai
st
 
ci
rc
um
fe
re
nc
e
8
252
S2
 T
ab
le
 C
ha
ra
ct
er
is
tic
s o
f t
he
 in
cl
ud
ed
 st
ud
ie
s t
ha
t a
ss
es
se
d 
th
e 
as
so
ci
at
io
n 
of
 se
x 
ho
rm
on
es
 w
ith
 th
e 
ris
k 
of
 ty
pe
 2
 d
ia
be
te
s
L
ea
d 
A
ut
ho
r, 
Pu
bl
ic
at
io
n 
D
at
e 
Source of 
participants 
Location
Ye
ar
 o
f 
ba
se
lin
e 
su
rv
ey
B
as
el
in
e 
ag
e 
ra
ng
e/
 a
ve
ra
ge
 
ag
e 
(y
ea
rs
)
St
ud
y 
de
si
gn
Follow up 
years
Total 
participants
N
o.
 o
f 
st
ud
y 
ev
en
ts
M
en
op
au
sa
l 
St
at
us
C
ov
ar
ia
te
s a
dj
us
te
d 
fo
r
Study 
quality*
G
am
bi
ne
ri 
20
12
NA
Italy
19
78
-1
99
9
23
.4
 ±
 6
.3
Pr
os
pe
ct
iv
e
16.9
255
42
Pr
e-
m
en
op
au
sa
l
A
ge
, 
B
M
I, 
fa
st
in
g 
gl
uc
os
e,
 w
ai
st
 t
o 
hi
p 
ra
tio
, s
ys
to
lic
 b
lo
od
 p
re
ss
ur
e,
 d
ia
st
ol
ic
 b
lo
od
 
pr
es
su
re
, 
fa
st
in
g 
in
su
lin
, 
H
bA
1C
, 
to
ta
l 
ch
ol
es
te
ro
l, 
H
D
L-
ch
ol
es
te
ro
l, 
tri
gl
yc
er
id
es
, 
lu
te
in
iz
in
g 
ho
rm
on
e,
 
fo
lli
cl
e-
st
im
ul
at
in
g 
ho
rm
on
e,
 e
st
ra
di
ol
, t
es
to
st
er
on
e,
 S
H
B
G
8
Li
nd
st
ed
t G
 e
t 
al
. 1
99
1
NA
Sweden
19
68
-1
96
9
38
-6
0
Pr
os
pe
ct
iv
e
12
1462
43
Pr
e 
an
d 
po
st
m
en
op
au
sa
l
7
B
oy
d-
W
os
ch
in
ko
NA
USA
36
-4
3
C
as
e-
co
ho
rt
8
119
10
Pr
e-
m
en
op
au
sa
l
5
O
ku
bo
 M
 e
t a
l. 
19
99
Medical survey
Hawaii and USA
19
92
-1
99
3
65
.4
 ±
 0
.5
Pr
os
pe
ct
iv
e 
3
280
23
Po
st
m
en
op
au
sa
l
A
ge
, b
od
y 
m
as
s i
nd
ex
 a
nd
 w
ai
st
 to
 h
ip
 ra
tio
6
Fe
ns
ke
 B
 e
t a
l. 
20
15
Study of Health in 
Pomerania
Germany
19
97
-2
00
1
48
.8
 ±
 1
6.
2
Pr
os
pe
ct
iv
e
5
1925
20
2*
Pr
e 
an
d 
po
st
m
en
op
au
sa
l
A
ge
, w
ai
st
 c
irc
um
fe
re
nc
e,
 p
hy
si
ca
l 
in
ac
tiv
ity
 a
nd
 a
lc
oh
ol
 c
on
su
m
pt
io
n.
 
8
H
u 
J e
t a
l. 
20
15
EIMDS
China
20
08
60
 ±
 1
1.
1
Pr
os
pe
ct
iv
e,
 
ne
st
ed
 c
as
e-
co
nt
ro
l 
5
174
87
Po
st
m
en
op
au
sa
l
BM
I, 
sy
sto
lic
 b
lo
od
 p
re
ss
ur
e, 
di
as
to
lic
 b
lo
od
 
pr
es
su
re
, 
cu
rre
nt
 
sm
ok
in
g,
 
al
co
ho
l 
us
e,
 
hy
pe
rte
ns
io
n,
 
ex
er
ci
se
 
fre
qu
en
cy
, 
fa
m
ily
 
hi
sto
ry
 o
f 
T2
D
, f
as
tin
g 
pl
as
m
a 
gl
uc
os
e, 
to
ta
l 
ch
ol
es
te
ro
l, 
hi
gh
-d
en
sit
y 
lip
op
ro
te
in
 ch
ol
es
te
ro
l 
an
d 
lo
w
 d
en
sit
y 
lip
op
ro
te
in
 ch
ol
es
te
ro
l. 
8
To
ta
l
12,972
19
12
B
M
I,
 B
od
y 
m
as
s 
in
de
x,
 E
IM
D
S
, T
he
 E
nv
ir
on
m
en
t, 
In
fl
am
m
at
io
n 
an
d 
M
et
ab
ol
ic
 D
is
ea
se
s 
S
tu
dy
; M
E
S
A
, M
ul
ti
-E
th
ni
c 
S
tu
dy
 o
f A
th
er
os
cl
er
os
is
; P
C
S
, P
iz
ar
ra
 C
oh
or
t S
tu
dy
; R
B
S
, 
R
an
ch
o 
B
er
na
rd
o 
St
ud
y;
 S
A
H
S,
 S
an
 A
nt
on
io
 H
ea
rt 
St
ud
y;
 T
A
R
FS
, T
ur
ki
sh
 A
du
lt 
R
is
k 
Fa
ct
or
 S
tu
dy
; W
H
S,
 W
om
en
 H
ea
lth
’s
 S
tu
dy
; *
ap
pr
ox
im
at
io
n 
 
253
4
C
ar
di
om
et
ab
ol
ic
 H
ea
lth
 in
 W
om
en
S1 Appendix  Potential confounding variables 
Information on current health status, medical history, medication use, smoking behaviour, and 
socioeconomic status was obtained at baseline for both studies. During the home interview, women 
were asked a special section of questions pertaining to menopausal status. One set of questions 
dealt with timing of the last menstrual period, gathering information on whether the respondent had 
a natural menstrual period within the 12 months, the past 3 months, and the age at last period for 
women who had no period for at least 3 months. One question addressed period regularity and the 
number of menstrual cycles. Postmenopausal women were defined women who reported absence 
of menstrual periods for 12 months. Participants were asked whether they were currently smoking 
cigarettes, cigars, or pipes. Alcohol intake was assessed in grams of ethanol per day. History of 
cardiovascular disease was defined as a history of coronary heart diseases (myocardial infarction, 
revascularization, coronary artery bypass graft surgery or percutaneous coronary intervention) and 
was verified from the medical records of the general practitioner. Blood pressure was measured in 
the sitting position at the right upper arm with a random-zero-sphygmomanometer. Physical height 
(m) and body weight (kg) were measured at baseline with the participants standing without shoes 
and heavy outer garments. Body mass index (BMI) was calculated as weight divided by height 
squared (kg/m2). All biochemical parameters were assessed in fasting serum. Thyroid stimulating 
hormone (TSH) was measured on the Vitros Eci (Ortho Diagnostics). Insulin, glucose, total 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and C-reactive 
protein (CRP) were measured on the COBAS 8000 Modular Analyzer (Roche Diagnostics GmbH). 
The corresponding interassay coefficients of variations are the following: TSH<13.2%, insulin 
<8%, glucose <1.4%, lipids <2.1%  and CRP <16.9%. Physical activity was assessed with an 
adapted version of the Zutphen Physical Activity Questionnaire1. Every activity mentioned in the 
questionnaire was attributed a MET-value according to the 20112.The questionnaire contained 
questions on walking, cycling, gardening, diverse sports, hobbies and on housekeeping. Total time 
spend on physical activity was calculated as the sum of minutes per week for each type of activity.
S4 Appendix Search strategy 
Embase.com  
(‘sex hormone’/de OR androgen/de OR ‘androgen blood level’/de OR ‘androgen deficiency’/de 
OR testosterone/de OR ‘testosterone blood level’/de OR ‘sex hormone binding globulin’/de OR 
estradiol/de OR ‘estradiol blood level’/de OR hypogonadism/exp OR ‘gonad dysfunction’/de OR 
‘ovary insufficiency’/exp OR ‘testis function’/de OR ‘hyperandrogenism’/exp OR (((sex OR sexual 
OR gonad* OR testicular* OR ovar*) NEXT/3 hormone*) OR  androgen* OR  hyperandrogen* OR 
hypoandrogen* OR testosterone* OR estradiol* OR oestradiol* OR hypogonad* OR hypergonad* 
OR ((gonad OR testis OR testes OR testicular OR ovar*) NEAR/3 (dysfunction* OR insufficien* 
OR failure* OR hypofunct* OR function*))):ab,ti) AND (‘non insulin dependent diabetes 
mellitus’/exp OR (((diabet* OR dm) NEAR/3 (‘type 2’ OR type2 OR ‘type ii’ OR ‘non insulin’ OR 
noninsulin OR ‘adult onset’ OR ‘slow onset’ OR ‘maturity onset’)) OR T2DM OR dmt2 OR dm2 
OR T2-DM OR dm-t2 OR dm-2 OR niddm OR nid-dm):ab,ti) NOT ([animals]/lim NOT [humans]/
lim) NOT ([Conference Abstract]/lim OR [Letter]/lim OR [Note]/lim OR [Editorial]/lim)
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S5 Appendix References of the articles included in the Systematic Review
1. Oh JY, Barrett-Connor E, Wedick NM, Wingard DL. Endogenous sex hormones and the 
development of type 2 diabetes in older men and women: The Rancho Bernardo Study. Diabetes 
Care 2002;25(1):55-60.
2. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, et al. Sex hormone-binding 
globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine 
2009;361(12):1152-63.
3. Chen BH, Brennan K, Goto A, Song Y, Aziz N, You NC, et al. Sex hormone-binding globulin and 
risk of clinical diabetes in American black, Hispanic, and Asian/Pacific Islander postmenopausal 
women. Clin Chem 2012;58(10):1457-66.
4. Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of 
endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal 
women. Journal of Clinical Endocrinology and Metabolism 2009;94(11):4127-35.
5. Onat A, Hergenc G, Bulur S, Ugur M, Kucukdurmaz Z, Can G. The paradox of high apolipoprotein 
A-I levels independently predicting incident type-2 diabetes among Turks. International Journal of 
Cardiology 2010;142(1):72-79.
6. Haffner SM, Valdez RA, Morales PA, Hazuda HP, Stern MP. Decreased sex hormone-binding 
globulin predicts noninsulin-dependent diabetes mellitus in women but not in men. Journal of 
Clinical Endocrinology and Metabolism 1993;77(1):56-60.
7. Soriguer F, Rubio-Martin E, Fernandez D, Valdes S, Garcia-Escobar E, Martin-Nunez GM, et 
al. Testosterone, SHBG and risk of type 2 diabetes in the second evaluation of the Pizarra cohort 
study. European Journal of Clinical Investigation 2012;42(1):79-85.
8. Gambineri A, Patton L, Altieri P, Pagotto U, Pizzi C, Manzoli L, et al. Polycystic ovary 
syndrome is a risk factor for type 2 diabetes: Results from a long-term prospective study. Diabetes 
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hormone-binding globulin concentration as independent risk factor for development of NIDDM: 
12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes 1991;40(1):123-
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10. Boyd-Woschinko G, Kushner H, Falkner B. Androgen excess is associated with insulin resistance 
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and sex hormone-binding globulin in women and risk of metabolic syndrome and type 2 diabetes. 
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13. Hu J, Zhang A, Yang S, Wang Y, Goswami R, Zhou H, et al. Combined effects of sex hormone-
binding globulin and sex hormones on risk of incident type 2 diabetes. J Diabetes 2015.
14. Ding EL, Song Y, Manson JE, Rifai N, Buring JE, Liu S. Plasma sex steroid hormones and risk 
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Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a 
systematic review and meta-analysis
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ABSTRACT
Importance: Estrogen receptor beta (ERβ) has been described to play a role in the female 
cardiovascular system; however, little work has been done to appraise the existing evidence on its 
function.
Objective: To systematically review studies evaluating the role of ERβ in the female cardiovascular 
system and the influence of age and menopause on ERβ functioning.
Methods: Five medical databases (Embase, Medline, Web of Science, PubMed, Cochrane and 
Google Scholar) were used to identify studies. We included female animal and human (women) 
model experimental studies, randomized trials, cohort, case-control and cross-sectional studies 
carried out in female adults that assessed the role of ERβ in the cardiovascular system. 
Results: Of 9472 references, 88 studies met our inclusion criteria: 71 animal model experimental 
studies, 15 human model experimental studies and 2 population-based studies. ERβ-signaling was 
shown to possess vasodilator and antiangiogenic properties by regulating the activity of nitric 
oxide, altering membrane ionic permeability in vascular smooth muscle cells (VSMC), inhibiting 
VSMC migration and by regulating adrenergic control of the arteries. A possible protective effect 
of ERβ-signaling against left ventricular hypertrophy and ischemia/reperfusion injury via genomic 
and non-genomic pathways was suggested in 27 studies. Five studies reported that the vascular 
effects of ERβ may be vessel specific and may differ by age and menopause status. 
Conclusions:  ERβ seems to possess multiple functions in the female cardiovascular system and 
further studies are needed to evaluate whether isoform-selective ERβ-ligands may contribute to 
cardiovascular disease prevention.
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INTRODUCTION
Despite improvements in prevention and treatment, cardiovascular disease (CVD) remains the 
leading cause of death for women worldwide1. Epidemiological studies have revealed that, 
compared with age-matched men, premenopausal women have a lower risk of coronary heart 
disease (CHD) which gradually increases after menopause so that by the sixth decade women have 
the same incidence of CHD as men2. 
The disparity between the incidence of CVD among women in pre- and post-menopause has been 
largely ascribed to the actions of estrogens on the cardiovascular system and, particularly, on the 
vascular endothelium. Extensive evidence from observational studies suggest cardio-protective 
effects of endogenous and exogenous estrogens in premenopausal women3. Similarly, results from 
clinical trials suggest that estrogen therapy started within the first years after menopause reduce 
cardiovascular risk’;4,5 whereas initiation of estrogen therapy many years after menopause  may 
have no or even deleterious cardiovascular effects5,6. Therefore, the vascular response to estrogens 
appears to change with increasing age and to depend on years after menopause. In line with this 
hypothesis, it has recently been suggested that favorable vascular effects of estrogen depend on 
the endothelium and are mediated mainly via estrogen receptors alpha (ERα) and beta (ERβ) 7. 
Therefore, age- and menopause-related endothelial injury, changes in vascular estrogen receptors 
expression, intracellular signaling or genomics may alter the cardiovascular effects of this sex 
hormone8. To date, however, whereas the role of ERα has been extensively studied, the actions of 
ERβ on the cardiovascular system and the age- and menopause-related changes of vascular ERβ 
actions remain unclear and may explain in part the sex differences observed in the influence of 
estrogen on the cardiovascular system9-11. 
Therefore, we aimed to systematically review the literature evaluating the role of ERβ in the 
cardiovascular system in females and the role of age and menopause on ERβ actions. 
METHODS
Literature search and selection criteria
We conducted a systematic search of electronic databases (Embase, Medline, Web of Science, 
PubMed, Cochrane and Google Scholar) until February 5th 2015 (date last searched) to retrieve 
scientific articles assessing the actions of ERβ on the cardiovascular system in females and the age- 
and/or menopause-related changes in vascular ERβ functions, intracellular signaling or its genomic 
actions (Appendix 1, 2 and 3 in the Online Supplemental Material). Reference lists of identified 
articles were also searched and experts in the field were contacted to identify further studies. In 
total, we found 9472 potentially unique relevant citations. 
Studies were included if the following criteria were fulfilled: (1) the study assessed the effect of ERβ 
on vascular reactivity (vasoconstriction, vasodilatation, actions on sympathetic nervous system, 
pulse wave velocity, blood pressure, vasopressin release, carbon dioxide, adenosine), endothelial 
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function and healing (angiogenesis, vascular smooth muscle cell proliferation and migration or 
collagen synthesis), endothelium- derived relaxing factor expression (nitric oxide or expression 
of other endothelium-derived compounds), inflammation, regulation of protein biosynthesis or 
expression and gene expression in the cardiovascular system, atherosclerosis (including proxies 
such as carotid intima-media thickness, coronary artery calcium, ankle brachial index, pulse wave 
velocity) or CVD (CHD, cardiomyopathy, heart failure, cerebrovascular disease, peripheral artery 
disease and inflammatory heart disease), (2) the study was conducted in females (animal or human) 
or (if both females and males were included in the studies) the studies that reported the results 
by gender (or no gender differences were shown), (3) the role of ERβ was assessed by its gene 
deletion, use of estrogen receptor agonist, antagonist, antibodies/vectors and its expression levels 
(4) there was a restriction to the original study results (review and duplicate publications were 
excluded). The step-wise inclusion and exclusion procedure outline is shown in Figure 1.
Study selection and data extraction
Two independent reviewers screened the retrieved titles and abstracts and selected eligible studies. 
Any disagreement between the two reviewers was resolved through consensus or consultation 
with a third independent reviewer. A predesigned data collection form was prepared to extract 
the relevant information from the selected studies, including study design (for human studies), 
sample type (animal species, number of animal/human participants, age and weight of participants, 
tissue used, method to assess ERβ function, outcome measures and results of the study (author’s 
conclusion).
Outcome assessment and statistical methods
For each animal model study, we defined whether a positive or negative effect (no effect) result 
was reported. For population-based studies, we reported the effect magnitude, direction and 
significance. Heterogeneity permitting, we sought to pool the results using a random effects meta-
analysis model. If pooled, the results were expressed as the pooled estimate and the corresponding 
95% confidence intervals.
RESULTS
In total we identified 15283 potentially relevant citations via Embase (n=7161), Medline (n=3240), 
Web of Science (n=4590), PubMed (n=64), Cochrane (n=28), Google Scholar (n=200) (Figure 
1). After exclusion of duplicates, 9472 references were identified and screened.Based on title and 
abstracts, full texts of 389 articles were selected for detailed evaluation. Of those, 88 articles met 
our eligibility criteria and were therefore included in the analysis (Table 1A-B).
General characteristics of included studies
Detailed characteristics of the 88 included studies (86 experimental studies based on animal 
models or human models and 2 population-based studies) are listed in Table 1A-B. There were 71 
experimental studies that used animal models (44 studies used tissue from mice, 21 from rats, 1 study 
used combined tissue from mice and rats and 5 studies used other animal tissue-ewe, rabbit, ovine, 
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Figure 1. Flowchart of studies investigating the role of estrogen receptor beta in the 
female cardiovascular system.
Records identified through database 
searching 
(n = 15283 ) 
Records after duplicates removed 
(n =9472) 
Records screened 
(n =9472) 
Records excluded based on 
title and abstract 
(n =9083) 
Records given full text 
detailed assessment 
(n = 389) 
Full-text articles excluded 
(n = 301) 
 Not the appropriate exposure 
or outcome (n=75) 
 No female tissue or results 
not presented gender specific 
(n=57) 
 Not the appropriate tissue 
(n=14) 
 Results are not ER-beta 
specific (n=22) 
 No full text available (n=6) 
 Other: data extraction 
unfeasible, conference 
abstracts, commentary , 
duplicates (n=127) 
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monkey and swine), 15 experimental studies used human tissue and 2 studies were population-
based studies. Of the 88 studies included in this review, 17 focused on vascular reactivity, 21 on 
endothelial function and healing, 1 on endothelial-derived relaxing factors, 5 on inflammation, 12 
on regulation of protein/gene expression in the cardiovascular system, 1 on atherosclerosis and 31 
of the included studies assessed two or more outcome measures. Among the 88 studies included 
in this review, 4 studies assessed the role of menopause or age on ERβ function whereas no study 
assessed the role of ERβ on cardiovascular disease outcomes in women as endpoint. 
Figure 1. Flowchart of studies investigating the role of estrogen receptor beta in the female cardiovascular 
system.
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Vascular reactivity
Vasoconstriction and vasodilatation  
Seventeen studies focused on the role of ERβ in vasoconstriction or vasodilatation (16 animal 
studies and 1 human study) (Supplemental Table 1A).   
ERβ ligands: Eight studies (7 animal model studies and 1 human model study) showed that 
activation of ERβ via its agonists (diarylpropionitrile (DPN), Biochanin A and Genistein)  was 
associated with increased relaxation of the vessels (thoracic aorta, inferior vena cava, descending 
coronary artery, aorta, mesenteric artery; and chorionic and myometrial arteries)12-19, whereas two 
studies showed no effect of ERβ on vascular reactivity (thoracic aorta and mesenteric artery)20,21. 
Furthermore, two studies showed that the effects of ERβ in vasodilatation are tissue-dependent: 
one study showed that DPN did not have any effect on relaxation of cephalic and thoracic arteries 
but provided a significant relaxation in abdominal arteries22 while the second study showed that the 
effect of DPN was more potent in the aorta than in the mesenteric artery14. 
Studies looking at the mechanism of action of ERβ agonists on vasodilatation were inconsistent. 
Three studies showed an endothelium-dependent effect of ERβ on vessel relaxation16,17,19 while just 
one study reported that the relaxation caused by ERβ actions was largely endothelium independent14. 
Three studies showed that relaxation of the vessel due to ERβ activation was NO-dependent12,18,19 
whereas three other studies showed that vasodilatation due to ERβ activation was not dependent 
on NO 13,14,16. A single study reported that the vessel relaxation induced by DPN was not mediated 
via the thromboxane receptor pathway16. 
Knockout mouse model: Six studies looked at the effect of ERβ gene deletion on vasodilatation 
and showed no consistent results. Three studies reported no effect of ERβ on endothelium-
dependent relaxation in thoracic aorta, the mesenteric artery and femoral arteries23-25. One study 
reported a role of ERβ on vessel relaxation via extracellular signal-regulated kinase/ mitogen 
activated protein kinase (ERK/MAPK) and phosphatidylinositol-3 kinase (PI3K) activation26. Two 
studies reported a direct involvement of ERβ in mediating vasodilatation exerted by estrogen25,27; 
one study reported that ERβ may exert a hitherto unrecognised inhibitory influence on the acute 
dilatory response to estrogen achieved through down regulation of ERα-mediated NO release27. 
Endothelial nitric oxide synthase (eNOS), neuronal nitric oxide synthase (nNOS), inducible 
nitric oxide synthase (iNOS), nitric oxide synthase (NOS) and nitric oxide (NO)
Ten studies overall (6 animal model studies15,16,23,28-30 and 4 human model studies 31-34) focused on 
the role of ERβ on eNOS (6 studies), nNOS (1 study), iNOS (2 studies), NOS (1 study) and NO 
expression (6 studies) (Supplemental Table 1B). 
eNOS: Two studies using ERβ agonists 31,34 reported an increase in eNOS expression due to the 
activation of ERβ whereas another study28 using ERβ antagonist showed a decrease in eNOS 
expression. Three knockout mouse model studies reported a decrease in eNOS expression 15,30 and 
phosphorylation 29 due to the deletion of the ERβ gene.
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iNOS, nNOS and NOS: Activation of ERβ via an ERβ agonist did not have any effect on iNOS or 
nNOS expression31 but the use of an ERβ antagonist was associated with lower iNOS expression28. 
One study examined the correlation between ERβ expression in the internal mammary artery and 
NOS but found none32.
NO: Increase in NO expression with activation of ERβ via ERβ agonist was reported in two 
studies16,34 whereas two other studies showed no change in NO expression31,33. One study15 reported 
a decrease in NO production due to the deletion of ERβ gene whereas another study reported no 
effect 23.
Adrenergic control of arteries
ERβ ligands: One study (using human tissue) (Supplemental Table 1B) investigated the role of 
ERβ agonist in α-2C adrenoreceptors expression and reported an increased expression of these 
receptors35 (α-2C adrenoreceptors are located on the vascular smooth muscle cells of certain blood 
vessels and binds both norepinephrine and epinephrine36. Its activation causes vasoconstriction of 
certain arteries, including the coronary artery37,38). 
Knockout mouse model: One study examined the effect of ERβ gene deletion on adrenergic 
control of arteries (mice femoral tissue) and showed no effect39 (Supplemental Table 1B). 
Blood pressure
ERβ ligands: Three studies (animal models) (Supplemental Table 1C) examined the effect of 
ERβ agonists  8β-VE2 and DPN  on blood pressure: of these, two studies showed a decrease in 
systolic and diastolic blood pressure in the aorta and one study showed a non-significant decrease 
in arterial pressure in the coronary arteries40-42. 
Knockout mouse model: There were two studies that examined the role of ERβ gene deletion 
on blood pressure regulation or hypertension (Table 2 and Supplemental Table 1B); one study 
reported that deletion of the ERβ gene was associated with hypertension (aorta tissue)11 whereas 
the other did not report any effect on systolic blood pressure (coronary artery tissue)43.
Overall, the studies looking at ERβ ligands suggest that activation of ERβ via ERβ agonist may 
cause relaxation, and therefore might prevent the pathological effect of excessive vasoconstriction; 
but this may depend on the type of vessel (Table 2). The studies from knockout mouse models 
are inconsistent in this respect (Table 2). The included studies suggest for both an endothelium-
dependent and -independent action of ERβ on vascular reactivity; but the results are contradictory 
on the mechanisms involved. Nevertheless, the included studies that used ERβ ligands or knockout 
mouse models are consistent in showing a role of ERβ on eNOS production, which might suggest 
that ERβ is responsible solely for eNOS-derived NO production. The possible mechanisms of 
action of ERβ on vascular reactivity are depicted in Figure 1 and may include eNOS, ERK/MAPK 
and PI3K signalling and adrenoreceptors. In line with the dilatory effects of ERβ, the included 
studies (although not conclusive) suggest that reduced blood pressure may be produced by the 
activation of ERβ. 
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Table 2: Summarizing the evidence from the studies included in this systematic review on the role of estrogen 
receptor on Vascular reactivity, endothelial functioning and healing and inflammation by the method used to 
assess the role of estrogen receptor beta function
Vasodilation
Increased No effect Decreased
ERβ agonist
No of studies using animal tissue 8 2 0
No of studies using human tissue 1 0 0
Knockout mice
No of studies using animal tissue 3 3
Endothelial nitric oxide synthase
Increased No effect Decreased
ERβ agonist
No of studies using animal tissue 1* 0 0
No of studies using human tissue 2 0 0
Knockout mice
No of studies using animal tissue 0 0 3
Nitric oxide synthase
Increased No effect Decreased
ERβ agonist
No of studies using animal tissue 1 0 0
No of studies using human tissue 1 2 0
Knockout mice
No of studies using animal tissue 0 1 1
Blood pressure
Increased No effect Decreased
ERβ agonist
No of studies using animal tissue 0 0 3**
No of studies using human tissue 0 0 0
Knockout mice
No of studies using animal tissue 1 1*** 0
Angiogenesis (arteriogenesis, capillary formation/density, re-endothelialisation)
ERβ agonist Increased No effect Decreased
No of studies using animal tissue 0 0 1
No of studies using human Tissue 0 1 3
Knockout mice
No of studies using animal tissue 3 1
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Affected protein and gene expression associated with angiogenesis
Yes No
ERβ agonist
No of studies using animal tissue 3 0
No of studies using human Tissue 3 1
Knockout mice
No of studies using animal tissue 4 0
Affected smooth muscle cell proliferation
Yes No
ERβ agonist
No of studies using animal tissue 3 1
No of studies using human Tissue 0 1
Knockout mice
No of studies using animal tissue 1 1****
Affected smooth muscle cell apoptosis and migration
Yes No
ERβ agonist
No of studies using animal tissue 4 0
No of studies using human Tissue 1 0
Knockout mice
No of studies using animal tissue 1 0
Affected inflammation 
Yes No
ERβ agonist
No of studies using animal tissue 2 3
No of studies using human Tissue 1 0
Knockout mice
No of studies using animal tissue 0 0
*One study used ERβ antagonist and showed that deactivation of ERβ decreased eNOS expression.
**One study showed a non-significant decrease in arterial pressure in the coronary artery with the use of ERβ agonist 
*** One study examined only systolic blood pressure 
****One study investigated whether the effect of estradiol on smooth muscle cells proliferation was mediated via estrogen 
receptor beta and found that estrogen receptor beta does not mediate the effects of estradiol on smooth muscle cells 
proliferation.  
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Angiogenesis 
Arteriogenesis, capillary formation/density, re-endothelialization
ERβ ligands: Five studies (1 animal model study44 and 4 human model studies45-48) focused on 
the role of ERβ agonists (DPN, Ginsenoside Rb1) in angiogenesis. Four studies44,46-48 showed 
anti-angiogenic effects of the ERβ agonist whereas one study 45 reported no effect on capillary 
formation (Supplemental Table 2A). 
Knockout mouse model: Three studies (animal models) investigated the role of the ERβ gene 
deletion on angiogenesis. Two of these studies49,50 reported no effect and one study 51 reported a 
reduction in capillary density after the deletion of the ERβ gene (Supplemental Table 2A). Also, 
one study52 showed that ERβ did not mediate the effect of estrogen in angiogenesis (Supplemental 
Table 2A). 
Protein and gene expression associated with angiogenesis
ERβ ligands: Seven studies (4 animal model studies 17,53-55 and 3 human model studies45,47,48) 
focused on the role of ERβ agonists on the expression of proteins or genes associated with 
angiogenesis (Table 2  and Supplemental Table 2B). One study17 reported that activation of ERβ 
was associated with attenuation of vascular cell adhesion protein-1 (VCAM-1) and tumor necrosis 
alpha (TNF-α) on the rat abdominal aorta whereas no effect was shown on intracellular adhesion 
molecule (ICAM). In contrast, activation of ERβ affected the expression of ICAM in human 
tissue47. One study demonstrated that ERβ activation was associated with decrease of vascular 
endothelial growth factor (VEGF) and hypoxia-inducible factor 1α (which has been shown to 
increase VEGF expression) in the murine middle cerebral artery53. Furthermore, one study reported 
that ERβ activation was associated with increased claudin-5 protein and mRNA content55. Two 
studies examining the role of ERβ activation on s-nitrosylation (SNO) showed contradictory 
results: one study 54 in animal tissue reported increase in SNO protein expression whereas the 
other study 45 using human tissue reported no effect. In tissue of premenopausal women, activation 
of ERβ was associated with activation of pigment epithelium-derived factor (PEDF)48. One study 
looked at genomic effects in human endothelial cells from the endometrium, myometrium and 
placenta. It reported that ERβ activation affected gene expression for 22 out of 99 genes associated 
with angiogenesis (Growth factors: GRWANG, CXL12, ECGF1, EDIL3, FGF2, GRN, MDK, 
PDGFB, TGFA, VEGF; Inhibitors: CXCL10, FLT1, IFNB1, SEMA3F, SERPINF1; Markers: 
CEACAM1, HEY1, Target: ENPP2, NRP2, TIE1, Lymph-angiogenesis: FIGF, FOXC2) 47. 
However, this study also showed that there were very few ERβ-dependent genes common to more 
than one of the three cell lines used and that several of the shared ERβ-dependent genes identified 
were regulated in opposite directions in endometrium and myometrium cell lines47.  
Knockout mouse model: Four studies (3 animal model studies15,56 and 1 human model 57) looked 
at the effect of ERβ gene deletion on protein or gene expression associated with angiogenesis 
(Supplemental Table 2B). Two animal studies showed that deletion of the ERβ gene was associated 
with a decrease in both VEGF and its kinase insert domain receptors (KDR); and with a reduction 
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in fibroblast growth factor-2 (FGF-2)15. One animal study showed an interaction between ERβ and 
specificity factor-1 (Sp1) site of the claudin-5 receptor, which consequently induced an increase 
in claudin-5 expression 56. One human study showed an inverse association between ERβ gene 
deletion in cyclo-oxygenase-2 (COX-2) RNA and its protein expression57.  
Collectively, these studies provide evidence for anti-angiogenic effects of ERβ agonists; whereas 
knock-out mouse models reported inconsistent results on the role of ERβ in angiogenesis (Table 
2). Both studies using ERβ ligands or knockout mouse models were consistent in showing ERβ to 
affect VEGF, claudin-5 and FGF-2 in protein and gene expression level; all of which are associated 
with angiogenesis. However, similar to the findings on vascular reactivity, the role of ERβ on 
angiogenesis may be vessel-specific47. Angiogenesis is the physiological process of formation of 
new blood vessels from pre-existing ones and therefore may be a target for combating diseases 
characterized by either poor vascularization (e.g., ischemic diseases) or abnormal vasculature 
(e.g., atherosclerosis). ERβ antagonists, by enhancing capillary growth and increasing blood 
perfusion in ischemic tissue, can be a novel treatment in cardiac and peripheral ischemia. On the 
other hand, ERβ agonists may be used in the treatment of atherosclerosis. Since neovascularization 
is a key factor in the development of advanced plaques and is considered a risk factor for plaque 
rupture58, ERβ agonists may be used to improve plaque stability and reduce plaque progression by 
inhibiting angiogenesis. In fact, targeting ERβ with agonists has been reported to be valuable in 
the treatment of cancer by supressing vascularization59.
Vascular smooth muscle cell proliferation, apoptosis, migration and inflammation 
Vascular smooth muscle cell proliferation, apoptosis, migration
Eight studies overall (6 animal model 15,17,29,44,60-63 and 2 human model studies64,65) examined the role 
of ERβ on smooth muscle cell (SMC) proliferation (6 studies), apoptosis (2 studies)  and migration 
(3 studies) (Supplemental Table 2C). 
ERβ ligands: An inhibitory effect of ERβ agonists on SMC proliferation were reported in 3 
studies17,44,61 whereas two studies reported no effect60,64. Two studies focused on the role of ERβ 
agonists on cell apoptosis and showed enhancement of this process with activation of ERβ 60,65. 
Three studies reported an anti-migratory effect by ERβ 17,61,62. Two studies showed this effect was 
mediated via ERβ playing a role on the phosphorylation of p38 60,65 whereas two other studies 
reported no effect of ERβ on ERK phosphorylation in the mediation of anti-migration60,64. 
Knockout mouse model: One study showed that ERβ may repress proliferation of SMC by means 
other than NO signalling63 while another study reported ERβ promoting the activation of pro-
apoptotic molecules15. One study in humans focused on the role of ERβ on estradiol signaling in 
SMC proliferation and found no effect66. 
Vascular smooth muscle cell and inflammation
ERβ ligands: Two animal studies67,68 focused on the role of ERβ agonist DPN on inflammation 
in vascular endothelium and SMC and reported an inhibitory effect of ERβ on TNF-α induced 
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inflammation (Supplemental Table 3). Another study using human endothelial cells from the 
endometrium, myometrium and placenta found that ERβ activation affected gene expression in 14 
of the 92 genes associated with inflammation (Lipase: PCLB2; Kinase: MAPK3; Prostaglandin 
metabolism: PTGS1, PTGS2, TBXAS1; Factor: NFKB1; GPCR Receptor: LTB4R, PTAFR, 
PTGIR, TBXA2R: Interleukin receptor: IL1RL1; Adhesion Molecule: ICAM and ITGB2)47. 
One study reported no effect of ERβ antagonist 2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]
pyrimidin-3-yl]phenol (PHTPP) on prostacyclin 69(Supplemental Table 3). Similarly, although 
not endothelium/SMC specific, two studies examining the role of DPN in the thoracic aorta and 
left anterior descending artery reported no effect of this agonist on TNF-α, interleukin-1 beta, 
C-reactive protein and p-cofilin levels 20,70(Supplemental Table 3). No studies were found to use a 
knockout mouse model to examine the role of ERβ in inflammation.  
Overall, the results from studies using either ERβ-ligands or knockout mouse models are consistent 
in supporting anti-migratory and pro-apoptotic effects of ERβ in SMC. Although no consistency 
was found on the role of ERβ in SMC proliferation and inflammation (Table 2), the included 
studies suggest a protective effect of ERβ against TNFα-induced inflammation. SMC migration 
and apoptosis are key factors in certain vascular diseases. Restenosis, a common adverse event 
of endovascular procedures to treat the vascular damage from atherosclerosis, is characterized 
by the sequence of inflammation and SMC proliferation and migration; whereas the role of SMC 
apoptosis in restenosis remains unclear58,71. Also, intimal SMC apoptosis in advanced atherosclerotic 
plaques may promote plaque rupture while medial apoptosis may promote aneurism formation71. 
Furthermore, SMC apoptosis may be directly pro-inflammatory by triggering the release of 
chemoattractant and cytokines from inflammatory cells71. Therefore, targeting ERβ through ERβ 
agonists may be valuable in the treatment of restenosis. Similarly, the use of ERβ antagonists may 
prove to be useful in the treatment of advanced atherosclerotic lesions and aneurisms. 
Proteins and genes in the cardiovascular system
Twenty seven studies (in animal models) focused on the role of ERβ signalling in cardiovascular 
targets (Supplemental Table 4). Among them, 21 studies10,30,43,49,57,60,72-87 investigated the molecular 
mechanism of ERβ cardioprotective actions against left ventricular hypertrophy and ischemia-
reperfusion injury. ERβ in the heart tissue was shown to play multiple roles such as: calcium 
homeostasis43,72,73,81, regulation of lipoprotein lipase activity77,83 and regulation of fatty acid 
metabolism gene expression30, S-nitrosylation protein expression57, activation of the functional 
estrogen response element of lipocalin-type prostanglandin D synthase79, bone morphogenetic 
protein-4 expression87, levels of ventricular atrial natriuretic peptide43,74 and heat shock protein 
27 as well as expression of 70 proteins78,82,85. Also, ERβ was reported to play a role in cardiac 
fibrosis and inflammation via genomic and non-genomic actions10,49,76,78,80,82,84,86. Furthermore, ERβ 
was shown to exert cardioprotective effects through regulation of apoptotic proteins and gene 
expression9,10,60,74,75,78, modulation of genes involved in mitochondrial modelling9,76,88, cytoskeletal 
regulation75,78,86,88, oxidative stress76,88, glucose and insulin pathways 75,78 and NO synthesis78. Two 
studies reported no role of ERβ on stromal cell-derived factor-1 production89 or on corticotrophin-
releasing hormone receptor 290 whereas one study, by using plasma from retro-orbital sinus plexus, 
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showed that deficiency of ERβ may affect the energy metabolism of platelets resulting in greater 
production of thrombogenic microvesicles in the circulation 91. In contrast to the study performed 
in hearts 78, in which ERβ selective agonist upregulated 122 genes and down-regulated 23 genes, 
a gene array study comparing gene expression in ovariectomized mice aorta treated with estrogen 
showed that 90% of the genes showing an estrogen-mediated decrease, were ERβ dependent88. 
Role of age and menopause status
Ovariectomy was reported to decrease relaxant response of ERβ-agonist DPN in the rat thoracic 
aorta; and induction of both ovariectomy and diabetes had synergistic effects on decreasing this 
relaxant response12. Also, two studies (one animal 92 and one human study93) focused on the role of 
ERβ in inflammation as a function of age and menopausal status. One study showed that estrogen 
through ERβ may inhibit inflammation in young but not in old mice92, whereas another human 
study showed an increased linear trend in ERβ expression with ageing and years since menopause, 
as well as a positive correlation between expression of ERβ and inflammatory markers such as 
interleukin-8 and TNF-α93. In contrast, one (cross-sectional) population-based study found that 
ERβ correlated with coronary calcification and atherosclerosis and tended to be greater correlated 
in women who reported no use of hormone replacement therapy. However, this correlation did not 
differ by menopausal status94.  
Collectively, these results support the notion that the actions of ERβ may depend on age, menopausal 
status and diabetes.
DISCUSSION
Based on the findings from 88 studies, the present review shows that ERβ has multiple functions 
that may contribute to protect the cardiovascular system in women. However, the majority of 
studies have been conducted in animals and none has evaluated the role of ERB function and 
treatment-related strategies on cardiovascular outcomes. The cardiovascular effects of ERβ 
signaling could occur through multiple mechanisms including a direct effect on the vessel wall. 
ERβ signaling may cause vasodilation (Figure 2), and therefore prevent the pathological effect 
of excessive vasoconstriction by regulating the bioavailability of nitric oxide, altering membrane 
ionic permeability in vascular smooth muscle cells and by regulating adrenergic control of the 
arteries. Also, ERβ may have angiogenic properties that may protect against vascular injury by 
inhibiting vascular smooth muscle cell migration. (Figure 2). Furthermore, the data from this 
systematic review suggest that ERβ may have anti-inflammatory properties mainly by suppressing 
TNF-α-induced inflammation. Supporting the role of ERβ in vasodilatation, wound healing, and 
inflammation, several population-based studies have reported an association between ERβ gene 
polymorphisms with blood pressure, inflammatory markers (e.g., TNF-α, fibrinogen) and venous 
ulceration in women95-101. Furthermore, various studies have shown tht activation of ERβ has 
resulted in suppression of IL-6 promoter activity in human endothelial cancer cells in vitro and to 
play a role in regulation of neutrophil infiltration following acute injury102,103.  
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Vessel-specific actions of ERβ
The vascular effects of ERβ may be vessel-specific, and therefore ERβ may play a role in site-
specific vascular diseases such as carotid intimal hyperplasia, peripheral artery disease and 
thoracic and abdominal aortic aneurysm as well as in localized atherosclerotic disease. Targeting 
ERβ with selective receptor agonists or antagonists may be of additional benefit in the treatment 
of localized vascular disease. For instance, specific ERβ agonists might be a therapeutic option in 
occlusive artery disease, whereas ERβ antagonist may be useful in vascular disease characterized 
by arterial wall distention and aneurysm. The combination of ERβ ligands with specific targeting 
or drug delivery techniques such as drug-eluting stents and perivascular gel might be effective 
in modulating the activity of ERβ in a specific blood vessel without altering other vessels in the 
systemic circulation. 
Figure 3. Possible mechanisms of estrogen receptor beta actions in cardiomyocytes. CAMP, cyclic adenosine 
monophosphate; ERK, extracellular signal-regulated kinase; PI3K, phosphatidylinositol-3 kinase, PKA, 
protein kinase A. 
Figure 3. Possible mechanisms of estrogen receptor beta actions in cardiomyocytes.
CAMP, cyclic adenosine monophosphate; ERK, extracellular signal-regulated kinase; 
PI3K, phosphatidylinositol-3 kinase, PKA, protein kinase A.
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ERβ in left ventricular hypertrophy and ischemic vascular diseases
The selected studies included in this systematic review indicate a possible protective effect of ERβ 
signaling against left ventricular hypertrophy and ischemia/reperfusion injury via genomic and 
non-genomic pathways (Figure 3). ERβ may play a role in the phosphorylation of p38-MAPK, 
activation of atrial natriuretic factor, inflammatory response, cardiac fibrosis, nitric oxide synthesis 
and in the regulation of several genes involved in cell metabolism and mitochondrial modelling. 
Additionally, ERβ was shown to exert the role of gatekeeper in the genomic response of the heart to 
pressure overload, and may thus play a protective role against cardiac hypertrophy76. These results 
are in line with the population-based studies showing an association between polymorphisms of 
ERβ gene and homocysteine, nitric oxide, ATP-binding cassette transporter A1 gene expression, 
left ventricular mass and wall thickness and with the risk of myocardial infarction in women104-108. 
Based on these experimental data from animal and human models, subsequent clinical studies are 
warranted to test if the results of these experimental investigations can be reproduced in interventions 
conducted in humans and to explore whether isoform-selective ERβ ligands could constitute an 
effective target for cardiovascular disease treatment. ERβ might confer the cardioprotective effects 
of estrogen while avoiding its specific adverse effects on other tissues such as those of the uterus 
and breast.  In fact, targeting ERβ with agonists has be shown to be valuable in the treatment of 
certain types of cancers, diminishing several aspects of the malignant process such as proliferation, 
vascularization, and dissemination109-111.
Role of age, menopause and diabetes in the actions of ERβ
Despite the evidence put forth, the effect of age on the regional distribution of ERs in the heart 
vessels remains unclear. The expression of ERβ nay be vulnerable to the effects of age not only 
in the cardiovascular system but also in other systems such as the nervous system112. It has been 
suggested that the change in the expression of ERs with ageing could be due to variation in 
methylation-associated inactivation of ER gene promoter in various types of tissues, including 
those of the cardiovascular system113,114. Similarly, loss of locally synthesized estrogen mainly 
after menopause can affect the expression of ERβ112. As also noted in this systematic review, ERβ-
mediated vascular actions may be affected by age, menopause status and diabetes. In line with 
this, it has been reported that diabetes undermines estrogen control of inducible NO synthase 
function in aortic smooth muscle cells through overexpression of ERβ115. In this respect, studying 
the differences in ERβ distribution and activity in the cardiovascular system of young versus old 
animals, in intact versus ovariectomized females or in non-diabetic and diabetes-induced females 
could provide further evidence on the potential usefulness of a specific estrogen receptor agonist/
antagonist to be used during and after menopause. Furthermore, it may be of interest to investigate 
the mechanisms regulating the localization of ERβ; for instance, future research may focus on 
whether age-related alterations in NO signaling can contribute to the age-related differences in 
ERβ expression and signaling.
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Animal models: ERβ ligands versus knockout mouse models
Notably, the protective role of ERβ in the cardiovascular system was consistently shown in studies 
using ERβ agonist/antagonist whereas some discrepancies with the results of the studies using 
knockout mice were observed (Table 2). These differences could be related to the animal model 
used and/or different tissue examined. In knockout mice studies, since ERβ has a lower affinity 
for estradiol, estradiol concentrations may not be sufficiently high to affect ERβ signaling. In 
contrast, local administration of ERβ agonists can result in more potent activation of ERβ signaling. 
Furthermore, the intervention at a certain time point in the knockout mice models may result in 
potential compensatory mechanisms which may ultimately affect ERβ signaling. Also, since the 
discovery of ERβ, certain mice strains have been genetically modified to delete their ERβ gene, 
which have shown markedly different phenotypes116,117 This may also add to the discrepancies 
found in the reported results116. Therefore, further research is required to better elucidate the 
differences between studies using animal models and ERβ agonists/antagonists. 
Limitations 
To our knowledge, this is the first systematic review on the subject that critically appraised the 
literature following an a priori designed protocol with clearly defined inclusion and exclusion 
criteria. After a systemic search in major electronic databases, few narrative or expert reviews 
evaluating the role of ERβ in the cardiovascular system were found8,118-120. They were all expert or 
narrative reviews without a systematic search. Nevertheless, some limitations from the included 
studies in this review merit careful consideration. Some of the results should be interpreted with 
cautions. For instance, six of 15 human studies included in this review used umbilical vein endothelial 
cells for which the sex of the donor was not reported. 121This may explain some of the discrepancies 
in the reported results. Although every effort has been made to undertake a comprehensive search 
of the published and unpublished literature, we cannot exclude the possibility of publication bias 
from underreporting of negative findings. Furthermore, a meaningful quantitative pooling of the 
existing data was unfeasible due to different animals and tissues used as samples in the included 
studies, heterogeneity in the input parameters, assumptions and the study designs.  
Conclusion
In summary, this systematic review summarizes all the available evidence on the role of ERβ 
signaling in the female cardiovascular system through multiple mechanisms. Although these 
findings contribute with the generation of hypotheses and the identification of potential therapeutic 
targets, the majority of the studies were conducted in animals and further evaluations in humans 
are warranted.
Supplementary Material can be found online: http://www.maturitas.org/article/S0378-
5122%2816%2930009-3/pdf
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ABSTRACT 
We performed a systematic review and meta-analysis of the observational or interventional studies 
assessing the association of vasomotor symptoms (hot flushes and night sweats) with various 
cardiovascular risk markers (systolic (SBP) and diastolic blood pressure (DBP), hypertension, 
total cholesterol, body mass index (BMI), and measures of subclinical atherosclerosis), in peri-
menopausal, menopausal, or postmenopausal women. Eleven unique studies were identified with 
data available on 19,667 non-overlapping participants.Pooled analysis showed that women with 
hot flushes, compared to those without, tended to have significant higher levels of SBP (mean 
difference (MD): 1.95 mmHg (95%CI, 0.27 to 33.63)), and DBP (MD 1.17 mmHg (95%CI, 
-0.21 to 2.54)) and higher odds of having hypertension (OR: 1.18, 95%CI: 0.93 to 1.51), albeit 
non-significant. Similarly, women who reported night sweats compared to those who did not, 
had significant higher levels of SBP, (MD: 1.33 mmHg (95%CI, 0.63 to 2.03)), DBP (MD: 0.55 
mmHg (95%CI, 0.19 to 0.91)), total cholesterol (MD: 0.17 mmHg (95%CI, 0.03 to 0.31)) and BMI 
(MD: 0.64 mmHg (95%CI, 0.47 to 0.80)).Vasomotor symptoms in women were not associated 
with measures of subclinical atherosclerosis. Women with vasomotor symptoms may have an 
unfavorable cardiovascular risk profile compared to women without vasomotor complaints. 
4.3
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INTRODUCTION
Menopause has been linked to increased risk of cardiovascular disease (CVD) among older women 
1-3. During their menopausal transition, women commonly report vasomotor symptoms (VMS), 
which typically include hot flushes along with night sweats4. VMS are known to impair the quality 
of life5,6 principally owing to irritability, fatigue, a generally depressed mood4,7 and disturbed sleep 
8. Up to 80% of women experience hot flashes and night sweats, mainly in the peri-menopausal 
and early post-menopausal period 9.  VMS remain the leading reason menopausal women seek 
menopause-related healthcare 8,10,11.
In addition to a decreasing quality of life in menopausal women, a growing body of evidence 
suggests a link between VMS and cardiovascular risk profile 12-17. Although many studies have 
reported associations between VMS and adverse cardiovascular risk profile, 15,16 others either failed 
to show such associations 18-21 or point towards a favorable link between VMS and cardiovascular 
parameters 22-24. Although the relation between VMS and cardiovascular risk is an area of active 
inquiry, interpretation of the often conflicting findings remains a challenge. As CVD remains the 
leading cause of death for women worldwide, 25-27 assessing the published evidence on VMS and 
cardiovascular risk markers in a systematic manner is of particular importance. 
In the present study, we have synthesised all available evidence of VMS in relationship with various 
conventional cardiovascular risk factors such as systolic (SBP) and diastolic blood pressure (DBP), 
hypertension, total cholesterol, body mass index (BMI) and measures of subclinical atherosclerosis.
METHODS
Data sources, search strategy and eligibility criteria
This review was conducted using a predefined protocol and in accordance with the PRISMA and 
MOOSE guidelines28,29 (eAppendix A and B). Relevant studies, published before February 12th, 
2015 (date last searched) were identified by two independent authors, through electronic searches 
without language restriction in MEDLINE, EMBASE, and Web of Science databases. Electronic 
searches were supplemented by scanning reference lists of articles identified for all relevant studies 
(including review articles), by hand searching of relevant journals and by correspondence with study 
investigators and experts in the field. The computer-based searches combined terms related to the 
exposure (e.g., hot flushes, night sweats) and outcomes (e.g., blood pressure, cholesterol, coronary 
artery calcification (CAC)). Details on the search strategy are provided in Appendix C. Studies 
were sought that had reported on associations of vasomotor symptoms (defined as hot flushes and/
or night sweats) with cardiovascular risk markers, including SBP, DBP, hypertension, serum total 
cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, BMI, 
CAC and carotid intima-media thickness (IMT).
Study selection 
Observational or interventional studies in humans with relevant data were eligible for inclusion if 
they reported on associations of any VMS (defined above) with cardiovascular risk factors in peri-
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menopausal, menopausal, or postmenopausal women. Two independent reviewers working in pairs 
screened the titles and abstracts of all initially identified studies according to the selection criteria. 
A third reviewer was available in case of disagreements. Full texts were retrieved from studies that 
satisfied all selection criteria. Reference lists of selected studies and relevant reviews identified on 
the topic were searched for additional publications. 
Data extraction 
Data were extracted by two independent authors and a consensus was reached with involvement of 
a third. A predesigned data extraction form was used to collect relevant information. This included 
questions on study size; study design; baseline population; location; age at baseline; duration of 
follow-up (for cohort studies); reported degree of adjustment (defined as ‘+’when risk estimates 
were adjusted for age and/or sex; ‘++’ further adjustment for established vascular risk factors (eg, 
age, sex, BMI, smoking status, lipids, hypertension, history of cardiometabolic disease); type of 
outcome and reported risk estimates (mean differences for continuous outcomes and odds ratios 
for categorical outcomes). Additionally, in the case of multiple publications, the most up-to-date or 
comprehensive publication was included. 
Assessing the risk of bias
Bias within each individual study was evaluated using the validated Newcastle-Ottawa Scale30, 
a semi-quantitative scale designed to evaluate the quality of nonrandomized studies. Study 
quality was judged by two independent reviewers based on the selection criteria of participants, 
comparability of cases and controls, and exposure and outcome assessment. Studies that received a 
score of nine stars were judged to be of at low risk of bias; studies that scored seven or eight stars 
were considered at medium risk; those that scored six or less were considered at high risk of bias. 
Statistical analysis
The inverse variance weighted method was used to combine mean differences (for continuous 
outcomes) and odds ratios (for categorical outcomes) to produce pooled respective estimates using 
random effects models to allow for between-study heterogeneity. Heterogeneity was assessed using 
the Cochrane χ2 statistic and the I2 statistic. Publication bias was evaluated through a funnel plot 
and Egger’s test. All tests were two-tailed and p-values of 0.05 or less were considered significant. 
STATA release 12 (Stata Corp, College Station, Texas) was used for all statistical analyses.
RESULTS
Literature search
A total of 13,636 potentially relevant citations were retrieved from electronic searches 
(Supplemental Figure 1). After the initial screening based on titles and abstracts, 103 articles in 
full text were extracted for further evaluation. In the full-text assessment, 16 of these articles and 11 
unique studies 12-15,31-37 met our inclusion criteria and were included in the current systematic review 
and meta-analysis. Of the 87 articles excluded following full text evaluation, 60 were based on 
unrelated exposures, 14 did not report relevant risk estimates and 13 were duplicate publications. 
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Of the 11 unique studies included in this review, 8 studies were solely cross-sectional and 2 were 
based solely on a prospective cohort design, whereas one remaining study published both a cross-
sectional and a separate prospective cohort report.
Characteristics of the included studies 
Characteristic details of the included studies are summarised in Table 1. Overall, data were 
available on 19,667 unique participants. The age of the participants at baseline across the included 
studies ranged from 18 to 79 years. Three studies were based in Europe, seven in North America 
and one in Asia-Pacific region. The year of baseline survey ranged in these studies from 1983 to 
2012. Overall, seven studies recruited subjects from healthcare registers, two from clinical trial 
registers, one involved participants from academic institutions and one from various marketing 
registers. All three cohort studies were judged as high-quality, and the quality varied across the 
cross-sectional studies.
Vasomotor symptoms, blood pressure and hypertension
Five studies with a total of 13,195 participants reported on the association of VMS (presence of hot 
flushes or night sweats) with levels of SBP. Pooled analysis showed that women who experienced 
hot flushes or night sweats compared to those who did not, tended to have a significant higher 
overall level of SBP [mean difference for hot flushes: 1.95 mmHg (95% CI, 0.27 to 3.63); mean 
difference for night sweats: 1.33 mmHg (95% CI, 0.63 to 2.03); Figure 1]. The pooled analysis 
for DBP outcome, based on four studies and including data from 13,041 total participants, showed 
a non-significant increase of 0.83 mmHg (95% CI, -0.12 to 1.78) in women reporting hot flushes 
compared to those without, and a significant higher DBP for women experiencing night sweats 
compared to those who did not (mean difference: 0.55 mmHg (95% CI, 0.19 to 0.91) (Figure 2). 
In the pooled analysis (based on available data from two studies with 6,126 total participants) 
women who reported to have hot flashes tended to have higher risk of having hypertension (OR: 
1.18, 95% CI: 0.93 to 1.51, Figure 3), albeit non-significant. The association between night sweats 
and hypertension was focus of only one paper which showed higher odds of having hypertension 
for women reporting night sweats compared to those without (OR: 1.17, 95% CI: 1.04 to 1.31).15
Vasomotor symptoms and blood lipids
Only one study reported on the association between presence of hot flushes and serum total 
cholesterol and showed significant higher levels of total cholesterol in women who experienced hot 
flashes compared to those who did not [mean difference: 0.27 mmol/L (95% CI, 0.15 to 0.39)].15 
Similarly, there was only one study to examine the association between presence of hot flushes and 
LDL-cholesterol, HDL-cholesterol and triglycerides reporting higher levels of these blood lipids 
in women experiencing hot flushes compared to those without35. Relevant data on night sweats and 
total cholesterol were available in two European studies comprising of 11,380 total participants 
(Figure 4). In these studies, symptoms of night sweats were associated with significant increased 
total cholesterol level of 0.17 mmol/L (95% CI, 0.03 to 0.31) compared to women with no symptoms 
of night sweats(Figure 4). Furthermore, two studies, comprising 9,159 total participants, examined 
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the association between night sweats and LDL-cholesterol, HDL-cholesterol and triglycerides 
(Supplemental Figure 2-4). Women who reported night sweats compared to those who did 
not, had a significant higher levels of LDL-cholesterol [mean difference: 0.07 mmol/L (95% CI, 
0.01 to 0.13); (Supplemental Figure 2)] and tended to have higher overall levels of HDL [mean 
difference: 0.33 mmol/L (95% CI, -0.42 to 1.08); (Supplemental Figure 3)] and triglycerides 
[mean difference: 3.09 mmol/L (95% CI, -3.01 to 9.19); (Supplemental Figure 4)], albeit non-
significant. The severity of VMS combined (hot flushes and night sweats) in relation to blood lipids 
was focus of only one study, which reported positive associations between the severity of VMS, 
LDL and triglycerides.38
Figure 1. Association of hot flushes with levels of blood pressure
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Figure 2. Association of night sweats with levels of blood pressureFigure 2. Association of night sweats with levels of blood pressure
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Figure 3. Association of night sweats with hypertension
Assessment of heterogeneity, X2 3= 4.18, I2=76%, 0 to 95%, P = 0.65. +, adjusted for 
age and /or sex; ++, adjusted for vascular risk factors.
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Figure 5. Association of night sweats with body mass index 
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Vasomotor symptoms and BMI
One study examined the association between presence of hot flushes and BMI and showed women 
who experienced hot flushes to have higher BMI [mean difference: 0.62 kg/m2 (95% CI, 0.04 to 
1.19)].15 Furthermore, in the pooled analysis of night sweats and BMI reported in two studies, 
there was a significant increase in the levels of body mass index of women experiencing night 
sweats compared to women without [mean difference: 0.64 kg/m2 (95% CI, 0.47 to 0.80); Figure 
5]. Furthermore, there was only one study to report on the severity of VMS combined in relation to 
BMI and showed that the severity of VMS was associated with higher levels of BMI.38
Vasomotor symptoms and surrogate CVD markers 
All studies reporting on the association of hot flushes, night sweats or combined (presence, history, 
duration or severity) and CAC were consistent in showing no association14,31,36,37. One study showed 
no cross-sectional association between severity of hot flashes or night sweats and IMT 37. Another 
study showed a positive cross-sectional association between number of days hot flashes or night 
sweats were experienced and IMT but no association with the progression of IMT 39.  Because of 
different exposure definition and outcome assessments used in these studies, pooling on CAC or 
IMT as outcome was not feasible.
Assessment of heterogeneity and publication bias
There was evidence of between-study heterogeneity across the studies (I2 estimates ranged from 
0% to 96% in these meta-analyses). Furthermore, visual examination of Begg’s funnel plots for 
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studies that examined associations with levels of blood pressure (Supplemental Figure 5) were 
moderately symmetrical, therefore providing little evidence for publication bias. This was further 
supported by the results of Egger’s test which were non-significant for both SBP, p=0.06, and DBP, 
p=0.45.
DISCUSSION
Findings of this review indicate that women with vasomotor symptoms including flushing and/or 
night sweats have an unfavorable cardiovascular risk profile compared to women without vasomotor 
complaints. Women experiencing VMS have significantly higher SBP and DBP, higher circulating 
total cholesterol levels and higher BMI than their counterparts with no symptoms. There is also a 
positive, albeit weak, association of VMS with hypertension. However, no signification association 
between VMS in women and risk of subliclinical atherosclerosis measures was observed in this 
analysis. 
The associations of VMS with some cardiovascular risk factors observed in this quantitative 
review may indicate a vulnerability of women to hormonal fluctuations that occur during 
menopause. Women with VMS tend to have lower levels of endogenous estrogen, which have 
been linked to cardiovascular risk 40,41. On the other hand, the associations reported in this review 
may indicate a cause-effect relationship. A possible mechanism linking women with VMS with 
increased risk of hypertension is a potential up-regulation in sympathetic nervous activity,15,32,42 
particularly associated with an increasing age at a higher rate than in men 32,43. Epinephrine and 
Nor-epinephrine (NE) secreted from the sympathetic nervous system are possible mediators for 
various vascular and metabolic abnormalities including hypertension and increased cholesterol 
levels 44-46. Additionally, VMS are associated with increased catecholaminergic activity and 
modification in calcitonin related peptide, which on the other hand are associated with increased 
cardiovascular risk 47,48. Furthermore, the hypothalamic-pituitary-adrenal axis and an increase 
in cortisol production observed in women who present VMS may represent another mechanism 
linking VMS with insulin resistance and alterations in lipid metabolism 49. The significant increase 
in the levels of BMI in older women with VMS, as observed in the current meta-analysis, may 
also be due to nor-epinephrine secretion from sympathetic nerves 15,42. Gast et al. have replicated 
findings of positive associations between VMS and BMI and Cholesterol levels as well as with 
systolic and diastolic blood pressures15,33 through the EPOS and WHILA studies. Recent evidence 
does not support the role of an unfavorable CVD risk profile as a risk factor for VMS later in 
life 50. However, whether vasomotor symptoms precede the risk for cardiovascular disease or are 
symptomatic manifestations of underlying adverse changes in a woman’s vasculature remains to 
be investigated. 
Our findings do not support an association between VMS and CAC. Furthermore, no consistent 
associations were found between VMS and IMT. However, there is evidence that these associations 
between VMS and measures of subclinical atherosclerosis may be modified by use and duration 
of hormone therapy, suggesting a positive association between VMS and subclinical measures 
of atherosclerosis mainly in women who report use of hormone therapy and who start hormone 
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therapy not shortly after menopause 31,36. Evidence of interactions by hormone replacement therapy 
is consistent with previous studies, reporting women with VMS and randomized to hormone 
replacement therapy to have the greatest CVD risk 51. Similarly, women who start hormone therapy 
later after menopause, especially if they also report VMS, have an increased risk of coronary heart 
disease 52. Experimental and clinical evidence suggest that the effects of estrogen on arteries vary 
with the stage of reproductive life, time since menopause, and extent of subclinical atherosclerosis 
53. In line with this concept, data from the Women’s Health Initiative suggest that the predictive 
value of vasomotor symptoms for cardiovascular risk may vary with onset of vasomotor symptoms 
at different stages of menopause 54. The relations between VMS, hormone replacement therapy 
use and cardiovascular risk are not well understood and require greater elucidation. Moreover, 
examining the relationships between VMS and surrogate CVD risk markers among women at 
different menopausal stages warrants investigation.
The strengths and limitations of the findings from this study merit careful consideration. The present 
analysis, involving data from nearly 20,000 individuals, is the first-ever quantitative synthesis of 
these associations thus far. However, as the present study was based on principally cross-sectional 
assessments, it does not establish causative associations between VMS and cardiovascular risk 
factors due to the possibility of reverse causation. Furthermore, we observed a moderate to high 
level of heterogeneity across the included studies (e.g., the meta-analysis for the association of 
VMS with blood pressure pooled the results from the studies based on either office-based or 
ambulatory blood pressure measurements with varying magnitude of the mean differences in SBP 
or DBP). In this respect, literature-based meta-analyses are influenced by the level of diversity 
across the studies, and do not provide detailed information necessary for the reliable assessment of 
any independent association. Furthermore, since the number of available studies in each analysis 
was generally small, it precluded our ability to investigate the sources of the observed heterogeneity 
by subgroup analyses involving various study-level characteristics (such as age, ethnicity, location, 
education level, menopausal status and parity), While individual studies attempted to adjust for 
these variables, the levels of adjustment was inconsistent across the studies. 
Nonetheless, our findings may have some important implications. First, they indicate a potential 
link between VMS and several cardiovascular risk factors. Second, these relations seem to be 
in line with available prospective evidence that show an association between VMS and clinical 
cardiovascular outcomes 16,54. Finally, they stimulate future research using large-scale studies with 
individual-level data to further reliably quantify these associations in greater detail and to identify 
potential mediators (or confounders) in associations of VMS with disease risk.  
In conclusion, findings of this review indicate that women with menopausal complaints including 
flushing and/or night sweats may have an unfavorable cardiovascular risk profile compared to 
women without vasomotor complaints. However, the available studies are generally limited and 
somewhat diverse – highlighting the need for further larger-scale investigations to reinforce these 
findings. 
Supplementary Material can be found online: http://www.sciencedirect.com/science/article/pii/
S0378512215006702
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ABSTRACT 
Importance: Vasomotor symptoms (hot flushes and night sweats) and other symptoms, including 
depression, anxiety and panic attacks, are commonly experienced by menopausal women and have 
been associated with an unfavourable cardiovascular risk profile.
Objective: To investigate whether presence of menopausal symptoms is associated with the 
development of cardiovascular disease (CVD).
Data Sources: Medical databases (Medline, EMBASE and Web of Science) until February 17th, 
2015.
Study Selection: Observational cohort studies or randomised intervention studies were eligible 
for inclusion if they followed participants prospectively (at least 1 year of follow-up), and reported 
relevant estimates on the association of any vasomotor symptoms, or other menopausal symptoms, 
with risk of CVD, coronary heart disease (CHD), or stroke in perimenopausal, menopausal, or 
postmenopausal women.
Data Extraction and Synthesis: Data were extracted by two independent reviewers using 
a pre-designed data collection form. Separate pooled relative risks (RRs) for age and non-
established cardiovascular risk factors (e.g., education, ethnicity) adjusted data and for established 
cardiovascular risk factors and potential mediators-adjusted data (e.g., smoking, body mass index, 
hypertension) were calculated.
4.4
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Main Outcomes: Composite CVD, CHD and stroke. 
Results: Out of 9,987 initially identified references, ten studies were selected, including 213,976 
women with a total of 10,037 cardiovascular disease outcomes. The age and non-established 
cardiovascular risk factors adjusted RRs) [95% confidence intervals] for development of CHD, 
Stroke and CVD comparing women with and without any menopausal symptoms were 1.34 [1.13-
1.58], 1.30 [0.99 -1.70], 1.48 [1.21-1.80] respectively, and the corresponding RRs adjusted for 
cardiovascular risk factors and potential mediators were 1.18 [1.03-1.35], 1.08 [0.89 -1.32], 1.29 
[0.98-1.71]. However, these analyses were limited by potential unmeasured confounding and the 
small number of studies on this topic. 
Conclusion: Presence of vasomotor symptoms and other menopausal symptoms are generally 
associated with an increased risk of cardiovascular disease, which is mainly explained by 
cardiovascular risk factors. 
Relevance: The findings from this study might indicate the potential usefulness of menopausal 
symptoms in assessing cardiovascular disease risk among women.
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INTRODUCTION
Hot flushes (also known as hot flashes) along with night sweats are collectively known as vasomotor 
symptoms (VMS). These well-known symptoms of the menopause are commonly experienced 
by menopausal women1. 50.3%2 to 82.1%3 of menopausal women experience VMS, and the 
intensity and duration of these symptoms also vary3. In addition to VMS, menopausal women often 
experience a range of other symptoms including anxiety, depression, irritability, fatigue, decreased 
libido, insomnia, and panic attacks, among others4-7. 
Menopausal transition represents a critical period in women’s lives that marks an increase in 
cardiovascular disease (CVD) risk. Traditional CVD risk factors, such as reduced glucose tolerance, 
increased blood pressure and endothelial dysfunction 8,9, tend to become very present during 
menopausal transition and post-menopausal years which can partly explain the augmentation in 
CVD risk among women. The natural decline in oestrogen levels during menopause has been 
associated with the increase in CVD risk among post-menopausal women 10. Similarly, VMS are 
postulated to originate from changes in brain neurotransmitters and instability in the hypothalamic 
thermoregulatory center brought about by decline in oestrogen levels 11. 
Oestrogen supplementation therefore has been considered as  the most effective treatment for these 
symptoms 12. However, it remains unclear whether presence of menopausal symptoms is associated 
with the development of CVD13. Since menopausal symptoms can vary greatly between women, 
they might help identify women at greater CVD risk that could benefit from effective preventative 
strategies.
In the present study, we aimed to synthesise all available observational evidence of cardiovascular 
disease risk in relation to either VMS or non-vasomotor symptoms of menopause, including 
depression, insomnia, and panic attacks, to determine the association between VMS and non-
vasomotor symptoms of menopause with risk of cardiovascular disease.
METHODS
Data Sources, Search Strategy and Eligibility Criteria
This review was conducted in accordance with the PRISMA14 and MOOSE15 guidelines (eAppendix 
1 and 2). Two independent authors, in duplication, sought studies published before February 17, 
2015 (date last searched) using Medline, EMBASE and Web of Science databases. The computer-
based searches combined terms related to the exposure (eg, hot flashes, night sweats) and outcomes 
(eg, cardiovascular disease, coronary disease), without any language restriction. Details on the 
search strategy are provided in eAppendix 3. Studies were sought that had reported on associations 
of vasomotor symptoms (defined as hot flashes and/or night sweats), or menopausal symptoms 
such as depression, insomnia, or panic attacks, with vascular outcomes defined as composite CVD 
(combination of CHD and stroke), fatal or non-fatal coronary heart disease (CHD), or stroke. 
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CHD events included myocardial infarction, coronary artery bypass graft, ischemic heart disease 
or sudden cardiac death if caused by myocardial infarction and CHD deaths. Stroke included both 
haemorrhagic and ischemic cerebrovascular events. 
Study Selection 
Observational cohort studies or randomised intervention studies were eligible for inclusion if they 
followed participants prospectively (at least 1 year of follow-up), and reported relevant estimates 
on the association of any vasomotor symptoms, or other menopausal symptoms (defined above), 
with risk of composite CVD, fatal or non-fatal CHD, or stroke in perimenopausal, menopausal, 
or postmenopausal women. Two independent reviewers, working in pairs, screened the titles and 
abstracts of all initially identified studies according to the selection criteria. In case of disagreement, 
decision was reached through consensus or consultation with a third independent author. Full texts 
were retrieved from studies that satisfied all selection criteria. 
Data Extraction 
Data were extracted by two independent authors. A predesigned data extraction form was used 
to collect relevant information. This included questions on study size; study design; baseline 
population; location; age at baseline; duration of follow-up; reported degree of adjustment (defined 
as ‘+’ when RRs were adjusted for age and non-established cardiovascular risk factors (e.g., 
education, income, ethnicity) and “++”further adjustment for established vascular risk factors 
and potential mediators (e.g., body mass index, smoking status, lipids, hypertension); type and 
numbers of vascular outcomes and reported RRs. Additionally, in the case of multiple publications, 
the most up-to-date or comprehensive information was included. 
Assessing the Risk of Bias
Bias within each individual study was evaluated using the validated Newcastle-Ottawa Scale, a 
semi-quantitative scale designed to evaluate the quality of nonrandomized studies16.  Study quality 
was judged on the selection criteria of participants, comparability of cases and controls, and 
exposure and outcome assessment. Studies that received a score of nine stars were judged to be of 
at low risk of bias; studies that scored seven or eight stars were considered at medium risk; those 
that scored six or less were considered at high risk of bias.
Data Synthesis and Analysis
The inverse variance weighted method was used to combine relative risks to produce a pooled 
relative risk using random- effects meta-analysis models to allow for between study heterogeneity. 
Separate summary estimates were obtained for age and potential cardiovascular risk factors adjusted 
data (e.g., education, income, ethnicity) and for established risk factors and potential mediators-
adjusted data (e.g., body mass index, smoking status, lipids, hypertension). Heterogeneity was 
assessed using the Cochrane χ2 statistic and the I2 statistic. Publication bias was evaluated 
through a funnel plot and Egger’s test. All tests were two-tailed and p-values of 0.05 or less were 
considered significant. STATA release 13 (Stata Corp, College Station, Texas) was used for all 
statistical analyses.
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Figure 1. Flow diagram of studies included in the current review 
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RESULTS
The search strategy identified 9,954 unique citations. Following initial screening based on titles 
and abstracts, 54 articles were retrieved and evaluated further. Of these articles, 48 were excluded 
for reasons shown in Figure 1. The remaining 12 articles17-28 (based on 10 distinct studies) were 
included in the review and meta-analysis (Table 1). Consequently, 213,976 individuals were 
included within the meta-analysis, with a total of 10,037 CVD outcomes. The average follow-up 
ranged from 5.3 to 15 years (Table 1). Eight studies included women from the USA, whilst the 
remaining study included Dutch, Swedish and Finish participants. The age of participants ranged 
from 30 to 89 years. Three studies assessed VMS whereas the rest of the included studies assessed 
other menopause symptoms; 4 studies assessed depression, 2 sleep disturbance and insomnia, and 
1 study panic attacks (eTable 1). All available studies were prospective cohorts in design which 
were judged as medium or high-quality studies, with few potential source of bias coming from 
participant selection (Table 2). 
Association of Menopausal Symptoms and CHD 
Menopausal symptoms, either VMS or other symptoms, in relation to risk of developing CHD 
were reported in ten prospective observational studies, three of which assessed VMS and seven 
assessed other menopausal symptoms. Pooled RRs for subsequent development of CHD, adjusted 
for age along with other potential cardiovascular risk factors, were 1.34 (95%CI: 1.13 -1.58) when 
comparing women with and without VMS (70,814 participants, 1,860 events), and 1.48 (95% CI: 
1.20-1.83) when comparing women with and without non-VMS (190,503 participants, 6,789 events) 
(Figures 2). Whilst the pooled RR, adjusted for age and other potential cardiovascular risk factors, 
comparing women with and without any menopausal symptoms, using data from 261,317 women 
with 8,649 CHD outcomes, was 1.34 (95%CI: 1.13-1.58) (Figures 2). Further adjustment for 
established cardiovascular risk factors and potential mediators attenuated but did not abolish the 
associations of VMS (RR=1.28; 95%CI=1.08; 1.52) and of any menopausal symptoms (RR=1.18; 
95%CI=1.03; 1.35) with CHD. In contrast, there was no significant association between non-
VMS and the risk of CHD after adjustment for established cardiovascular risk factors and 
potential mediators (RR=1.14; 95%CI=0.98; 1.34) (Figure 2). There was evidence of between-
study heterogeneity for non-VMS and any for menopausal symptom analyses (I2=92% (95%CI: 
86%, 96%) and χ2: p<0.001 for non-vasomotor symptoms and I2=91% (95%CI:85%, 95%) and 
χ2: p<0.001 for all menopausal symptoms). There was no evidence of heterogeneity for the VMS 
analysis (I2 =35% and χ2: p=0.21 for VMS) (Figure 2). Restricting the CHD outcome to fatal CHD 
events only, no associations were found between any menopausal symptoms, VMS or non-VMS, 
with fatal CHD in both models (eFigure 1).
Association of Menopausal Symptoms and Stroke
Menopausal symptoms in relation to subsequent stroke risk were reported in three prospective 
observational studies; VMS was evaluated by one study and two studies assessed non-VMS. From 
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the single study evaluating stroke risk in women with and without VMS, the age and potential 
risk factors- adjusted RR was 1.43 (95% CI: 1.07-1.92) (60,027 participants, 1226 stroke events) 
(Figure 3). Age and potential cardiovascular risk factors- adjusted summary estimate of the 
RR was 1.34 (95%CI: 0.73-2.46) when comparing women with and without non-VMS (97,045 
participants, 504 stroke events) (Figure 3). The pooled RR for subsequent stroke, adjusted for 
age and potential cardiovascular risk factors, was 1.30 (95% CI: 0.99-1.70) when comparing the 
presence and absence of any menopausal symptoms (157,072 participants, 1,727 stroke events) 
(Figure 3). After multiple adjustments for cardiovascular risk factors and potential mediators, 
the overall summery estimates of the RRs decreased to 1.14 ((95% CI: 0.82-1.59), 1.19 (95% 
CI: 0.68-2.11) and 1.08 (95% CI: 0.89-1.32) for VMS, non-VMS and any menopausal symptoms 
respectively (Figure 3). There were some evidence of between study heterogeneity, however, in 
either meta-analysis: I2=51% and χ2: p=0.15 for non-vasomotor symptoms and I2=39% and χ2: 
p=0.20 for all menopausal symptoms. 
Association of Menopausal Symptoms and CVD 
Four cohort studies reported menopausal symptoms in relation to subsequent risk of combined 
CVD outcomes. All of these studies included American participants. Only one study examined the 
association between VMS and the risk of CVD and showed a RR adjusted for age and potential 
risk factors of 1.54 (1.27-1.86) (60,027 participants, 2,812 CVD events) for women experiencing 
VMS compared to women who did not (Figure 4). Pooled RRs for subsequent development of 
CVD, adjusted for age along with other potential established cardiovascular risk factors was 1.51 
(95% CI: 1.12-2.02) (92,147 participants, CVD 7,758 events) when comparing women with and 
without non-VMS (Figure 4). The pooled RR for CVD, adjusted for age but not for conventional 
cardiovascular risk factors, comparing women with and without any menopausal symptoms was 
1.48 (95%CI: 1.21-1.80) (152,174 participants with 10,570 CVD events, Figure 4). Multiple 
adjustment for established cardiovascular risk factors attenuated the overall RRs: 1.23 (95% CI: 
1.00-1.52)  for VMS, 1.40 (95% CI: 0.88 -2.25) for non-VMS and 1.29 (95% CI: 0.98-1.71) for 
any menopausal symptom (Figure 4). There was evidence of between-study heterogeneity in these 
meta-analysis: I2 =72% (95%CI: 4%, 92%) and χ2: p=0.045 for non-VMS; I2=7% (95%CI: 12%, 
92%) and I2=70% (95%CI: 13%, 90%) and χ2: p=0.02 for all menopausal symptoms combined.
Publication Bias
Under visual examination, Begg’s funnel plots for studies assessing the risk of CHD (eFigure 2) 
or combined cardiovascular outcomes (eFigure 2) were not symmetrical, and therefore, providing 
evidence for publication bias. This was further supported by the results of Egger’s test which were 
significant for both CHD and composite CVD, in particular for the established cardiovascular 
risk factors and potential mediators-adjusted data (eFigure 2). No evidence of publication bias 
was observed for fatal CHD analysis, either graphically from the funnel plot (eFigure 2) or 
quantitatively (P=0.60 for Egger’s test asymmetry). 
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DISCUSSION
This is the first meta-analysis investigating the association between the presence of menopausal 
symptoms and subsequent development of cardiovascular disease. Overall we found that VMS and 
other menopausal symptoms are associated with increased risk of CHD, stroke or CVD. While the 
associations observed for menopausal symptoms with stroke and overall CVD could be explained, 
at least in part, by established cardiovascular risk factors; the association between menopausal 
symptoms and CHD was only partially attenuated, however, remained significant once corrected 
for cardiovascular risk factors and potential mediators.
Our study showed that VMS are associated with an increased risk of CVD, which was attenuated 
after adjustment for cardiovascular risk factors. These results are in line with the notion that 
menopausal symptoms may reflect an increased risk of CVD13. As well as other menopausal 
symptoms, VMS might serve as a CVD risk marker, as women with VMS may have a higher 
prevalence of other CVD risk factors 9,13,29,30, with conventional CVD risk factors (e.g., hypertension 
and total cholesterol) being possible mediators in the association between VMS and CVD. Although 
epidemiological studies such as those included in this review cannot provide causal evidence, some 
previous findings indicate that menopausal women with VMS have a higher prevalence of CVD 
risk factors including higher blood pressure and cholesterol levels 9,29. 
On the other hand, mental health disorders, including depression, anxiety and panic attacks are 
already known to be CVD risk factors in both men and women of any age 31-33. Short and long sleep 
duration, indicative of poor physical and mental health, has also been associated with CVD in the 
general population 34. These different risk factors may work in tandem, as for instance depression 
has been implicated in the association between sleep quality and CVD 35. It has also been suggested 
that these symptoms affect CVD risk through established risk factors such as raised BMI 36,37. 
Table 2: Assessment of study quality through the Newcastle-Ottawa Scale
Lead Author, Publication Date Selection Comparability Outcome
W-Smoller, 2004; 
Szmuilowicz 2011 ** ** ***
Smoller, 2007 ** ** **
Svartberg, 2009 ** * ***
Gast, 2011 *** ** ***
Sands-Lincoln, 2013 *** ** ***
Penninx, 1998,  
Mendes de Leon, 1998 *** ** **
Ahto, 2007 ** * ***
Ferketich, 2000 ** ** ***
Whooley, 1998 ** * ***
Chandola 2010 ** ***
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Moreover, depression and anxiety may result in autonomic activation, leading to increased blood 
pressure and heart rate and decreased endothelial function 38,39 or through affecting coagulation, 
by increasing platelet activity and plasma viscosity among others 38. The sympathetic nervous 
activation following the panic attacks could also mediate an increased CVD risk 40. 
Any results regarding the association between menopausal symptoms and CVD should be 
cautiously interpreted, as women with symptoms are more likely to commence hormone therapy 
than women without symptoms. Hormone therapy is taken to ameliorate menopausal symptoms, 
but might adversely affect the development of CVD 8.  Although several of the included studies 
adjusted the associations for hormone therapy use, the possibility of residual confounding cannot 
be entirely eliminated. However, the most common reason for using hormone therapy is VMS 41; 
therefore if there was residual confounding by hormone therapy use, an association with VMS over 
and above other menopausal symptoms would be expected. 
Our results might indicate the potential usefulness of menopausal symptoms in assessing CVD 
risk among women. As up to 20% of CHD events in women occur in the absence of conventional 
risk factors 42, better risk assessment among women is warranted. The magnitude of the observed 
association between menopausal symptoms and CVD (RR of 1.54) is similar to the estimates 
reported for other female-specific CVD risk factors such as gestational diabetes43 and pregnancy-
induced hypertension44, which have recently been implicated for CVD risk classification among 
women by the American Heart Association45. Considering this potential, subsequent studies to 
further evaluate these associations are warranted.
This review underscores a number of gaps in the literature concerning CVD risk and menopausal 
symptoms. For instance (i) not all available studies assessed the severity or duration of menopausal 
symptoms, (ii) interaction with the age at which women experienced these symptoms was not 
consistently evaluated, and (iii) VMS were often grouped together, impeding the assessment of 
individual symptoms. Experiencing menopausal symptoms in isolation or in combination might 
carry different cardiovascular risk17,21.  
This review involved aggregate data from 213,613 women from the general population with over 
10,000 cardiovascular events. A number of limitations, however, need to be considered. A number 
of studies did not adjust for several CVD risk factors; including alcohol consumption17,20-22  and 
socioeconomic status17,19-23. Moreover, the results might also be subject to residual confounding. 
Due to using self-reported exposure and not specifying whether women with CVD at baseline 
were excluded, most studies failed to score well on selection as indicated by the Newcastle-Ottawa 
Scale. Although there is a risk of reverse-causation, one study excluded events that occurred in 
the first 6 months of follow-up, which had no material effect on the association20. Between-study 
heterogeneity was found in a number of analyses, which may have resulted from different levels 
of adjustment and differing methods of case ascertainment (ranging from death certificates to 
self-report validated by record linkage). Also, another potential source of bias include possible 
misclassification of exposure. The age-range of women included in our analysis varies across 
the included studies, with three studies including women age 64 and above, and therefore the 
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symptoms can occur beyond the menopausal transition. However, two of these studies examined 
the association of menopausal symptoms with CHD-mortality, and therefore, may have had little 
or no impact on the other results reported in this systematic review. Furthermore, VMS and other 
menopausal symptoms were assessed by questionnaire which is subject to some measurement 
error. However, because the outcome in all studies included in this systematic review was assessed 
prospectively, the subjective measure of menopausal symptoms would likely lead to non-differential 
misclassification with respect to the outcome, and therefore would likely bias our estimates toward 
the null in our analysis. Also, a major limitation of the studies included in our systematic review 
is the reliance on retrospective self-report of menopausal symptoms, particularly of VMS, which 
are subject to fault memory and reporting bias. Assessing VMS physiologically with, for example, 
an ambulatory hot flash monitor to measure skin conductance, would be an alternative objective 
measure of vasomotor symptoms. Also, the studies varied on the time when they assessed the 
presence of menopausal symptoms, which may be an important factor in determining the risk for 
CVD. Data from the Women’s Health Initiative suggest that the predictive value of vasomotor 
symptoms for cardiovascular risk may vary with onset of vasomotor symptoms at different stages 
of menopause22. Furthermore, studies usually combined assessment of VMS frequency and 
severity, constructs which are not interchangeable. The majority of studies were based in a single 
country (USA). Given that CVD rates, menopausal symptoms and age at menopause46 all vary 
between countries, it is possible that the strength or existence of the associations also varies by 
population. Therefore, to improve the generalizability of the findings, these associations would 
need to be evaluated in other populations. Finally, we found evidence of reporting bias in our 
systematic review, and therefore, some relevant studies may have been overlooked in the current 
systematic review.
CONLSUSION 
The evidence from observational studies indicate that women who experience VMS and other 
menopausal symptoms, including depression, anxiety and panic attacks during menopause are at 
greater risk of developing CVD. Further studies are needed to reliably establish which menopausal 
symptoms are independently associated with CVD outcomes and further clarify the potential 
mechanisms behind these associations. 
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Supplemental material
Supplemental Table 1: Exposure and methods of assessment used in the studies included in the review 
Lead Author, Publication 
Date Exposure Method used to assess the exposure
Ahto, 2007 Depression Zung Self-Rating Depression Scale
Penninx, 1998; Mendes 
de Leon, 1998 Depression 
The Center for Epidemiologic Studies 
Depression Scale 
Chandola, 2010 Sleep disturbance General Heath Questionnaire 
Ferketich, 2000 Depression CES-D Scale- a Self-report depression scale 
Gast, 2011
Vasomotor Symptoms Presence in 
the previous week or during the 
preceding 3 months
Questionnaire 
Sands-Lincoln, 2013 Insomnia WHI Insomnia Rating Scale (WHIIRS)
Smoller, 2007 Panic Attacks in the previous 6 months Questionnaire 
Svartberg, 2009 Vasomotor Symptoms Self-administered questionnaire
Whooley, 1998 Depression The Geriatric Depression Scale short form- a self-report questionnaire 
W-Smoller, 2004; 
Szmuilowicz 2011
Late Vasomotor Symptoms (also 
early and persistent vasomotor 
symptoms) 
Self-administered questionnaire
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eAppendix 3: Literature search strategy for prospective studies of cardiovascular outcomes
Relevant studies, published before February 17, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and Web of 
Science databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals 
and by correspondence with study investigators. The computer-based searches combined search 
terms related to markers related to vasomotor symptoms, related to vascular outcomes and related 
to study design without language restriction.
(hot flashes[MeSH Terms] OR “night sweat”[Text Word] OR “hot flash”[ All Fields] OR “sweat”[ 
All Fields] OR “flush”[ All Fields] OR “hot flush”[ All Fields] OR “ember flash”[All Fields] OR 
“vasomotor symptom”[All Fields] OR menopause[MeSH Terms] OR “menopause”[All Fields] 
OR perimenopause[MeSH Terms] OR postmenopause[MeSH Terms]) 
AND 
(“Cardiovascular Diseases” [Mesh] OR “Coronary Artery Disease” [MeSH] OR “Atherosclerosis” 
[MeSH] OR “Coronary Disease” [MeSH] OR “Myocardial Infarction” [MeSh] OR “Myocardial 
Ischemia” [MeSH] OR “Stroke” [MeSH]) 
AND 
(“longitudinal studies”[MeSH Terms] OR “prospective”[All Fields] OR “cohort”[All Fields] OR 
“follow up”[All Fields]  OR (“Clinical Trials as Topic”[Mesh]) OR “Randomized Controlled Trial” 
[Publication Type])
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Duration from Onset of Menopause with 
Cardiovascular Outcomes, Intermediate 
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a Systematic Review and Meta-Analysis 
of Observational Studies
4.5
Taulant Muka*, Clare Oliver-Williams*, Setor Kunutsor, Joop S.E. Laven, 
Bart CJM Fauser, Rajiv Chowdhury, Maryam Kavousi*, Oscar H. Franco*.
* Authors contributed equally
ABSTRACT
Background: Early menopause and a longer duration since menopause, due to the early cessation 
of the protective effect of endogenous oestrogen, are suggested to result in a greater cardiovascular 
risk.
Methods and Results: Three medical databases were searched for studies (observational cohort, 
case-control or cross-sectional) that assessed age at menopause or duration since onset of menopause 
as exposures, and risk of cardiovascular outcomes (composite cardiovascular disease (CVD), 
fatal and non-fatal coronary heart disease (CHD) and overall stroke and stroke mortality), CVD-
mortality, all-cause mortality and intermediate CVD endpoints, in perimenopausal, menopausal, or 
postmenopausal women. Out of initially identified references, 32 studies were selected, including 
310,329 non-overlapping women. Women with a menopausal age of younger than 45 years 
compared to women with a menopausal age of 45 years or older, the relative risk (RR) [95% 
confidence intervals (CI)] was 1.50(1.28-1.76) for overall CHD, 1.11(1.03-1.20) for fatal CHD, 
1.23 (0.98-1.53) for overall stroke, 0.99 (0.92-1.07) for stroke mortality, 1.19(1.08-1.31) for CVD 
mortality and 1.12(1.03-1.21) for all-cause mortality. For women with a menopausal age between 
50-54 years compared to women with a menopausal age of younger than 50 years, there was a 
decreased risk of fatal CHD (RR:0.87(95%CI:0.80-0.96)), and no effect on stroke. Duration since 
menopause in relation to risk of developing intermediate cardiovascular traits or CVD outcomes 
was reported in 4 observational studies, reporting no consistent results. 
Conclusions: The findings of this review indicate an excess CHD, CVD-mortality and overall 
mortality risk in women who have an early or premature menopause. 
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INTRODUCTION
Risk of cardiovascular disease (CVD) increases with age and, as women tend to live longer 
than men, the absolute number of women living with and dying from CVD is greater than men1. 
Therefore, early recognition of women at high risk for CVD and timely implementation of 
appropriate lifestyle or therapeutic interventions are of tremendous public health importance. 
Adverse changes in cardiovascular risk factors occur around the menopausal transition2-4, 
highlighting the need of CVD risk assessment during this period  and of introduction of appropriate 
preventive or treatment modalities. While the average age at menopause is 51 years5, menopausal 
age varies significantly among women with a range between 40-60 years of age. Women who have 
a premature or early menopause may not only be at risk from a younger age, but may also live 
more years of their lives at an increased risk of adverse outcomes6-83–5. This highlights the need 
to evaluate the role of both menopausal age and time since onset of menopause as risk factors for 
CVD.
Age at menopause may be a marker for not only reproductive ageing but also for general health 
and somatic ageing9. Menopause has been proposed as the first step in a causal pathway that, due to 
hormonal changes, eventually results in organ dysfunction10. A hormonal change that is often cited 
as an important determinant in post-menopausal CVD development is the decrease in endogenous 
estrogen synthesis11. Estrogens are involved in the relaxation and expansion of blood vessels, 
helping to accommodate blood flow, and consequently, decreased levels of oestrogen would result 
in stiffer blood vessels 12. Furthermore, loss of the ovarian function through menopause is associated 
with the activation of the renin-angiotensin-aldosterone system, leading to downstream endothelial 
dysfunction, inflammation and immune dysfunction13. These processes are associated with obesity, 
diabetes and hypertension13. Thus, early menopause has been hypothesized to be detrimental to 
cardiovascular health, due to the early cessation of the protective effect of endogenous oestrogen. 
Longer duration since menopause would therefore result in a greater risk of intermediate and hard 
CVD outcomes. However, whether this is indeed the case remains unclear given that there is not yet 
a comprehensive assessment of menopause in association with subsequent adverse cardiovascular 
outcomes.
Hence, we conducted a systematic review and meta-analysis of all available observational evidence 
to quantify the associations of age at menopause and duration since onset of menopause with (i) 
primarily clinical CVD outcomes and intermediate vascular traits; and (ii) all-cause mortality.
METHODS
Data sources and search strategy 
This review was conducted using a predefined protocol and in accordance with the PRISMA and 
MOOSE guidelines (eAppendix 1 and 2). Two independent reviewers, in duplication, sought studies 
329
4
C
ar
di
om
et
ab
ol
ic
 H
ea
lth
 in
 W
om
en
published up to March, 2015 (date last searched) using Medline, EMBASE and Web of Science 
electronic databases. The computer-based searches combined terms related to the exposure (eg, 
age at menopause, duration from onset of menopause) and outcomes (eg, endothelial dysfunction, 
inflammation, cardiovascular disease, mortality), without any language restriction. Details on the 
search strategy are provided in eAppendix 3. Furthermore, in order to identify further studies, we 
checked reference lists and contacted authors and experts in the field
Study selection and eligibility criteria
Studies were sought if they (i) were observational cohort, case-control, or cross-sectional studies; 
(ii) had reported on age at menopause (for the natural menopause it is defined as occurring 12 
months after the last menstrual period, and for surgical menopause it is the age at which ovaries are 
removed (by bilateral oophorectomy) or if the oophorectomy occurred before natural menopause), 
and/or duration from onset of menopause (defined as age of menopause onset until outcome 
event or diagnosis) as exposures; and (iii) had assessed associations with risk of CVD-related 
outcomes (composite CVD, fatal and non-fatal coronary heart disease (CHD) and overall and fatal 
stroke), CVD-mortality, all-cause mortality, or intermediate CVD endpoints (such as metabolic 
syndrome, obesity or BMI, hypertension, and markers of endothelial dysfunction and vascular 
inflammation) in menopausal or postmenopausal women. Two independent reviewers screened 
the titles and abstracts of all initially identified studies according to the selection criteria. Full texts 
were retrieved from studies that satisfied all selection criteria. 
Data extraction and quality assessment 
Data were extracted by two independent reviewers and a consensus was reached with involvement 
of a third. A predesigned data abstraction form was used to extract relevant information. This 
included questions on study size; study design; baseline population; location; age at baseline; 
duration of follow-up (for cohort studies); reported degree of adjustment (defined as ‘+’ when 
risk estimates were adjusted for age only;‘++’ further adjustment for established CVD risk factors 
and other potential confounders (such as, smoking status, lipids, hypertension, body mass index 
(BMI), history of cardiometabolic disease, hormone therapy); type of outcome and reported risk 
estimates. Additionally, in the case of multiple publications, the most up-to-date or comprehensive 
information was included. Study quality (for cohort and case-control studies) was assessed based on 
the nine-star Newcastle–Ottawa Scale(NOS)14 using three pre-defined domains namely: selection 
of participants (population representativeness), comparability (adjustment for confounders), and 
ascertainment of outcomes of interest. The NOS assigns a maximum of four points for selection, 
two points for comparability, and three points for outcome. Nine points on the NOS reflects the 
highest study quality. A score of ≥ 5 indicated adequate quality for inclusion in the review. 
Data synthesis and analysis
The inverse variance weighted method was used to combine relative risks to produce a pooled 
relative risk using random-effects models to allow for between study heterogeneity. Heterogeneity 
was assessed using the Cochrane χ2 statistic and the I2 statistic. Publication bias was evaluated 
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through a funnel plot and Egger’s test. All tests were two-tailed and p-values of 0.05 or less were 
considered significant. STATA release 12 (Stata Corp, College Station, Texas) was used for all 
statistical analyses.
RESULTS
Identification of relevant studies
The search strategy identified 9,444 citations. Following initial screening based on titles and 
abstracts, full-texts of 73 articles were evaluated further. Of these articles, 40 articles were 
excluded for reasons shown in Figure 1. The remaining 33 articles, based on 32 unique studies, 
met inclusion criteria, and therefore, were included in the review. 
General characteristics of the included studies
Tables 1 and Supplemental Table S1 summarize the key characteristics of the studies that assessed 
age at menopause as an exposure and those which had duration since menopause as an exposure, 
respectively. All studies except one evaluated the risk in relation to the age at menopause, with 
4 additionally evaluating the risk in relation to duration since menopause. In aggregate, in all 
included studies, 342,284 women were included in this review. However, not all studies provided 
relevant data that could be meta-analysed and it was not possible to combine any results related to 
duration since menopause, although an analysis of age at menopause was possible. Consequently, 
there were 297,496 participants in the age at menopause analysis, which included 44,962 cases. The 
average follow-up in these studies ranged from 4.0 to 51.8 years. The majority of studies (n=12) 
were based in Western European countries, 11 were from the United States, and the remaining 
9 studies were based in East Asia. The baseline age of participants ranged from 28 to 89 years. 
The majority of studies (n=24) were prospective cohort studies, whilst the remaining studies were 
case-control (n=2) or cross-sectional studies (n=6). Overall, age at menopause in relation to risk 
of developing CVD intermediates or outcomes, or all-cause mortality was reported in 31 studies. 
Of these, 1 study provided risk estimates of overall CVD outcomes, 5 estimated risk of CHD, 
and 6 studies quantified risk of stroke. Additionally, 3 studies assessed risk of intermediate CVD 
endpoints, 9 estimated risk of all-cause mortality, 7 estimated risk of CVD-mortality, 8 estimated 
risk of CHD-mortality and 7 studies estimated risk of stroke-mortality. Among the prospective 
cohort and case-control studies, 14 studies were judged to be at low risk of bias, 10 were at medium 
risk, and two studied were evaluated to be at high risk of bias (Table 1 and Supplemental Table 
S1).
Association of age at menopause with incident (composite) cardiovascular disease, coronary 
heart disease and stroke
There was only one study examining the association between age of menopause and incidence of 
CVD and showed a pooled RR of 1.56 (1.08-2.26) for a menopausal age of younger than 45 years 
compared to a menopausal age of 45 years or older.15 In the meta-analysis of 50,125 participants 
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Figure 1. Flow diagram of studies included in the current review Figure 1. Flow diagram of studies of included in the current review 
 
9,444 Potentially relevant citations identified 
3,964 PubMed 
3,021 Web of Science 
2,459 EMBASE 
9,375 excluded on the basis of title and abstract: 
 3,423  Review, letter, editorial or case 
reports 
 221  In vitro, functional or animal studies 
 362  No relevant population (eg, paediatric) 
     5,367  No relevant exposure or intervention or 
outcome 
  
 
40 excluded due to: 
  5 No relevant estimates reported 
  30 No relevant exposure or outcome  
    5 Duplicate publication 
 
 
33 articles based on 32 unique studies 
24 Prospective cohort studies 
6 Cross-sectional studies 
2 Case-control studies  
  
 73 Full-text articles retrieved for more 
detailed evaluation 
 
Identification 
 
Screening 
 
Eligibility 
 
Included 
and 1,217 CHD events, pooled RR (95%CI), comparing a menopausal age of younger than 45 
years relative to a menopausal age of 45 years or older and adjusted for several established CVD 
risk factors and other potential confounders (such as, age, smoking status, lipids, hypertension, 
BMI, history of cardiometabolic disease, hormone therapy), was 1.50 (1.28-1.76) (Figure 2). 
Corresponding results, based on the meta-analysis of 49,246 participants and 770 stroke events, 
were 1.23 (0.98-1.53) for stroke risk (Figure 3). There was little evidence of between-study 
heterogeneity in these meta-analyses:CHD and stroke analyses: I2=0% and χ2: p=0.65, and I2=51% 
and χ2: p=0.09, respectively.
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When women with a menopausal age between 45-49 years were compared to women with a 
menopausal age of 50 years or older, the corresponding adjusted pooled RRs (95%CI) were 1.12 
(0.95-1.31; based on 36,483 participants and 784 CHD events) for CHD risk and 0.95 (0.74-1.23; 
based on 109,928 participants and 536 stroke events) for stroke risk (Supplemental Figure S1 and 
S2). There was no evidence of between-study heterogeneity in both these analyses: I2 =0% and χ2: 
p=0.37, I2=0% and χ2:p=0.78 for CHD and stroke analysis respectively.
Due to differences in age categories, it was not possible to include one study in these meta-analyses. 
Lisabeth and colleagues16 evaluated risk of ischaemic stroke for women between 42-54 years old at 
menopause compared to women with a premature menopause (before 42 years of age). They found 
a decreased risk of ischaemic stroke (RR=0.50; 95%CI:0.29-0.89) for women who reported being 
between 42-54 years old at menopause relative to prematurely menopausal women. An additional 
lower risk was found for women who had menopause after 55 years of age (RR=0.31; 95%CI:0.13-
0.76).
Association of age at menopause with all-cause, (composite) cardiovascular disease, coronary 
heart disease and stroke mortality
Pooling results of the risk for different mortality outcomes estimated for women with a menopausal 
age of younger than 45 years relative to a menopausal age of 45 years or older, adjusted for several 
Figure 2. Age at menopause < 45 years and risk of incident CHD with menopausal age ≥ 45 years as reference 
category
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 = 2.49, I2=0%, 0 to 79%; P = 0.647. 
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Figure 3. Age at menopause > 45 years and risk of total stroke with menopausal age ≥ 45 years as reference 
category
established CVD risk factors and other potential confounders, yielded combined RRs (95% CI) 
of 1.12 (1.03-1.21) for all-cause mortality (109,898 participants and 31,427 all-cause deaths), 
1.19 (1.08-1.31) for CVD mortality (65,653 participants and 6,979 CVD-deaths), 1.11 (1.03-1.20) 
for CHD mortality (118,150 participants and 8,737 CHD-deaths) and 0.99 (0.92-1.07) for stroke 
mortality (143,833 participants and 6,706 stroke-deaths) (Figure 4-6 and Supplemental Figure 
S3). There was evidence of between-study heterogeneity for all-cause mortality analysis (I2=63% 
(95%CI: 20-83%) and χ2: p=0.009) whereas little evidence of between-study heterogeneity was 
found for the other analyses (Figure 4-6 and Supplemental Figure S3). Corresponding pooled 
RR (95%CI) for all-cause mortality, CVD, CHD and stroke mortality comparing menopausal age 
of 45-49 years to menopausal age of 50 years or older were 1.03 (1.00-1.05) for all-cause mortality 
(90,691 participants, 28,188 all-cause deaths), 0.99 (0.92 -1.07) for CVD mortality (62,995 
participants, 5,786 CVD-deaths), 0.98 (0.93 -1.04) for CHD mortality (121,444 participants, 5,954 
CHD-deaths) and 1.03 (0.91 -1.16) for stroke mortality (141,175 participants, 6,320 stroke-deaths) 
( Supplemental Figures S3-S7. When comparing menopausal age between 50-54 years relative 
to menopausal age of younger than 50 years, the corresponding pooled RRs (95%CI) were 1.02 
(0.89-1.15) for all-cause mortality (7,341 participants; 1,408 all-cause deaths), 0.96 (0.74-1.24) 
for CVD mortality (12,108 participants; 2,256 CVD-deaths), 0.87 (0.80- 0.96) for CHD mortality 
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(31,417 participants;3,279 CHD-deaths) and 1.19 (0.93-1.52) for stroke mortality (12,108 
participants;623 stroke deaths) (Supplemental Figures S8-S11). There was little evidence of 
between-study heterogeneity in all these analyses (Supplemental Figures S3-S11). Due to 
differences in age categories, it was not possible to include one study in the pooled results17. Wu 
and colleagues reported an increased risk of all-cause mortality (RR=1.16, 95% CI:1.04-1.29) for 
women of menopausal age < 46.64 years compared to women aged between 48.80-50.15 years at 
menopause (Supplemental Table S2).  
Association of age at menopause with intermediate cardiovascular traits
Only two studies were identified that evaluated risk for carotid atherosclerosis. Pooled RR (95% 
CI) for the risk of carotid atherosclerosis was 0.74 (0.63-0.87) when comparing women with 
a menopause age at or after 50 years to women with a menopausal of younger than 50 (3,388 
participants) (Supplemental Figure S12). There was, however, evidence of between study 
heterogeneity: I2 =69% (95%CI:0, 93%) and χ2: p=0.073. Three studies could not be included 
in the meta-analysis of intermediate cardiovascular traits11,12 (Supplemental Table S2). They all 
evaluated risk of diabetes depending on age at menopause. Two of the studies found no excess risk 
for Chinese women who experienced menopause before or after age 50, relative to women who 
underwent the menopause at age approximately 50 years. The same findings were observed in a 
study of European women; where relative to women who experienced menopause between the 
ages of 50-54, neither women who experienced an early menopause, between 45-49 years old, nor 
women who had their menopause after age 55 were at greater risk for diabetes. 
Years since menopause with CVD outcomes and intermediate cardiovascular traits 
Duration since menopause in relation to risk of developing intermediate cardiovascular traits or 
CVD outcomes was reported in four observational studies. Of these, two studies reported risk of 
overall CVD outcomes, and three studies estimated risk of intermediate cardiovascular traits. The 
age at baseline ranged from 40 to 81. Two studies, conducted in Italy and China, evaluated risk 
of CVD outcomes, including CHD, stroke and composite CVD outcomes (Supplemental Table 
S3), and three studies assessed risk of intermediate cardiovascular traits, including metabolic 
syndrome, obesity or BMI, and hypertension (Supplemental Table S4) in Korean, Chinese and 
German populations. Owing to a substantial heterogeneity in the comparison groups used across 
these studies, no quantitative synthesis could be performed. The findings of these studies, therefore, 
were only qualitatively reviewed. In a Chinese population13, relative to women less than 1 year post 
menopause, women 2-6 years post menopause were at a greater risk of CVD, with evidence for an 
increased risk after 6 years. In the same study, there was also evidence for a greater risk of CHD 
and stroke more than 1 year post menopause. However, these findings were in contrast to those in 
an Italian population14, which found no increased risk of myocardial infarction in post-menopausal 
women less than 10 years, 10-20 years and more than 20 years post menopause compared with 
pre- or peri-menopausal women. Stockl and colleagues15 found no association between time 
since menopause and the presence of carotid atherosclerosis, however time since menopause was 
dichotomised into broad groups, comparing women less than 15 years post menopause, to women 
more than 15 years post-menopause.
342
Relative to premenopausal women, postmenopausal Korean women were at greater risk of 
metabolic syndrome, and this risk increased with the time since menopause, with the greatest risk 
found in women between 10 and 14 years post-menopause16. Within the same population, there 
was evidence for increased risk of hypertension, abdominal obesity and high glucose levels, in 
postmenopausal women; however, risk did not vary with duration since menopause. Conversely, 
no increased risk of obesity, hypertension or diabetes was found in Chinese women who were more 
than 2 years post-menopause compared with women less than 1 year post-menopause13. Similarly, 
within the same study, systolic and diastolic blood pressure, BMI, WHR, and glucose levels did 
not vary with time since menopause.
Publication bias
Under visual examination, Begg’s funnel plots for those analyses that included a minimum of 5 
studies were mostly symmetrical (Supplemental Figure S13), with possible exception of studies 
evaluating overall CHD risk and CHD mortality risk in women with menopausal age of less than 
45 years. However, there was no statistical evidence of publication bias based on Egger’s test, 
which was non-significant (P>0.05) for all analyses that involved 5 or more studies. 
 
Figure 4. Age at menopause < 45 years and risk of mortality with menopausal age ≥ 45 years as reference category  
 
 
 
 
 
 
 
 
 
 
 
 
 
 +, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 7= 18.80, I2=63%, 20 to 83%; P = 0.009 
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DISCUSSION
Overall, we found that women who experienced an early menopause (i.e. younger than 45 years) 
appear to have an excess risk of CHD, CVD-mortality and all-cause mortality and no association 
with stroke risk. By contrast, being 45-49 years at menopause compared to ≥50 years had no 
apparent association with adverse outcomes except for an increased risk of carotid atherosclerosis. 
Only a few studies evaluating risk in relation to duration since menopause could be found. Those 
that were identified had somewhat conflicting results, with some studies finding a greater risk 
of hypertension, abdominal obesity and high glucose levels, and others reporting essentially null 
associations. 
Interpretation of findings
The current study supports previous findings that there is an increased risk of CVD with premature 
or early menopause, specifically identifying a greater risk with CHD, and potentially with carotid 
atherosclerosis. The findings of this systematic review on the risk of CVD associated with early 
menopause generally concur with and further extend a previous review18, which reported an 
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Figure 6. Age at menopause < 45 years and risk of CHD mortality with menopausal age ≥ 45 years as 
reference category.
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 = 8.65, I2=42%, 0 to 77%; P = 0.124.  
increased risk of CVD for women at  menopausal age of 50 years or younger compared with 
menopausal age ≥51 years. However, the findings of the previous review were based only on 
few prospective studies (7 prospective cohort studies) and therefore the authors were not able 
to compare other age categories with the risk of CVD. Our finding on an association between 
premature or early menopause with carotid atherosclerosis needs to be interpreted with some 
caution, given the relatively small number of studies currently available and due to the presence of 
between-study heterogeneity. However, the number of participants in both studies were relatively 
large (12,108 participants in both studies).
The association between early menopause and CHD risk may have several mechanistic 
interpretations. Early loss of the ovarian function through menopause may lead to long term 
activation of the renin-angiotensin-aldosterone system, leading to endothelial dysfunction, 
inflammation and immune dysfunction, and therefore causing vascular damage13,19. This process 
may be partially mediated via the membrane G protein-coupled estrogen receptor13. Also, another 
common explanation is that menopause marks the start of a biological mechanism, led by hormonal 
changes, which causes tissue damage and organ dysfunction10. The multi-organ impact of the 
menopause proposed by this theory, and supported by findings of an increased risk of depression, 
dementia and osteoporosis20-22, seems to be consistent with the increased risk of all-cause mortality 
found in the current analysis. 
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Alternatively, there may be shared risk factors, either genetic or environmental, that result in early 
menopause and also increase the risk of adverse health outcomes10. In this case, early menopause 
could be considered as only a marker of risk. In support of a shared genetic basis, a large-scale 
genome-wide association study of age at menopause identified a number of loci, including the ones 
relevant to cardiovascular disease, that were involved in inflammatory response, oxidative stress 
and genome stability23. Speculative environmental factors could include obstetric history, such as 
parity or having a stillbirth. These explanations are not necessarily mutually exclusive, however, 
and a combination of these mechanisms may be responsible for the observed increase in CVD and 
all-cause mortality risk.
Strengths and limitations
This is the first comprehensive quantitative review of observational evidence that assessed both 
the associations of age at menopause and duration since menopause with clinical CVD outcomes, 
intermediate cardiovascular traits and all-cause mortality. Our analyses included >300,000 women 
and evaluated the risk of a wide-range of outcomes in relation to various menopausal age-groups. 
However, strengths and limitations in the current study merit careful consideration. First, all 
systematic reviews are prone to reporting bias, owing to the possibility that studies with more 
extreme results are more likely to be published. Nonetheless, as demonstrated by Egger’s test 
estimates, there was little evidence of publication bias in the current analyses. Additionally, all 
meta-analyses are limited by the quality of the individual published studies. However, the majority 
of studies included in the current analyses were of high quality, with a low risk of bias. In order to 
allow for a uniform analysis, it was necessary to combine some overlapping age-groups for some 
studies (eg, studies that reported estimates for menopausal age of 50-54 years and those based 
on >50 years). This might have introduced some heterogeneity into the analyses. Additionally, 
due to differential categorisation of menopausal age in various studies or only few studies 
evaluating a particular outcome (eg, carotid atherosclerosis), some of our analysis are based on a 
small number of studies. Therefore, these results need to be interpreted with caution, particularly 
those which yielded moderate between-study heterogeneity estimates. Furthermore, the lack of 
studies evaluating risk in relation to duration since menopause limited us from performing any 
meaningful quantitative synthesis using this exposure. Most studies that were identified adjusted 
for a range of relevant confounders, although one study was entirely unadjusted24, and three only 
adjusted for age25-27. Therefore, the risk of residual confounding cannot be entirely ruled out. A 
specific concern is confounding from HRT use, which particularly may vary depending on the 
age at menopause. Women who experience menopause at a younger age may be more likely 
to start HRT than women who reach menopause in their 50s. Consequently, hormone therapy 
use may confound the relationship between age at menopause and CVD risk. Indeed, HRT was 
only adjusted for in a minority of identified studies28-32. However, the complex interplay between 
exogenous hormones and CVD risk is not fully understood, and the results regarding HRT and 
CVD risk are conflicting33-35. 
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Clinical and scientific implications
This review underscores a potential increased risk of adverse cardiovascular outcomes in women 
who experience early or premature menopause, which may have important clinical and public 
health implications. This study has also identified a number of gaps in the literature concerning the 
relations between duration since menopause, age at menopause and intermediate cardiovascular 
traits and CVD outcomes. Few studies were identified that assessed duration since menopause as 
an exposure, limiting the review to four studies. Additionally, there were only few studies focusing 
on intermediate cardiovascular endpoints or risk factors leading to conflicting results and therefore 
impeding meaningful interpretation. These intermediate factors are of potential importance in 
interpretation of the observed excess cardiovascular  risk, and thus, further research focusing on the 
intermediate cardiovascular traits is required. Finally, other areas of interest are the relation between 
age at menopause and duration since menopause and whether there are common determinants for 
premature menopause and CVD. The observed link between premature menopause and CVD risk 
may be modified by differing durations since the onset of the menopause among women. The 
excess CHD risk may be driven in part by a longer duration since the onset of the menopause 
in women with early menopause. Alternatively, the increased relative risk found with premature 
menopause may be present only in the first years after menopause, ameliorating over time. Thus 
far, the known risk factors for premature menopause, include genetics21; reproductive factors, i.e. 
parity and age at menarche31; as well as lifestyle factors such as smoking and BMI31. However, the 
role of these factors in mediating the association between premature menopause and CVD remains 
unclear and therefore warrants further research. 
CONCLUSION
The findings of this review indicate an excess coronary heart disease, cardiovascular mortality 
and overall mortality risk in women who have an early or premature menopause below the age 
of 45 years. However, this review also highlights important gaps in the existing literature, calling 
for further research to reliably establish whether cardiovascular risk may vary in relation to 
the duration since menopause and the mechanisms leading early menopause to cardiovascular 
outcomes and mortality.
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Supplemental Figure S1. Age at menopause 45-49 years and risk of total CHD with menopausal age ≥ 50 years as reference category 
 
 
 
 
Legend for Supplemental Figure S1 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 1= 0.81, I2=0%; P = 0.368  
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Supplemental Figure S2. Age at menopause 45-49 years and risk of total stroke with menopausal age ≥ 50 years as reference 
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Legend for Supplemental Figure S2 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 1= 0.08, I2=0%; P = 0.783 
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Supplemental Figure S3. Age at menopause < 45 years and risk of stroke mortality with menopausal age ≥ 45 years as reference category 
 
 
 
Legend for Supplemental Figure S3 
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+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 7.59, I2=34%, 0 to 74%; 
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+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 5.19, I2=23%, 0 to 68%; P = 0.268
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Supplemental Figure S4. Age at menopause 45-49 years and risk of mortality with menopausal age ≥ 50 years as reference category 
Legend for Supplemental Figure S4 
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Supplemental Figure S6. Age at menopause 45-49 years and risk of fatal CHD with menopausal age ≥ 50 years as reference category
Legend for Supplemental Figure S6 
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Supplemental Figure S5. Age at menopause 45-49 years and risk of CVD with menopausal age ≥ 50 years 
as reference category
Supplemental Figure S6. Age at menopause 45-49 years and risk of fatal CHD with menopausal age ≥ 50 
years as reference category
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 0.62, I2=0%, 0 to 85%; P = 0.891
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 1.89, I2=0%, 0 to 85%; P = 0.595
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Supplemental Figure S5. Age at menopause 45-49 years and risk of CVD with menopausal age ≥ 50 years as reference category
Legend for Supplemental Figure S5 
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Supplemental Figure S7. Age at menopause 45-49 years and risk of stroke mortality with menopausal age ≥ 
50 years as reference category
Supplemental Figure S8. Age at menopause 50-54 years and risk of mortality with menopausal age < 50 
years as reference category
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 11.28, I2=65%, 7 to 87%; P = 0.024
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 0.26, I2=0%, 0 to 0%; P = 0.612
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+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 3= 1.89, I2=0%, 0 to 85%; P = 0.595 
 
Supplemental Figure S7. Age at menopause 45-49 years and risk of stroke mortality with menopausal age ≥ 50 years as reference category 
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Legend for Supplemental Figure S7 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 4= 11.28, I2=65%, 7 to 87%; P = 0.024 
Supplemental Figure S8. Age at menopause 50-54 years and risk of mortality with menopausal age < 50 years as reference category 
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Supplemental Figure S10. Age at menopause 50-54 years and risk of fatal CHD with menopausal age < 50 years as reference category
Legend for Supplemental Figure S10 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 2= 0.87, I2=0%, 0 to 90%; P = 0.648   
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Legend for Supplemental Figure S8 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 1= 0.26, I2=0%, 0 to 0%; P = 0.612  
 
Supplemental Figure S9. Age at menopause 50-54 years and risk of CVD with menopausal age < 50 years as reference category 
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Supplemental Figure S9. Age at menopause 50-54 years and risk of CVD with menopausal age < 50 years 
as reference category
Supplemental Figure S10. Age at menopause 50-54 years and risk of fatal CHD with menopausal age < 50 
years as reference category
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 3.17, I2=68%, 0 to 93%; P = 0.075 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 0.87, I2=0%, 0 to 90%; P = 0.648 
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Supplemental Figure 11. Age at menopause 50-54 years and risk of stroke mortality with menopausal age < 
50 years as reference category
Supplemental Figure 12. Age at menopause ≥ 50 years and risk of carotid atherosclerosis with menopausal 
age < 50 years as reference category in cross-sectional studies
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 1.01, I2=1%; P = 0.314 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2= 3.21, I2=69%, 0 to 93%; P = 0.073 
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Supplemental Figure S11. Age at menopause 50-54 years and risk of stroke mortality with menopausal age < 50 years as reference category 
 
Legend for Supplemental Figure S11 
+, adjusted for age; ++, adjusted for vascular risk factors; Assessment of heterogeneity, X2 1= 1.01, I2=1%; P = 0.314  
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Supplemental Figure S12. Age at menopause ≥ 50 years and risk of carotid atherosclerosis with menopausal age < 50 years as reference 
category in cross-sectional studies 
 
 
 
 
 
Legend for Figure Supplemental Figure S12 
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Appendix 3. Search strategy
Relevant studies, published before February 05, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and Web of 
Science databases. Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals 
and by correspondence with study investigators. The computer-based searches combined search 
terms related to age at menopause or duration from onset of menopause and endothelial dysfunction 
or inflammation or cardiovascular disease or mortality without language restriction.
(i) MEDLINE strategy to identify relevant exposures:
(“age at menopause”[All Fields] OR “duration from onset of menopause”[All Fields] OR 
“Menopause”[Mesh] OR “menopause”[All Fields] OR “Climacteric”[Mesh] OR “climacteric”[All 
Fields] OR “Perimenopause”[Mesh] OR “perimenopause”[All Fields] OR “Postmenopause”[Mesh] 
OR “postmenopause”[All Fields]) 
(ii) MEDLINE strategy to identify relevant outcomes: 
(“Endothelial dysfunction”[Mesh] OR “endothelial dysfunction”[All Fields] OR 
“Inflammation”[Mesh] OR “inflammation”[All Fields] OR “Vasodilatation”[Mesh] OR 
“vasodilatation”[All Fields] OR “Nitric oxide”[Mesh] OR “nitric oxide”[All Fields] OR 
“Vasoconstriction”[Mesh] OR “vasoconstriction”[All Fields] OR “Hypertension”[Mesh] OR 
“hypertension”[All Fields] OR “Hypercholeserolemia”[Mesh] OR “hypercholesterolemia”[All 
Fields] OR “Diabetes mellitus”[Mesh] OR “diabetes”[All Fields] OR “Blood Coagulation”[Mesh] 
OR “Platelet Adhesiveness”[Mesh] OR “percentage flow mediated dilatation”[All Fields] OR 
“peripheral arterial tonometry”[All Fields] OR “Acetylcholine”[Mesh] OR “acetylcholine”[All 
Fields] OR “Angiotensin II”[Mesh] OR “angiotensin II”[All Fields] OR “Endothelin-1”[Mesh] OR 
“endothelin-1”[All Fields] OR “Hyperhomocysteinemia”[Mesh] OR “hyperhomocysteinemia”[All 
Fields] OR “Reactive Oxygen Species”[Mesh] OR “reactive oxygen species”[All Fields] OR 
“Interleukin”[Mesh] OR “interleukin”[All Fields] OR “Vasculitis”[Mesh] OR “vasculitis”[All Fields] 
“C-Reactive Protein”[Mesh] OR “C-reactive protein”[All Fields] OR “Atherosclerosis”[Mesh] 
OR “atherosclerosis”[All Fields]  OR “P-Selectin”[Mesh] OR “p-selectin”[All Fields] OR “Tumor 
Necrosis Factor”[Mesh] OR “tumor necrosis factor”[All Fields] OR “Vascular Cell Adhesion 
Molecule-1”[Mesh] OR “vascular cell adhesion molecule-1”[All Fields] OR “intercellular adhesion 
molecule-1”[All Fields] “E-Selectin”[Mesh] OR “e-selectin”[All Fields] OR “mortality”[All 
Fields] OR “all cause mortality”[All Fields] OR “death”[All Fields] OR “survival”[All Fields] 
OR “Cardiovascular Diseases”[Mesh] OR “Coronary heart disease”[Mesh] OR “Coronary artery 
disease”[Mesh] OR “Cerebrovascular disease”[Mesh] OR “Stroke”[Mesh]) 
(iii) MEDLINE strategy to identify relevant population:
(“humans”[MeSH Terms]) 
Parts i, ii and iii were combined using ‘AND’ to search the MEDLINE. Additionally, each part was 
specifically translated for searching alternative databases.
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Effects of Natural and Plant-Based 
Therapies on Menopausal Symptoms: 
a Systematic Review and Meta-Analysis
Oscar H. Franco, Rajiv Chowdhury*, Jenna Troup*, Trudy Voortman, Setor 
Kunutsor, Maryam Kavousi, Clare Oliver-Williams*, Taulant Muka*
*indicates equal contribution
ABSTRACT 
CONTEXT: The proportion of women in Western countries who use complimentary therapies to 
manage menopausal symptoms is estimated to be 40-50%.
OBJECTIVE: To determine the impact of natural and plant-based therapies on the presence and 
severity of menopausal symptoms. 
DATA SOURCES: The electronic databases MEDLINE, EMBASE, and Cochrane Central were 
systematically searched to identify appropriate studies published before December 16th 2015. 
Reference lists of the included studies were searched for further identification of relevant studies.
STUDY SELECTION: Randomized controlled trials (RCTs) and observational studies that 
assessed natural or plant-based therapies and the presence of one or more menopausal symptoms 
(e.g. hot flashes and night sweats). 
DATA EXTRACTION: Data were extracted by two independent reviewers using a pre-designed 
data collection form.  
MAIN OUTCOME AND MEASURES: Menopausal symptoms including, but not limited to, hot 
flashes, night sweats, and Kupperman Index.
RESULTS: In total, 119 articles based on 113 unique studies (101 RCTs and 12 prospective 
non-randomized intervention or observational studies) were identified, including a total of12,443 
individual women. After meta-analyses of RCTs’ estimates, use of phytoestrogens significantly 
reduced the reported number of daily hot flashes between the treatment groups [pooled mean 
4.6
366
difference of changes: -1.26 (95%CI: -1.87, -0.65)] and significantly improved vaginal dryness score 
[pooled mean difference of changes: -0.31 (-0.52, -0.10)]. Individual phytoestrogen interventions 
such as dietary and supplemental soy isoflavones were beneficial for menopausal outcomes in 
general, and number of night sweats in 24 hours in particular. Additionally, behavioural therapies, 
acupuncture, and several herbal remedies in aggregate improved overall menopausal symptoms as 
measured by the Kupperman Index [pooled mean differences: -11.10 (-17.17, -5.03), -8.41 (-11.81, 
-5.0), and 6.72 (-8.10, -5.33), respectively]. There was substantial diversity in quality across the 
available studies. 
CONCLUSIONS AND RELEVANCE: Findings indicate that composite and certain specific 
phytoestrogen supplementations may confer a benefit of reducing menopausal symptoms in 
women. Additionally, several other plant-based and natural therapies may also effectively improve 
menopausal symptoms. However, owing to a generally sub-optimal quality and the heterogeneous 
nature of the current evidence, further rigorous studies are needed to determine their impact on 
menopausal health and symptoms alleviation.
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INTRODUCTION
Menopause is considered the end of a woman’s reproductive life, generally indicated by the time 
when menstrual periods stop permanently1. While menopause is usually a natural change, the 
menopausal transition and its associated changes vary widely2,3. There is a range of symptoms that 
have been associated with menopause, including hot flashes, night sweats and vaginal dryness, with 
50.3% to 82.1% of menopausal women reporting hot flashes or night sweats4,5. Medical treatments 
for these symptoms are available, including hormone replacement therapy (HT); however, given 
the potentially negative health consequence of HT on cardiovascular health and breast cancer6,7, 
many women choose to use natural or plant-based therapies. The proportion of women in Western 
countries using complimentary therapies to manage menopausal symptoms is approximately 40-
50%8,9.
There is a broad range of natural and plant-based therapies that purport to have a positive effect 
on menopausal symptoms. These therapies include the oral use of phytoestrogens such as dietary 
isoflavones and soy extracts; herbal remedies such as red clover and black cohosh; and non-
biological treatments, such as acupuncture and yoga. Although the potential impact of these 
treatments on menopausal symptoms has been assessed in many individual randomized trials10-12, 
most of these intervention studies were limited by (i) inadequate power (i.e. limited sample size), 
(ii) short follow-up period, (iii) suboptimal quality (eg, high dropout rates), and (iv) inconsistent 
findings. While several attempts to summarize the available evidence have been conducted, they 
are also limited owing to (i) a focus on a specific therapy (eg, effects of phytoestrogens)13, (ii) 
evaluation of a specific symptom (eg, hot flashes), and being (iii) non-quantitative14 or largely 
non-systematic in nature15. Therefore, considering the increasingly wide-ranging use of natural and 
plant-based therapies by women to alleviate menopausal symptoms, an updated and comprehensive 
quantitative review on their efficacy is essential.  
We present a systematic review and meta-analysis of all available intervention and observational 
studies to quantify the impact of a range of natural and plant-based therapies on menopausal 
symptoms. 
METHODS
Data Sources and Search Strategy 
This review was conducted using a predefined protocol and in accordance with PRISMA and 
MOOSE guidelines (Appendices 1 and 2). Three electronic databases (Medline Ovid, Embase 
and Cochrane Central) were searched until December 16th 2015 without language restriction. The 
computer-based searches combined terms related to (1) the exposures (or interventions, where 
appropriate) such as phytoestrogens, black cohosh, ERr731 rhubarb raponticin, and various 
alternative or complimentary natural therapies referred as to whole medical system (including 
herbal medicine, traditional Chinese medicine, ayurveda, naturopathy, chiropractic, osteopathy, 
368
massage, yoga, relaxation therapy, homeopathy, aromatherapy, and therapeutic touch)16; and (2) 
menopausal outcomes (e.g., hot flashes, night sweats, vasomotor symptoms) in humans (Appendix 
3). Two independent reviewers screened the titles and abstracts of all studies initially identified, 
according to the selection criteria, and any disagreement was resolved through consensus or 
consultation with a third independent reviewer. Full texts were retrieved from studies that satisfied 
all selection criteria. Reference lists of selected studies and reviews identified on the topic were 
searched to identify additional publications. 
Study Selection and Eligibility Criteria
Intervention studies were eligible if they: (1) were randomized controlled trials (RCTs) or non-
randomized trials; (2) assessed effects of any complementary or alternative therapy listed above in 
perimenopausal, menopausal, or postmenopausal women compared to a placebo or no treatment; 
and (3) collected endpoints for menopausal symptoms, including hot flashes, night sweats, the 
Kupperman Index 17 and Greene Climacteric Scale18. To maintain consistency and due to difficulty 
of interpreting results without a placebo or control, head-to-head trials without a placebo group 
that compared non-hormonal therapies with estrogen or with other medications were excluded. 
Study populations in the eligible trials included women experiencing menopausal symptoms 
recruited from health care settings or general populations. No restrictions on length of follow up 
were applied for RCTs. 
Prospective observational studies were eligible for inclusion if they followed study participants 
for at least one year, and if they assessed associations between any of the exposures of interest (as 
defined above) and subsequent risk of perimenopausal, menopausal, or postmenopausal women 
experiencing menopausal symptoms.
Data Extraction 
The exposures or interventions eligible for inclusion in the current review were summarized using 
the following broad groupings: (i) biologically-based therapies such as phytoestrogens (including 
dietary isoflavones and extracts of soy, red clover and other phytoestrogens), black cohosh, and 
ERr731 rhubarb raponticin; (ii) non-biological therapies, such as mind-body and behavioural 
therapies (including yoga and applied relaxation), manipulative, body-based, and energy therapies 
(including reflexology, therapeutic massage. and aromatherapy), and acupuncture; and (iii) 
medicinal herbs (including Chinese or other medicinal herbs). Two authors independently extracted 
data and a consensus was reached in case of any inconsistency with involvement of a third author. 
A predesigned electronic data abstraction form was used to extract relevant information. In case of 
multiple publications, the most up-to-date or comprehensive information was extracted. 
Assessing the Risk of Bias 
Two reviewers independently rated the quality of studies. The Cochrane Collaboration’s tool19 
and the Newcastle-Ottawa Scale20 were used to assess the risk of bias in RCTs and in prospective 
observational studies respectively. Detailed information on the assessment of study quality and risk 
of bias is provided in Appendix 4.  
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Statistical Analysis
For intervention studies, treatment effects were defined as the differences in outcomes between 
the treatment and placebo at the end of the trial. For continuous outcomes, summary measures 
were presented as mean differences. For data reported as medians, ranges, or 95% confidence 
intervals (CIs), we calculated means and standard deviations as previously described21. To enable 
a consistent approach to the meta-analysis and enhance interpretation of the findings, units of 
measurement were converted where appropriate. Most crossover trials in this review did not report 
adequate crossover analysis, and therefore, we used data from the first period only22. The inverse 
variance weighted method was used to combine summary measures using random-effects models 
to minimise effects of between-study heterogeneity23. Fixed-effect models were used in subsidiary 
analyses. Heterogeneity was assessed using the Cochrane χ2 statistic and the I2 statistic, and was 
distinguished as low (I2 ≤25%), moderate (I2 >25% and <75%) or high (I2 ≥75%)24. Publication 
bias was evaluated through funnel plots and Egger’s regression symmetry tests25. Sensitivity 
analyses were done to assess the influence of each individual study, by omitting the studies that 
had the largest effect on the overall result one by one. Furthermore, we restricted the analysis to 
studies that did not include participants with a history of breast cancer. Study-level characteristics 
including geographical location, duration of treatment, number of total participants, and risk of 
bias were pre-specified as characteristics for assessment of heterogeneity, and were evaluated using 
stratified analyses and random effects meta-regression26. Only estimates derived from RCTs were 
pooled in the meta-analysis. Given the heterogeneous nature of the study characteristics, exposures 
evaluated, and outcomes, we did not perform a quantitative summarization of observational or 
non-randomized studies. A narrative synthesis and construction of descriptive summary tables 
were done for these studies that could not be quantitatively pooled. All tests were two-tailed and 
p-values of 0.05 or lower were considered significant. STATA release 13 (Stata Corp, College 
Station, Texas, US) software was used for all analyses.
RESULTS
Study Identification and Selection
In total, we identified 4,908 relevant citations. After screening based on titles and abstracts, 207 articles 
were selected for detailed evaluation of their full texts. Of those, 119 articles, based on 113 unique 
studies, met our inclusion criteria and were included in the review: seventy articles about biologically-
based therapies, 36 on whole medical systems, nine on mind-body and behaviour-related therapies and 
four articles on manipulative, body-based, and energy therapies (Figure 1; Appendix 4). 
Characteristics of Included Studies
Among the 113 included studies, 101 were RCTs and 12 were prospective non-randomized 
intervention or observational studies (Table 1 and eTables 1-3). In aggregate, the 113 studies 
reported results for 12,443 unique women. Thirty-nine studies were based in Europe; 32 in Asia; 
2220 in North America; 11 in South America; eight in Australia, and one in Egypt. The baseline age 
of participants ranged from 18 to 75 years. For the RCTs, the duration of the interventions ranged 
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Table 1 Summary characteristics of the included studies
Biologically-
based therapies
Whole medical 
systems
Mind-body and 
behavioural 
therapies
Manipulative, 
body-based and 
energy therapies
Eligible studies
No. of unique studies 69 33 7 4
Median (IQR) duration of 
follow-up, weeks
12.0 (12.0-24.0) 12.0 (7-13) 12.0 (12.0-13.0) 14.7 (8.0-18.2)
Study Design
Randomised trials 64 26 7 4
Non-randomised trials 3 0 0 0
Non-randomised observational 
studies
2 6 0 0
Other 0 1* 0 0
Participants
Total no. of participants 8344 2883 863 353
Median (IQR) no of participants 84 (54-145) 72 (46-102) 120 (70-200) 68 (45-132)
Median age (IQR), years 53 (52-54) 52 (50-53) 50 (49-55) 52 (51-53)
Location
Europe 27 9 2 1
North America 12 7 2 1
Asia-Pacific 20 16 3 1
South America 10 0 0 1
Africa 0 1 0 0
*Used both randomised trial and non-randomised observational study designs
from four weeks to two years, but the majority had a 12-week intervention period. The follow-
up period or duration of treatment for prospective non-randomized intervention or observational 
studies ranged from four weeks to six years. 
Effects of Biological Therapies on Menopausal Outcomes
Forty-six studies examined the effect of overall phytoestrogen supplementation on menopausal 
symptoms and scores. Of those, only data from thirty-five studies (all RCTs) contributed to the 
meta-analysis, which showed a decrease in the number of daily hot flashes with a pooled mean 
difference between the treatment groups of -1.26 (95% CI: -1.87, -0.65) (Figure 2). There was 
evidence of similar beneficial effects on vaginal dryness scores (pooled mean difference of changes 
between treatment groups: -0.31 (-0.52, -0.10) and 24-hour night sweat symptoms (pooled mean 
difference of changes: -2.14 (-5.57, 1.29), though the latter effect was not significant. There was no 
improvement in the score-based menopausal symptom assessments quantified by the Kupperman 
Index (pooled mean difference between treatment groups: -3.21 (-6.09, 1.61)) or by Greene 
Climacteric Scale (pooled mean difference between treatment groups: -0.62 (-2.14, 0.89)) (Figure 
2 and eFigures 1-2). Study-specific estimates from studies not included in the meta-analyses 
generally supported improvements in individual symptoms, particularly in the number of hot 
flashes within 24 hours (eTables 4-6). 
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Separate meta-analyses were performed for different types of interventions, including evaluation 
of dietary isoflavones and supplements and extracts of soy isoflavones (twenty studies), and 
red clover (9 studies) (Figure 3 and eFigures 3-6). The results of the analyses on the effects of 
supplements and extracts of soy isoflavones overall replicated the findings of the larger combined 
analyses (eFigure 4). For dietary soy isoflavones there was evidence of significant reductions in 
the number of night sweats in 24 hours (pooled mean difference of changes: -0.40 (-0.79, -0.01)), 
but the result was based on a single trial only (eFigure 5). There was no association between red 
clover and any of the menopausal symptoms or scores, except for the number of night sweats in 
24 hours (eFigure 6). 
The effect of black cohosh on menopausal symptoms was assessed in six RCTs. Overall, black 
cohosh did not have any beneficial effect on the number of hot flashes or night sweats within 24 
hours, or the Kupperman Index. Black cohosh improved the Greene Climacteric Scale significantly 
(pooled mean difference of changes: -4.45 (-7.18, -1.72)), but was only assessed in one study 
(Figure 3 and eFigure 7). Of the six studies of black cohosh that could not be included in the 
meta-analysis, one study found an improvement in menopausal symptoms score, another study 
reported an improvement in the Kupperman Index and in a variety of other menopausal symptoms, 
including hot flashes, sweating, and insomnia, as did two other studies that combined black cohosh 
with other therapies (eTables 5 and 6). One study did not find any effect of black cohosh on 
menopausal symptoms (eTables 5 and 6). Nine additional studies of other biological therapies 
were identified and have been summarized in eTable 5. 
Figure 2 Effects of Phytoestrogens supplementation on menopausal outcomes in the available randomised controlled trials
(1) Score-based
Kupperman Index
Greene Climacteric Scale
(2) Symptom-based
Number of hot ashes in 24 hours
Number of night sweats in 24 hours
Vaginal dryness score
Outcome
10
6
18
2
3
No. of 
Studies
404
154
998
80
137
Intervention
426
156
1022
89
101
Control
-3.21 (-8.03, 1.61)
-0.62 (-2.14, 0.89)
-1.32 (-2.02, -0.61)
-2.14 (-5.57, 1.29)
-0.31 (-0.52, -0.10)
Mean dierence 
(95% CI)
Favoursintervention  Favourscontrols 
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No. of Participants
i re 2 Effects of Phytoestrogens supplementation n menopausal outcomes in the available randomised 
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Briefly, five studies found an improvement in symptoms with therapies including evening primrose, 
flaxseed, St. John’s Wort, and combined therapies, while three studies of guar gum, flaxseed, and St 
John’s Wort with Chaste tree found no difference (eTable 5).
Effects of Non-biological Therapies and Herbal Remedies 
Findings from the meta-analyses were based solely on available data from RCTs, including three 
on mind, body, and behavioural therapies; eight on acupuncture; four on Chinese medicinal herbs; 
and three on other medicinal herbs (Figure 4 and eFigures 8-11). A single study demonstrated 
an improvement in overall menopausal symptoms measured by the Kupperman Index with mind, 
body, and behavioural therapies, specifically relaxation sessions (pooled mean difference of 
changes: -11.10 (-1.17, -5.03)). For the same intervention, based on three RCTs, a similar, albeit 
weaker, reduction in the number of hot flashes in a 24 hour period was observed (pooled mean 
difference of changes: -1.61 (-3.40, 0.19)). The results of additional studies that assessed other non-
biological therapies are summarized in eTable 7. Specifically, while two studies demonstrated an 
improvement in symptoms through treatments including therapeutic massage and aromatherapy, 
studies that used yoga or passive movement as interventions found no such improvements.
The meta-analyses of six RCTs that used acupuncture as the intervention found significant 
reductions in the number of daily hot flashes (pooled mean difference of changes: -1.99 (-3.38, 
-0.60)) and an improvement in the Kupperman Index (pooled mean difference of changes: -8.41 
(-11.81, -5.02)) across treatment groups (Figure 4). Similarly, meta-analyses of the studies that 
used non-Chinese medicinal herbs also demonstrated significant improvements in the number 
of hot flashes in 24-hours (pooled mean difference of changes: -1.62 (-2.29, -0.95)) and total 
Kupperman Index (pooled mean difference of changes: 6.72 (-8.10, -5.33)). No overall evidence 
of improvements in menopausal outcomes was observed for Chinese medicinal herbs (Figure 4). 
Sensitivity analyses and assessments of Bias, Study Quality and Heterogeneity
For pooled analyses involving five or more studies, exclusion of any single study at one time from 
the meta-analysis, or exclusion of trials that included participants with a history of breast cancer 
had minimal effect on the pooled estimates (data available upon request). Seventy of the included 
RCTs demonstrated a high risk of bias within one or more areas of study quality (eTable 8). Three 
RCTs were found to have a low risk of bias in all areas. An additional 38 studies were found to be at 
low risk but with some lack of clarity in important aspects. All of the non-randomized studies were 
also considered to be at high risk of bias (eTable 3). Ten of 17 analyses showed high between-study 
heterogeneity, with an I2 estimate exceeding 75% (p<0.01 for the Cochrane χ2 statistic) (eTable 
8). This level of heterogeneity could be explained by differences between studies due to results 
derived from heterogeneous populations, methods, and effect estimates (eTable 9). Furthermore, 
for trials evaluating the effect of phytoestrogen supplementation on Kupperman Index and the 
number of hot flashes in 24 hours, the identified heterogeneity was explained to a large extent by 
differences in the study quality and location (eTable 9) (eFigures 12-13). For trials on the effect 
of soy isoflavones on the number of daily hot flashes, the identified heterogeneity was explained 
by location whereas for trials examining the effect of red clover supplementation on the number of 
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hot flashes in 24 hours, heterogeneity was not explained by any of the study-level characteristics 
assessed (eTable9) (eFigures 14-15). Publication bias was assessed visually using Begg’s funnel 
plots for those meta-analyses that included five or more studies. Upon examination, four out of six 
of the plots were approximately symmetrical (eFigure 16), while the rest (n=2) were asymmetrical. 
The Egger’s test estimates were non-significant (p>0.05) for all analyses that involved a minimum 
of five studies.
DISCUSSION
In this systematic review and meta-analysis we found that a number of plant-based and natural 
therapies might help improve both individual and collective menopausal symptoms in women. 
Composite phytoestrogen supplementation and individual phytoestrogen interventions such as 
dietary and supplemental soy isoflavones significantly improved menopausal symptoms in general, 
and vasomotor symptoms in particular. Additionally, several mind, body, and behavioural therapies 
including relaxation, acupuncture, and various medicinal herbs improved collective menopausal 
symptoms. Nonetheless, there was substantial diversity in scientific rigour and quality across the 
available studies. 
We observed significant beneficial effects of composite phytoestrogen supplementation on 
menopausal symptoms in the RCTs. Our subsidiary analyses to differentiate the overall effects of 
phytoestrogens into whole foods, soy protein, and isoflavone extract supplementation groups yielded 
broadly similar results. While, supplementing with red clover, a rich source of phytoestrogens 
formononetin, biochanin A, daidzein, and genistein27, was not associated with the frequency of 
hot flashes, it generally conferred a benefit for night sweats, but the evidence is too limited to 
draw a conclusion. Compared with the most recent previous quantitative reviews, our review had 
substantially greater power (overall and in specific associations); evaluated the impacts of a wide 
range of plant-based and other natural therapies on several menopausal symptoms (including hot 
flashes, night sweats, vaginal dryness score and Kupperman Index) in one single comprehensive 
investigation; and yielded similar (albeit more precise) effect estimates for various supplements 
such as soy isoflavone extracts and red clover13,28. 
There may be a plausible biological argument for these effects of phytoestrogens. It is well-
known that estrogen levels decrease during menopause and that, menopausal symptoms are a 
consequence29. Accordingly, phytoestrogens, plant compounds with estrogen-like properties30 can 
be an effective treatment. The two major subtypes of phytoestrogen, isoflavones and lignans, have a 
similar chemical structure to estradiol (i.e., a form of estrogen) and therefore also appear to exhibit 
an estrogenic effect. Taken together, this may explain the aggregate beneficial effects observed in 
this review in the phytoestrogen supplementation trials. However, this mechanism of action could 
also cause adverse effects; there is evidence that isoflavone supplement use was associated with an 
increased rate of endometrial hyperplasia31. 
Second, we found no association between black cohosh (Cimicifuga racemosa or Actaea racemosa) 
supplementation and menopausal symptoms. Although black cohosh remains a widely studied and 
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popular herbal remedy, there has been lack of clarity regarding the identity of its active compounds 
and its mechanism of action, as well as concerns over possible adverse effects32. Beyond these 
existing uncertainties, the lack of beneficial effects evident in the current meta-analysis does not 
support the use of black cohosh to reduce menopausal symptoms. Third, among the non-biological 
interventions, there was evidence that acupuncture and behavioural therapies were beneficial. It has 
been proposed that acupuncture, defined as the practice of inserting needles into certain points in 
the body for therapeutic purposes33, may favourably affect menopausal symptoms by increasing the 
activity of hypothalamic β-endorphin34, and may favourably affect the nervous system by modulating 
the levels of various neurotransmitters and neuropeptides35. Nonetheless, given the insufficient 
number of powerful, high-quality, and detailed trials, especially those adequately controlled for 
sham treatment or placebo in the comparison arm, further evidence is needed to conclude whether 
acupuncture effectively reduces menopausal symptoms. Similarly, while behavioral interventions 
appeared to be safe and potentially effective in our analysis, this early, limited-scale evidence 
requires further careful study.  Finally, our analyses involving trials of medicinal herbal remedies 
showed no overall effect of Chinese medicinal herbs such as dong quai on the Kupperman index 
for. By contrast, combined analyses involving trials that assessed other newer herbal remedies such 
as EstroG-100 (a mixture of standardized extracts of Cynanchum wilfordii, Phlomis umbrosa and 
Angelica gigas), ERr 731 (an extract isolated from Rheum rhaponticum), and pycnogenol (extract 
from pine bark), appeared to improve the Kupperman index. However, more trials are needed to 
determine the efficacy of these products on menopausal symptoms since only a few trials have 
been conducted.
To the best of our knowledge, this is the first quantitative review of randomized and non-randomized 
studies that assesses a wide range of plant-based and natural therapies in relation to menopausal 
symptoms in a single comprehensive investigation. The analyses, in aggregate, included more 
than twelve thousand women and evaluated a broad array of menopausal symptoms, ranging from 
specific symptoms such as vaginal dryness and hot flashes, to collective symptom scores. There 
are a number of limitations to this study. Firstly, typical to any literature-based meta-analysis, it is 
possible that both measured and unmeasured publication bias can limit, at least in part, our overall 
findings. In this regard, although evaluations with the conventional funnel plots and Egger’s test 
estimates indicate minimal impact of publication bias, these approaches are limited by a qualitative 
nature reliant on visual inspection and the fact that the majority of these assessments were based 
on between five to ten studies. Therefore, despite all efforts made to undertake a comprehensive 
search of the published and unpublished literature, we cannot exclude the possibility of publication 
bias stemming from underreporting of negative findings. Also, inclusion of data from potentially 
poorly conducted studies is undoubtedly a limitation of the current review. Variation in study 
quality has contributed to the heterogeneity of findings noted in several of the meta-analyses. 
Other sources of heterogeneity are likely to include population differences, including ethnicity, 
a factor in the presence of menopausal symptoms36,37 and differing age ranges. Furthermore, the 
supplements used in the trials included in this study may vary in quality and composition (ie, how 
much of the active ingredient is actually in the supplement), which might have contributed in 
the heterogeneity in effects observed in our analyses. Also, while we assessed different outcome 
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measures of menopause symptoms, covering their frequency and severity, there may be problems 
of comparability due the varying degrees of the outcome measures38. Since the number of available 
studies in some analyses was small, it precluded our ability to quantitatively investigate the sources 
of the observed heterogeneity beyond the qualitative descriptions of the individual studies presented 
in eTable 9. Also, self-reported measures of vasomotor symptoms may be subject to memory and 
reporting bias. Therefore, future studies that assess vasomotor symptoms physiologically with, for 
example, an ambulatory hot flash monitor to measure skin conductance, are needed. Considering 
the levels of heterogeneity identified and the low degree of quality of some of the studies included, 
the results of this systematic review and meta-analysis should be interpreted with caution. Further 
randomized clinical studies utilizing an adequately designed strict protocol with sufficient sample 
size, adequate blinding of outcome assessment, participants and personnel, proper allocation 
concealment, and sufficient follow up period are needed.
There may be several implications of our review. First, our findings reinforce that a number 
of plant-based and natural therapies may improve both individual and collective menopausal 
symptoms.  Second, it highlights major research and knowledge gaps both in potentially beneficial 
therapies and assessment of a wider range of outcomes. For instance, while the majority of the 
available studies focus appropriately on hot flashes, which are the most common symptom of 
the menopausal transition, a few studies additionally evaluated other menopausal symptoms (e.g. 
night sweats). There were insufficient numbers of studies on other therapies such as behavioural 
therapies, acupuncture, and herbal remedies. Therefore, our review should stimulate future 
research, concentrating on large, well-designed studies that evaluate a wider range of menopausal 
symptoms. Finally, it also underscores the lack of data on adverse effects that may arise from 
long term use of plant-based and natural therapies. Information on any detrimental health effects, 
typically available in long-term intervention studies, is essential given their potential relevance to 
post-menopausal health. 
In conclusion, available evidence indicates that composite and specific phytoestrogen 
supplementations may confer significant benefit in reducing common menopausal symptoms in 
women. Additionally, several other plant-based and natural therapies may also effectively improve 
menopausal symptoms. However, owing to the general sub-optimal quality and heterogeneous 
nature of the current evidence, further rigorous studies are needed to determine the impact of plant-
based and natural therapies on menopausal health.
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eTable 8 Between-study heterogeneity statistics
Intervention Outcome No. of 
studies
I-squared (95% 
confidence interval)
P-value
Phytoestrogen Kupperman index 10 99 (99-99) < 0.001
Phytoestrogen Green Climacteric Scale 6 0 (0-75) 0.940
Phytoestrogen No. of hot flashes in 24 hours 18 93 (91-95) < 0.001
Phytoestrogen Number of night sweats in 24 
hours
2 99 (98-99) < 0.001
Phytoestrogen Vaginal dryness score 3 48 (0-85) 0.145
Dietary and 
supplementary soy 
isoflavones
Kupperman index 5 88 (75-94) < 0.001
Dietary and 
supplementary soy 
isoflavones
No. of hot flashes in 24 hours 10 83 (69-90) < 0.001
Red clover Kupperman index 2 100 (100-100) < 0.001
Red clover Green Climacteric Scale 3 0 (0-90) 0.747
Red clover No. of hot flashes in 24 hours 7 97 (95-98) < 0.001
Black cohosh Kupperman index 2 0 0.464
Black cohosh No. of hot flashes in 24 hours 3 60 (0-89) 0.081
Mind, body, and 
behavioural therapies
No. of hot flashes in 24 hours 3 85 (57-95) 0.001
Acupuncture Kupperman index 2 0 0.925
Acupuncture No. of hot flashes in 24 hours 4 48 (0-83) 0.121
Chinese medicinal herbs Kupperman index 2 84 (34-96) 0.012
Other medicinal herbs Kupperman index 2 98 (95-99) < 0.001
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eFigure 2 Effect of Phytoestrogens supplementation on vasomotor symptoms 
Number of hot flashes in 24 hours
Knight, 1999
van de Weijer, 2002
Hachul, 2011
Baber, 1999
Penotti, 2003
Cheng, 2007
Jeri, 2002
Lewis, 2006
Faure, 2002
Petri, 2007
Lipovac, 2012
Albertazzi, 1998
Aso, 2012
Van Patten, 2002
Tice, 2003
Ferrari, 2009
Atkinson, 2004
Danna, 2007
Subtotal
Number of night sweats in 24 hours
Cheng, 2007
Lipovac, 2012
Subtotal
Vaginal dryness score
Colacurci, 2004
Kotsopoulos, 2000
Brzezinski, 1997
Subtotal
Author, year 
of publication
13
16
19
25
28
30
30
33
39
40
50
51
77
78
84
85
102
198
30
50
15
44
78
Intervention
12
14
19
26
34
30
30
33
36
40
59
53
83
79
85
95
103
191
30
59
15
50
36
Control
-0.30 (-2.66, 2.06)
-2.37 (-5.75, 1.01)
0.57 (-0.26, 1.40)
0.59 (-0.43, 1.61)
-0.70 (-1.98, 0.58)
-0.80 (-1.19, -0.41)
-2.80 (-3.65, -1.95)
0.22 (-0.62, 1.06)
-4.20 (-7.26, -1.14)
-2.30 (-3.50, -1.10)
-7.70 (-8.88, -6.52)
-1.59 (-1.95, -1.20)
-0.90 (-1.49, -0.31)
0.70 (-0.37, 1.77)
-0.60 (-1.38, 0.18)
-1.30 (-2.03, -0.57)
0.20 (-0.34, 0.74)
-2.50 (-3.07, -1.93)
-1.31 (-2.02, -0.61)
-0.40 (-0.79, -0.01)
-3.90 (-4.50, -3.30)
-2.14 (-5.57, 1.29)
-0.46 (-0.83, -0.09)
-0.20 (-0.24, -0.16)
-0.49 (-0.89, -0.09)
-0.31 (-0.52, -0.10)
Mean difference (95% CI)
Red clover 160 mg
Red clover 80 mg
Supplements/Extracts of SI 80 mg
Red clover 40 mg
Supplements/Extracts of SI 72 mg
Dietary soy isoflavones 60 mg
Red clover 40 mg
Dietary soy isoflavones 42 mg
Supplements/Extracts of SI 17.5 mg
Supplements/Extracts of SI 100 mg
Red clover 80 mg
Dietary soy isoflavones 76 mg
Supplements/Extracts of SI 10 mg
Dietary soy isoflavones 90 mg
Red clover 82 mg
Supplements/Extracts of SI 80 mg
Red clover 40 mg
Other phytoestrogens 54 mg
Dietary soy isoflavones 60 mg
Red clover 80 mg
Supplements/Extracts of SI 75 mg
Supplements/Extracts of SI 118 mg
Other phytoestrogens
Specific intervention
Favours intervention Favours controls
0-8.88 8.88
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eFigure 3 Effects of dietary and supplemental soy isoflavones on menopausal scores and symptoms 
Number of hot flashes in 24 hours
Hachul, 2011
Penotti, 2003
Cheng, 2007
Lewis, 2006
Faure, 2002
Petri, 2007
Albertazzi, 1998
Aso, 2012
Van Patten, 2002
Ferrari, 2009
Subtotal
Kupperman Index
Colacurci, 2004
Hachul, 2011
Lee, 2010
Cancellieri, 2007
Ferrari, 2009
Subtotal
Number of night sweats in 24 hours
Cheng, 2007
Subtotal
Vaginal dryness score
Colacurci, 2004
Kotsopoulos, 2000
Subtotal
Green Climacteric Scale total score
Knight, 2001
Secreto, 2004
Subtotal
Author, year
of publication
19
28
30
33
39
40
51
77
78
85
15
19
43
60
85
30
15
44
12
64
Intervention
19
34
30
33
36
40
53
83
79
95
15
19
44
65
95
30
15
50
12
67
Control
0.57 (-0.26, 1.40)
-0.70 (-1.98, 0.58)
-0.80 (-1.19, -0.41)
0.22 (-0.62, 1.06)
-4.20 (-7.26, -1.14)
-2.30 (-3.50, -1.10)
-1.59 (-1.95, -1.20)
-0.90 (-1.49, -0.31)
0.70 (-0.37, 1.77)
-1.30 (-2.03, -0.57)
-0.79 (-1.35, -0.23)
-4.11 (-6.12, -2.10)
-3.47 (-4.27, -2.67)
-3.46 (-6.74, -0.18)
-3.80 (-5.70, -1.90)
1.50 (-0.09, 3.09)
-2.61 (-4.78, -0.43)
-0.40 (-0.79, -0.01)
-0.40 (-0.79, -0.01)
-0.46 (-0.83, -0.09)
-0.20 (-0.24, -0.16)
-0.26 (-0.48, -0.04)
-2.30 (-6.98, 2.38)
-0.30 (-3.44, 2.84)
-0.92 (-3.53, 1.69)
Mean difference (95% CI)
Favours intervention Favours controls 
0-7.26 7.26
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eFigure 3 Effects of dietary and supplemental soy isoflavones on menopausal scores and symptoms
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eFigure 4 Effects of supplements and extracts of soy isoflavones on menopausal scores and symptoms
Number of hot flashes in 24 hours
Hachul, 2011
Penotti, 2003
Faure, 2002
Petri, 2007
Aso, 2012
Ferrari, 2009
Subtotal
Kupperman Index
Colacurci, 2004
Hachul, 2011
Lee, 2010
Cancellieri, 2007
Ferrari, 2009
Subtotal
Vaginal dryness score
Colacurci, 2004
Kotsopoulos, 2000
Subtotal
Green Climacteric Scale total score
Secreto, 2004
Subtotal
Author, year
of publication
19
28
39
40
77
85
15
19
43
60
85
15
44
64
Intervention
19
34
36
40
83
95
15
19
44
65
95
15
50
67
Control
0.57 (-0.26, 1.40)
-0.70 (-1.98, 0.58)
-4.20 (-7.26, -1.14)
-2.30 (-3.50, -1.10)
-0.90 (-1.49, -0.31)
-1.30 (-2.03, -0.57)
-1.09 (-1.96, -0.22)
-4.11 (-6.12, -2.10)
-3.47 (-4.27, -2.67)
-3.46 (-6.74, -0.18)
-3.80 (-5.70, -1.90)
1.50 (-0.09, 3.09)
-2.61 (-4.78, -0.43)
-0.46 (-0.83, -0.09)
-0.20 (-0.24, -0.16)
-0.26 (-0.48, -0.04)
-0.30 (-3.44, 2.84)
-0.30 (-3.44, 2.84)
Mean difference (95% CI)
Favours intervention Favours controls
0-7.26 7.26
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eFigure 5 Effects of dietary soy isoflavones on menopausal scores and symptoms
Number of hot flashes in 24 hours
Cheng, 2007
Lewis, 2006
Albertazzi, 1998
Van Patten, 2002
Subtotal
Number of night sweats in 24 hours
Cheng, 2007
Subtotal
Green Climacteric Scale total score
Knight, 2001
Subtotal
Author, year
of publication
30
33
51
78
30
12
Intervention
30
33
53
79
30
12
Control
-0.80 (-1.19, -0.41)
0.22 (-0.62, 1.06)
-1.59 (-1.95, -1.20)
0.70 (-0.37, 1.77)
-0.48 (-1.35, 0.40)
-0.40 (-0.79, -0.01)
-0.40 (-0.79, -0.01)
-2.30 (-6.98, 2.38)
-2.30 (-6.98, 2.38)
Mean difference (95% CI)
Favours intervention Favours controls 
0-6.98 6.98
eFigure 4 Effects of supplements and extracts of soy isoflavones on menopausal scores and symptoms
eFigure 5 Effects of dietary soy isoflavones on menopausal scores and symptoms
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eFigure 6 Effects of red clover on menopausal scores and symptoms
Number of hot flashes in 24 hours
Knight, 1999
van de Weijer, 2002
Baber, 1999
Jeri, 2002
Lipovac, 2012
Tice, 2003
Atkinson, 2004
Subtotal
Green Climacteric Scale total score
Knight, 1999
van de Weijer, 2002
Baber, 1999
Subtotal
Kupperman Index
Lipovac, 2012
Hidalgo, 2005
Subtotal
Number of night sweats in 24 hours
Lipovac, 2012
Subtotal
Author, year
of publication
13
16
25
30
50
84
102
12
16
25
50
53
50
Intervention
12
14
26
30
59
85
103
12
14
26
59
53
59
Control
-0.30 (-2.66, 2.06)
-2.37 (-5.75, 1.01)
0.59 (-0.43, 1.61)
-2.80 (-3.65, -1.95)
-7.70 (-8.88, -6.52)
-0.60 (-1.38, 0.18)
0.20 (-0.34, 0.74)
-1.85 (-3.88, 0.19)
-0.10 (-5.69, 5.49)
-2.40 (-7.38, 2.58)
-0.29 (-2.92, 2.34)
-0.65 (-2.80, 1.49)
-22.20 (-24.83, -19.57)
15.00 (12.08, 17.92)
-3.61 (-40.06, 32.85)
-3.90 (-4.50, -3.30)
-3.90 (-4.50, -3.30)
Mean difference (95% CI)
Favours intervention Favours controls 
0-40.1 40.1
 9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eFigure 7: Effects of black cohosh on menopausal scores and symptoms
Green Climacteric Scale total score
Amsterdam, 2009
Subtotal
Kupperman Index
Geller, 2009
Frei-Kleiner, 2005
Subtotal
Number of hot flashes in 24 hours
Shahnazi, 2013
Pockaj, 2006
Newton, 2006
Frei-Kleiner, 2005
Subtotal
Number of night sweats in 24 hours
Newton, 2006
Subtotal
Author, year
of publication
15
22
81
42
66
80
81
80
Intervention
13
22
41
42
65
84
41
84
Control
-4.45 (-8.59, -3.12)
-4.45 (-7.18, -1.71)
1.00 (-2.50, 4.50)
-0.70 (-3.60, 2.20)
-0.01 (-2.24, 2.23)
-3.43 (-4.66, -2.20)
1.32 (0.07, 2.57)
-0.28 (-1.16, 0.60)
-0.19 (-0.81, 0.43)
-0.63 (-2.15, 0.89)
0.08 (-0.30, 0.47)
0.08 (-0.31, 0.47)
Mean difference (95% CI)
Favours intervention Favours controls
0-8.59 8.59
eFigure 6 Effects of red clover on menopausal scores and symptoms
eFigure 7: Effects of black cohosh on menopausal scores and symptoms
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eFigure 8 Effects of mind, body, and behavioural therapies on menopausal scores and symptoms
Number of hot flashes in 24 hours
Zaborowska, 2007
Lindh, 2013
Newton, 2014
Subtotal
Kupperman Index
Zaborowska, 2007
Subtotal
Author, year
of publication
13
33
107
13
Intervention
20
27
142
20
Control
-1.50 (-3.05, 0.05)
-3.10 (-4.28, -1.92)
-0.30 (-1.20, 0.60)
-1.61 (-3.40, 0.19)
-11.10 (-17.17, -5.03)
-11.10 (-17.17, -5.03)
Mean difference (95% CI)
Favours intervention Favours controls
0-17.2 17.2
 12
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eFigure 9: Effects of acupuncture on menopausal scores and symptoms
Number of hot flashes in 24 hours
Nir, 2007
Zaborowska, 2007
Liljergen, 2010
Deng, 2007
Kim, 2010
Borud, 2009_b
Subtotal
Kupperman Index
Zaborowska, 2007
Hervik, 2009
Shen, 2005
Subtotal
Author, year
of publication
12
28
38
38
116
134
28
30
35
Intervention
17
20
36
27
59
133
20
29
30
Control
-1.59 (-3.34, 0.16)
-3.00 (-4.68, -1.32)
0.60 (-0.50, 1.70)
-2.00 (-2.70, 0.90)
-4.25 (-6.00, -2.50)
-2.10 (-3.10, -1.10)
-1.99 (-3.38, -0.60)
-10.00 (-15.20, -4.80)
-6.10 (-6.90, -5.30)
-10.28 (-12.89, -7.67)
-8.41 (-11.81, -5.02)
Mean difference (95% CI)
Favours intervention Favours controls
0-15.2 15.2
eFigure 8 Effects of mind, body, and behavioural therapies on menopausal scores and symptoms
eFigure 9: Effects of acupuncture on menopausal scores and symptoms
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Number of night sweats in 24 hours
Haines, 2008
Subtotal
Kupperman Index
Hirata, 1997
Sun, 2012
Subtotal
Number of hot flashes in 24 hours
Sluijs, 2009
Subtotal
Author, year
of publication
50
35
36
46
Intervention
50
36
36
46
Control
2.70 (0.35, 5.05)
2.70 (0.35, 5.05)
-0.20 (-2.67, 2.27)
-5.50 (-8.83, -2.17)
-2.73 (-7.92, 2.46)
0.52 (-1.13, 2.17)
0.52 (-1.13, 2.17)
Mean difference (95% CI)
Favours intervention Favours controls 
0-8.83 8.83
 15
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
eFigure 11 Effects of other medicinal herbs on menopausal scores and symptoms
Kupperman Index
Chang, 2012
Kohama, 2013
Subtotal
Number of hot flashes in 24 hours
Heger, 2006
Subtotal
Author, year
of publication
31
79
55
Intervention
33
77
55
Control
-12.70 (-14.92, -10.48)
-2.90 (-4.68, -1.12)
-6.71 (-8.10, -5.33)
-1.62 (-2.29, -0.96)
-1.62 (-2.28, -0.96)
Mean difference (95% CI)
EstroG-100
Pycnogenol
ERr 731
Specific intervention
Favours intervention Favours controls
0-14.9 14.9
eFigure 10: Effects of Chinese medicinal herbs on menopausal scores and symptoms
eFigure 11: Effects of other medicinal herbs on menopausal scores and symptoms
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eAppendix 3 Literature search strategy for studies of natural and plant-based therapies in 
menopausal health
Relevant studies, published before May 01, 2015 (date last searched), were identified through 
electronic searches not limited to the English language using MEDLINE, EMBASE, and the 
Cochrane databases.  Electronic searches were supplemented by scanning reference lists of articles 
identified for all relevant studies (including review articles), by hand searching of relevant journals 
and by correspondence with study investigators. The computer-based searches combined search 
terms related to markers related to vasomotor symptoms, related to vascular outcomes and related 
to study design without language restriction.
(i) MEDLINE strategy to identify relevant exposures:
(“Panax”[MeSH Terms] OR “Panax*”[All Fields] OR “Renshen*”[All Fields] OR “Shinseng*”[All 
Fields] OR “Ninjin*” [All Fields] OR “Schinseng*” [All Fields] OR “Jen Shen*” [All Fields] 
OR “Ginseng*” [All Fields] OR  “Soy Foods”[MeSH Terms] OR “Soy*” [All Fields] OR 
“Natto”[All Fields] OR “Tempeh”[All Fields] OR “Texturized Soy Protein*”[All Fields] OR 
“Texturized Vegetable Protein*”[All Fields] OR “Tofu”[All Fields] OR “Miso”[All Fields] OR 
“vitex”[MeSH Terms] OR “Vitex”[All Fields] OR  “Vitices”[All Fields] OR “Chasteberr*”[All 
Fields] OR “Chasteberry Tree*”[All Fields] OR “Chaste Tree*” [All Fields] OR “Chastetree*” 
[All Fields] OR “Passiflora”[MeSH Terms] OR “Passiflora*”[All Fields] OR “Passionfruit*”[All 
Fields] OR “Passion Flower*” [All Fields] OR “Granadilla*”[All Fields] OR “Hypericum”[MeSH 
Terms] OR “Hypericum*”[All Fields] OR “Hypericum perforatum*”[All Fields] OR “St. Johns 
Wort”[All Fields] OR “St. Johnswort”[All Fields] OR “Saint Johns Wort”[All Fields] OR “Saint 
Johnswort”[All Fields] OR “St. John’s Wort”[All Fields] OR “St. John Wort”[All Fields] OR “Saint 
John’s Wort”[All Fields] OR “Saint John Wort”[All Fields] OR “Cimicifuga”[MeSH Terms] OR 
“Cimicifuga*”[All Fields] OR “Cimicifuga racemosa*”[All Fields] OR “Black Bugbane*”[All 
Fields] OR “Actaea racemosa*”[All Fields] OR “Black Cohosh*”[All Fields] OR “Kava”[MeSH 
Terms] OR “Kava*”[All Fields] “Kawa*”[All Fields] OR “Piper methysticum*”[All Fields] 
OR “Medicine, Traditional”[Mesh] OR “Traditional Chinese Medicine”[All Fields] OR “Folk 
Remed*”[All Fields] OR “Folk Remed*”[All Fields] OR “Home Remed*”[All Fields] OR 
“Primitive Medicine”[All Fields] OR “Folk Medicine”[All Fields] OR “Indigenous Medicine”[All 
Fields] OR “Ethnomedicine”[All Fields] OR “Efamol”[Supplementary Concept] OR “efamol”[All 
Fields] OR “Efamol G”[All Fields] OR “Preglandin”[All Fields] OR “evening primrose oil”[All 
Fields] OR “naudicelle”[All Fields] OR “Efamast”[All Fields] OR “Epogam”[All Fields] OR 
“Trifolium”[MeSH Terms] OR “Trifolium*”[All Fields] OR “red clover”[All Fields] OR “Dietary 
fiber”[MeSH Terms] OR “fibre”[All Fields] OR “fiber”[All Fields] OR “Roughage*”[All 
Fields] OR “Wheat Bran*”[All Fields] OR “Isoflavones”[MeSH Terms] OR “*Isoflavone*”[All 
Fields] OR “3-Benzylchroman-4-*”[All Fields] OR “3 Benzylchroman 4 Ones”[All Fields] OR 
“Benzylidene 4 Chromanones” [All Fields] OR “rheum”[MeSH Terms] OR “rheum”[All Fields] 
OR “Da Huang”[All Fields] OR  “rhubarb”[All Fields] OR “Complementary Therapies”[MeSH 
Terms] OR “Complementary Therap*”[All Fields] OR “Complementary Medicine*”[All 
Fields] OR “alternative medicine*”[All Fields] OR “aromatherapy”[MeSH Terms] OR 
“aromatherap*”[All Fields] OR “Aroma Therap*”[All Fields] OR “Withania”[MeSH Terms] OR 
“Withania*”[All Fields] OR “therapeutic touch”[MeSH Terms] OR “therapeutic touch”[All Fields] 
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OR “Reiki”[All Fields] OR “Laying-on-of-Hands”[All Fields] OR “Phytoestrogens”[MeSH 
Terms] OR “Phytoestrogens”[Pharmacological Action] OR “Phyto-Estrogen*”[All Fields] OR 
“Phyto Estrogen*”[All Fields] OR “Phytoestrogen*”[All Fields] OR  “Angelica sinensis”[MeSH 
Terms] OR “dong quai”[Supplementary Concept] OR “Angelica sinens*”[All Fields] OR 
“herbal medicine”[MeSH Terms] OR “herbal medicine*”[All Fields] OR “Ayurveda”[All Fields] 
OR “Herbalism”[All Fields] OR “naturopathy”[MeSH Terms] OR “naturopath*”[All Fields] 
OR  “relaxation therapy”[MeSH Terms] OR “relaxation therap*”[All Fields] OR “relaxation 
technique*”[All Fields] OR “chiropractic”[MeSH Terms] OR “chiropractic*”[All Fields] OR 
“ashwagandha”[MeSH Terms] OR “ashwagandha*”[All Fields] OR “wild yam*”[All Fields] 
OR  “coumestrol”[MeSH Terms] OR “coumestrol*”[All Fields] OR “homeopathy”[MeSH 
Terms] OR “homeopath*”[All Fields] OR “Massage”[MeSH Terms] OR “Massage*”[All 
Fields] OR “osteopath*”[All Fields] OR “yoga”[MeSH Terms] OR “yoga”[All Fields] OR 
“acupuncture”[MeSH Terms] OR “acupuncture*”[All Fields] OR “mindfulness”[MeSH Terms] 
OR “mindfulness”[All Fields])
(ii) MEDLINE strategy to identify relevant outcomes:
(“hot flash*”[All Fields] OR “night sweat*”[All Fields] OR “menopause”[MeSH Terms] OR 
“menopaus*”[All Fields] OR “post menopaus*”[All Fields] OR “post-menopaus*”[All Fields] 
OR “postmenopaus*”[All Fields] OR “perimenopaus*”[All Fields] OR “peri-menopaus*”[All 
Fields] OR “peri menopaus*”[All Fields] OR “climacteric”[MeSH Terms] OR “climacteric”[All 
Fields] OR “Vaginal dryness”[All Fields] OR “mood swing*”[All Fields] OR “unstable 
mood*”[All Fields] OR  “Postmenopausal Osteoporosis”[MeSH Terms] OR “Postmenopausal 
Osteoporos*”[All Fields] OR “Postmenopausal Bone Loss*”[All Fields] OR “Perimenopausal 
Bone Loss*”[All Fields] OR “Post Menopausal Osteoporos*”[All Fields] OR “Post-Menopausal 
Osteoporos*”[All Fields] OR “headache”[MeSH Terms] OR “headache*”[All Fields] OR 
“libido”[MeSH Terms] OR “Decreased Libido”[All Fields] OR “loss of libido”[All Fields] OR 
“palpitations”[All Fields] OR (“depression”[MeSH Terms] AND “menopause” [MeSH Terms]) 
OR (“depression”[All Fields] AND “menopause”[MeSH Terms]) OR (“anxiety”[MeSH Terms] 
AND “menopause”[MeSH Terms]) OR (“anxiety”[All Fields] AND “menopause”[MeSH Terms]) 
OR “sleep* problem*”[All Fields] OR “sleep* difficult*”[All Fields] OR “difficult* sleep*”[All 
Fields] OR “problem* sleep*”[All Fields])
(iii) MEDLINE strategy to identify relevant population:
(“humans”[MeSH Terms])
(iv) MEDLINE strategy to identify relevant study designs:
(“longitudinal studies”[MeSH Terms] OR “prospective”[All Fields] OR “cohort”[All Fields] OR 
“follow up”[All Fields]  OR (“Clinical Trials as Topic”[Mesh]) OR “Randomized Controlled 
Trial” [Publication Type])
Parts i, ii, iii, and iv were combined using ‘AND’ to search MEDLINE. Each part was specifically 
translated for searching alternative databases.
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INTRODUCTION
Despite improvements in prevention and treatment, cardiovascular disease (CVD) remains the 
leading cause of death worldwide and is a major public health problem1. Type 2 diabetes (T2D) 
is an important risk factor for CVD, and most subjects with T2D die from CVD2. Investigating 
the economic impact of non-communicable diseases (NCDs), including CVD and T2D, can help 
shape future healthcare plans and strategies to reduce the economic burden of these diseases. The 
need for prevention strategies to maintain optimal cardiometabolic health is a priority in middle- 
and high income countries, given the increasing prevalence of cardiometabolic disorders in the 
population and the increasing economic burden of these disorders to society. Maintaining optimal 
cardiometabolic health is a multifactorial endeavor. Several dietary and metabolic factors determine 
the overall risk of poor cardiometabolic health3-6. Identifying new risk factors and pathways for 
these cardiometabolic diseases could thus shed more light into the complex pathophysiology of 
cardiometabolic diseases and in potential novel preventing strategies to reduce the burden of these 
diseases. In addition, the etiology of CVD might be different in women, which can result from unique 
biologic characteristics in the coronary systems of women7. In particular, the onset of menopause is 
associated with a sharply increased risk of CVD risk in women8, highlighting the need to evaluate 
menopause and its related physiological changes and symptoms as cardiometabolic risk factors. 
In this chapter, we give an overview of the main findings of the studies in this thesis, what they add to 
the existing body of evidence and possible implications. Furthermore, we consider methodological 
issues and give suggestions for future research.
MAIN FINDINGS 
Economic Impact of Non-Communicable Diseases
In chapter 2 we found that NCDs (CVD, T2D, cancer, chronic obstructive pulmonary disease and 
chronic kidney disease) pose a significant financial burden on health care budgets, macroeconomic 
productivity and nation’s welfare by summarizing the findings from more than 200 papers. Among 
all NCDs, healthcare expenditures for CVD were the highest. The estimated DALY (a measure of 
productivity loss) for CVD ranged from 4.2 in Spain to 68 in Kenya. Additionally, in our review, 
we found that costs increased as did severity of the disease and years lived with the disease. 
We identified a gap in literature concerning the economic impact of NCDs in low and middle 
income countries. Limited research capacity, inadequate financial investment, healthcare system 
development, a lack of electronic health records, and language restrictions may contribute to this 
shortage of data and analysis9. Also, we identified several methodological concerns of the studies 
reviewed, related to sample selection, case definition and the nature of costs included. 
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Nutrition and Cardiometabolic Health 
Fatty acids
In recent decades, the quality of nutrition worldwide has changed 10. The level of certain fatty 
acids intake, including polyunsaturated fatty acids (PUFAs), has increased, currently representing 
28-42% of total energy consumed by European populations10,11. Among subtypes of fatty acids, the 
current guidelines for CVD encourage high consumption of PUFAs as a replacement for other types 
of fatty acids such as saturated fatty acids12,13. Therefore, due also to the increased consumption of 
linoleic acid-rich vegetable oils in the Western diet, consumption of n-6 PUFA has progressively 
increased much more than has consumption of n-3 PUFA14. Concerns have been raised that high 
dietary consumption of n-6 PUFAs along with low intake of n-3 PUFA may shift the physiological 
state to one that is pro-inflammatory and that, therefore, may contribute to increased risk of 
cardiometabolic diseases, including an unfavorable body fat distribution15,16. These concerns come 
from the fact that n-6 PUFAs intake, contrary to n-3 PUFA, has been generally associated with 
production of eicosanoids which have pro-inflammatory properties17. Furthermore, different fatty 
acids have different oxidation rates, and the last is associated with the development of obesity18-20. 
Therefore, the shift in n-3 to n-6 PUFA ratio may have an impact in body fat distribution. Moreover, 
in the Western diet, the consumption of plant derived n-3 PUFAs has almost doubled during the 
last decades (from 1 to 1.9 g/day)21. Recent evidence show that marine derived n-3 PUFA may 
have a different effect on health outcomes like cancer than do non-marine derived n-3 PUFA22 23. 
In our study we examined the association between total PUFAs and individual PUFAs intake (n-3, 
n-6 and n-3/n-6 PUFAs ratio) and serum C-reactive protein, a marker of chronic inflammation. We 
found that high intake of PUFA were associated with diminished chronic inflammation, which was 
mainly driven by n-6 PUFA. 
We did not find an association between total n-3 PUFA and C-reactive protein levels, However, 
when we stratified the analysis by gender, we found that high n-3 PUFA intake was associated 
with increased levels of inflammation only in women. Although, the underlying mechanism for the 
observed gender differences in the association between n-3 PUFAs and CRP is not known, previous 
evidence showed that women have more ALA availability than men because of lower partitioning 
of women toward beta oxidation24,25. Furthermore, gender differences have been reported in the 
activity of desaturation-elongation pathway for the conversion of EPA to DHA26. In our study, 
the main sources of n-3 PUFAs were butter and margarine (the main source of short chain n-3 
PUFA), and 39% of the study participants did not consume fish (the main food source of long 
chain n-3 PUFA).  Thus far, studies have been consistent in showing the beneficial role of marine-
derived n-3 PUFAs supplementation on chronic systemic inflammation27, but  little is known about 
the role of plant derived n-3 PUFAs on inflammation and cardiometabolic health22. Our findings 
suggest that it is important to consider the dietary source of n-3 PUFAs when evaluating their 
role on inflammation and other health outcomes. Our results may provide additional support for 
the maintenance of the present recommended level of n-6 PUFAs intake. At the same time, these 
results suggest that substitution of plant-derived n-3 PUFAs with marine derived n-3 PUFAs should 
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be considered and further evaluated. Furthermore, in chapter 3.2 we examined the hypothesis that 
dietary fat composition (i.e. dietary ratios of n-3/n-6 PUFAs and SFAs/PUFAs) is associated with 
total body fat and regional body fat distribution, as measured by dual-energy X-ray absorptiometry 
(DXA). To test this hypothesis, we used data from two population-based cohorts in the Netherlands 
and Australia, including middle-aged and elderly women. Overall, we found no consistent 
association of dietary fat composition with total fat and regional body fat distribution. Although 
not statistically significant, effects in opposite directions were observed in the two studies for the 
association between dietary fat composition and total body fat. This may be due to differences in 
the food sources of PUFAs in the two populations used for this analysis. 
Vitamin D
Main sources of vitamin D include exposure to sunlight, diet and dietary supplements28. An 
inappropriate diet or exposure to ultraviolet B rays may lead to vitamin D deficiency, which is 
estimated to be highly prevalent in elderly people with prevalence estimates usually reported to 
be above 40% 29,30. Although the best-characterized effects of vitamin D deficiency involve the 
musculoskeletal system, recent evidence suggests that vitamin D has effects on human health 
beyond bone health29. Low serum 25(OH)D concentrations have been associated with many 
obesity-related disorders including CVD and T2D29,31. Receptors for vitamin D are present in 
adipocytes32-34, suggesting a role of vitamin D in obesity. Also, low serum 25 hydroxy vitamin 
D (25(OH)D) concentrations lead to an increase in parathyroid hormone levels as a normal 
physiological response, which, in turn, favors the lipid storage metabolism 35,36. Furthermore, a 
study using the bidirectional Mendelian randomization approach found that higher body mass 
index leads to lower 25(OH)D, but lower 25(OH)D did not lead to higher body mass index37. 
However, results from long-term studies linking vitamin D to body fat, and in particular body fat 
distribution, remain scarce. Furthermore, most of the research on this topic has been performed in 
younger populations and has generally used less precise anthropometric measures such as waist 
circumference or body mass index instead of more accurate measures of body composition by 
DXA. 
We studied the relationship between vitamin D status and body composition including measures of 
fat and lean mass and fat distribution in the elderly. In our study we found an inverse association 
between vitamin D status and total body fat mass and body mass index. Furthermore, we found 
that adequate vitamin D status was positively associated with lean mass percentage in the elderly. 
Nevertheless, these results should be interpreted with caution, since adjustment for baseline body 
mass index (which highly correlates with total fat mass, Pearson Correlation=0.87) abolished 
the association between vitamin D, total body fat and lean mass (data not shown), and therefore, 
providing some evidence that these associations might not be causal. Our results do not support the 
hypothesis that vitamin D plays a role in the regional distribution of body fat. Moreover, we found 
an interaction between 25(OHD), total body fat and the presence of cardio-metabolic diseases. The 
association between vitamin D and total fat percentage was present only in subjects free of cardio-
metabolic disease. Although the reasons for this effect modification are not clear, this observation 
may be due to changes in lifestyle after diagnosis among people with cardiometabolic diseases. 
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Alternatively, it may be due to increased clearance of vitamin D associated with the development 
of cardiometabolic diseases, which may dilute the association in individuals with CVD and T2D38. 
Biomarkers
A growing body of evidence shows gamma-glutamyltransferase (GGT) to be associated with 
adverse cardiometabolic health, including obesity, T2D, and CVD 39-44. GGT has been associated 
with oxidative stress 45,46, which has been implicated in both the pathogenesis of obesity and T2D47. 
Furthermore, GGT is capable of inducing lipid oxidation46, a process involved in the etiology of 
insulin resistance48 and that is closely linked to abdominal obesity and T2D49. Nevertheless, little 
attention has been given to normal range GGT and its role on obesity and/or body fat distribution. 
Even though the studies are consistent in showing a strong association between high circulating 
levels of GGT and T2D risk, it is yet unclear whether this association is causal50.  Measurement of 
serum GGT is accurate, reliable, easy and inexpensive 51. Therefore, if serum GGT is a marker that 
may play a role in the etiology of T2D, it could have implications for prevention and clinical care 
of T2D. In our study, we found no association between circulating GGT levels and total body fat. 
However, higher circulating levels of GGT within normal range were associated with higher android 
fat and higher android/gynoid fat ratio, independent of the presence of nonalcoholic fatty liver 
disease or insulin resistance. These findings may suggest that an increase in GGT concentrations 
within its physiological normal range is a sensitive and early biomarker of unfavorable body fat 
distribution. We also found a strong association between GGT plasmatic levels, glycemic traits 
(glucose and insulin) and T2D. However, using GGT-related genetic variants combined in a genetic 
risk score, we found no evidence for a causal relationship between GGT levels and these outcomes. 
The lack of evidence of a causal relationship may suggest that the corresponding observational 
association is due to confounding and/or reverse causation. 
Cardiometabolic Health in Women
Endogenous sex hormones 
The shift in hormonal balance during the menopause transition, which is characterized by a decline 
in endogenous estradiol levels and a relative androgen excess52, has been associated with impairment 
of glucose regulation and visceral adiposity53. Therefore, it has been suggested that endogenous 
sex hormones, and in particular estradiol, may play an important role in the pathophysiology of 
T2D in women53,54. This hypothesis is in line with data showing that pregnancy, characterized 
by high endogenous estrogen levels and polycystic ovary syndrome, a condition of anovulation 
and hyperandrogenism, have been both associated with insulin resistance and increased risk of 
T2D 55,56. This thesis provides further insights in the association of endogenous sex hormones (sex 
hormone-binding globulin (SHBG), free testosterone (FT), total testosterone (TT), free estradiol 
(FE) and total estradiol (TE)) with the risk of T2D. By using data from the Rotterdam Study and 
a systematic review approach, we showed that lower levels of SHBG and higher levels of TE are 
associated with higher risk of T2D in postmenopausal women, independent of established risk 
factors such as glucose and inulin. Our study showed no association between TT and the risk of 
T2D though a suggestive positive association was observed between FT and T2D. Our findings 
support the notion that endogenous sex hormones may play a role in the pathophysiology of T2D.
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Estrogen receptor beta
Estrogen, including estradiol, has many physiological effects in the female cardiovascular system, 
all of which are mediated by estrogen receptors57,58. A newly discovered estrogen receptor beta 
(ERβ) is widely distributed throughout the vascular system58,59. Consequently, high expression of 
ERβ in the vascular bed has raised interest in the question of whether this receptor could offer a 
new possibility for pharmacological interventions to prevent and treat CVD. However, the role of 
ERβ and its mechanism of action in the cardiovascular system remain unclear. Furthermore, the 
vascular response to estrogens appears to change with increasing age and to depend on years after 
menopause60,61. It is therefore unknown whether age- and menopause-related changes of vascular 
ERβ may explain the influence of these factors on estrogen’s actions.  By summarizing the evidence 
from 88 studies, we found that ERβ signaling possess vasodilator and antiangiogenic properties 
by regulating the activity of nitric oxide, altering membrane ionic permeability in vascular smooth 
muscle cells, inhibiting vascular smooth muscle cell migration and proliferation, and by regulating 
adrenergic control of the arteries. Also, there was a possible protective effect of ERβ signaling 
against left ventricular hypertrophy and ischemia/reperfusion injury. Furthermore, we found 
that the vascular effects of ERβ may be vessel-specific and may differ by age and menopause 
status. These findings contribute to the generation of hypotheses and the identification of potential 
therapeutic targets for the prevention and treatment of CVD. However, the majority of the studies 
were conducted in animals and further studies in humans are needed to evaluate whether isoform-
selective ERβ-ligands might contribute in CVD prevention. 
Menopause
Menopause transition, a physiological state of a women’s life, is associated with the emergence 
of a preferential increase in intra-abdominal fat, a shift towards a more atherogenic lipid profile 
and increased glucose and insulin levels, particularly aggressive for the female cardiovascular 
system62-65. These adverse changes in cardiovascular risk factors during the menopause transition 
have been mainly attributed to the loss of the protective effect of estrogens, but also to the activation 
of the renin-angiotensin-aldosterone system66.  Thus, early menopause has been hypothesized to 
be especially detrimental to cardiovascular health. About 5 to 10% of women experience early 
natural menopause by the age of 4567-69. Hence, it is important to examine the impact that early 
menopause might have on CVD. Furthermore, during the menopausal transition and afterwards, 
up to 80% of women experience vasomotor symptoms (hot flushes and night sweats), depression, 
fatigue, insomnia and panic attacks 70. Previous studies have linked menopausal symptoms with 
adverse cardiometabolic health, including hypertension and dyslipidemia, but the results are 
contradictory71-79. Furthermore, many women chose to use HT as medical treatment for these 
symptoms. However, there are concerns that HT may have a negative impact on cardiovascular 
health61, and therefore, identifying other medical treatments for managing these symptoms 
avoiding the adverse effects on cardiometabolic health is of public health importance. In our 
systematic review, we found an increased risk of coronary heart disease, cardiovascular mortality 
and overall mortality in women who experienced the menopause transition before the age of 
45 years. Also, vasomotor symptoms and other menopausal symptoms were associated with an 
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unfavorable cardiovascular risk profile and increased risk of CVD. However, the association 
between menopausal symptoms and CVD was mainly explained by cardiovascular risk factors 
such as blood lipids and body mass index. Further studies are needed to reliably establish which 
menopausal symptoms are independently associated with CVD outcomes and further clarify 
the potential mechanisms behind these associations. Moreover, in our systematic review and 
meta-analysis, by summarizing the evidence from 113 randomized clinical trials, we found that 
composite and certain specific phytoestrogen supplementations (i.e. soy isoflavones, soy protein) 
may confer a benefit of reducing menopausal symptoms in women, including hot flashes and 
night sweats. We found no association between black cohosh (Cimicifuga racemosa or Actaea 
racemosa) supplementation and menopausal symptoms. Behavioral therapies, acupuncture, and 
several herbal remedies in aggregate improved overall menopausal symptoms. However, in our 
systematic review, there was substantial diversity in quality across the available studies, limiting 
the validity and the generalizability of our findings.
METHODOLOGICAL CONSIDERATIONS
Bias in Dietary Intake and Biomarkers
The dietary intake in the studies presented in Chapter 3 was assessed through a food frequency 
questionnaire (FFQ). FFQs are relatively inexpensive and easy to administer, and therefore they 
are frequently used in epidemiological studies to evaluate an individual’s usual intake of the type 
and amount of foods over a defined period of time. However, FFQs and other self-report measures 
of diet are prone to information bias due to errors in reporting and by incomplete assessment of 
all sources of micro- and macronutrient intake. This may introduce misclassification. In the study 
presented in Chapter 3.1, because the outcome was assessed prospectively, the subjective measure 
of dietary intake would likely lead to non-differential misclassification with respect to the outcome, 
and therefore would likely bias the estimates toward the null. On the other hand, in the studies 
presented in Chapter 3.2 and 3.3, since the exposure and outcome were both assessed in the same 
time point, it can be possible the misclassification to be differential. However, the data obtained by 
an FFQ are suitable for ranking people and the FFQ we used was validated and showed a relatively 
high correlation with the intake of fatty acids. Furthermore, dietary fat intake was assessed at 
baseline, and there may have been changes in fat consumption over time. Nevertheless, it has been 
shown that dietary habits change  little over time in middle-aged adults80. Similarly, to examine 
the association between vitamin D and body fat, we assessed vitamin D in fasting samples only 
in one time point. The vitamin D levels fluctuate over time and therefore a single measurement 
of vitamin D in the blood may not be sufficient to assess its relationship with different health 
outcomes. However, it has been shown that the correlation of vitamin D blood levels between 
baseline, 12-months and 14 years were 0.8 and 0.52 respectively, providing some support for the 
use of a single measurement of vitamin D in predicting future health outcomes81. Furthermore, 
the current immunoassays used in assessing vitamin D levels are not able to accurately detect 
25OHD2, which can lead to underestimation of 25OHD levels, and therefore may result in a biased 
estimate82. Developments of more accurate measures of vitamin D are needed. 
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Confounding
A confounding factor is an extraneous variable in a statistical model that is not an intermediate in 
the causal pathway between the exposure and the outcome but correlates with both the independent 
variable (fatty acids) and the dependent variable (total body fat)83. Biased estimates may be 
obtained if a confounding factor is not taken into account in analyses. However, in all our analysis, 
we adjusted for multiple potential confounders, which were selected based on the literature and/
or when the potential confounder factor provided a change in effect estimate of more than 10%84. 
However, as in any observational study, residual confounding may be present.  Some of the 
unmeasured confounders might include physical activity at the time when exposure was evaluated 
and the non-fasting blood samples collected in the baseline measurement, and therefore the results 
in Chapter 3 may be explained by residual confounding. We did not have ultrasound measures of 
fatty liver from the same time the GGT was assessed.  Ultrasound is a more accurate measure for 
the diagnosis of fatty liver, and therefore we cannot exclude the presence of residual confounding 
of the presence of nonalcoholic fatty liver disease in the results presented in Chapter 3.4 and 3.5. 
Also, our results presented in Chapter 3.5 show a non-causal effect of GGT levels on T2D risk and 
that the observed association between GGT levels and the risk for prediabetes and T2D may be due 
to residual confounding, such as mediators related to oxidative stress and inflammation pathways. 
These unmeasured confounders may also explain the observed association between GGT levels 
and body fat distribution and will need to be further elucidated in future studies. However, the 
results presented in Chapter 3.5 should be interpreted with caution since several issues may have 
compromised our approach in assessing causality, e.g., use of a weak instrument, the pleiotropic 
effect of the genetic variants, and lack of sufficient power. Moreover, some confounding factors we 
considered for the analysis in Chapter 3 were self-reported (smoking status, socio-economic status 
and alcohol consumption), and therefore measurement error of the confounding variable might 
have occurred. Residual confounding can lead to either overestimation or underestimation of the 
observed effect estimate, depending on how the confounding factor is related to both outcome and 
exposure85. 
Heterogeneity and Publication Bias
A systematic review of studies addressing a research question will inevitably bring together 
studies with different population characteristics, design, interventions, and exposure and outcome 
definitions. Such diversity is defined as heterogeneity and is a key factor to consider, evaluate, 
and report in studies summarizing the evidence (e.g. systematic reviews and meta-analyses)86. 
Depending on the level of heterogeneity, effect estimates from individual studies may not be able to 
be combined. In some of the systematic reviews presented in this thesis, a meaningful quantitative 
pooling of the existing data was unfeasible due to heterogeneity in the input parameters (e.g., 
exposure and outcome assessment), assumptions, and the study design. Furthermore, in the studies 
in which we performed a meta-analysis, there was some evidence of heterogeneity between studies 
(I2 estimates ranged from 0% to 96% in these meta-analyses). Since the number of available studies 
in each analysis was generally small, it precluded our ability to extensively explore the sources of 
the observed heterogeneity by subgroup analyses involving various study-level characteristics, 
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including age, ethnicity and socio-economic stats.  In this respect, literature-based meta-analyses 
are influenced by the level of diversity across the studies and do not provide detailed information 
necessary for the reliable assessment of associations independent of potential confounding factors. 
In the systematic reviews presented in this thesis, we included data from potentially poorly 
conducted studies and therefore, variation in study quality has contributed to the heterogeneity 
of findings noted in several of the meta-analyses. Therefore the results should be interpreted with 
caution. Another threat to a meta-analysis is the issue of publication bias due to underreporting of 
negative findings.  The results of a meta-analysis are threatened if the sample of studies retrieved 
for review is biased. In the meta-analyses presented in this thesis, although evaluations with the 
conventional funnel plots and Egger’s test estimates indicate minimal impact of publication bias 
in most of our analyses, these approaches are limited by a qualitative nature reliant on visual 
inspection and the fact that the majority of these assessments were based on between five to ten 
studies. Therefore, despite all efforts made to undertake a comprehensive search of the published 
and unpublished literature, we cannot exclude the possibility of publication bias stemming from 
underreporting of negative findings. 
Missing Data, Validity and The Generalizability of The Results
In the studies presented in Chapter 3 and Chapter 4.1, a general methodological concern is that 
there were missing data on exposure (e.g., dietary intake or GGT levels) and/or outcome data (e.g. 
body composition measurements). This may have happened in our study because participants were 
lost to follow-up, not invited to participate in the assessment, or they did not return or complete 
the food frequency questionnaire. Selection bias might be present and, therefore, the missing data 
in exposure and outcome could have influenced the validity of our results. However, we did not 
observe significant differences between the examined characteristics of the participants included 
in the analyses and those excluded (e.g., in the study in Chapter 3.4, there was no differences 
in GGT levels among participants included in our study and those excluded due to no data on 
DXA measurements). Therefore, it is unlikely that selection bias happened. A selection towards a 
healthier population might have occurred in the studies focused on the role of diet. Nevertheless, 
it has been shown that using a restricted source population for a cohort study may not compromise 
validity of exposure-outcome association87.  Also, in the studies examining the role of diet and 
biomarkers in relation to body fat in Chapter 3, the assessment of the exposure (diet, vitamin D 
and GGT levels) and the outcome of body fat distribution occurred at different times, and changes 
could have occurred in the interim. We were not able to study the change of diet over time, because 
we assumed that diet is constant over time or that the rank order of dietary variables is the same 
across time if changes occur. It has been shown that the potential of a single FFQ measurement 
to rank subjects according to nutrient intake is relatively stable over time in middle-aged adults80. 
Also, use of a single baseline dietary assessment usually leads to attenuation of the effect estimates, 
compared to the use of repeated dietary measurements 88. For some of biomarkers used in the 
studies of Chapter 3 we were able to assess the changes over time in a subgroup of participants, 
supporting internal consistency and validity (e.g., we measured serum GGT levels at the baseline 
visit of The Rotterdam Study (1990-1993) in a subgroup of study participants (n=2753 participants) 
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and at the fifth visit (2009-2011) (n=1395 participants). In the subgroup analysis, we observed high 
correlations with GGT measure at the third visit (1997-1999) (interclass correlation coefficients 
between the first and the third visit and the third and the fifth visit of the Rotterdam Study were 
0.84 and 0.81 respectively)). Another concern is the generalizability of the results presented in 
Chapter 3 and 4.1. The studies included in this chapter are performed in Caucasian populations. 
Ethnic differences in exposures (vitamin D) or outcomes (body composition) examined have been 
previously reported89,90. Thus, our findings may not be extended to non-Caucasian groups. Also, in 
Chapter 4.1 we included only postmenopausal women in the analysis, and therefore our findings 
cannot be generalized to pre-menopausal women or men. 
FUTURE RESEARCH
Diet and Cardiometabolic Health
Polyunsaturated fatty acids
Our study showed that higher levels of both classes of PUFA were associated with diminished 
chronic inflammation, which was mainly driven by n-6 PUFA. Our findings are in line with previous 
studies showing a non-detrimental effect of PUFA on CVD and provide additional support for the 
maintenance of the present level of n-6 PUFA intake cardiovascular outcomes91,92. However, in 
our study we used CRP as a marker of inflammation, which has not yet been established to have a 
causal effect on cardiometabolic diseases93. Therefore, clinical trials are needed to assess whether 
PUFA supplementation can reduce the cardiometabolic risk by reducing inflammation. In this 
respect, examination of other inflammatory markers including interleukin-6 and tumor necrosis 
alpha would further clarify the association between fatty acids intake and inflammation. Also, 
investigation of other inflammatory markers, such as interleukin-6 or tumor necrosis-alpha can 
help to give insight into the role of fatty acids in the inflammation process. Furthermore, our results 
suggested that dietary sources of n-3 PUFA may be important to take into account when evaluating 
their role on inflammation and other health outcomes. Further studies are needed in order to assess 
the role of dietary sources of n-3 PUFA in cardiometabolic health. Also, we found that the presence 
of chronic diseases may influence the association between dietary fat intake and body composition, 
which needs to be clarified in future studies. Also, randomized control studies should examine 
whether supplementation of different fatty acids may impact total body fat and its distribution. 
Vitamin D
We observed that vitamin D sufficiency was associated with body composition in elderly, and was 
particularly closely associated with total body fat mass and lean mass. Our study used accurate 
measures of body composition, but it was limited from the the use of one single measurement of 
body composition. Furthermore, adjustment for baseline BMI in these analyses (data not shown), 
abolished the association between vitamin D, total body fat and lean mass, providing some 
evidence that these associations are not causal. However, this should be interpreted with coution 
since BMI and total body fat are highly correlated, and it ramins a challenge in analyzing data 
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that are highly correlated withing subject. Failure to incorporate properly these correlations on 
depdentent variables, can lead to incorrect estimation of regression model parameters, particularly 
when such correlations are large. The literature lacks studies assessing whether vitamin D levels 
can have a causal effect on body composition, and further studies are needed to address this aspect. 
Since obesity is a major public health problem, examining whether vitamin D can have a causal 
effect, would present a novel preventive measurement in combating obesity. This can also be 
investigated with longitudinal studies using repeteaed meassurements of body composition and 
proper statistical methots to account for the correlation of responses on the dependent variables 
(such as generelaized estimating equations) or well-organized clinical trials examining whether 
vitamin D supplementation can be of additional value in weight loss treatment. Also, it may be 
valuable to assess whether screening for vitamin D deficiency in obese individuals and providing 
vitamin D supplementation could be cost-effective intervention.  Furthermore, experimental 
studies are needed to investigate the underlying mechanisms linking vitamin D levels with body 
composition.  These future studies should also examine further the role of cardometabolic diseases 
in the association between vitamin D and body fat. Also, as many epidemiological studies, we 
used total circulating 25OHD which is the sum of 25OHD2 and 25OHD3. 25OH3 is synthesized 
in skin after ultraviolet B exposure and obtained from animal food sources, whereas 25OHD2 is 
synthesized from vitamin D2 obtained from plant sources. Previous studies have shown that these 
subtypes of vitamin D may have different effect on health, including the risk for CVD31,94, and 
therefore, studies looking at the role of these metabolites individually in body composition are 
needed.  
Biomarkers
In Chapter 3.4 we found that an increase in GGT concentrations within its physiological normal 
range is a sensitive and early biomarker of unfavorable body fat distribution. As measurement of 
serum GGT is reliable, easy and inexpensive, its assessment may have clinical utility in identifying 
individuals who are at high risk of metabolic disturbances later in life and who could benefit from 
effective preventive interventions. However, our study was of cross-sectional design and therefore 
the causality could not be addressed. Future studies using repeated measurements of both GGT 
and body fat measures are necessary to determine whether levels of GGT can affect body fat 
distribution. Furthermore, clinical trials examining whether medication or lifestyle factors that 
alter GGT metabolism can be used to prevent obesity and its complications may help to clarify 
the role of GGT in obesity. Also, future studies should examine whether GGT levels can be used 
as an indicator of visceral fat levels, which is associated with more adverse outcomes. It has been 
shown that visceral adipose tissue is associated with more adverse cardiometabolic risk factor 
profiles than is abdominal subcutaneous adipose tissue. 95 Furthermore, in Chapter 3.5 we found 
no evidence that genetically influenced elevation of GGT levels affect glycemic traits and increase 
risk of prediabetes and T2D. Therefore, we do not support the hypothesis that there is a causal 
relationship between GGT levels and these outcomes. However, large-scale studies (observational 
studies using a mendelian randomization approach or randomized trials) are needed to establish 
the causality and explore the role of metabolic pathways, including mediators of oxidative stress 
and inflammation in the association between GGT and T2D. Furthermore, it has been reported that 
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GGT is made up of four fractions namely big-, medium-, small- and free- GGT, each one having its 
own molecular weight and distinct physiochemical property96. There might be differences in types 
and levels of GGT fractions in serum and plasma samples97. Future studies investigating the role of 
individual fractions of GGT in obesity and T2D would be of interest. 
Cardiovascular Health in Women
Estrogen receptor beta and estradiol
In many of the studies in this thesis, we evaluated cardiometabolic health in women. We 
showed that estrogen receptor has multiple functions in the female cardiovascular system that 
may contribute to protect the cardiovascular system. However, the majority of studies were 
conducted in animals, and therefore it remains unclear if these findings apply to humans. 
Future prospective population-based studies and randomized controlled trials in humans should 
examine whether targeting ERβ ligands can confer the cardioprotective effects of estradiol while 
avoiding its specific adverse effects on other tissues such as those of uterus and breast and in 
cardiometabolic health, including diabetes as shown in this thesis. The findings of an association 
between estradiol levels and the risk of T2D raise a concern on the safety of hormone replacement 
therapy (HRT) use in postmenopausal women. HRT has been shown to affect the risk of CVD as 
well61,98. Thus, studies further evaluating the role of HRT in cardiometabolic health are needed. 
Furthermore, the clinical usefulness of plasma levels of sex hormones in patient stratification 
and intervention based on the risk of developing T2D in women warrants further investigation. 
Menopause
Menopause is a natural phase of a women’s life cycle which is associated with changes in CVD 
risk factors, such body fat distribution, reduce glucose tolerance, increased blood pressure that 
contribute to increased risk of CVD63. In this thesis, early menopause, defined as a menopausal 
age of younger than 45 years, was shown to be associated with increased CVD risk, independent 
of traditional CVD risk factors. Furthermore, in our study, early menopause was associated 
with increased risk of all-cause mortality. The frequency of ovarian failure before age 40 is ≤ 
1% but about 5-10% of women experience natural menopause by age of 4567-69. Therefore, the 
increased risk of CVD and all-cause mortality associated with early menopause, represents an 
important factor affecting risk of disease and mortality among older women. Larger prospective 
population-based studies focusing on the association between early menopause and intermediate 
cardiovascular traits, including obesity, hypertension, and dyslipidemia are required, since they 
may provide new insights into the underlying mechanisms of the observed excess CVD risk. Also, 
to date, there is little information on the changes that occur in cardiovascular risk factors during the 
perimenopause and different stages of the menopause transition and the impact of these changes on 
the risk of CVD. Identifying the changes that might occur in cardiovascular risk factors during the 
menopause transition (i.e. early vs. late menopause) might help to identify which women should be 
target for intervention while they cross through different stages of menopause. Also, future studies 
exploring the hormonal changes in perimenopause and early menopause and how they correlate 
with cardiovascular risk factors and the risk of cardiovascular disease, might help to shape future 
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preventive strategies in reducing the burden of CVD in postmenopausal years.  Furthermore, 
vasomotor symptoms during the menopause transition, may present a new factor affecting CVD 
risk in women. However, the current evidence is too limited to draw any conclusions regarding 
the potential usefulness of menopausal symptoms in assessing CVD risk among women. Thus far, 
findings have largely been derived from post hoc analyses of studies using brief self-report measures 
of vasomotor symptoms, which are subject to faulty memory and reporting bias. Therefore, 
prospective studies looking at physiologically-assessed vasomotor symptoms and the risk of 
CVD are needed in order to reliably establish whether menopausal symptoms are independently 
associated with CVD outcomes and in order to further clarify the potential mechanisms behind 
this association. In this respect, future studies should adjust for sex hormones levels to investigate 
whether the observed association is due to changes in hormone levels associated with menopause. 
Our findings showed that a number of plant-based and natural therapies (i.e. phytoestrogens, yoga) 
may be used as a complementary therapy in managing menopausal symptoms.  Nevertheless, the 
majority of the available studies focus appropriately on hot flashes, and few studies additionally 
evaluated other menopausal symptoms (i.e. night sweats). Therefore, future randomized control 
trials should look at the impact of plant-based and natural therapies on a wide range of menopausal 
symptoms. Also, there is lack of data on adverse effects that may arise from long term use of plant-
based and natural therapies, and therefore, future studies providing information on any detrimental 
health effects, typically available in long-term intervention studies, is essential. Moreover, in our 
systematic review, we found low degree of quality of randomized control trials evaluating the 
impact of plant-based and natural therapies on menopausal symptoms. Further randomized clinical 
studies utilizing an adequately designed strict protocol with sufficient sample size, adequate 
blinding of outcome assessment, participants and personnel, proper allocation concealment, and 
sufficient follow up period are needed. 
CLINICAL AND PUBLIC HEALTH IMPLICATIONS
Our results on the financial burden of NCDs on healthcare expenditure and national income may 
be important for policy makers to help shape future healthcare plans and strategies to reduce 
the impact of NCDs. These strategies may include various activities, ranging from disease 
surveillance, drug research and development, health staff training, preparedness and response 
planning and execution, to public education, behavior change and disease prevention campaigns. 
Furthermore, our results highlight the need for future studies, assessing the economic burden of 
NCDs in low and middle-income country settings. We identified several nutritional factors and 
biomarkers to be associated with the risk of adverse cardiometabolic health. Our findings can have 
important clinical implications since they may contribute to identify high-risk individuals for the 
development of preventive strategies. For example, since measurement of serum GGT is reliable, 
easy, and inexpensive, its assessment may have clinical utility in identifying individuals at high risk 
of metabolic disturbances later in life who could benefit from effective preventive interventions. 
Our findings provide further support for the maintenance of the present level of n-6 PUFAs intake. 
At the same time, our results suggest that substitution of plant-derived n-3 PUFAs with marine 
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derived n-3 PUFAs may be considered when shaping  future guidelines and recommendations 
for CVD and T2D prevention. The results presented on estrogen receptor beta may present new 
frontiers in the development of novel therapies for cardiometabolic diseases. For instance, specific 
ERβ agonists might be a therapeutic option in occlusive artery disease, whereas ERβ antagonist 
may be useful in vascular disease characterized by arterial wall distention and aneurysm. The 
combination of ERβ ligands with specific targeting or drug delivery techniques such as drug-
eluting stents and perivascular gel might be effective in modulating the activity of ERβ in a specific 
blood vessel without altering other vessels in the systemic circulation. Also, our results presented 
within the framework of women’s health indicate that menopause is a critical period to evaluate 
women’s risk for CVD and that it may be an appropriate time to introduce interventions to reduce 
the risk of adverse cardiometabolic health. For instance, screening for medical conditions such 
as hypertension, dyslipidemia, insulin resistance and other cardiometabolic risk factors may be 
considered for women going into menopause at or before age 45, since it may help in identifying 
women at high risk for developing cardiovascular disease, who could profit from lifestyle or 
pharmacological interventions. Furthermore, our findings on the impact of plant-based and natural 
therapies on menopausal symptoms, stimulate the use of phytoestrogens, behavioral therapies 
and acupuncture in managing menopausal symptoms while avoiding the adverse cardiovascular 
health effects of HT. Nevertheless, the available evidence remains scarce and of poor quality, 
well designed studies with sufficient sample size and follow up are key for the establishment of 
effective strategies in the prevention of cardiovascular disease and diabetes.
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Chapter 6 
Short Summary
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Short Summary 
In chapter 1, we describe the background of the research presented in this thesis. NCDs, 
particularly cardiometabolic diseases, are the world’s main killer and pose a heavy financial burden 
on governments and society. Obesity is among the major risk factors of cardiometabolic diseases 
including hyperglycemia, hypertension and dyslipidemia. Nutrition is suggested to play a crucial 
role in maintaining cardiometabolic health. Biomarkers on the other hand, provide a dynamic and 
powerful approach for homogenous classification of a disease and risk factors that can extend our 
knowledge about the underlying pathogenesis of cardiometabolic disease and may help to identify 
subgroups in the population with greater susceptibility to these diseases. Furthermore, women face 
a higher CVD risk after reaching menopause, which has been attributed, in part, to the physiological 
and hormonal changes that occur during the menopause transition. Therefore, we aimed to study 
the role of nutrition, biomarkers, menopause and its related changes on cardiometabolic health. 
In chapter 2, we performed systematic reviews of the literature on the economic impact of NCDs. 
In chapter 2.1 we present a systematic review of the literature on the global economic impact 
of NCDs on health care spending and national income. The results showed that NCDs pose a 
significant financial burden on healthcare budgets and nations’ welfare, which is likely to increase 
over time. Our study also shows that among the NCDs, CVD and cancer present the highest costs. 
In chapter 2.2 we present a systematic review of the literature on macro-economic productivity. 
Overall NCDs generate a large impact on macro-economic productivity in most World Health 
Organization regions irrespective of continent and income. However, the absolute global impact 
in terms of dollars and disability adjusted life years remains an elusive challenge due to the wide 
heterogeneity in the included studies as well as limited information from low and middle-income 
countries. 
In chapter 3, we examined the associations of dietary fatty acids intake, serum vitamin D and 
GGT levels with cardiometabolic risk factors, including inflammation, body composition and 
glycemic traits. In chapter 3.1, we describe the association of total and individual PUFA intake 
with C-reactive protein levels. We observed that total PUFA intake and n-6 PUFA intake, but not 
n-3 PUFA intake, were associated with diminished chronic inflammation. Stratification by sex 
revealed that these associations were more prominent in women. Possible sex differences in the 
association of PUFA intake and cardiometabolic health should be further explored. In chapter 
3.2, we assessed whether dietary fat composition was associated with total body fat and regional 
body fat composition in two Caucasian populations. Our results showed no consistent association 
between dietary fat composition and total body fat or regional body fat distribution. However, we 
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found evidence for potential effect modification by chronic disease on the association between 
dietary fat intake and body fat distribution. Future studies should clarify to what extent these 
findings may be influenced by the presence of chronic disease.  In chapter 3.3, we aimed to 
assess the association between serum vitamin D levels, body fat, lean mass and regional body fat 
distribution. We observed that lower vitamin D concentrations were associated with a lower lean 
mass and a higher fat mass. Furthermore, we found an interaction between serum vitamin D levels, 
total body fat and cardio-metabolic diseases. The stratification analysis showed that vitamin D was 
inversely associated with fat mass only in subjects free of cardiometabolic diseases. Our results did 
not support a role for vitamin D status in the regional distribution of body fat.  In chapter 3.4, we 
examined whether GGT levels within normal range are prospectively associated with total body fat 
and regional body fat distribution. We found no association between GGT concentrations and total 
body fat mass. However, increased GGT was associated with higher android fat, lower gynoid fat 
and higher android fat/gynoid fat ratio. Our results suggest that an increase in GGT concentrations 
within its physiological normal range is a sensitive and early biomarker of unfavorable body fat 
distribution. In chapter 3.5, we investigated whether GGT related genetic variants, combined in 
a genetic risk score, and GGT1 genetic variant, rs2017869, were associated with GGT levels and, 
in turn, with an increased risk prediabetes and T2D or influencing glycemic traits in the Rotterdam 
Study. In this study we found that GGT levels predict risk of prediabetes and T2D. However, we 
did not find any significant association between formerly studied GGT1 genetic variant or GGT 
genetic risk score with glycemic traits, prediabetes and T2D. Our results provide no evidence that 
genetically elevated GGT levels affect the risk prediabetes and of T2D, and thus do not support a 
causal relationship role for GGT levels. 
In chapter 4, we present original data analysis, systematic reviews and meta-analysis of the 
literature on the association of unique cardiometabolic risk factors in women.  In chapter 4.1 we 
present an original data analysis and comprehensive review on the association of endogenous sex 
hormones levels with the risk of T2D in women. We showed that lower levels of sex hormone-
binding globulin and higher levels of total estradiol were associated with the risk of T2D. These 
associations were independent of established risk factors, including body mass index, glucose 
and insulin. In our study, however, we did not find any association between testosterone and 
the risk of T2D. Further studies are needed to establish hormones thresholds at which diabetes 
risk is increased, because this may aid in identifying high-risk postmenopausal women in the 
clinical setting. In chapter 4.2, we present a comprehensive review of the literature on the role 
of estrogen receptor beta in the female cardiovascular system. By summarizing findings from 88 
studies, we found that estrogen receptor beta possess abundant functions that might contribute 
to protecting the cardiovascular system in women. Our findings suggest that estrogen receptor 
beta signaling may cause vasodilation, and therefore prevents the pathological effect of excessive 
vasoconstriction by regulating the bio-availability of nitric oxide, altering membrane ionic 
permeability in vascular smooth muscle cells and by regulating adrenergic control of the arteries. 
Also, estrogen receptor beta may have angiogenic properties and may protect against vascular 
injury by inhibiting vascular smooth muscle cell migration and proliferation. Additionally, the 
results of the current study indicate a possible protective effect of estrogen receptor beta signaling 
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in left ventricular hypertrophy and ischemia/reperfusion injury via genomic and non-genomic 
pathways. Furthermore, our systematic review suggests that the vascular effects of estrogen 
receptor beta may be vessel specific and may differ by age and menopause status. In chapter 
4.3, we undertook a systematic review and meta-analysis of studies assessing the association of 
vasomotor symptoms with various cardiovascular risk factors such as systolic and diastolic blood 
pressure, hypertension, blood lipids, body mass index and measures of subclinical atherosclerosis. 
By quantifying data of nearly 20,000 individuals, we found that women with vasomotor symptoms 
including flushing and/or night sweats have significantly higher systolic and diastolic blood 
pressure, higher circulating total cholesterol and low-density lipoprotein levels, higher body 
mass index and higher odds of having hypertension than their counterparts with no symptoms. 
However, our study found no consistent associations between vasomotor symptoms and measures 
of subclinical atherosclerosis.  In chapter 4.4, we present a systematic review and meta-analysis 
of the literature on the association of either vasomotor symptoms or other menopausal symptoms 
with the risk of coronary heart disease, stroke and CVD. By quantifying data of nearly 214,000 
individuals, we found that women with vasomotor symptoms or other menopausal symptoms had 
up to 48% increased risk of coronary heart disease, stroke and CVD. However, these associations 
were mainly explained by the conventional cardiovascular risk factors. Further prospective large-
scale studies are needed to extend our understating on the possible role of menopausal symptoms 
in cardiovascular disease. In chapter 4.5, we performed a systematic review and meta-analysis of 
all available observational evidence to quantify the associations of age at menopause and duration 
since onset of menopause with (i) primarily clinical CVD outcomes and intermediate vascular 
traits; and (ii) all-cause mortality. We found that women who experienced an early menopause (i.e. 
younger than 45 years) have an excess risk of coronary heart disease, CVD-mortality and all-cause 
mortality. Furthermore, being 45-49 years at menopause compared to ≥50 years was associated with 
increased risk of carotid atherosclerosis. Duration since menopause in relation to risk of developing 
intermediate cardiovascular traits or CVD outcomes was reported in 4 observational studies, 
reporting no consistent results. Our review also highlights important gaps in the existing literature, 
calling for further research to reliably establish whether cardiovascular risk may vary in relation 
to the duration since menopause and the mechanisms leading early menopause to cardiovascular 
outcomes and mortality. In chapter 4.6, we undertook a systematic review and meta-analysis 
of randomized controlled trials and prospective studies assessing the impact of plant-based and 
natural therapies on menopausal symptoms. By summarizing the evidence from 101 randomized 
controlled trials and 12 prospective non-randomized intervention or observational studies, including 
12,443 individual women, we found that composite phytoestrogens and individual phytoestrogen 
interventions such as dietary and supplemental soy isoflavones were beneficial for menopausal 
outcomes in general, and number of night sweats in 24 hours in particular. Additionally, we found 
that behavioral therapies, acupuncture, and several herbal remedies in aggregate improved overall 
menopausal symptoms. 
In chapter 5, we provide a general discussion in which the studies described in this thesis 
are described in broader context. Furthermore, this chapter describes major methodological 
considerations, as well as implications for clinical practice and suggestions for future research.
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Korte samenvatting
In hoofdstuk 1 wordt de achtergrond van de onderzoeken die zijn uitgevoerd in dit proefschrift 
beschreven. Niet overdraagbare chronische ziekten (in het Engels “Non Communicable Diseases”; 
NCDs), waaronder cardiometabole ziekten, zijn wereldwijd de belangrijkste oorzaak van sterfte 
en dragen bij aan verhoogde ziektekosten van de maatschappij. Overgewicht is een belangrijke 
risicofactor voor het krijgen van cardiometabole ziekten zoals een verhoogde bloedsuikerspiegel, 
of verhoogde bloeddruk. Voeding kan een  belangrijke rol spelen bij het behouden van een goede 
gezondheid van het hart en bloedvaten. Ook het gebruik van specifieke biomarkers is een aanpak die 
zou kunnen bijdragen aan het identificeren van risicogroepen voor het ontstaan van cardiometabole 
ziekten. Vrouwen hebben een hoger risico om hart- en vaatziekten te krijgen na de overgang. 
Dit verhoogde risico wordt deels veroorzaakt door fysiologische en hormonale veranderingen die 
opreden tijdens de overgang. Samengenomen, wasdaarom  het doel van dit proefschrift om te 
bestuderen in hoeverre voeding, biomarkers en de overgang geassocieerd zijn met  cardiometabole 
ziektes. 
In hoofdstuk 2 is de beschikbare literatuur over de economische impact van NCDs op een 
systematische manier samengevat.  In hoofdstuk 2.1. hebben we de literatuur over de wereldwijde 
impact van NDS op zorgkosten en het nationaal inkomen bestudeert. De resultaten laten zien 
dat NCDs een belangrijke bijdrage leveren aan de nationale zorgkosten en nationaal inkomen 
en dat deze bijdrage waarschijnlijk zal groeien over de tijd. Dit geldt met name voor hart- en 
vaatziekten en kanker. In hoofdstuk 2.2 is de literatuur over de impact van NCDs op macro-
economische productiviteit samengevat. NCDs genereren een grote impact op macro-economische 
productiviteit in de meeste regio’s van de Wereld Gezondheidsraad (“World Healh Organisation 
(WHO)”) ongeacht het land of het inkomen. Echter, het vaststellen van de absolute wereldwijde 
impact uitgedrukt in valuta per beperking-gecorrigeerde levensjaren (“Disability adjusted life 
years (DALYs)”) blijft een uitdaging door de grote heterogeniteit van de beschikbare studies en 
door het gebrek aan studies uit landen met lagere inkomens.  
In hoofdstuk 3 hebben we de relatie tussen vetzuren uit de voeding, vitamine D, gamma GT waardes 
en cardiometabole risicofactoren bestudeerd. In hoofdstuk 3.1. beschrijven we de relatie tussen 
totale en individuele meervoudig onverzadigde vetzuren (Polyunsaturated fatty acid (PUFAs)) met 
C-reactive protein levels. We hebben gevonden dat de totale inname van PUFAs en de inname van 
n-6 PUFAs maar niet van n-3 PUFA’s gerelateerd was aan verminderde chronische ontstekingen. 
Stratificatie op basis van geslacht liet zien dat deze relatie sterker was in vrouwen dan in mannen. 
Deze mogelijke verschillen tussen mannen en vrouwen in de relatie tussen PUFAs uit de voeding 
en cardiometabole gezondheid dienen in de toekomst verder te worden onderzocht. In hoofdstuk 
3.2. hebben we bestudeerd of vetten uit de voeding gerelateerd waren aan totaal lichaamsvet en de 
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verdeling van lichaamsvet in twee Kaukasische populaties. Onze resultaten lieten een consistente 
relatie zien tussen vetinname uit de voeding en vetmassa. Echter, onze resultaten lieten zien dat 
deze effecten mogelijk anders zijn voor mensen met chronische ziekten. Deze mogelijke interactie 
met chronische ziekten dient verder te worden bestudeerd in toekomstige studies. In hoofdstuk 
3.3. hebben we de relaties tussen vitamine D in het bloed en verschillende componenten van 
lichaamssamentelling bestudeerd (vetmassa, ververdeling en vetvrije massa) . We hebben gevonden 
dat lage vitamine D concentraties gerelateerd waren aan een lagere vetvrije massa en een hogere 
vetmassa. Daarnaast hebben we gevonden dat de relatie tussen lage vitamine D spiegel en hoge 
vetmassa alleen aanwezig was in gezonde mensen zonder cardiometabole ziekten terwijl er geen 
relatie met vetverdeling werd gevonden. In hoofdstuk 3.4. hebben we bestudeerd of GGT spiegels 
binnen de normale range gerelateerd zijn aan vetmassa en de verdeling van lichaamsvet. We 
vonden geen relatie tussen GGT en vetmassa. Echter, hogere GGT spiegels waren wel gerelateerd 
aan hogere hoeveelheid buikvet, lagere hoeveelheid heupvet en een hogere middel-heup ratio. 
Daarmee suggereren onze resultaten dat verhoogde GGT spiegels binnen de normale range 
mogelijk een biomarker van ongunstige vetverdeling zou kunnen zijn. In hoofdstuk 3.5 hebben 
we bestudeerd of een gecombineerde genetische risicoscore en een specifieke genetische variant 
(rs2017869) gerelateerd waren aan GGT spiegels en (pre-)diabetes in de Rotterdam Studie. We 
hebben gevonden dat GGT spiegels het risico op (pre-)diabetes voorspelde. We vonden echter dat 
de genetische score en  de losse genetische variant gelinked aan GG niet significant gerelateerd was 
aan (pre-)diabetes. Onze resultaten vormen geen bewijs voor hypothese dat genetisch verhoogde 
GGT spiegels het risico op (pre-)diabetes verhogen en onderbouwen daarom geen causale relatie 
tussen GGT en (pre)diabetes. 
In hoofdstuk 4 beschrijven we originele data analyses, een systematische review en een meta-
analyse van de literatuur over cardiometabole risicofactoren in vrouwen. In hoofdstuk 4.1 
beschrijven we de resultaten van een originele data analyse en een samenvatting van de relatie 
tussen endogene geslachtshormonen en het risico op diabetes type 2. We lieten zien dat lage spiegels 
van het sexhormoonbindend globuline en hogere estradiol spiegels gerelateerd waren aan het risico 
op diabetes. De relatie van onafhankelijk van bestaande risicofactoren zoals body mass index 
(BMI), glucose en insuline concentraties. In onze studie vonden we geen relatie tussen testosteron 
spigels en het risico op diabetes. Vervolgstudies zijn nodig om de minimum waardes van deze 
hormoonspiegels te bepalen waarbij het risico op diabetes begint te stijgen. Het vaststellen van een 
dergelijk minimum kan zinvol zijn om diabetes risicogroepen van postmenopauzale vrouwen te 
identificeren in de klinische setting. In hoofdstuk 4.2. hebben we de literatuur over de rol van de 
estrogen receptor beta (ER-β) in het vrouwelijk hart- en vaatsysteem samengevat. Op basis van 88 
studies hebben we geconcludeerd dat de receptor een breed scala aan functies vervult die zouden 
kunnen bijdragen aan de bescherming van het vrouwelijk hart- en vaatsysteem. Onze bevindingen 
suggereren dat de ER-β vaatverwijding veroorzaakt en daardoor de pathologische effecten van 
vaatvernauwing mogelijk helpt te voorkomen. Vaatverwijding wordt veroorzaakt doordat de ER-β 
de biobeschikbaarheid van productie van stikstofoxide reguleert, de idoorlaatbaarheid van ioenn en 
membranen van gladde spiercellen van de vaten verandert en de adrenerge controle van de arteriën 
reguleert.  Daarnaast, heeft ER-β angiogene eigenschappen en kan mogen beschermen tegen 
vaatschade door het tegengaan van migratie en proliferatie van gladde spiercellen in de bloedvaten. 
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Daarnaast laten de resultaten van de huidige studie zien dat ER-β signalering mogelijk beschermt 
tegen hypertrofie van de linker ventrikels en vaatschade vermindert. Ook suggereren de resultaten 
van onze systematische review dat de effecten van de ER-β vaat-specifiek zijn en mogelijk anders 
zijn voor vrouwen van verschillende leeftijden en menopausale status. In hoofdstuk 4.3 beschrijven 
we een systematische review en meta-analyse van studies over de relatie tussen vasomotorische 
symptomen (zoals opvliegers) en verschillende risicofactoren voor hart- en vaatziekten. Daarbij valt 
te denken aan bloeddruk, cholesterol, overgewicht en maten van subklinische aderverkalking. Op 
basis van data van bijna 20.000 individuen hebben we geconcludeerd dat vrouwen met vasomotor 
symptomen zoals opvliegers en nachtzweten een signficant hogere bloeddruk, totaal en LDL- 
cholesterol waarden en BMI hadden dan vrouwen zonder deze symptomen. Onze studie vond 
echter geen consistente relatie tussen vasomotorische symptomen en subklinische aderverkalking. 
In hoofdstuk 4.4 worden de resultaten van een systematische review en meta-analyse van de 
literatuur over de relatie tussen vasomotorische- of andere overgangssymptomen en het risico op 
cardiovasculaire ziekten beschreven. Gebaseerd op gegevens van bijna 214,000 personen hebben 
we gevonden dat vrouwen met vasomotorische- of andere overgangssymptomen een 48% hoger 
risico hadden op cardiovasculaire ziekten  dan vrouwen zonder deze symptomen. Deze relatie 
werd echter voornamelijk verklaard door verschillen in bestaande risicofactoren voor hart- en 
vaatziekten. Grote prospectieve studies zullen in de toekomst nodig zijn om onze huidige kennis 
over de mogelijke rol van overgangssymptomen in het ontstaan van hart- en vaatziekten uit te 
breiden. In hoofdstuk 4.5 hebben we een systematische review en meta-analyse uitgevoerd op 
basis van alle beschikbare observationele studies over de leeftijd waarop de menopauze is begonnen 
en de duur van de menopauze in relatie tot (i) primaire klinische cardiovasculaire uitkomsten en 
intermediaire vaatmetingen en (ii) sterfte door alle oorzaken. We hebben gevonden dat vrouwen 
die op jonge leeftijd (<45 jaar) in de overgang raken een verhoogd risico hebben op coronaire 
hartziekte, sterfte door hart- en vaatziekten en totale sterfte (door alle oorzaken). Daarnaast was 
het risico op aderverkalking hoger voor vrouwen die tussen de 45 en 49 in de overgang raakten 
groter dan voor vrouwen die ouder dan 50 waren. Duur van de overgang in relatie tot hart- en vaat 
uitkomsten werd onderzocht in 4 studies, maar deze lieten geen consistente resultaten zien. Onze 
review laat ook de gaten in de huidige kennis zien. Toekomstige studies zullen moeten uitwijzen 
of de duur van de overgang gerelateerd is aan hart- en vaat uitkomsten en welke mechanismes 
de relatie tussen overgang op vroege leeftijd en hart- en vaatziekten en sterfte zouden kunnen 
verklaren.  In hoofdstuk 4.6 hebben we een systematische review en meta-analyse uitgevoerd op 
basis van gerandomiseerde interventie studies (RCTs) en prospectieve studies over plantaardige 
en natuurlijke behandelingen voor het verminderen van overgangsklachten. We hebben 101 RCTs 
en prospectieve (niet- gerandomiseerde of observationele) studies geïncludeerd waarin 12,443 
vrouwen zijn bekeken. We vonden dat phytoestrogeen interventies bestaande uit soja isoflavonen 
uit de voeding of uit supplementen mogelijk gunstig werken tegen algemene overgangsklachten , en 
in eht bijzonder tegen de mate van nachtzweten. Ook vonden we dat gedragstherapie, acupunctuur 
en verschillende kruidentherapieën mogelijk overgangsklachten kunnen verminderen. 
In hoofdstuk 5 hebben we in een algemene discussie de studies beschreven in dit proefschrift in 
een bredere context geplaatst. Ook komen belangrijke methodologische overwegingen, klinische 
implicaties en aanbevelingen voor toekomstig onderzoek in dit hoofdstuk aan bod. 
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